BackgroundHuman	O
stem	O
cells	O
are	O
viewed	O
as	O
a	O
possible	O
source	O
of	O
neurons	O
for	O
a	O
cell	O
-	O
based	O
therapy	O
of	O
neurodegenerative	O
disorders	O
,	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Several	O
protocols	O
that	O
generate	O
different	O
types	O
of	O
neurons	O
from	O
human	O
stem	O
cells	O
(	O
hSCs	O
)	O
have	O
been	O
developed	O
.	O

Nevertheless	O
,	O
the	O
cellular	O
mechanisms	O
that	O
underlie	O
the	O
development	O
of	O
neurons	O
in	O
vitro	O
as	O
they	O
are	O
subjected	O
to	O
the	O
specific	O
differentiation	O
protocols	O
are	O
often	O
poorly	O
understood	O
.	O

ResultsWe	O
have	O
designed	O
a	O
focused	O
DNA	O
(	O
oligonucleotide	O
-	O
based	O
)	O
large	O
-	O
scale	O
microarray	O
platform	O
(	O
named	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
and	O
used	O
it	O
to	O
study	O
gene	O
expression	O
patterns	O
in	O
hSCs	O
as	O
they	O
differentiate	O
into	O
neurons	O
.	O

We	O
have	O
selected	O
genes	O
that	O
are	O
relevant	O
to	O
cells	O
(	O
i	O
)	O
being	O
stem	O
cells	O
,	O
(	O
ii	O
)	O
becoming	O
neurons	O
,	O
and	O
(	O
iii	O
)	O
being	O
neurons	O
.	O

The	O
NeuroStem	O
Chip	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
NeuroStem	O
Chip	O
in	O
detail	O
and	O
describe	O
the	O
special	O
advantages	O
it	O
offers	O
to	O
the	O
fields	O
of	O
experimental	O
neurology	O
and	O
stem	O
cell	O
biology	O
.	O

To	O
illustrate	O
the	O
utility	O
of	O
NeuroStem	O
Chip	O
platform	O
,	O
we	O
have	O
characterized	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
,	O
cell	O
line	O
SA02	B
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
performed	O
a	O
comparative	O
gene	O
expression	O
analysis	O
of	O
those	O
cells	O
versus	O
a	O
heterogeneous	O
population	O
of	O
hESC	O
-	O
derived	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	B
stromal	O
cells	O
for	O
16	O
days	O
and	O
containing	O
a	O
few	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

ConclusionWe	O
characterized	O
the	O
gene	O
expression	O
profiles	O
of	O
undifferentiated	O
and	O
dopaminergic	O
lineage	O
-	O
committed	O
hESC	O
-	O
derived	O
cells	O
using	O
a	O
highly	O
focused	O
custom	O
microarray	O
platform	O
(	O
NeuroStem	O
Chip	O
)	O
that	O
can	O
become	O
an	O
important	O
research	O
tool	O
in	O
human	O
stem	O
cell	O
biology	O
.	O

We	O
propose	O
that	O
the	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
hSC	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

Modern	O
DNA	O
microarrays	O
permit	O
a	O
comprehensive	O
analysis	O
of	O
quantitative	O
and	O
qualitative	O
changes	O
in	O
RNA	O
transcript	O
abundance	O
,	O
outlining	O
the	O
cross	O
-	O
sections	O
of	O
gene	O
expression	O
and	O
alterations	O
of	O
these	O
in	O
response	O
to	O
genetic	O
or	O
environmental	O
stimuli	O
.	O

Genome	O
-	O
scale	O
microarrays	O
(	O
cDNA-	O
or	O
oligonucleotide	O
-	O
based	O
)	O
are	O
most	O
valuable	O
when	O
screening	O
populations	O
of	O
cells	O
for	O
the	O
novel	O
genes	O
reflecting	O
potential	O
diagnostic	O
and	O
prognostic	O
markers	O
or	O
for	O
an	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

On	O
the	O
other	O
hand	O
,	O
custom	O
microarray	O
platforms	O
that	O
focus	O
on	O
specific	O
pre	O
-	O
selected	O
subset	O
of	O
genes	O
relevant	O
to	O
a	O
particular	O
field	O
of	O
investigation	O
can	O
be	O
less	O
costly	O
and	O
more	O
suitable	O
for	O
detection	O
of	O
smaller	O
gene	O
expression	O
changes	O
.	O

Microarray	O
technology	O
has	O
added	O
important	O
information	O
on	O
both	O
normal	O
development	O
and	O
pathological	O
changes	O
in	O
neurons	O
.	O

This	O
is	O
well	O
illustrated	O
by	O
multiple	O
studies	O
on	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
which	O
degenerate	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
[	O
1	O
-	O
5	O
]	O
.	O

The	O
shortcomings	O
of	O
pharmacological	O
therapies	O
in	O
PD	O
have	O
stimulated	O
a	O
search	O
for	O
alternative	O
treatment	O
strategies	O
.	O

In	O
successful	O
cases	O
,	O
transplants	O
of	O
human	O
embryonic	O
mesencephalic	O
dopaminergic	O
neurons	O
can	O
both	O
restore	O
dopaminergic	O
neurotransmission	O
and	O
provide	O
some	O
symptomatic	O
relief	O
[	O
6	O
-	O
8	O
]	O
.	O

A	O
wider	O
application	O
of	O
neural	O
transplantation	O
in	O
PD	O
is	O
,	O
however	O
,	O
currently	O
not	O
feasible	O
due	O
to	O
the	O
unpredictable	O
and	O
variable	O
outcome	O
,	O
the	O
risks	O
of	O
unwanted	O
side	O
-	O
effects	O
(	O
dyskinesias	O
)	O
[	O
9,10	O
]	O
and	O
ethical	O
and	O
practical	O
problems	O
associated	O
with	O
using	O
donor	O
cells	O
obtained	O
from	O
aborted	O
embryos	O
and	O
fetuses	O
[	O
11,12	O
]	O
.	O

Human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
considered	O
a	O
promising	O
future	O
source	O
of	O
cells	O
for	O
cell	O
replacement	O
therapy	O
in	O
PD	O
and	O
other	O
neurological	O
conditions	O
[	O
13	O
]	O
.	O

They	O
could	O
constitute	O
a	O
virtually	O
infinite	O
source	O
of	O
self	O
-	O
renewing	O
cells	O
that	O
can	O
be	O
persuaded	O
to	O
differentiate	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
,	O
including	O
dopaminergic	O
neurons	O
[	O
14	O
-	O
16	O
]	O
.	O

The	O
molecular	O
mechanisms	O
that	O
govern	O
development	O
of	O
cultured	O
hESCs	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

To	O
promote	O
our	O
understanding	O
of	O
such	O
mechanisms	O
,	O
it	O
would	O
be	O
valuable	O
to	O
have	O
tools	O
that	O
readily	O
and	O
reproducibly	O
can	O
help	O
to	O
characterize	O
the	O
cells	O
as	O
they	O
differentiate	O
from	O
pluripotent	O
stem	O
cells	O
into	O
post	O
-	O
mitotic	O
neurons	O
.	O

This	O
important	O
issue	O
was	O
addressed	O
in	O
earlier	O
studies	O
by	O
Luo	O
et	O
al.	O
and	O
Yang	O
et	O
al.	O
,	O
who	O
designed	O
small	O
-	O
to	O
-	O
moderate	O
scale	O
custom	O
microarray	O
platforms	O
(	O
281	O
and	O
755	O
gene	O
targets	O
,	O
respectively	O
)	O
[	O
17,18	O
]	O
.	O

In	O
addition	O
SuperArray	O
Bioscience	O
Corporation	O
(	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
have	O
manufactured	O
a	O
range	O
of	O
small	O
-	O
scale	O
arrays	O
(	O
263	O
gene	O
targets	O
for	O
human	O
array	O
;	O
[	O
19	O
]	O
)	O
.	O

We	O
sought	O
to	O
create	O
an	O
improved	O
and	O
updated	O
microarray	O
platform	O
for	O
hESC	O
/	O
neuronal	O
differentiation	O
-	O
oriented	O
gene	O
expression	O
studies	O
.	O

Therefore	O
,	O
we	O
generated	O
a	O
specialized	O
large	O
-	O
scale	O
DNA	O
microarray	O
platform	O
(	O
the	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
that	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

Here	O
we	O
introduce	O
the	O
platform	O
and	O
the	O
advantages	O
it	O
can	O
offers	O
to	O
neuroscientists	O
and	O
stem	O
cell	O
biologists	O
:	O
particularly	O
,	O
in	O
the	O
niche	O
of	O
gene	O
expression	O
-	O
oriented	O
characterization	O
of	O
the	O
samples	O
using	O
an	O
assay	O
of	O
pre	O
-	O
selected	O
,	O
already	O
established	O
gene	O
targets	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
use	O
the	O
NeuroStem	O
Chip	O
to	O
characterize	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
hESCs	O
(	O
cell	O
line	O
SA02	B
,	O
Cellartis	O
AB	O
,	O
GÃ¶teborg	O
,	O
Sweden	O
)	O
and	O
compare	O
the	O
gene	O
expression	O
in	O
those	O
cells	O
with	O
that	O
of	O
a	O
hESC	O
-	O
derived	O
cell	O
population	O
rich	O
in	O
neurons	O
,	O
including	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

Stem	O
cells	O
have	O
unique	O
biological	O
characteristics	O
,	O
but	O
only	O
a	O
limited	O
number	O
of	O
genes	O
are	O
currently	O
recognized	O
as	O
established	O
stem	O
cell	O
markers	O
.	O

Examples	O
include	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
(	O
Oct3	O
/	O
4	O
)	O
,	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
,	O
teratocarcinoma	O
-	O
derived	O
growth	O
factor	O
(	O
Tdgf1	O
)	O
,	O
Enk	O
-	O
pending	O
(	O
Nanog	O
)	O
,	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
and	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
[	O
20	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
hundreds	O
of	O
genes	O
are	O
suggested	O
as	O
candidate	O
markers	O
for	O
""""	O
stemness	O
""""	O
,	O
but	O
their	O
coupling	O
to	O
the	O
undifferentiated	O
stem	O
cell	O
state	O
is	O
not	O
yet	O
fully	O
verified	O
[	O
21	O
]	O
.	O

The	O
concept	O
of	O
""""	O
stemness	O
""""	O
(	O
term	O
introduced	O
in	O
1986	O
by	O
Grossman	O
&	O
Levine	O
)	O
is	O
defined	O
as	O
""""	O
core	O
stem	O
cell	O
properties	O
that	O
underlie	O
self	O
-	O
renewal	O
and	O
the	O
ability	O
to	O
generate	O
differentiated	O
progeny	O
""""	O
[	O
22	O
]	O
.	O

Considering	O
the	O
complexity	O
of	O
the	O
processes	O
involved	O
,	O
stemness	O
can	O
hardly	O
be	O
ensured	O
by	O
co	O
-	O
operation	O
of	O
just	O
a	O
few	O
genes	O
.	O

Nevertheless	O
,	O
three	O
stemness	O
genes	O
(	O
namely	O
,	O
Oct3	O
/	O
4	O
,	O
Stat3	O
and	O
Nanog	O
)	O
are	O
considered	O
""""	O
master	O
"""-"	O
genes	O
that	O
control	O
the	O
self	O
-	O
renewing	O
process	O
[	O
23,24	O
]	O
.	O

Various	O
types	O
of	O
stem	O
cells	O
,	O
such	O
as	O
hematopoietic	O
,	O
mesenchymal	O
and	O
neural	O
(	O
HSCs	O
,	O
MSCs	O
and	O
NSCs	O
,	O
respectively	O
)	O
,	O
embryonic	O
germ	O
and	O
embryonic	O
carcinoma	O
cells	O
(	O
EGCs	O
and	O
ECCs	O
,	O
respectively	O
)	O
are	O
all	O
characterized	O
by	O
variations	O
in	O
gene	O
expression	O
profiles	O
,	O
and	O
only	O
a	O
few	O
gene	O
markers	O
are	O
associated	O
with	O
all	O
these	O
cell	O
types	O
[	O
25,26	O
]	O
.	O

We	O
have	O
aimed	O
to	O
embrace	O
the	O
most	O
comprehensive	O
set	O
of	O
those	O
genes	O
into	O
a	O
solitary	O
array	O
,	O
the	O
NeuroStem	O
Chip	O
.	O

Thereby	O
,	O
it	O
is	O
possible	O
to	O
employ	O
it	O
to	O
monitor	O
the	O
relative	O
expression	O
levels	O
of	O
numerous	O
known	O
and	O
candidate	O
stemness	O
genes	O
in	O
a	O
single	O
experiment	O
.	O

Similar	O
to	O
the	O
genetic	O
bases	O
underlying	O
stemness	O
,	O
cell	O
differentiation	O
is	O
associated	O
with	O
altered	O
expression	O
levels	O
of	O
certain	O
recognized	O
or	O
candidate	O
genes	O
[	O
25	O
]	O
.	O

We	O
therefore	O
incorporated	O
gene	O
markers	O
of	O
development	O
and	O
differentiation	O
in	O
general	O
,	O
and	O
that	O
of	O
neuronal	O
and	O
dopaminergic	O
differentiation	O
in	O
particular	O
,	O
into	O
the	O
NeuroStem	O
Chip	O
.	O

Examples	O
include	O
markers	O
for	O
the	O
processes	O
of	O
neuronal	O
maturation	O
,	O
axonal	O
branching	O
,	O
neural	O
/	O
neuronal	O
survival	O
,	O
etc	O
.	O

Finally	O
,	O
we	O
ensured	O
that	O
known	O
markers	O
for	O
specific	O
types	O
of	O
neurons	O
,	O
allowing	O
identification	O
of	O
individual	O
cell	O
types	O
,	O
were	O
present	O
on	O
the	O
chip	O
.	O

We	O
paid	O
special	O
attention	O
to	O
genes	O
associated	O
with	O
the	O
differentiation	O
and	O
maturation	O
of	O
dopaminergic	O
neurons	O
.	O

In	O
many	O
published	O
studies	O
,	O
the	O
expression	O
of	O
only	O
a	O
single	O
(	O
tyrosine	O
hydroxylase	O
,	O
TH	O
)	O
or	O
2â3	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
e.g.	O
amino	O
acid	O
decarboxylase	O
(	O
AADC	O
)	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
,	O
vesicular	O
monoamine	O
transporter	O
2	O
(	O
VMAT2	O
)	O
)	O
have	O
been	O
used	O
to	O
indicate	O
dopaminergic	O
identity	O
of	O
neurons	O
.	O

In	O
contrast	O
,	O
the	O
NeuroStem	O
Chip	O
includes	O
oligonucleotide	O
probes	O
for	O
88	O
genes	O
related	O
to	O
dopaminergic	O
neurons	O
,	O
thus	O
being	O
more	O
comprehensive	O
in	O
this	O
sense	O
,	O
compared	O
to	O
other	O
existing	O
microarray	O
platforms	O
,	O
including	O
focused	O
ones	O
[	O
17,18	O
]	O
.	O

Those	O
entries	O
encompass	O
recognized	O
and	O
candidate	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
mature	O
and	O
early	O
)	O
and	O
progenitors	O
,	O
as	O
well	O
as	O
markers	O
for	O
the	O
maturation	O
and	O
differentiation	O
of	O
the	O
latter	O
(	O
Table	O
1	O
)	O
.	O

Table	O
2	O
represents	O
conditional	O
functional	O
breakdown	O
of	O
genes	O
targeted	O
by	O
the	O
NeuroStem	O
microarray	O
platform	O
.	O

A	O
number	O
of	O
important	O
gene	O
groups	O
that	O
are	O
included	O
in	O
the	O
chip	O
are	O
not	O
mentioned	O
in	O
Table	O
2	O
.	O

Among	O
these	O
,	O
entries	O
related	O
to	O
Dickkopf	O
gene	O
family	O
,	O
galanin-	O
,	O
melatonin-	O
,	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
-	O
,	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
and	O
B	O
cell	O
leukemia	O
2	O
(	O
Bcl2	O
)	O
oncogene	O
-	O
related	O
are	O
present	O
.	O

Many	O
of	O
them	O
play	O
potentially	O
important	O
,	O
yet	O
undefined	O
,	O
roles	O
in	O
the	O
biology	O
of	O
stem	O
cells	O
.	O

Additionally	O
,	O
we	O
included	O
some	O
genes	O
implicated	O
in	O
disease	O
mechanisms	O
of	O
neurodegenerative	O
disorders	O
(	O
most	O
importantly	O
,	O
Parkinson	O
's	O
disease	O
and	O
Alzheimer	O
's	O
disease	O
)	O
in	O
the	O
chip	O
.	O

Furthermore	O
,	O
we	O
incorporated	O
a	O
number	O
of	O
markers	O
for	O
distinct	O
differentiation	O
pathways	O
(	O
e.g.	O
hematopoietic	O
and	O
pancreatic	O
)	O
and	O
cell	O
types	O
(	O
e.g.	O
cancer	O
subtypes	O
and	O
a	O
range	O
of	O
normal	O
cell	O
types	O
)	O
to	O
serve	O
as	O
essential	O
controls	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
that	O
in	O
its	O
present	O
form	O
NeuroStem	O
Chip	O
represents	O
currently	O
most	O
comprehensive	O
gene	O
expression	O
platform	O
for	O
studies	O
on	O
stem	O
cells	O
,	O
neural	O
/	O
neuronal	O
differentiation	O
,	O
human	O
neurodegeneration	O
and	O
neuronal	O
survival	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
complete	O
layout	O
of	O
NeuroStem	O
Chip	O
will	O
be	O
disclosed	O
to	O
the	O
academic	O
community	O
,	O
upon	O
request	O
.	O

The	O
microarray	O
format	O
we	O
selected	O
relies	O
on	O
long	O
oligonucleotide	O
molecules	O
(	O
69â71	O
nucleotides	O
)	O
printed	O
over	O
a	O
solid	O
surface	O
.	O

We	O
spotted	O
the	O
synthesized	O
oligonucleotides	O
(	O
Operon	O
Biotechnologies	O
)	O
with	O
a	O
constant	O
concentration	O
across	O
the	O
slides	O
,	O
and	O
evaluated	O
the	O
quality	O
and	O
consistency	O
of	O
spotting	O
in	O
a	O
series	O
of	O
control	O
experiments	O
.	O

We	O
then	O
illustrated	O
the	O
utility	O
and	O
technical	O
reliability	O
of	O
the	O
NeuroStem	O
Chip	O
by	O
characterizing	O
the	O
gene	O
expression	O
profile	O
of	O
commonly	O
utilized	O
hESC	O
line	O
SA02	B
(	O
Sahlgrenska	B
2	I
;	O
[	O
27	O
]	O
)	O
,	O
including	O
(	O
i	O
)	O
undifferentiated	O
cells	O
and	O
(	O
ii	O
)	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
.	O

For	O
the	O
first	O
of	O
these	O
,	O
we	O
used	O
total	O
RNA	O
sample	O
purified	O
from	O
hESC	O
colonies	O
that	O
exhibited	O
morphology	O
consistent	O
with	O
cell	O
proliferation	O
and	O
the	O
absence	O
of	O
spontaneous	O
differentiation	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
expression	O
of	O
the	O
cell	O
cycle	O
marker	O
Ki67	O
and	O
the	O
pluripotency	O
marker	O
OCT3	O
/	O
4	O
in	O
the	O
sample	O
by	O
immunocytochemistry	O
(	O
Figure	O
1B	O
â	O
E	O
)	O
.	O

Co	O
-	O
culturing	O
of	O
ESCs	O
with	O
murine	O
stromal	O
cells	O
(	O
including	O
PA6	B
cell	O
line	O
)	O
rapidly	O
generates	O
dopaminergic	O
neurons	O
from	O
ESCs	O
by	O
an	O
unexplained	O
mechanism	O
termed	O
stromal	O
cell	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

We	O
therefore	O
committed	O
hESCs	O
toward	O
the	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	B
cells	O
for	O
16	O
days	O
,	O
resulting	O
in	O
appearance	O
of	O
cells	O
positive	O
for	O
early	O
and	O
late	O
neuronal	O
markers	O
,	O
including	O
nestin	O
,	O
Î²	O
-	O
III	O
-	O
tubulin	O
,	O
and	O
TH	O
,	O
the	O
established	O
marker	O
of	O
dopaminergic	O
neurons	O
(	O
Figure	O
2	O
)	O
.	O

To	O
verify	O
the	O
expression	O
of	O
some	O
key	O
stem	O
cell-	O
and	O
neural	O
phenotype	O
-	O
associated	O
genes	O
we	O
performed	O
RT	O
-	O
PCR	O
comparing	O
RNA	O
samples	O
from	O
the	O
undifferentiated	O
hESCs	O
with	O
hESCs	O
of	O
the	O
same	O
line	O
differentiated	O
toward	O
neuronal	O
/	O
dopaminergic	O
pathway	O
,	O
as	O
described	O
above	O
.	O

The	O
expression	O
profile	O
outlined	O
by	O
RT	O
-	O
PCR	O
confirmed	O
the	O
identity	O
of	O
the	O
sample	O
used	O
(	O
Figure	O
3	O
)	O
.	O

After	O
performing	O
RNA	O
integrity	O
tests	O
,	O
we	O
incorporated	O
fluorescent	O
labels	O
to	O
the	O
amplified	O
RNA	O
samples	O
from	O
hESCs	O
(	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
and	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
)	O
)	O
,	O
hESC	O
-	O
derived	O
cells	O
containing	O
TH	O
-	O
positive	O
neurons	O
(	O
Cy3	O
and	O
Cy5	O
)	O
and	O
human	O
universal	O
reference	O
RNA	O
(	O
Cy5	O
)	O
,	O
and	O
hybridized	O
aliquots	O
with	O
NeuroStem	O
microarray	O
slides	O
using	O
the	O
following	O
conditions	O
:	O
hESC	O
vs.	O
reference	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
i	O
)	O
20:10	O
pmol	O
,	O
and	O
(	O
ii	O
)	O
10:5	O
pmol	O
;	O
and	O
hESC	O
vs.	O
hESC	O
-	O
derived	O
cells	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
iii	O
)	O
30:20	O
pmol	O
,	O
respectively	O
.	O

Universal	O
reference	O
RNA	O
has	O
been	O
previously	O
established	O
as	O
a	O
standard	O
reference	O
material	O
for	O
microarray	O
experiments	O
,	O
proving	O
an	O
ability	O
to	O
effectively	O
hybridize	O
to	O
a	O
large	O
fraction	O
of	O
microarray	O
spots	O
[	O
30	O
]	O
.	O

We	O
performed	O
two	O
-	O
color	O
hybridizations	O
(	O
e.g.	O
for	O
the	O
experiment	O
vs.	O
reference	O
)	O
following	O
an	O
established	O
protocol	O
[	O
31	O
]	O
,	O
and	O
included	O
dye	O
-	O
flip	O
technical	O
replicates	O
in	O
the	O
analysis	O
(	O
Figure	O
4	O
)	O
.	O

Using	O
the	O
online	O
software	O
program	O
BASE	O
[	O
32	O
]	O
we	O
sequentially	O
filtered	O
the	O
data	O
by	O
background	O
subtraction	O
,	O
negative	O
flagging	O
,	O
negative	O
intensities	O
and	O
for	O
inconsistent	O
data	O
amongst	O
replicates	O
[	O
33	O
]	O
.	O

Figure	O
5A	O
shows	O
a	O
comparison	O
of	O
the	O
spot	O
intensities	O
prior	O
to	O
normalization	O
(	O
M	O
versus	O
A	O
plot	O
)	O
,	O
with	O
the	O
Log2	O
of	O
the	O
expression	O
ratio	O
between	O
Cy3	O
/	O
Cy5	O
being	O
plotted	O
as	O
a	O
function	O
of	O
the	O
log10	O
of	O
the	O
mean	O
of	O
the	O
total	O
expression	O
intensities	O
for	O
Cy3	O
and	O
Cy5	O
channels	O
.	O

The	O
deviation	O
of	O
the	O
line	O
from	O
zero	O
revealed	O
a	O
need	O
for	O
normalization	O
,	O
so	O
prior	O
to	O
data	O
analyses	O
we	O
normalized	O
signals	O
using	O
a	O
locally	O
weighted	O
scatterplot	O
-	O
smoothing	O
regression	O
(	O
LOWESS	O
)	O
algorithm	O
(	O
Figure	O
5A	O
â	O
B	O
;	O
fitted	O
line	O
)	O
implemented	O
in	O
BASE	O
.	O

Since	O
the	O
reproducibility	O
of	O
two	O
-	O
color	O
microarray	O
gene	O
expression	O
data	O
is	O
critically	O
important	O
,	O
we	O
calculated	O
Pearson	O
correlation	O
coefficients	O
of	O
the	O
reporters	O
present	O
in	O
the	O
filtered	O
database	O
comparing	O
the	O
average	O
expression	O
ratios	O
(	O
7005	O
for	O
hESCs	O
vs.	O
universal	O
reference	O
;	O
6947	O
for	O
undifferentiated	O
vs.	O
neuronal	O
/	O
dopaminergic	O
lineage	O
-	O
committed	O
hESCs	O
)	O
.	O

Results	O
obtained	O
revealed	O
that	O
data	O
were	O
consistent	O
across	O
technical	O
replicates	O
(	O
dye	O
-	O
swap	O
and	O
amount	O
of	O
loaded	O
material	O
)	O
,	O
showing	O
general	O
high	O
reproducibility	O
:	O
e.g.	O
,	O
correlation	O
coefficients	O
were	O
greater	O
than	O
0.96	O
for	O
technical	O
replicates	O
and	O
0.78	O
for	O
dye	O
-	O
swapping	O
samples	O
in	O
hESCs	O
vs.	O
universal	O
reference	O
hybridizations	O
(	O
Table	O
3	O
)	O
.	O

To	O
detect	O
genes	O
with	O
high	O
expression	O
levels	O
in	O
hESC	O
samples	O
,	O
we	O
filtered	O
data	O
for	O
intensity	O
values	O
>	O
100	O
in	O
the	O
hESC	O
sample	O
and	O
performed	O
clustering	O
analysis	O
using	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

To	O
visualize	O
variations	O
of	O
spot	O
/	O
reporter	O
per	O
technical	O
replicate	O
,	O
hierarchical	O
clustering	O
was	O
performed	O
by	O
K	O
-	O
means	O
classifier	O
based	O
on	O
the	O
linear	O
-	O
correlation	O
-	O
based	O
distance	O
(	O
Pearson	O
,	O
centred	O
)	O
method	O
.	O

The	O
optimal	O
number	O
of	O
clusters	O
was	O
determined	O
empirically	O
to	O
produce	O
the	O
most	O
balanced	O
ratio	O
of	O
entries	O
to	O
cluster	O
of	O
highly	O
expressed	O
genes	O
.	O

A	O
cluster	O
of	O
101	O
genes	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
[	O
see	O
Additional	O
file	O
1	O
]	O
,	O
was	O
plotted	O
in	O
a	O
centroid	O
graph	O
(	O
Figure	O
5C	O
)	O
;	O
the	O
variation	O
across	O
technical	O
replicates	O
was	O
low	O
.	O

We	O
merged	O
technical	O
replicates	O
to	O
generate	O
a	O
list	O
of	O
the	O
most	O
up	O
-	O
regulated	O
genes	O
expressed	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
(	O
Table	O
4	O
)	O
.	O

Standard	O
error	O
of	O
the	O
mean	O
expressed	O
as	O
percentage	O
was	O
calculated	O
for	O
the	O
4	O
technical	O
replicates	O
,	O
and	O
was	O
6.7	O
%	O
for	O
the	O
top	O
25	O
genes	O
up	O
-	O
regulated	O
in	O
hESC	O
samples	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

We	O
performed	O
the	O
analysis	O
of	O
microarray	O
data	O
,	O
as	O
described	O
in	O
the	O
Methods	O
,	O
and	O
spot	O
error	O
values	O
were	O
generally	O
in	O
the	O
lower	O
range	O
,	O
indicating	O
high	O
stringency	O
of	O
the	O
signals	O
and	O
low	O
variance	O
.	O

As	O
seen	O
in	O
Table	O
4	O
and	O
Table	O
5	O
,	O
the	O
NeuroStem	O
Chip	O
identified	O
numerous	O
genes	O
associated	O
with	O
stem	O
cells	O
.	O

In	O
particular	O
,	O
homeo	O
box	O
expressed	O
in	O
ES	O
cells	O
1	O
(	O
Hesx1	O
)	O
gene	O
was	O
identified	O
as	O
the	O
most	O
up	O
-	O
regulated	O
in	O
the	O
ES	O
cell	O
preparation	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

Highly	O
expressed	O
in	O
pluripotent	O
ESCs	O
,	O
Hesx1	O
expression	O
is	O
down	O
-	O
regulated	O
upon	O
embryonic	O
stem	O
cell	O
differentiation	O
[	O
35,36	O
]	O
,	O
as	O
also	O
clearly	O
seen	O
in	O
differentiation	O
experiment	O
of	O
our	O
own	O
(	O
Table	O
4	O
)	O
.	O

Similarly	O
,	O
Gremlin	O
1	O
homolog	O
,	O
cysteine	O
knot	O
superfamily	O
gene	O
(	O
Grem1	O
,	O
also	O
known	O
as	O
Cktsf1b1	O
and	O
Dand2	O
)	O
is	O
a	O
recognized	O
factor	O
of	O
cell	O
-	O
fate	O
determination	O
of	O
ESCs	O
[	O
37	O
]	O
.	O

Many	O
more	O
genes	O
highly	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
in	O
comparison	O
with	O
universal	O
reference	O
RNA	O
are	O
associated	O
with	O
stem	O
cells	O
:	O
further	O
examples	O
include	O
Gap	O
junction	O
protein	O
Î±1	O
(	O
Gja1	O
)	O
and	O
Zic	O
family	O
member	O
3	O
heterotaxy	O
1	O
(	O
Zic3	O
)	O
(	O
Table	O
4	O
)	O
[	O
20	O
]	O
.	O

The	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
Fgfr2	O
)	O
is	O
of	O
particular	O
interest	O
.	O

Basic	O
fibroblast	O
growth	O
factor	O
(	O
FGF2	O
,	O
bFGF	O
)	O
supports	O
hESC	O
proliferation	O
and	O
their	O
ability	O
to	O
maintain	O
undifferentiated	O
phenotype	O
when	O
cultured	O
in	O
vitro	O
[	O
38,39	O
]	O
.	O

Moreover	O
,	O
in	O
some	O
hESC	O
lines	O
a	O
very	O
high	O
concentration	O
of	O
FGF2	O
could	O
substitute	O
for	O
the	O
need	O
of	O
feeder	O
cells	O
[	O
40	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
genes	O
listed	O
in	O
Table	O
4	O
represent	O
the	O
most	O
highly	O
up	O
-	O
regulated	O
entries	O
in	O
a	O
relatively	O
limited	O
group	O
of	O
genes	O
(	O
Figure	O
5C	O
)	O
.	O

Many	O
other	O
genes	O
involved	O
in	O
maintenance	O
of	O
ESC	O
phenotype	O
(	O
i.e.	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
)	O
have	O
lower	O
levels	O
of	O
expression	O
(	O
Table	O
5	O
)	O
.	O

Examples	O
include	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
,	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
,	O
developmental	O
pluripotency	O
associated	O
4	O
(	O
Dppa4	O
,	O
a	O
newly	O
established	O
pluripotency	O
marker	O
[	O
41	O
]	O
)	O
and	O
numerous	O
candidate	O
markers	O
of	O
""""	O
stemness	O
""""	O
:	O
e.g.	O
genes	O
for	O
KIAA1573	O
protein	O
,	O
forkhead	O
box	O
O1A	O
(	O
Foxo1a	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
1	O
(	O
Hmgb1	O
)	O
,	O
C	O
-	O
terminal	O
binding	O
protein	O
2	O
(	O
Ctbp2	O
)	O
and	O
left	O
-	O
right	O
determination	O
factor	O
1	O
(	O
Lefty1	O
)	O
,	O
as	O
well	O
as	O
others	O
.	O

For	O
numerous	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
the	O
expression	O
levels	O
were	O
not	O
considerably	O
higher	O
(	O
Log2	O
ratio	O
<	O
1	O
)	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
.	O

For	O
example	O
,	O
the	O
expression	O
of	O
Nanog	O
,	O
DNA	O
(	O
cytosine-5-	O
)	O
-methyltransferase	O
3Î±	O
(	O
Dnmt3a	O
)	O
,	O
MutS	O
homolog	O
2	O
,	O
colon	O
cancer	O
,	O
nonpolyposis	O
type	O
1	O
(	O
E.	O
coli	O
)	O
(	O
Msh2	O
)	O
,	O
Thy-1	O
cell	O
surface	O
antigen	O
(	O
Thy1	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
2	O
(	O
Hmgb2	O
)	O
,	O
transcription	O
factor	O
3	O
(	O
Tcf3	O
)	O
,	O
Nanos	O
homolog	O
1	O
(	O
Nanos1	O
)	O
,	O
MyoD	O
family	O
inhibitor	O
(	O
Mdfi	O
)	O
,	O
Calumenin	O
(	O
Calu	O
)	O
and	O
soluble	O
thymidine	O
kinase	O
1	O
(	O
Tk1	O
)	O
was	O
detected	O
in	O
hES	O
SA02	B
cells	O
with	O
Log2	O
ratio	O
value	O
<	O
1	O
.	O

Expression	O
levels	O
of	O
those	O
genes	O
range	O
from	O
being	O
inconsiderably	O
higher	O
to	O
nearly	O
equal	O
to	O
that	O
in	O
universal	O
reference	O
RNA	O
sample	O
.	O

We	O
believe	O
that	O
those	O
findings	O
could	O
be	O
explained	O
by	O
cellular	O
composition	O
of	O
human	O
universal	O
reference	O
RNA	O
sample	O
[	O
42	O
]	O
,	O
which	O
includes	O
pooled	O
RNA	O
samples	O
from	O
proliferating	O
cells	O
(	O
e.g.	O
,	O
skin	O
and	O
testis	O
cell	O
lines	O
)	O
.	O

Thus	O
,	O
the	O
relative	O
difference	O
between	O
gene	O
expression	O
of	O
certain	O
markers	O
of	O
stem	O
cells	O
in	O
undifferentiated	O
hESCs	O
and	O
universal	O
reference	O
RNA	O
is	O
naturally	O
decreased	O
.	O

Taken	O
together	O
,	O
the	O
gene	O
expression	O
signature	O
of	O
hES	O
SA02	B
cell	O
line	O
profiled	O
by	O
NeuroStem	O
Chip	O
is	O
indeed	O
characteristic	O
for	O
pluripotent	O
stem	O
cells	O
,	O
providing	O
proof	O
-	O
of	O
-	O
concept	O
.	O

Notably	O
,	O
comparison	O
of	O
expression	O
profiles	O
of	O
undifferentiated	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
committed	O
toward	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
SDIA	O
for	O
16	O
days	O
have	O
revealed	O
that	O
many	O
of	O
the	O
stem	O
cell	O
marker	O
genes	O
mentioned	O
above	O
were	O
down	O
-	O
regulated	O
in	O
differentiation	O
(	O
Table	O
5	O
)	O
.	O

Expectedly	O
,	O
Hesx1	O
,	O
Grem1	O
,	O
Dnmt3b	O
,	O
Utf1	O
and	O
Nanog	O
could	O
be	O
listed	O
among	O
these	O
.	O

At	O
the	O
same	O
time	O
,	O
numerous	O
other	O
genes	O
,	O
including	O
Pitx2	O
,	O
Dlk1	O
and	O
Msx1	O
were	O
up	O
-	O
regulated	O
in	O
the	O
latter	O
sample	O
(	O
[	O
see	O
Additional	O
file	O
2	O
]	O
,	O
Figure	O
3	O
)	O
.	O

Table	O
1	O
lists	O
24	O
dopaminergic	O
system	O
-	O
related	O
entries	O
(	O
e.g.	O
,	O
Ptx3	O
,	O
Th	O
,	O
Lhx1	O
)	O
with	O
gene	O
expression	O
up	O
-	O
regulated	O
by	O
Day	O
16	O
of	O
hESC	O
differentiation	O
protocol	O
;	O
few	O
more	O
genes	O
have	O
demonstrated	O
less	O
prominent	O
up	O
-	O
regulation	O
(	O
Log2	O
ratio	O
values	O
in	O
the	O
range	O
of	O
0.7	O
/	O
0.97â1.0	O
)	O
.	O

The	O
gene	O
expression	O
profiles	O
generated	O
are	O
therefore	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
utilizing	O
hSC	O
-	O
derived	O
samples	O
with	O
similar	O
characteristics	O
[	O
43,44	O
]	O
.	O

Diversity	O
of	O
NeuroStem	O
Chip	O
entries	O
responsive	O
to	O
hESC	O
commitment	O
toward	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
clearly	O
illustrates	O
the	O
complexity	O
of	O
that	O
pathway	O
.	O

The	O
cell	O
population	O
obtained	O
after	O
16	O
day	O
exposure	O
to	O
SDIA	O
is	O
highly	O
heterogeneous	O
.	O

Only	O
around	O
0.2	O
%	O
of	O
the	O
cells	O
are	O
TH	O
-	O
positive	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

This	O
heterogeneity	O
,	O
with	O
an	O
apparent	O
presence	O
of	O
residual	O
pluripotent	O
cells	O
explains	O
the	O
presence	O
of	O
stem	O
cell	O
marker	O
genes	O
,	O
including	O
homeobox	O
transcription	O
factor	O
Nanog	O
,	O
as	O
revealed	O
by	O
RT	O
-	O
PCR	O
data	O
(	O
Figure	O
3	O
)	O
.	O

It	O
would	O
be	O
therefore	O
impossible	O
to	O
apply	O
the	O
platform	O
to	O
identify	O
novel	O
genes	O
associated	O
with	O
the	O
process	O
of	O
differentiation	O
;	O
for	O
that	O
application	O
,	O
the	O
genome	O
-	O
scale	O
microarray	O
platforms	O
(	O
e.g.	O
,	O
Affymetrix	O
)	O
are	O
clearly	O
superior	O
.	O

Nevertheless	O
,	O
being	O
based	O
upon	O
a	O
moderate	O
assay	O
of	O
pre	O
-	O
selected	O
specific	O
gene	O
targets	O
,	O
the	O
comparative	O
analysis	O
of	O
microarray	O
data	O
derived	O
from	O
undifferentiated	O
and	O
dopaminergic	O
differentiate	O
pathway	O
-	O
committed	O
hESCs	O
provides	O
a	O
valuable	O
cross	O
-	O
cut	O
of	O
complex	O
relationship	O
between	O
factors	O
driving	O
or	O
indicative	O
to	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

RT	O
-	O
PCR	O
analyses	O
have	O
validated	O
the	O
overall	O
reliability	O
of	O
NeuroStem	O
microarray	O
platform	O
:	O
all	O
of	O
the	O
entries	O
detected	O
in	O
the	O
hybridization	O
experiments	O
have	O
demonstrated	O
similar	O
trends	O
when	O
analyzed	O
by	O
RT	O
-	O
PCR	O
means	O
(	O
Figure	O
3	O
)	O
.	O

Those	O
entries	O
include	O
Sox2	O
,	O
En1	O
and	O
Nanog	O
(	O
ratio	O
of	O
differentiated	O
/	O
undifferentiated	O
hESC	O
sample	O
normalized	O
spot	O
intensity	O
<	O
0.75	O
,	O
down	O
-	O
regulated	O
)	O
,	O
Gadph	O
,	O
Aldh1a1	O
,	O
Sdha	O
,	O
Tubb	O
and	O
Nestin	O
(	O
ratio	O
.1.0	O
,	O
unchanged	O
)	O
,	O
Actb	O
,	O
Th	O
,	O
Msx1	O
and	O
Pitx2	O
(	O
ratio	O
>	O
1.25	O
,	O
up	O
-	O
regulated	O
)	O
.	O

Some	O
of	O
the	O
housekeeping	O
genes	O
(	O
Gapdh	O
,	O
Sdha	O
,	O
Tubb	O
,	O
Actb	O
)	O
have	O
somewhat	O
different	O
expression	O
in	O
undifferentiated	O
vs.	O
differentiated	O
cells	O
,	O
consistent	O
with	O
previous	O
reports	O
on	O
certain	O
established	O
housekeeping	O
genes	O
(	O
including	O
Gapdh	O
)	O
being	O
variable	O
in	O
human	O
samples	O
[	O
45	O
]	O
.	O

Importantly	O
,	O
all	O
the	O
observed	O
gene	O
expression	O
trends	O
were	O
similar	O
in	O
both	O
microarray	O
and	O
RT	O
-	O
PCR	O
.	O

Our	O
experiment	O
therefore	O
confirms	O
that	O
the	O
NeuroStem	O
Chip	O
microarray	O
platform	O
can	O
still	O
identify	O
gene	O
expression	O
changes	O
related	O
to	O
early	O
stages	O
of	O
differentiation	O
of	O
hESC	O
into	O
dopaminergic	O
neurons	O
.	O

Recent	O
technological	O
advances	O
have	O
led	O
to	O
DNA	O
microarrays	O
which	O
contain	O
over	O
hundred	O
thousand	O
of	O
spots	O
of	O
DNA	O
material	O
,	O
reaching	O
a	O
truly	O
genomic	O
scale	O
.	O

Highly	O
specialized	O
DNA	O
microarrays	O
of	O
smaller	O
scale	O
(	O
e.g.	O
the	O
NeuroStem	O
Chip	O
)	O
still	O
have	O
an	O
important	O
role	O
in	O
the	O
directed	O
studies	O
in	O
particular	O
fields	O
.	O

Since	O
they	O
are	O
significantly	O
less	O
expensive	O
,	O
compared	O
to	O
many	O
recognized	O
large	O
-	O
scale	O
platforms	O
(	O
e.g.	O
Affymetrix	O
Human	O
Genome	O
platforms	O
)	O
,	O
they	O
have	O
a	O
clear	O
advantage	O
in	O
routine	O
work	O
involving	O
samples	O
from	O
,	O
e.g.	O
,	O
multiple	O
cell	O
culture	O
conditions	O
.	O

While	O
there	O
is	O
a	O
risk	O
that	O
one	O
will	O
miss	O
out	O
on	O
changes	O
in	O
genes	O
previously	O
not	O
believed	O
to	O
be	O
relevant	O
to	O
neural	O
differentiation	O
,	O
the	O
restricted	O
number	O
of	O
genes	O
in	O
the	O
NeuroStem	O
Chip	O
also	O
simplifies	O
analysis	O
and	O
adds	O
power	O
.	O

NeuroStem	O
Chip	O
is	O
comparable	O
to	O
other	O
stem	O
cell	O
-	O
related	O
focused	O
microarray	O
platforms	O
in	O
regards	O
to	O
manufacturing	O
costs	O
and	O
technical	O
simplicity	O
of	O
the	O
recommended	O
hybridization	O
protocols	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
currently	O
implies	O
an	O
advantage	O
in	O
both	O
the	O
scale	O
and	O
the	O
spectrum	O
of	O
pre	O
-	O
selected	O
,	O
specific	O
gene	O
targets	O
assayed	O
.	O

Some	O
suggested	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
human	O
stem	O
cell	O
(	O
hSC	O
)	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

In	O
addition	O
,	O
the	O
NeuroStem	O
Chip	O
can	O
be	O
used	O
to	O
characterize	O
gene	O
changes	O
in	O
intracerebral	O
grafts	O
of	O
human	O
cells	O
,	O
even	O
when	O
they	O
are	O
transplanted	O
into	O
experimental	O
animals	O
.	O

We	O
specifically	O
wish	O
to	O
stress	O
that	O
we	O
are	O
about	O
to	O
make	O
the	O
NeuroStem	O
Chip	O
available	O
at	O
a	O
non	O
-	O
profit	O
cost	O
to	O
the	O
research	O
community	O
.	O

We	O
believe	O
it	O
has	O
the	O
potential	O
to	O
become	O
an	O
important	O
screening	O
tool	O
in	O
the	O
expanding	O
field	O
of	O
hSC	O
studies	O
in	O
application	O
to	O
neurological	O
/	O
neurodegenerative	O
disorders	O
.	O

Human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
culturesUndifferentiated	O
hESCs	O
of	O
SA02	B
(	O
Sahlgrenska	B
2	I
)	O
line	O
(	O
Cellartis	O
AB	O
,	O
GÃ¶teborg	O
,	O
Sweden	O
;	O
see	O
NIH	O
Human	O
Embryonic	O
Stem	O
Cell	O
Registry	O
at	O
[	O
46	O
]	O
)	O
were	O
maintained	O
over	O
a	O
monolayer	O
of	O
human	O
""""	O
feeder	O
cells	O
""""	O
(	O
hFCs	O
;	O
human	O
foreskin	O
fibroblasts	O
,	O
ATCC	O
;	O
cell	O
line	O
CCD-1112Sk	B
)	O
.	O

Feeder	O
cells	O
were	O
grown	O
in	O
hFC	O
medium	O
(	O
Iscove	O
's	O
modified	O
Dulbecco	O
's	O
medium	O
(	O
IMDM	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
USA	O
)	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
)	O
for	O
11	O
passages	O
.	O

One	O
day	O
prior	O
to	O
hESC	O
plating	O
,	O
hFC	O
medium	O
was	O
washed	O
away	O
from	O
the	O
hFCs	O
,	O
the	O
latter	O
were	O
resuspended	O
in	O
a	O
hESC	O
proliferation	O
medium	O
(	O
VitroHES	O
media	O
(	O
Vitrolife	O
AB	O
,	O
Sweden	O
)	O
supplemented	O
with	O
4	O
ng	O
/	O
ml	O
human	O
recombinant	O
basic	O
FGF	O
(	O
hrbFGF	O
,	O
Biosource	O
International	O
,	O
USA	O
)	O
and	O
plated	O
in	O
a	O
central	O
ring	O
of	O
gelatinized	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
dishes	O
with	O
a	O
cell	O
density	O
of	O
120,000	O
cells	O
/	O
dish	O
.	O

The	O
outer	O
rings	O
of	O
the	O
IVF	O
dishes	O
were	O
filled	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
.	O

One	O
half	O
of	O
the	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
Â°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

Every	O
6	O
days	O
,	O
fragments	O
of	O
the	O
hESC	O
colonies	O
(	O
around	O
10â14	O
colonies	O
per	O
dish	O
,	O
measuring	O
around	O
0.015	O
Ã	O
0.015	O
mm	O
)	O
that	O
had	O
an	O
unaltered	O
morphology	O
(	O
indicating	O
lack	O
of	O
spontaneous	O
differentiation	O
)	O
were	O
mechanically	O
cut	O
from	O
dishes	O
using	O
stem	O
cell	O
knives	O
/	O
transfer	O
pipettes	O
(	O
SweMed	O
Lab	O
International	O
AB	O
,	O
Sweden	O
)	O
and	O
then	O
plated	O
on	O
fresh	O
hFCs	O
.	O

Commitment	O
of	O
hESCs	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathwayCo	O
-	O
culturing	O
with	O
the	O
PA6	B
stromal	O
cell	O
line	O
(	O
MC3T3-G2	O
/	O
Pa6	O
,	O
from	O
RIKEN	O
Cell	O
Bank	O
Japan	O
(	O
RCB	O
1127	O
)	O
,	O
derived	O
from	O
newborn	O
mouse	O
calvaria	O
rapidly	O
generates	O
high	O
numbers	O
of	O
DA	O
neurons	O
from	O
mouse	O
and	O
monkey	O
ESCs	O
by	O
an	O
unknown	O
mechanism	O
named	O
stromal	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

For	O
differentiation	O
experiments	O
,	O
PA6	B
cells	O
were	O
plated	O
on	O
gelatine	O
-	O
coated	O
T25	O
flasks	O
at	O
16	O
Ã	O
103	O
cells	O
/	O
cm2	O
(	O
400,000	O
cells	O
/	O
flask	O
)	O
density	O
2	O
days	O
prior	O
to	O
introducing	O
hESCs	O
into	O
the	O
co	O
-	O
culture	O
and	O
cultured	O
at	O
PA6	B
culturing	O
media	O
(	O
containing	O
minimum	O
essential	O
medium	O
alpha	O
(	O
Î±	O
-	O
MEM	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
)	O
.	O

Alternatively	O
,	O
PA6	B
cells	O
were	O
plated	O
over	O
Type	O
I	O
collagen	O
-	O
coated	O
glass	O
cover	O
-	O
slips	O
placed	O
in	O
wells	O
of	O
4-well	O
-	O
plates	O
(	O
50,000	O
cells	O
/	O
well	O
,	O
for	O
immunocytochemical	O
(	O
ICC	O
)	O
analysis	O
)	O
.	O

Three	O
hours	O
prior	O
to	O
initiation	O
of	O
co	O
-	O
culture	O
,	O
PA6	B
cells	O
were	O
rinsed	O
3	O
times	O
with	O
PBS	O
and	O
media	O
was	O
replaced	O
with	O
co	O
-	O
culture	O
media	O
(	O
Glasgow	O
's	O
modified	O
Eagle	O
's	O
media	O
(	O
G	O
-	O
MEM	O
)	O
supplemented	O
with	O
8	O
%	O
knock	O
-	O
out	O
serum	O
replacement	O
(	O
KSR	O
)	O
,	O
2	O
mM	O
glutamine	O
,	O
0.1	O
mM	O
non	O
-	O
essential	O
amino	O
-	O
acids	O
(	O
NEAA	O
)	O
,	O
1	O
mM	O
pyruvate	O
,	O
0.1	O
mM	O
Î²	O
-	O
mercaptoethanol	O
(	O
Î²ME	O
)	O
and	O
4	O
ng	O
/	O
Î¼l	O
bFGF	O
)	O
.	O

Fragments	O
of	O
hESC	O
colonies	O
(	O
80â90	O
per	O
flask	O
;	O
4â5	O
per	O
well	O
of	O
4-well	O
-	O
plate	O
)	O
presenting	O
undifferentiated	O
morphology	O
were	O
manually	O
passaged	O
onto	O
the	O
confluent	O
PA6	B
monolayer	O
and	O
cell	O
co	O
-	O
cultures	O
were	O
maintained	O
at	O
37	O
Â°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

One	O
half	O
of	O
the	O
co	O
-	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
for	O
first	O
10	O
days	O
,	O
and	O
daily	O
onwards	O
.	O

Characterization	O
of	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
by	O
immunocytochemistry	O
(	O
ICC	O
)	O
and	O
RT	O
-	O
PCRIVF	O
dishes	O
with	O
hESCs	O
grown	O
atop	O
hFCs	O
and	O
4-well	O
plate	O
dishes	O
with	O
hESCs	O
growing	O
atop	O
PA6	B
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
15	O
minutes	O
at	O
the	O
day	O
of	O
passage	O
/	O
harvest	O
(	O
Day	O
6	O
of	O
hESC	O
/	O
hFC	O
co	O
-	O
culturing	O
)	O
and	O
Day	O
16	O
of	O
co	O
-	O
culturing	O
with	O
PA6	B
cells	O
,	O
respectively	O
.	O

Cells	O
were	O
pre	O
-	O
incubated	O
with	O
blocking	O
solution	O
containing	O
PBS	O
,	O
0.5	O
%	O
Triton	O
X-100	O
and	O
5	O
%	O
of	O
donkey	O
serum	O
.	O

They	O
were	O
then	O
incubated	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
three	O
washes	O
with	O
PBS	O
,	O
cells	O
were	O
incubated	O
with	O
the	O
donkey	O
anti	O
-	O
rabbit	O
IgG	O
conjugated	O
with	O
FITC	O
or	O
anti	O
-	O
mouse	O
Cy3	O
(	O
1:200	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
.	O

Cells	O
were	O
then	O
washed	O
once	O
with	O
PBS	O
,	O
incubated	O
with	O
1:1000	O
DAPI	O
in	O
PBS	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
another	O
wash	O
with	O
PBS	O
.	O

Coverslips	O
were	O
mounted	O
onto	O
glass	O
slides	O
with	O
PVA	O
mounting	O
medium	O
containing	O
anti	O
-	O
fading	O
reagent	O
DABCO	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
mouse	O
anti	O
-	O
Oct3	O
/	O
4	O
(	O
1:500	O
,	O
Santa	O
Cruz	O
Biotechnology	O
Inc.	O
)	O
;	O
rabbit	O
anti	O
-	O
Ki67	O
(	O
1:200	O
,	O
Novocastra	O
Ltd.	O
)	O
;	O
rabbit	O
anti	O
-	O
TH	O
(	O
1:500	O
,	O
Chemicon	O
)	O
.	O

Immunostained	O
cell	O
cultures	O
were	O
visualized	O
using	O
a	O
Zeiss	O
fluorescent	O
microscope	O
attached	O
to	O
a	O
Nikon	O
digital	O
camera	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
all	O
RNA	O
samples	O
used	O
in	O
this	O
study	O
were	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
gDNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
intron	O
-	O
spanning	O
primers	O
for	O
RT	O
-	O
PCR	O
were	O
selected	O
from	O
published	O
works	O
or	O
designed	O
using	O
Oligo	O
4.0	O
software	O
(	O
Molecular	O
Biology	O
Insight	O
)	O
or	O
Clone	O
Manager	O
Suite	O
7.1	O
(	O
Sci	O
Ed	O
Software	O
,	O
NC	O
,	O
USA	O
)	O
and	O
ordered	O
from	O
TAG	O
Copenhagen	O
A	O
/	O
S	O
,	O
Denmark	O
,	O
as	O
the	O
following	O
:	O
Sox2	O
,	O
SRY	O
-	O
box	O
2	O
:	O
5'-TAC	O
CTC	O
TTC	O
CTC	O
CC	O
CTC	O
CA-3	O
'	O
,	O
5'-ACT	O
CTC	O
CTC	O
TTT	O
TGC	O
ACC	O
CC-3	O
'	O
;	O
En1	O
,	O
Engrailed	O
1	O
:	O
5'-AAG	O
GGA	O
CGA	O
AAC	O
TGC	O
GAA	O
CTC	O
C-3	O
'	O
,	O
5'-GAC	O
ACG	O
AAA	O
GGA	O
AAC	O
ACA	O
CAC	O
TCT	O
CG-3	O
'	O
[	O
47	O
]	O
;	O
Nanog	O
:	O
5'-TGC	O
TTA	O
TTC	O
AGG	O
ACA	O
GCC	O
T-3	O
'	O
,	O
5'-TCT	O
GGT	O
CTT	O
CTG	O
TTT	O
CTT	O
GAC	O
T-3	O
'	O
[	O
48	O
]	O
;	O
Gapdh	O
,	O
glyceraldehydes-3-phosphate	O
dehydrogenase	O
:	O
5'-GGA	O
AGG	O
TGA	O
AGG	O
TCG	O
GAG	O
TCA	O
A-3	O
'	O
,	O
5'-GAT	O
CTC	O
GCT	O
CCT	O
GGA	O
AGA	O
TGG	O
T-3	O
'	O
;	O
Aldh1A1	O
,	O
aldehyde	O
dehydrogenase	O
1	O
family	O
,	O
member	O
A1	O
:	O
5'-GGG	O
CAG	O
CCA	O
TTT	O
CTT	O
CTC	O
AC-3	O
'	O
,	O
5'-CTT	O
CTT	O
AGC	O
CCG	O
CTC	O
AAC	O
AC-3	O
'	O
[	O
49	O
]	O
;	O
Sdha	O
,	O
succinate	O
dehydrogenase	O
:	O
5'-TGG	O
GAA	O
CAA	O
GAG	O
GGC	O
ATC	O
TG-3	O
'	O
,	O
5'-CCA	O
CCA	O
CTG	O
CAT	O
CAA	O
ATT	O
CAT	O
G-3	O
'	O
[	O
50	O
]	O
;	O
Tubb	O
,	O
Î²	O
-	O
tubulin	O
:	O
5'-CTC	O
ACA	O
AGT	O
ACG	O
TGC	O
CTC	O
GAG-3	O
'	O
,	O
5'-GCA	O
CGA	O
CGC	O
TGA	O
AGG	O
TGT	O
TCA-3	O
'	O
;	O
Nestin	O
:	O
5'-AGA	O
GGG	O
GAA	O
TTC	O
CTG	O
CT	O
GAG-3	O
'	O
,	O
5'-CTG	O
AGG	O
ACC	O
AGG	O
ACT	O
CTC	O
TA-3	O
'	O
[	O
47	O
]	O
;	O
Actb	O
,	O
Î²	O
-	O
actin	O
:	O
5'-CAT	O
CGA	O
GCA	O
CGG	O
CAT	O
CGT	O
CA-3	O
'	O
,	O
5'-TAG	O
CAC	O
AGC	O
CTG	O
GAT	O
AGC	O
AAC-3	O
'	O
[	O
51	O
]	O
;	O
Th	O
,	O
Tyrosine	O
hydroxylase	O
:	O
5'-CGA	O
GCT	O
GTG	O
AAG	O
GTG	O
TTT	O
G-3	O
'	O
,	O
5'-TTG	O
GTG	O
ACC	O
AGG	O
TGA	O
TGA	O
C-3	O
'	O
;	O
Msx1	O
,	O
homolog	O
of	O
Drosophila	O
muscle	O
segment	O
homolog	O
1	O
:	O
5'-CTC	O
AAG	O
CTG	O
CCA	O
GAA	O
GAT	O
GC-3	O
'	O
,	O
5'-TCC	O
AGC	O
TCT	O
GCC	O
TCT	O
TGT	O
AG-3	O
'	O
;	O
Pitx2	O
,	O
paired	O
-	O
like	O
homeodomain	O
transcription	O
factor	O
2	O
:	O
5'-ACC	O
TTA	O
CGG	O
AAG	O
CCC	O
GAG	O
TC-3	O
'	O
,	O
5'-TGG	O
ATA	O
GGG	O
AGG	O
CGG	O
ATG	O
TA-3	O
'	O
[	O
49	O
]	O
.	O

cDNA	O
was	O
synthesized	O
from	O
1	O
mg	O
of	O
total	O
RNA	O
using	O
SuperScript	O
II	O
(	O
Invitrogen	O
)	O
,	O
and	O
RT	O
-	O
PCR	O
amplifications	O
were	O
performed	O
using	O
the	O
MiniOpticon	O
system	O
(	O
Bio	O
-	O
Rad	O
)	O
with	O
REDTaq	O
Polymerase	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
essentially	O
as	O
described	O
by	O
the	O
manufacturer	O
.	O

Following	O
initial	O
denaturation	O
for	O
5	O
min	O
at	O
95	O
Â°	O
C	O
,	O
DNA	O
amplifications	O
were	O
performed	O
for	O
35	O
(	O
En1	O
,	O
Nanog	O
,	O
Aldh1a1	O
)	O
,	O
33	O
(	O
Sox2	O
,	O
Nestin	O
,	O
Th	O
,	O
Msx1	O
)	O
,	O
32	O
(	O
Tubb	O
,	O
Pitx2	O
)	O
,	O
27	O
(	O
Sdha	O
)	O
,	O
25	O
(	O
Actb	O
)	O
or	O
22	O
(	O
Gapdh	O
)	O
cycles	O
of	O
1	O
min	O
at	O
95	O
Â°	O
C	O
,	O
1	O
min	O
at	O
55	O
Â°	O
C	O
(	O
En1	O
,	O
Pitx2	O
)	O
,	O
57	O
Â°	O
C	O
(	O
Sox2	O
,	O
Nanog	O
,	O
Sdha	O
,	O
Nestin	O
)	O
,	O
58	O
Â°	O
C	O
(	O
Tubb	O
)	O
,	O
58.5	O
Â°	O
C	O
(	O
Aldh1a1	O
,	O
Th	O
)	O
or	O
59	O
Â°	O
C	O
(	O
Gapdh	O
,	O
Actb	O
,	O
Msx1	O
)	O
,	O
and	O
1	O
min	O
at	O
72	O
Â°	O
C	O
.	O

The	O
final	O
extension	O
was	O
5	O
min	O
at	O
72	O
Â°	O
C	O
.	O

Twenty	O
Î¼l	O
volumes	O
of	O
RT	O
-	O
PCR	O
products	O
were	O
analyzed	O
by	O
electrophoresis	O
at	O
1	O
%	O
agarose	O
gels	O
and	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

RNA	O
purification	O
and	O
fluorescent	O
dye	O
incorporationFor	O
RNA	O
purification	O
of	O
undifferentiated	O
hESCs	O
,	O
the	O
latter	O
were	O
mechanically	O
separated	O
from	O
hFCs	O
,	O
collected	O
in	O
a	O
500	O
Î¼l	O
volume	O
of	O
VitroHES	O
media	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
at	O
300	O
rcf	O
for	O
5	O
min	O
.	O

hESC	O
-	O
derived	O
cells	O
grown	O
atop	O
PA6	B
cells	O
were	O
harvested	O
using	O
a	O
papain	O
dissociation	O
kit	O
(	O
Worthington	O
Biochemical	O
Corporation	O
)	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
as	O
described	O
above	O
.	O

The	O
resulting	O
cell	O
pellets	O
were	O
resuspended	O
in	O
RLT	O
buffer	O
(	O
Qiagen	O
,	O
USA	O
)	O
,	O
passed	O
through	O
the	O
shredder	O
column	O
(	O
Qiagen	O
)	O
and	O
stored	O
at	O
-80	O
Â°	O
C	O
until	O
the	O
RNA	O
sample	O
was	O
purified	O
following	O
the	O
RNeasy	O
Micro	O
Kit	O
(	O
Qiagen	O
)	O
protocol	O
(	O
without	O
carrier	O
RNA	O
)	O
;	O
with	O
DNase	O
I	O
(	O
Quiagen	O
)	O
treatment	O
incorporated	O
to	O
the	O
latter	O
.	O

RNA	O
integrity	O
was	O
tested	O
using	O
both	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
,	O
USA	O
)	O
and	O
RNA	O
Nano	O
LabChip	O
/	O
2100	O
Bioanalyzer	O
system	O
(	O
Agilent	O
Technologies	O
,	O
USA	O
)	O
.Fluorescent	O
label	O
(	O
24	O
nmol	O
of	O
the	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
;	O
PerkinElmer	O
,	O
USA	O
)	O
was	O
incorporated	O
to	O
350â500	O
ng	O
of	O
total	O
RNA	O
amplified	O
using	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
,	O
generally	O
following	O
the	O
kit	O
manufacturer	O
's	O
protocol	O
.	O

Similarly	O
,	O
24	O
nmols	O
of	O
the	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
;	O
PerkinElmer	O
)	O
fluorescent	O
label	O
were	O
incorporated	O
to	O
400	O
ng	O
sample	O
of	O
Human	O
Universal	O
Reference	O
RNA	O
(	O
Stratagene	O
,	O
USA	O
)	O
;	O
in	O
addition	O
,	O
dye	O
-	O
swap	O
replicate	O
amplification	O
were	O
performed	O
.	O

Amplified	O
fluorescent	O
cRNA	O
samples	O
were	O
purified	O
using	O
RNeasy	O
mini	O
-	O
columns	O
(	O
Quiagen	O
)	O
,	O
and	O
fluorescence	O
of	O
the	O
eluted	O
products	O
was	O
measured	O
using	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
)	O
.	O

Microarray	O
technologyLong	O
oligonucleotide	O
probes	O
(	O
69â71	O
nucleotides	O
)	O
matching	O
gene	O
targets	O
of	O
interest	O
were	O
selected	O
from	O
Operon	O
V2	O
and	O
V3	O
human	O
AROS	O
sets	O
(	O
Operon	O
Biotechnologies	O
Inc.	O
,	O
USA	O
)	O
.	O

Arrays	O
were	O
produced	O
by	O
the	O
SweGene	O
DNA	O
Microarray	O
Resource	O
Centre	O
,	O
Department	O
of	O
Oncology	O
at	O
Lund	O
University	O
(	O
Sweden	O
)	O
using	O
a	O
MicroGrid	O
II	O
600R	O
arrayer	O
fitted	O
with	O
MicroSpot	O
10	O
K	O
pins	O
(	O
Harvard	O
BioRobotics	O
,	O
USA	O
)	O
.	O

Printing	O
was	O
performed	O
in	O
a	O
temperature-	O
(	O
18â20	O
Â°	O
C	O
)	O
and	O
humidity-	O
(	O
44â49	O
%	O
RH	O
)	O
controlled	O
area	O
on	O
Corning	O
UltraGAPS	O
aminosilane	O
slides	O
(	O
Corning	O
Inc.	O
,	O
USA	O
)	O
with	O
140	O
Î¼m	O
spot	O
-	O
to	O
-	O
spot	O
centerdistance	O
and	O
90â110	O
Î¼m	O
average	O
spot	O
size	O
.	O

Following	O
printing	O
,	O
arrays	O
were	O
dried	O
for	O
48	O
hours	O
andstored	O
in	O
a	O
dessicator	O
until	O
used	O
.	O

Microarray	O
slides	O
were	O
UV	O
-	O
cross	O
-	O
linked	O
(	O
800	O
mJ	O
/	O
cm2	O
)	O
,	O
pre	O
-	O
hybridizedwith	O
fluorescently	O
labeled	O
samples	O
using	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
(	O
Corning	O
)	O
and	O
subsequently	O
hybridized	O
with	O
test	O
(	O
Cy3-labeled	O
)	O
/	O
reference	O
(	O
Cy5-labeled	O
)	O
RNA	O
samples	O
(	O
or	O
in	O
reverse	O
dye	O
-	O
labeling	O
order	O
)	O
at	O
42	O
Â°	O
C	O
for	O
17	O
h	O
using	O
a	O
MAUI	O
hybridization	O
station	O
(	O
BioMicro	O
Systems	O
Inc.	O
,	O
USA	O
)	O
and	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
,	O
generally	O
following	O
manufacturer	O
's	O
instructions	O
,	O
with	O
several	O
minor	O
adaptations	O
[	O
31	O
]	O
.	O

Data	O
acquisition	O
and	O
statistical	O
analysisImmediately	O
following	O
the	O
washing	O
steps	O
,	O
the	O
fluorescence	O
intensities	O
were	O
measured	O
using	O
a	O
confocal	O
laser	O
scanner	O
(	O
G2505B	O
,	O
Agilent	O
Technologies	O
)	O
.	O

After	O
image	O
formatting	O
by	O
Tiff	O
Image	O
Channel	O
Splitter	O
Utility	O
(	O
Agilent	O
Technologies	O
)	O
and	O
grid	O
annotation	O
,	O
a	O
complete	O
set	O
of	O
spots	O
was	O
visually	O
inspected	O
for	O
each	O
slide	O
.	O

Using	O
GenePix	O
Pro	O
(	O
Molecular	O
Devices	O
Corp.	O
USA	O
)	O
flags	O
for	O
artifactual	O
spots	O
were	O
annotated	O
for	O
each	O
spot	O
.	O

Median	O
pixel	O
intensity	O
minus	O
the	O
median	O
local	O
background	O
for	O
both	O
dyes	O
was	O
used	O
to	O
obtain	O
a	O
test	O
over	O
reference	O
intensity	O
ratio	O
.	O

Data	O
normalization	O
was	O
performed	O
per	O
array	O
subgrid	O
using	O
LOWESS	O
curve	O
fitting	O
with	O
a	O
smoothing	O
factor	O
of	O
0.33	O
[	O
52,53	O
]	O
.	O

All	O
normalizations	O
,	O
filtering	O
,	O
merging	O
of	O
technical	O
replicates	O
and	O
analyses	O
were	O
performed	O
in	O
the	O
BioArray	O
Software	O
Environment	O
database	O
[	O
32	O
]	O
.	O

To	O
visualize	O
sample	O
-	O
dependent	O
variation	O
of	O
spot	O
intensities	O
,	O
data	O
was	O
uploaded	O
to	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

In	O
a	O
new	O
orthotopic	O
murine	O
model	O
of	O
MPM	O
,	O
we	O
found	O
that	O
the	O
kinetics	O
of	O
REN	B
cell	O
tumorigenesis	O
is	O
accelerated	O
versus	O
MS	B
-	I
1	I
or	O
M9	B
K	I
cells	O
,	O
and	O
that	O
REN	B
instillates	O
generated	O
larger	O
tumors	O
expressing	O
increased	O
uPAR	O
,	O
were	O
more	O
invasive	O
,	O
and	O
caused	O
earlier	O
mortality	O
.	O

Because	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
and	O
its	O
reversed	O
process	O
mesenchymal	O
-	O
to	O
-	O
epithelial	O
transition	O
(	O
MET	O
)	O
are	O
also	O
involved	O
in	O
cancer	O
progression	O
,	O
we	O
investigated	O
whether	O
BMP7	O
plays	O
a	O
role	O
in	O
WM	B
-	I
266	I
-	I
4	I
melanoma	O
cell	O
growth	O
and	O
metastasis	O
.	O

Kufs	O
'	O
disease	O
or	O
NCL4	O
(	O
neuronal	O
ceroid	O
lipofuscinosis	O
type	O
4	O
)	O
is	O
a	O
rare	O
and	O
poorly	O
characterized	O
,	O
adult	O
-	O
onset	O
form	O
of	O
NCL	O
.	O

However	O
,	O
overexpression	O
of	O
the	O
SAMD9	O
gene	O
failed	O
to	O
induce	O
significant	O
cell	O
death	O
in	O
U251MG	B
cells	O
.	O

Several	O
compounds	O
possessing	O
substituted	O
indazole	O
residues	O
,	O
such	O
as	O
4e	O
,	O
4p	O
,	O
and	O
4r	O
,	O
potently	O
inhibited	O
cell	O
proliferation	O
at	O
submicromolar	O
concentrations	O
in	O
the	O
A375	B
and	O
WM266	B
cell	O
lines	O
,	O
and	O
the	O
latter	O
two	O
compounds	O
also	O
exhibited	O
good	O
therapeutic	O
indices	O
in	O
cells	O
.	O

On	O
PC	O
82	O
days	O
,	O
tumor	O
incidences	O
and	O
mortalities	O
of	O
group	O
A	O
,	O
B	O
and	O
C	O
were	O
72	O
%	O
,	O
34	O
.	O
8	O
%	O
and	O
50	O
%	O
,	O
84	O
%	O
,	O
21	O
.	O
7	O
%	O
and	O
20	O
%	O
,	O
respectively	O
.	O

Quantitative	O
[	O
11C	O
]	O
14	O
-	O
PET	O
studies	O
showed	O
that	O
the	O
tumor	O
uptake	O
of	O
[	O
11C	O
]	O
14	O
in	O
the	O
NCI	B
-	I
H1975	I
xenografts	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
NCI	B
-	I
H520	I
xenografts	O
,	O
which	O
is	O
consistent	O
with	O
their	O
corresponding	O
immunohistochemical	O
tissue	O
staining	O
patterns	O
of	O
MET	O
receptors	O
from	O
the	O
same	O
animals	O
.	O

Using	O
oligonucleotide	O
microarrays	O
,	O
we	O
found	O
104	O
up	O
-	O
regulated	O
genes	O
in	O
the	O
metastatic	O
cell	O
line	O
CMT	B
-	I
W1	I
M	I
and	O
21	O
up	O
-	O
regulated	O
genes	O
in	O
the	O
primary	O
CMT	B
-	I
W1	I
cell	O
line	O
.	O

In	O
this	O
study	O
,	O
physiological	O
hypoxia	O
was	O
shown	O
to	O
attenuate	O
G2	O
/	O
M	O
arrest	O
and	O
apoptosis	O
induced	O
in	O
CHP126	B
cells	O
by	O
VP	O
-	O
16	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
IgA	O
binding	O
to	O
CHO	B
cells	O
transfected	O
with	O
mutated	O
FcalphaR	O
showed	O
that	O
deglycosylation	O
of	O
FcalphaR	O
at	O
individual	O
N44	O
,	O
N120	O
,	O
N156	O
,	O
N165	O
or	O
N177	O
site	O
did	O
not	O
affect	O
IgA	O
binding	O
but	O
deglycosylation	O
at	O
N58	O
resulted	O
in	O
marked	O
increase	O
of	O
IgA	O
binding	O
.	O

The	O
oxygen	O
enhancement	O
ratio	O
for	O
HCT8	B
and	O
HT29	B
receiving	O
fractionated	O
doses	O
was	O
1	O
.	O
2	O
and	O
2	O
.	O
0	O
,	O
respectively	O
,	O
and	O
virus	O
infection	O
altered	O
them	O
slightly	O
.	O

While	O
,	O
when	O
BALBc	O
(	O
nu	O
/	O
nu	O
)	O
mice	O
with	O
OV90	B
tumor	O
xenograft	O
in	O
the	O
flanks	O
were	O
injected	O
with	O
NRF2	O
shRNA	O
containing	O
viral	O
particles	O
and	O
treated	O
with	O
doxorubicin	O
a	O
pattern	O
of	O
retardation	O
in	O
tumor	O
growth	O
was	O
seen	O
in	O
shRNA	O
group	O
compared	O
to	O
scRNA	O
group	O
,	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
Karyotypically	O
abnormal	O
chHES	B
-	I
3	I
cells	O
had	O
a	O
more	O
developed	O
capacity	O
for	O
proliferation	O
,	O
resistance	O
to	O
apoptosis	O
and	O
less	O
genetic	O
stability	O
compared	O
to	O
normal	O
chHES	B
-	I
3	I
cells	O
and	O
may	O
be	O
an	O
excellent	O
model	O
for	O
studying	O
and	O
characterizing	O
initial	O
stages	O
that	O
determine	O
transition	O
of	O
embryonic	O
stem	O
cells	O
into	O
cancer	O
stem	O
cells	O
.	O

We	O
have	O
used	O
KYSE	B
-	I
510	I
cells	O
from	O
a	O
human	O
oesophageal	O
carcinoma	O
as	O
an	O
in	O
vitro	O
model	O
to	O
investigate	O
whether	O
cisplatin	O
(	O
CDDP	O
)	O
could	O
be	O
combined	O
with	O
PDT	O
to	O
increase	O
cell	O
death	O
with	O
respect	O
to	O
single	O
treatments	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
used	O
real	O
-	O
time	O
dynamic	O
monitoring	O
of	O
cell	O
impedance	O
to	O
demonstrate	O
that	O
anti	O
-	O
VGCC	O
Abs	O
from	O
patients	O
with	O
T1D	O
inhibit	O
the	O
adherence	O
of	O
Rin	B
A12	I
cells	O
.	O

We	O
compared	O
the	O
antiglioma	O
effect	O
of	O
simvastatin	O
,	O
atorvastatin	O
,	O
lovastatin	O
,	O
pravastatin	O
,	O
rosuvastatin	O
,	O
rosiglitazone	O
,	O
pioglitazone	O
and	O
their	O
combinations	O
at	O
several	O
concentrations	O
on	O
human	O
glioblastoma	O
cell	O
lines	O
U87	B
,	O
U	B
138	I
,	O
LN	B
405	I
and	O
rat	O
RG	B
II	I
.	O

An	O
AMPK	O
activator	O
(	O
AICAR	O
or	O
metformin	O
)	O
stimulated	O
osteoblast	O
differentiation	O
with	O
increases	O
in	O
ALP	O
and	O
OC	O
protein	O
production	O
as	O
well	O
as	O
the	O
induction	O
of	O
AMPK	O
phosphorylation	O
in	O
MC3T3E1	B
cells	O
.	O

In	O
addition	O
,	O
treatment	O
with	O
BMS1	O
,	O
a	O
combined	O
inhibitor	O
of	O
farnesyl	O
transferase	O
and	O
Rab	O
GGT	O
,	O
resulted	O
in	O
a	O
high	O
cytostatic	O
effect	O
in	O
WSU	B
-	I
NHL	I
cells	O
,	O
demonstrated	O
by	O
reduced	O
cell	O
viability	O
and	O
decreased	O
proliferation	O
.	O

Three	O
Leu	O
residues	O
at	O
amino	O
acid	O
positions	O
461	O
,	O
474	O
and	O
477	O
in	O
the	O
MAP2	O
-	O
binding	O
core	O
module	O
of	O
KIND2	O
contributed	O
to	O
the	O
interaction	O
.	O

The	O
genetic	O
,	O
immunophenotypic	O
,	O
and	O
biologic	O
data	O
presented	O
here	O
confirm	O
the	O
validity	O
of	O
the	O
MWCL	B
-	I
1	I
cell	O
line	O
as	O
a	O
representative	O
model	O
of	O
WM	O
.	O

Here	O
we	O
compare	O
the	O
impact	O
of	O
interferon	O
-	O
gamma	O
treatment	O
on	O
activities	O
of	O
GTP	O
-	O
cyclohydrolase	O
I	O
(	O
EC	O
3	O
.	O
5	O
.	O
4	O
.	O
16	O
)	O
,	O
6	O
-	O
pyruvoyl	O
tetrahydropterin	O
synthase	O
,	O
and	O
sepiapterin	O
reductase	O
(	O
EC	O
1	O
.	O
1	O
.	O
1	O
.	O
153	O
)	O
in	O
human	O
peripheral	O
blood	O
-	O
derived	O
macrophages	O
,	O
normal	O
dermal	O
fibroblasts	O
,	O
THP	B
-	I
1	I
myelomonocytic	O
cells	O
,	O
and	O
the	O
T	B
24	I
bladder	O
transitional	O
-	O
cell	O
carcinoma	O
line	O
.	O

Hematogenous	O
metastasis	O
in	O
gastric	O
cancer	O
requires	O
isolated	O
tumor	O
cells	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
.	O

PURPOSE	O
:	O
Recent	O
studies	O
of	O
cancer	O
metastasis	O
have	O
focused	O
on	O
the	O
role	O
of	O
premetastatic	O
gene	O
expression	O
and	O
circulating	O
tumor	O
cells	O
.	O

We	O
did	O
a	O
blind	O
prospective	O
study	O
in	O
gastric	O
cancer	O
to	O
assess	O
the	O
significance	O
of	O
isolated	O
tumor	O
cells	O
(	O
ITC	O
)	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
(	O
VEGFR	O
-	O
1	O
)	O
is	O
expressed	O
within	O
the	O
bone	O
marrow	O
at	O
tumor	O
-	O
specific	O
,	O
premetastatic	O
sites	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Both	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
samples	O
from	O
810	O
gastric	O
cancer	O
patients	O
were	O
collected	O
at	O
the	O
Central	O
Hospital	O
,	O
National	O
Cancer	O
Center	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
samples	O
were	O
transferred	O
to	O
Kyushu	O
University	O
Hospital	O
(	O
Beppu	O
,	O
Japan	O
)	O
where	O
they	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
for	O
three	O
epithelial	O
cell	O
markers	O
,	O
carcinoembryonic	O
antigen	O
,	O
cytokeratin	O
-	O
19	O
,	O
and	O
cytokeratin	O
-	O
7	O
,	O
as	O
well	O
as	O
VEGFR	O
-	O
1	O
.	O

RESULTS	O
:	O
ITCs	O
were	O
observed	O
in	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
even	O
in	O
early	O
stages	O
of	O
gastric	O
cancer	O
.	O

The	O
frequency	O
of	O
ITC	O
in	O
bone	O
marrow	O
was	O
significantly	O
associated	O
with	O
the	O
stage	O
of	O
disease	O
by	O
ANOVA	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Gastric	O
cancer	O
metastasized	O
when	O
ITCs	O
were	O
observed	O
in	O
the	O
presence	O
of	O
VEGFR	O
-	O
1	O
.	O

In	O
the	O
380	O
patients	O
who	O
were	O
ITC	O
negative	O
and	O
showed	O
low	O
VEGFR	O
-	O
1	O
expression	O
,	O
synchronous	O
(	O
at	O
the	O
time	O
of	O
surgery	O
)	O
and	O
heterochronous	O
(	O
recurrent	O
)	O
metastases	O
were	O
not	O
observed	O
.	O

CONCLUSIONS	O
:	O
ITCs	O
circulate	O
even	O
in	O
early	O
stages	O
of	O
disease	O
.	O

Furthermore	O
,	O
elevated	O
expression	O
of	O
VEGFR	O
-	O
1	O
facilitates	O
the	O
establishment	O
of	O
hematogenous	O
metastases	O
in	O
gastric	O
cancer	O
.	O

This	O
study	O
indicates	O
that	O
the	O
simultaneous	O
presence	O
of	O
ITC	O
and	O
VEGFR	O
-	O
1	O
expression	O
at	O
premetastatic	O
sites	O
is	O
clinically	O
significant	O
for	O
disease	O
progression	O
.	O

Analysis	O
of	O
processivity	O
of	O
mungbean	O
dideoxynucleotide	O
-	O
sensitive	O
DNA	O
polymerase	O
and	O
detection	O
of	O
the	O
activity	O
and	O
expression	O
of	O
the	O
enzyme	O
in	O
the	O
meristematic	O
and	O
meiotic	O
tissues	O
and	O
following	O
DNA	O
damaging	O
agent	O
.	O

Analysis	O
of	O
the	O
processivity	O
of	O
mungbean	O
ddNTP	O
-	O
sensitive	O
DNA	O
polymerase	O
showed	O
the	O
incorporation	O
of	O
approximately	O
35	O
-	O
40	O
nucleotides	O
per	O
binding	O
event	O
in	O
the	O
replication	O
assays	O
involving	O
M13	O
ss	O
DNA	O
template	O
with	O
5	O
'	O
-	O
labeled	O
17	O
-	O
mer	O
primer	O
.	O

Optimal	O
processivity	O
was	O
obtained	O
with	O
100	O
-	O
150	O
mM	O
KCl	O
and	O
6	O
-	O
8	O
mM	O
Mg2	O
+	O
at	O
pH	O
7	O
.	O
5	O
.	O

The	O
enzyme	O
showed	O
preference	O
for	O
Mg2	O
+	O
over	O
Mn2	O
+	O
as	O
the	O
metal	O
activator	O
for	O
processivity	O
.	O

2	O
'	O
,	O
3	O
'	O
dideoxythymidine	O
5	O
'	O
triphosphate	O
(	O
ddTTP	O
)	O
and	O
rat	O
DNA	O
pol	O
beta	O
antibody	O
strongly	O
influenced	O
distributive	O
synthesis	O
.	O

Considerable	O
enhancement	O
in	O
processivity	O
was	O
noticed	O
at	O
1mM	O
ATP	O
and	O
2	O
-	O
4	O
mM	O
spermidine	O
while	O
higher	O
concentrations	O
of	O
spermidine	O
caused	O
distributive	O
synthesis	O
.	O

The	O
enzyme	O
was	O
found	O
to	O
be	O
active	O
in	O
both	O
meristematic	O
and	O
meiotic	O
tissues	O
and	O
distinctly	O
induced	O
by	O
EMS	O
treatment	O
.	O

DNA	O
-	O
binding	O
assays	O
revealed	O
distinct	O
binding	O
ability	O
of	O
the	O
enzyme	O
to	O
template	O
/	O
primer	O
and	O
damaged	O
DNA	O
substrate	O
.	O

Together	O
these	O
observations	O
illustrate	O
the	O
probable	O
involvement	O
of	O
the	O
enzyme	O
in	O
replication	O
and	O
repair	O
machinery	O
in	O
higher	O
plants	O
.	O

Acute	O
ethanol	O
exposure	O
disrupts	O
VEGF	O
receptor	O
cell	O
signaling	O
in	O
endothelial	O
cells	O
.	O

Physiological	O
angiogenesis	O
is	O
regulated	O
by	O
various	O
factors	O
,	O
including	O
signaling	O
through	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
receptors	O
.	O

We	O
previously	O
reported	O
that	O
a	O
single	O
dose	O
of	O
ethanol	O
(	O
1	O
.	O
4	O
g	O
/	O
kg	O
)	O
,	O
yielding	O
a	O
blood	O
alcohol	O
concentration	O
of	O
100	O
mg	O
/	O
dl	O
,	O
significantly	O
impairs	O
angiogenesis	O
in	O
murine	O
wounds	O
,	O
despite	O
adequate	O
levels	O
of	O
VEGF	O
,	O
suggesting	O
direct	O
effects	O
of	O
ethanol	O
on	O
endothelial	O
cell	O
signaling	O
(	O
40	O
)	O
.	O

To	O
examine	O
the	O
mechanism	O
by	O
which	O
ethanol	O
influences	O
angiogenesis	O
in	O
wounds	O
,	O
we	O
employed	O
two	O
different	O
in	O
vitro	O
angiogenesis	O
assays	O
to	O
determine	O
whether	O
acute	O
ethanol	O
exposure	O
(	O
100	O
mg	O
/	O
dl	O
)	O
would	O
have	O
long	O
-	O
lasting	O
effects	O
on	O
VEGF	O
-	O
induced	O
capillary	O
network	O
formation	O
.	O

Ethanol	O
exposure	O
resulted	O
in	O
reduced	O
VEGF	O
-	O
induced	O
cord	O
formation	O
on	O
collagen	O
and	O
reduced	O
capillary	O
network	O
structure	O
on	O
Matrigel	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
ethanol	O
exposure	O
decreased	O
expression	O
of	O
endothelial	O
VEGF	O
receptor	O
-	O
2	O
,	O
as	O
well	O
as	O
VEGF	O
receptor	O
-	O
2	O
phosphorylation	O
in	O
vitro	O
.	O

Inhibition	O
of	O
ethanol	O
metabolism	O
by	O
4	O
-	O
methylpyrazole	O
partially	O
abrogated	O
the	O
effect	O
of	O
ethanol	O
on	O
endothelial	O
cell	O
cord	O
formation	O
.	O

However	O
,	O
mice	O
treated	O
with	O
t	O
-	O
butanol	O
,	O
an	O
alcohol	O
not	O
metabolized	O
by	O
alcohol	O
dehydrogenase	O
,	O
exhibited	O
no	O
change	O
in	O
wound	O
vascularity	O
.	O

These	O
results	O
suggest	O
that	O
products	O
of	O
ethanol	O
metabolism	O
are	O
important	O
factors	O
in	O
the	O
development	O
of	O
ethanol	O
-	O
induced	O
changes	O
in	O
endothelial	O
cell	O
responsiveness	O
to	O
VEGF	O
.	O

In	O
vivo	O
,	O
ethanol	O
exposure	O
caused	O
both	O
decreased	O
angiogenesis	O
and	O
increased	O
hypoxia	O
in	O
wounds	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
direct	O
effect	O
of	O
ethanol	O
on	O
the	O
response	O
to	O
hypoxia	O
in	O
endothelial	O
cells	O
,	O
as	O
ethanol	O
diminished	O
nuclear	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
protein	O
levels	O
.	O

Together	O
,	O
the	O
data	O
establish	O
that	O
acute	O
ethanol	O
exposure	O
significantly	O
impairs	O
angiogenesis	O
and	O
suggest	O
that	O
this	O
effect	O
is	O
mediated	O
by	O
changes	O
in	O
endothelial	O
cell	O
responsiveness	O
to	O
both	O
VEGF	O
and	O
hypoxia	O
.	O

Management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
:	O
therapeutic	O
issues	O
.	O

PURPOSE	O
:	O
The	O
staging	O
of	O
colorectal	O
cancer	O
,	O
therapeutic	O
decision	O
making	O
in	O
the	O
management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
,	O
and	O
dilemmas	O
posed	O
by	O
drug	O
-	O
related	O
toxicity	O
are	O
discussed	O
.	O

SUMMARY	O
:	O
Staging	O
of	O
colorectal	O
cancer	O
occurs	O
after	O
surgery	O
and	O
is	O
based	O
on	O
the	O
extent	O
of	O
disease	O
invasiveness	O
and	O
dissemination	O
.	O

Surgery	O
is	O
the	O
primary	O
treatment	O
for	O
stage	O
I	O
disease	O
.	O

Adjuvant	O
chemotherapy	O
is	O
recommended	O
after	O
resection	O
in	O
selected	O
high	O
-	O
risk	O
patients	O
with	O
stage	O
II	O
disease	O
and	O
in	O
all	O
patients	O
with	O
stage	O
III	O
disease	O
.	O

Convenience	O
of	O
administration	O
,	O
tolerability	O
,	O
and	O
patient	O
factors	O
not	O
necessarily	O
age	O
may	O
be	O
considerations	O
in	O
decisions	O
about	O
adjuvant	O
therapy	O
after	O
resection	O
.	O

Treatment	O
of	O
stage	O
IV	O
colorectal	O
cancer	O
is	O
based	O
on	O
the	O
type	O
of	O
prior	O
therapy	O
and	O
patient	O
-	O
specific	O
factors	O
.	O

Recently	O
,	O
significant	O
improvements	O
in	O
survival	O
have	O
been	O
achieved	O
through	O
the	O
use	O
of	O
combination	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
regimens	O
.	O

Bevacizumab	O
in	O
combination	O
with	O
chemotherapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
stage	O
IV	O
disease	O
.	O

Age	O
alone	O
should	O
not	O
preclude	O
the	O
use	O
of	O
chemotherapy	O
in	O
stage	O
IV	O
colorectal	O
cancer	O
,	O
although	O
the	O
ability	O
to	O
tolerate	O
drug	O
-	O
related	O
toxicity	O
may	O
be	O
a	O
consideration	O
.	O

The	O
optimal	O
duration	O
of	O
chemotherapy	O
in	O
patients	O
with	O
early	O
and	O
metastatic	O
colorectal	O
cancer	O
is	O
unclear	O
.	O

CONCLUSION	O
:	O
The	O
optimal	O
approach	O
to	O
the	O
treatment	O
of	O
colorectal	O
cancer	O
depends	O
on	O
several	O
considerations	O
,	O
including	O
patient	O
-	O
specific	O
factors	O
.	O

Serum	O
and	O
urine	O
levels	O
of	O
interleukin	O
-	O
8	O
in	O
patients	O
with	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
many	O
types	O
of	O
cancer	O
.	O

Interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	O
cytokine	O
,	O
and	O
IL	O
-	O
8	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
tumor	O
progression	O
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	O
.	O

However	O
,	O
the	O
role	O
of	O
IL	O
-	O
8	O
in	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	O
and	O
urine	O
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	O
.	O

We	O
developed	O
reference	O
intervals	O
for	O
serum	O
and	O
urine	O
IL	O
-	O
8	O
level	O
in	O
131	O
control	O
individuals	O
.	O

We	O
measured	O
serum	O
IL	O
-	O
8	O
and	O
urine	O
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	O
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O

The	O
reference	O
intervals	O
for	O
serum	O
IL	O
-	O
8	O
and	O
urine	O
IL	O
-	O
8	O
corrected	O
by	O
creatinine	O
(	O
Cr	O
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
were	O
significantly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
IL	O
-	O
8	O
concentrations	O
between	O
NHL	O
patients	O
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
and	O
serum	O
IL	O
-	O
8	O
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
serum	O
and	O
urine	O
concentrations	O
of	O
IL	O
-	O
8	O
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

This	O
study	O
indicated	O
that	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	O
.	O

Adenomatoid	O
tumour	O
of	O
the	O
liver	O
.	O

An	O
unusual	O
primary	O
adenomatoid	O
tumour	O
arising	O
in	O
the	O
normal	O
liver	O
is	O
described	O
.	O

Hepatectomy	O
was	O
performed	O
,	O
and	O
the	O
patient	O
is	O
alive	O
and	O
free	O
of	O
disease	O
1	O
year	O
postsurgery	O
.	O

Grossly	O
,	O
the	O
tumour	O
showed	O
a	O
haemorrhagic	O
cut	O
surface	O
with	O
numerous	O
microcystic	O
structures	O
.	O

Histological	O
examination	O
revealed	O
cystic	O
or	O
angiomatoid	O
spaces	O
of	O
various	O
sizes	O
lined	O
by	O
cuboidal	O
,	O
low	O
-	O
columnar	O
,	O
or	O
flattened	O
epithelioid	O
cells	O
with	O
vacuolated	O
cytoplasm	O
and	O
round	O
to	O
oval	O
nuclei	O
.	O

The	O
epithelioid	O
cells	O
were	O
entirely	O
supported	O
by	O
proliferated	O
capillaries	O
and	O
arteries	O
together	O
with	O
collagenous	O
stroma	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
the	O
epithelioid	O
cells	O
were	O
strongly	O
positive	O
for	O
a	O
broad	O
spectrum	O
of	O
cytokeratins	O
(	O
AE1	O
/	O
AE3	O
,	O
CAM5	O
.	O
2	O
,	O
epithelial	O
membrane	O
antigen	O
and	O
cytokeratin	O
7	O
)	O
and	O
mesothelial	O
markers	O
(	O
calretinin	O
,	O
Wilms	O
'	O
tumour	O
1	O
and	O
D2	O
-	O
40	O
)	O
.	O

These	O
cells	O
were	O
negative	O
for	O
Hep	O
par	O
-	O
1	O
,	O
carcinoembryonic	O
antigen	O
,	O
neural	O
cell	O
adhesion	O
molecule	O
,	O
CD34	O
,	O
CD31	O
and	O
HMB45	O
.	O

Atypically	O
,	O
abundant	O
capillaries	O
were	O
observed	O
;	O
however	O
,	O
the	O
cystic	O
proliferation	O
of	O
epithelioid	O
cells	O
with	O
vacuoles	O
and	O
immunohistochemical	O
profile	O
of	O
the	O
epithelioid	O
element	O
were	O
consistent	O
with	O
hepatic	O
adenomatoid	O
tumour	O
.	O

Research	O
advances	O
of	O
endostatin	O
and	O
its	O
short	O
internal	O
fragments	O
.	O

Endostatin	O
,	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	O
XVIII	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

At	O
present	O
,	O
there	O
are	O
a	O
large	O
number	O
of	O
research	O
papers	O
on	O
endostatin	O
.	O

However	O
,	O
the	O
action	O
mechanism	O
of	O
endostatin	O
is	O
still	O
a	O
matter	O
of	O
ongoing	O
discussion	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
elucidate	O
its	O
origin	O
and	O
elementary	O
structure	O
,	O
and	O
to	O
discuss	O
its	O
structure	O
basis	O
of	O
activity	O
and	O
action	O
mechanisms	O
based	O
on	O
the	O
latest	O
research	O
.	O

Furthermore	O
,	O
some	O
published	O
studies	O
reporting	O
the	O
antiangiogenic	O
effects	O
of	O
endostatin	O
-	O
derived	O
peptides	O
were	O
also	O
reviewed	O
.	O

It	O
is	O
proposed	O
that	O
the	O
amino	O
acid	O
sequence	O
of	O
endostatin	O
contains	O
both	O
angiosuppressive	O
and	O
angiostimulatory	O
domains	O
.	O

Short	O
endostatin	O
fragments	O
may	O
be	O
exploited	O
as	O
a	O
new	O
angiogenesis	O
inhibitor	O
for	O
therapeutic	O
applications	O
,	O
in	O
substitution	O
of	O
the	O
full	O
length	O
endostatin	O
.	O

These	O
studies	O
on	O
endostatin	O
fragments	O
also	O
shed	O
light	O
on	O
our	O
understanding	O
of	O
the	O
molecular	O
action	O
mechanisms	O
of	O
endostatin	O
.	O

Microscopic	O
technique	O
for	O
the	O
detection	O
of	O
nitric	O
oxide	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
vascular	O
homeostasis	O
.	O

The	O
importance	O
of	O
NO	O
in	O
the	O
vasculature	O
is	O
demonstrated	O
by	O
several	O
experimental	O
conditions	O
,	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
angiogenesis	O
.	O

Thus	O
,	O
the	O
NO	O
metabolic	O
pathway	O
in	O
endothelial	O
cells	O
could	O
be	O
one	O
of	O
the	O
main	O
contributing	O
factors	O
for	O
angiogenesis	O
.	O

Although	O
several	O
methods	O
have	O
been	O
used	O
for	O
measuring	O
in	O
vitro	O
angiogenesis	O
,	O
a	O
proper	O
technique	O
has	O
not	O
been	O
developed	O
for	O
identifying	O
in	O
vivo	O
NO	O
-	O
dependent	O
angiogenesis	O
.	O

This	O
chapter	O
provides	O
a	O
new	O
intravital	O
microscopic	O
method	O
for	O
detecting	O
and	O
measuring	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
a	O
mouse	O
model	O
.	O

This	O
technique	O
showed	O
strong	O
abdominal	O
neovascularization	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
eNOS	O
knockout	O
mice	O
,	O
locally	O
injected	O
with	O
VEGF	O
,	O
as	O
well	O
as	O
stimulation	O
of	O
angiogenesis	O
in	O
NO	O
donor	O
-	O
injected	O
mice	O
.	O

This	O
technique	O
also	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
the	O
NOS	O
inhibitor	O
N	O
(	O
G	O
)	O
-	O
iminoethyl	O
-	O
L	O
-	O
ornithine	O
in	O
VEGF	O
-	O
mediated	O
in	O
vivo	O
angiogenesis	O
.	O

This	O
chapter	O
describes	O
intravital	O
microscopy	O
as	O
a	O
new	O
imaging	O
technique	O
for	O
detecting	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

The	O
tyrosine	O
kinase	O
inhibitor	O
cediranib	O
blocks	O
ligand	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Solid	O
tumors	O
express	O
a	O
range	O
of	O
factors	O
required	O
to	O
sustain	O
their	O
growth	O
and	O
promote	O
their	O
dissemination	O
.	O

Among	O
these	O
are	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
,	O
the	O
key	O
angiogenic	O
stimulant	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
a	O
primary	O
mediator	O
of	O
lymphangiogenesis	O
.	O

Small	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
offer	O
the	O
potential	O
to	O
inhibit	O
more	O
than	O
one	O
kinase	O
and	O
impede	O
tumor	O
growth	O
by	O
multiple	O
mechanisms	O
.	O

However	O
,	O
their	O
potency	O
toward	O
individual	O
targets	O
can	O
vary	O
.	O

Cediranib	O
(	O
RECENTIN	O
;	O
AZD2171	O
)	O
is	O
an	O
inhibitor	O
of	O
VEGF	O
signaling	O
that	O
has	O
been	O
shown	O
in	O
experimental	O
models	O
to	O
prevent	O
VEGF	O
-	O
A	O
-	O
induced	O
angiogenesis	O
and	O
primary	O
tumor	O
growth	O
,	O
yet	O
the	O
effects	O
of	O
cediranib	O
on	O
VEGF	O
receptor	O
(	O
VEGFR	O
)	O
-	O
3	O
-	O
mediated	O
endothelial	O
cell	O
function	O
and	O
lymphangiogenesis	O
are	O
unknown	O
.	O

To	O
better	O
understand	O
the	O
activity	O
of	O
cediranib	O
against	O
VEGFR	O
-	O
3	O
and	O
its	O
associated	O
signaling	O
events	O
compared	O
with	O
its	O
activity	O
against	O
VEGFR	O
-	O
2	O
,	O
we	O
used	O
the	O
receptor	O
-	O
specific	O
ligands	O
VEGF	O
-	O
E	O
and	O
VEGF	O
-	O
C156S	O
.	O

In	O
human	O
endothelial	O
cells	O
,	O
cediranib	O
inhibited	O
VEGF	O
-	O
E	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
VEGF	O
-	O
C156S	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
3	O
at	O
concentrations	O
of	O
less	O
than	O
/	O
=	O
1nmol	O
/	O
L	O
and	O
inhibited	O
activation	O
of	O
downstream	O
signaling	O
molecules	O
.	O

Additionally	O
,	O
cediranib	O
blocked	O
VEGF	O
-	O
C156S	O
-	O
induced	O
and	O
VEGF	O
-	O
E	O
-	O
induced	O
proliferation	O
,	O
survival	O
,	O
and	O
migration	O
of	O
lymphatic	O
and	O
blood	O
vascular	O
endothelial	O
cells	O
.	O

In	O
vivo	O
,	O
cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
d	O
)	O
prevented	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
VEGF	O
-	O
E	O
-	O
expressing	O
and	O
VEGF	O
-	O
C156S	O
-	O
expressing	O
adenoviruses	O
,	O
respectively	O
.	O

Cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
day	O
)	O
also	O
blocked	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
adenoviruses	O
expressing	O
VEGF	O
-	O
A	O
or	O
VEGF	O
-	O
C	O
and	O
compromised	O
the	O
blood	O
and	O
lymphatic	O
vasculatures	O
of	O
VEGF	O
-	O
C	O
-	O
expressing	O
tumors	O
.	O

Cediranib	O
may	O
,	O
therefore	O
,	O
be	O
an	O
effective	O
means	O
of	O
preventing	O
tumor	O
progression	O
,	O
not	O
only	O
by	O
inhibiting	O
VEGFR	O
-	O
2	O
activity	O
and	O
angiogenesis	O
,	O
but	O
also	O
by	O
concomitantly	O
inhibiting	O
VEGFR	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Effects	O
of	O
cyclooxygenase	O
-	O
2	O
non	O
-	O
selective	O
and	O
selective	O
inhibitors	O
on	O
proliferation	O
inhibition	O
and	O
apoptosis	O
induction	O
of	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
aspirin	O
and	O
nimesulide	O
on	O
cell	O
proliferation	O
,	O
apoptosis	O
and	O
its	O
potential	O
mechanisms	O
in	O
EC9706	B
and	O
EC109	B
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

EC9706	B
and	O
EC109	B
cells	O
were	O
incubated	O
with	O
varying	O
concentrations	O
of	O
aspirin	O
and	O
nimesulide	O
,	O
and	O
the	O
effects	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
were	O
monitored	O
by	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
thiazol	O
-	O
2yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
and	O
flow	O
cytometry	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
assays	O
were	O
used	O
to	O
investigate	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
Bax	O
.	O

Prostaglandin	O
E2	O
production	O
was	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O

Pretreatment	O
with	O
aspirin	O
and	O
nimesulide	O
inhibited	O
EC9706	B
and	O
EC109	B
cell	O
growth	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
accompanied	O
with	O
a	O
decrease	O
of	O
prostaglandin	O
E2	O
production	O
.	O

In	O
EC9706	B
cells	O
,	O
the	O
mechanism	O
of	O
aspirin	O
and	O
nimesulide	O
induced	O
growth	O
inhibition	O
was	O
a	O
consequence	O
of	O
cell	O
cycle	O
arrest	O
at	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
check	O
point	O
.	O

In	O
EC109	B
cells	O
,	O
growth	O
arrest	O
was	O
by	O
induction	O
of	O
apoptosis	O
,	O
associated	O
with	O
downregulation	O
of	O
Bcl	O
-	O
2	O
,	O
but	O
not	O
Bax	O
.	O

In	O
conclusion	O
,	O
aspirin	O
and	O
nimesulide	O
could	O
inhibit	O
cell	O
proliferation	O
and	O
induce	O
apoptosis	O
in	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

Cyclooxygenase	O
-	O
2	O
inhibitor	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
for	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

Contemporary	O
perspectives	O
on	O
vital	O
pulp	O
therapy	O
:	O
views	O
from	O
the	O
endodontists	O
and	O
pediatric	O
dentists	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
level	O
of	O
agreement	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
at	O
a	O
pulp	O
therapy	O
symposium	O
conjointly	O
sponsored	O
by	O
the	O
American	O
Association	O
of	O
Endodontists	O
(	O
AAE	O
)	O
and	O
the	O
American	O
Academy	O
of	O
Pediatric	O
Dentistry	O
(	O
AAPD	O
)	O
on	O
November	O
2	O
-	O
3	O
,	O
2007	O
.	O

Presymposium	O
and	O
postsymposium	O
tests	O
were	O
administered	O
,	O
and	O
respondent	O
answers	O
were	O
compared	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
.	O

Opinions	O
on	O
3	O
areas	O
were	O
sought	O
:	O
pulp	O
therapy	O
for	O
cariously	O
involved	O
primary	O
teeth	O
;	O
indirect	O
pulp	O
treatment	O
(	O
IPT	O
)	O
for	O
cariously	O
involved	O
immature	O
permanent	O
teeth	O
;	O
and	O
innovative	O
treatment	O
options	O
including	O
pulpal	O
revascularization	O
and	O
regeneration	O
.	O

Results	O
were	O
analyzed	O
with	O
chi2	O
tests	O
.	O

Comparisons	O
of	O
presymposium	O
and	O
postsymposium	O
responses	O
and	O
between	O
the	O
2	O
groups	O
of	O
attendees	O
indicated	O
that	O
the	O
pediatric	O
dentistry	O
and	O
endodontic	O
communities	O
agree	O
that	O
formocresol	O
will	O
be	O
replaced	O
as	O
a	O
primary	O
tooth	O
pulpotomy	O
agent	O
,	O
that	O
mineral	O
trioxide	O
is	O
the	O
first	O
choice	O
to	O
take	O
its	O
place	O
,	O
that	O
IPT	O
in	O
primary	O
teeth	O
holds	O
hope	O
as	O
a	O
replacement	O
for	O
pulpotomy	O
,	O
and	O
that	O
IPT	O
is	O
an	O
acceptable	O
pulp	O
therapy	O
technique	O
for	O
cariously	O
involved	O
young	O
permanent	O
teeth	O
.	O

Both	O
groups	O
believe	O
that	O
pulp	O
revascularization	O
and	O
regeneration	O
will	O
be	O
viable	O
treatment	O
modalities	O
in	O
the	O
future	O
.	O

The	O
AAE	O
and	O
the	O
AAPD	O
are	O
positioned	O
to	O
begin	O
preparation	O
of	O
best	O
practice	O
guidelines	O
that	O
share	O
common	O
language	O
and	O
treatment	O
recommendations	O
for	O
pulp	O
therapies	O
performed	O
by	O
both	O
specialties	O
.	O

Neurotrophin	O
p75	O
receptor	O
(	O
p75NTR	O
)	O
promotes	O
endothelial	O
cell	O
apoptosis	O
and	O
inhibits	O
angiogenesis	O
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	O
neovascularization	O
in	O
ischemic	O
limb	O
muscles	O
.	O

Diabetes	O
impairs	O
endothelial	O
function	O
and	O
reparative	O
neovascularization	O
.	O

The	O
p75	O
receptor	O
of	O
neurotrophins	O
(	O
p75	O
(	O
NTR	O
)	O
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	O
cells	O
(	O
ECs	O
)	O
,	O
becomes	O
strongly	O
expressed	O
by	O
capillary	O
ECs	O
after	O
induction	O
of	O
peripheral	O
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	O
p75	O
(	O
NTR	O
)	O
expression	O
impairs	O
the	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
capacities	O
of	O
cultured	O
ECs	O
and	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
and	O
inhibits	O
angiogenesis	O
in	O
vitro	O
.	O

Moreover	O
,	O
intramuscular	O
p75	O
(	O
NTR	O
)	O
gene	O
delivery	O
impairs	O
neovascularization	O
and	O
blood	O
flow	O
recovery	O
in	O
a	O
mouse	O
model	O
of	O
limb	O
ischemia	O
.	O

These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	O
survival	O
and	O
angiogenesis	O
.	O

In	O
fact	O
,	O
p75	O
(	O
NTR	O
)	O
depresses	O
the	O
VEGF	O
-	O
A	O
/	O
Akt	O
/	O
eNOS	O
/	O
NO	O
pathway	O
and	O
additionally	O
reduces	O
the	O
mRNA	O
levels	O
of	O
ITGB1	O
[	O
beta	O
(	O
1	O
)	O
integrin	O
]	O
,	O
BIRC5	O
(	O
survivin	O
)	O
,	O
PTTG1	O
(	O
securin	O
)	O
and	O
VEZF1	O
.	O

Diabetic	O
mice	O
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	O
neovascularization	O
and	O
blood	O
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	O
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	O
(	O
NTR	O
)	O
.	O

Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	O
action	O
of	O
p75	O
(	O
NTR	O
)	O
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	O
(	O
NTR	O
)	O
inhibition	O
to	O
combat	O
diabetes	O
-	O
induced	O
microvascular	O
liabilities	O
.	O

Intraoperative	O
handling	O
and	O
wound	O
healing	O
of	O
arthroscopic	O
portal	O
wounds	O
:	O
a	O
clinical	O
study	O
comparing	O
nylon	O
suture	O
with	O
wound	O
closure	O
strips	O
.	O

This	O
prospective	O
,	O
single	O
-	O
centre	O
study	O
compared	O
wound	O
closure	O
methods	O
in	O
patients	O
undergoing	O
arthroscopy	O
.	O

Closure	O
of	O
arthroscopic	O
portal	O
wounds	O
with	O
sterile	O
adhesive	O
strips	O
is	O
effective	O
and	O
convenient	O
for	O
wound	O
management	O
.	O

The	O
method	O
was	O
associated	O
with	O
a	O
reduced	O
potential	O
for	O
infection	O
,	O
faster	O
renewal	O
of	O
tensile	O
strength	O
,	O
greater	O
cost	O
effectiveness	O
,	O
and	O
better	O
cosmetic	O
effects	O
comparing	O
with	O
suture	O
closure	O
.	O

This	O
method	O
of	O
wound	O
closure	O
may	O
also	O
reduce	O
the	O
incidence	O
of	O
needle	O
stick	O
injury	O
in	O
the	O
theatre	O
environment	O
.	O

Thereby	O
the	O
incidence	O
of	O
percutaneous	O
exposure	O
following	O
a	O
surgical	O
procedure	O
may	O
not	O
facilitate	O
transmission	O
of	O
blood	O
borne	O
pathogens	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
hepatitis	O
C	O
virus	O
and	O
hepatitis	O
B	O
virus	O
.	O

As	O
a	O
result	O
it	O
may	O
reduce	O
litigation	O
in	O
today	O
'	O
s	O
changing	O
healthcare	O
climate	O
.	O

Tumor	O
endothelial	O
cell	O
targeted	O
cyclic	O
RGD	O
-	O
modified	O
heparin	O
derivative	O
:	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

PURPOSE	O
:	O
We	O
prepared	O
tumor	O
endothelium	O
targeted	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
(	O
cRGD	O
-	O
HL	O
)	O
by	O
coupling	O
heparin	O
-	O
lithocholic	O
acid	O
(	O
HL	O
)	O
with	O
cRGDyK	O
,	O
and	O
evaluated	O
inhibition	O
effects	O
of	O
cRGD	O
-	O
HL	O
on	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

METHODS	O
:	O
To	O
evaluate	O
antiangiogenic	O
activity	O
of	O
cRGD	O
-	O
HL	O
,	O
we	O
performed	O
tests	O
on	O
endothelial	O
cell	O
adhesion	O
and	O
migration	O
to	O
vitronectin	O
,	O
tube	O
formation	O
,	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
,	O
and	O
in	O
vivo	O
Matrigel	O
plug	O
assay	O
.	O

The	O
antitumor	O
activity	O
of	O
cRGD	O
-	O
HL	O
was	O
also	O
evaluated	O
by	O
monitoring	O
tumor	O
growth	O
and	O
microvessel	O
formation	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC7	O
)	O
tumor	O
.	O

RESULTS	O
:	O
The	O
cRGD	O
-	O
HL	O
significantly	O
inhibited	O
adhesion	O
and	O
migration	O
of	O
endothelial	O
cells	O
to	O
vitronectin	O
,	O
and	O
tubular	O
structures	O
of	O
endothelial	O
cells	O
.	O

Compared	O
to	O
cRGDyK	O
and	O
HL	O
,	O
cRGD	O
-	O
HL	O
has	O
high	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
.	O

The	O
enhanced	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
confirmed	O
in	O
Matrigel	O
assay	O
by	O
showing	O
the	O
significant	O
inhibition	O
of	O
bFGF	O
-	O
driven	O
angiogenesis	O
and	O
blood	O
vessel	O
formation	O
.	O

It	O
was	O
thought	O
that	O
potent	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
probably	O
due	O
to	O
the	O
interference	O
of	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
-	O
mediated	O
interaction	O
,	O
resulting	O
in	O
the	O
enhanced	O
antitumoral	O
activity	O
against	O
SCC7	B
tumor	O
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
enhanced	O
anti	O
-	O
angiotherapeutic	O
effects	O
against	O
solid	O
tumor	O
,	O
and	O
therefore	O
,	O
it	O
could	O
be	O
applied	O
to	O
treat	O
various	O
cancers	O
and	O
angiogenic	O
diseases	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

The	O
role	O
of	O
platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
factor	O
/	O
thymidine	O
phosphorylase	O
in	O
tumor	O
behavior	O
.	O

Platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
-	O
factor	O
(	O
PD	O
-	O
ECGF	O
)	O
is	O
similar	O
to	O
the	O
pyrimidine	O
enzyme	O
thymidine	O
phosphorylase	O
(	O
TP	O
)	O
.	O

A	O
high	O
TP	O
expression	O
at	O
tumor	O
sites	O
is	O
correlated	O
with	O
tumor	O
growth	O
,	O
induction	O
of	O
angiogenesis	O
,	O
and	O
metastasis	O
.	O

Therefore	O
,	O
high	O
TP	O
is	O
most	O
likely	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

TP	O
is	O
not	O
only	O
expressed	O
in	O
tumor	O
cells	O
but	O
also	O
in	O
tumor	O
surrounding	O
tissues	O
,	O
such	O
as	O
tumor	O
infiltrating	O
macrophages	O
.	O

TP	O
catalyzes	O
the	O
conversion	O
of	O
thymidine	O
to	O
thymine	O
and	O
doxyribose	O
-	O
1	O
-	O
phosphate	O
(	O
dR	O
-	O
1	O
-	O
P	O
)	O
.	O

The	O
latter	O
in	O
its	O
parent	O
form	O
or	O
in	O
its	O
sugar	O
form	O
,	O
deoxyribose	O
(	O
dR	O
)	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
angiogenesis	O
.	O

It	O
may	O
modulate	O
cellular	O
energy	O
metabolism	O
or	O
be	O
a	O
substrate	O
in	O
a	O
chemical	O
reaction	O
generating	O
reactive	O
oxygen	O
species	O
.	O

L	O
-	O
deoxyribose	O
(	O
L	O
-	O
dR	O
)	O
and	O
thymidine	O
phosphorylase	O
inhibitor	O
(	O
TPI	O
)	O
can	O
reverse	O
these	O
effects	O
.	O

The	O
mechanism	O
of	O
TP	O
induction	O
is	O
not	O
yet	O
completely	O
clear	O
,	O
but	O
TNF	O
,	O
IL10	O
and	O
other	O
cytokines	O
have	O
been	O
clearly	O
shown	O
to	O
induce	O
its	O
expression	O
.	O

The	O
various	O
complex	O
interactions	O
of	O
TP	O
give	O
it	O
an	O
essential	O
role	O
in	O
cellular	O
functioning	O
and	O
,	O
hence	O
,	O
it	O
is	O
an	O
ideal	O
target	O
in	O
cancer	O
therapy	O
.	O

[	O
Inhibitory	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	O
carcinoma	O
in	O
mice	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	O
cancer	O
in	O
mice	O
and	O
its	O
mechanism	O
of	O
action	O
.	O

METHODS	O
:	O
Transplant	O
tumor	O
model	O
was	O
induced	O
by	O
subcutaneous	O
inoculation	O
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	O
lung	O
cancer	O
(	O
LLC	O
)	O
cells	O
into	O
the	O
back	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
mice	O
were	O
treated	O
by	O
intratumoral	O
injection	O
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	O
-	O
mEndostatin	O
.	O

The	O
expression	O
of	O
endostatin	O
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O

The	O
endostatin	O
level	O
in	O
serum	O
was	O
determined	O
by	O
ELISA	O
.	O

The	O
inhibition	O
of	O
tumor	O
growth	O
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	O
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	O
and	O
CD105	O
antibodies	O
.	O

The	O
tumor	O
apoptosis	O
was	O
observed	O
by	O
electron	O
microscopy	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
significantly	O
inhibited	O
the	O
tumor	O
growth	O
and	O
metastasis	O
,	O
and	O
prolonged	O
the	O
survival	O
rate	O
of	O
mice	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Strong	O
positive	O
expression	O
of	O
mEndostatin	O
was	O
seen	O
in	O
the	O
tumor	O
tissue	O
after	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
,	O
immunhistochemically	O
ostained	O
by	O
mouse	O
endostatin	O
monoclonal	O
antibody	O
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	O
or	O
absence	O
.	O

Serum	O
endostatin	O
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	O
,	O
the	O
expression	O
of	O
endostatin	O
diminished	O
a	O
month	O
later	O
.	O

The	O
microvessel	O
density	O
(	O
MVD	O
)	O
)	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	O
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	O
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

More	O
apoptotic	O
tumor	O
cells	O
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O

CONCLUSION	O
:	O
Endostatin	O
gene	O
therapy	O
mediated	O
by	O
adenoviral	O
vector	O
efficiently	O
induces	O
expression	O
of	O
endostatin	O
in	O
vivo	O
,	O
and	O
inhibits	O
the	O
growth	O
and	O
metastasis	O
of	O
tumor	O
.	O

It	O
is	O
concluded	O
that	O
its	O
action	O
is	O
targeted	O
to	O
tumor	O
neovasculature	O
and	O
the	O
mechanism	O
is	O
inhibition	O
of	O
tumor	O
angiogenesis	O
.	O

Investigation	O
of	O
the	O
effect	O
of	O
kaolin	O
and	O
tissue	O
-	O
factor	O
-	O
activated	O
citrated	O
whole	O
blood	O
,	O
on	O
clot	O
-	O
forming	O
variables	O
,	O
as	O
evaluated	O
by	O
thromboelastography	O
.	O

BACKGROUND	O
:	O

The	O
Thrombelastograph	O
(	O
TEG	O
;	O
Haemoscope	O
Corp	O
.	O
)	O
analyzes	O
clot	O
formation	O
in	O
whole	O
blood	O
(	O
WB	O
)	O
and	O
treatment	O
based	O
on	O
this	O
analysis	O
has	O
been	O
shown	O
to	O
reduce	O
transfusion	O
requirements	O
in	O
liver	O
and	O
cardiac	O
surgery	O
when	O
compared	O
to	O
conventional	O
coagulation	O
analysis	O
.	O

Implementing	O
TEG	O
as	O
a	O
routine	O
laboratory	O
-	O
based	O
analysis	O
,	O
however	O
,	O
requires	O
validation	O
of	O
the	O
activators	O
employed	O
and	O
the	O
effect	O
of	O
storage	O
of	O
the	O
WB	O
sample	O
in	O
citrate	O
before	O
analysis	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O

The	O
effect	O
of	O
kaolin	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
1	O
:	O
17	O
,	O
000	O
,	O
or	O
TF	O
1	O
:	O
42	O
,	O
500	O
on	O
TEG	O
clotting	O
time	O
(	O
R	O
)	O
,	O
Angle	O
(	O
velocity	O
of	O
clot	O
formation	O
)	O
,	O
and	O
maximum	O
clot	O
strength	O
(	O
amplitude	O
[	O
MA	O
]	O
)	O
were	O
evaluated	O
,	O
together	O
with	O
day	O
-	O
to	O
-	O
day	O
variation	O
,	O
the	O
coefficient	O
of	O
variance	O
(	O
CV	O
%	O
)	O
,	O
and	O
the	O
effect	O
of	O
citrate	O
storage	O
time	O
.	O

RESULTS	O
:	O

Clot	O
formation	O
variables	O
were	O
equally	O
affected	O
by	O
TF	O
1	O
:	O
17	O
,	O
000	O
and	O
kaolin	O
activation	O
,	O
whereas	O
R	O
was	O
significantly	O
longer	O
when	O
TF	O
1	O
:	O
42	O
,	O
500	O
was	O
used	O
.	O

The	O
CV	O
for	O
the	O
different	O
variables	O
varied	O
from	O
3	O
to	O
13	O
percent	O
with	O
no	O
significant	O
differences	O
between	O
assays	O
.	O

Storage	O
of	O
citrated	O
WB	O
significantly	O
affected	O
the	O
TEG	O
variables	O
in	O
a	O
hypercoagulable	O
direction	O
.	O

Only	O
the	O
R	O
,	O
however	O
,	O
was	O
significantly	O
affected	O
(	O
12	O
%	O
)	O
when	O
samples	O
rested	O
for	O
0	O
and	O
30	O
minutes	O
were	O
evaluated	O
with	O
kaolin	O
as	O
the	O
activator	O
.	O

CONCLUSION	O
:	O

The	O
TEG	O
assays	O
evaluated	O
were	O
reproducible	O
and	O
present	O
with	O
an	O
acceptable	O
CV	O
%	O
for	O
routine	O
clinical	O
practice	O
.	O

Kaolin	O
and	O
TF	O
1	O
:	O
17	O
,	O
000	O
equally	O
affected	O
the	O
clot	O
formation	O
variables	O
.	O

Storage	O
of	O
WB	O
for	O
up	O
to	O
30	O
minutes	O
in	O
citrate	O
did	O
not	O
,	O
except	O
for	O
R	O
,	O
affect	O
clot	O
formation	O
variables	O
when	O
kaolin	O
was	O
used	O
as	O
activator	O
allowing	O
for	O
immediate	O
analysis	O
when	O
the	O
sample	O
arrives	O
in	O
the	O
laboratory	O
.	O

Reversal	O
of	O
the	O
malignant	O
phenotype	O
of	O
ovarian	O
cancer	O
A2780	B
cells	O
through	O
transfection	O
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
.	O

OBJECTIVE	O
:	O
PTEN	O
(	O
phosphatase	O
and	O
tensin	O
homologue	O
deleted	O
on	O
chromosome	O
10	O
)	O
is	O
a	O
tumor	O
suppressor	O
gene	O
identified	O
on	O
human	O
chromosome	O
10q23	O
.	O

Substantial	O
studies	O
have	O
demonstrated	O
that	O
PTEN	O
can	O
inhibit	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
many	O
cancer	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
upregulation	O
of	O
PTEN	O
gene	O
by	O
transfection	O
wild	O
-	O
type	O
PTEN	O
gene	O
to	O
ovarian	O
cancer	O
cells	O
can	O
inhibit	O
growth	O
and	O
migration	O
and	O
to	O
explore	O
the	O
potential	O
for	O
PTEN	O
gene	O
therapy	O
of	O
ovarian	O
cancers	O
.	O

METHOD	O
:	O
Wild	O
-	O
type	O
and	O
phosphatase	O
-	O
inactive	O
(	O
C124A	O
)	O
PTEN	O
plasmids	O
were	O
transfected	O
into	O
ovarian	O
epithelial	O
cancer	O
A2780	B
cells	O
,	O
and	O
their	O
effects	O
on	O
cell	O
apoptosis	O
,	O
cell	O
proliferation	O
,	O
cell	O
migration	O
and	O
cell	O
invasion	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
analysis	O
,	O
TUNEL	O
assay	O
,	O
MTT	O
assay	O
,	O
wound	O
-	O
healing	O
assay	O
and	O
transwell	O
assay	O
.	O

RESULTS	O
:	O
Both	O
wild	O
-	O
type	O
and	O
mutant	O
PTEN	O
can	O
upregulate	O
the	O
expression	O
of	O
PTEN	O
gene	O
dramatically	O
;	O
however	O
,	O
it	O
is	O
wild	O
-	O
type	O
PTEN	O
not	O
phosphatase	O
-	O
inactive	O
PTEN	O
that	O
can	O
induce	O
apoptosis	O
and	O
decrease	O
cell	O
migration	O
,	O
invasion	O
and	O
proliferation	O
in	O
ovarian	O
cancer	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
PTEN	O
had	O
played	O
an	O
important	O
role	O
in	O
the	O
cell	O
proliferation	O
,	O
cell	O
migration	O
and	O
invasion	O
dependent	O
on	O
its	O
phosphatase	O
activity	O
.	O

Enhanced	O
expression	O
of	O
PTEN	O
by	O
gene	O
transfer	O
is	O
sufficient	O
to	O
reverse	O
the	O
malignant	O
phenotype	O
of	O
ovarian	O
cancer	O
cells	O
and	O
transfection	O
of	O
ovarian	O
cancer	O
cells	O
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
might	O
be	O
another	O
novel	O
approach	O
for	O
therapeutic	O
intervention	O
in	O
ovarian	O
cancer	O
.	O

Artemisinin	O
inhibits	O
tumor	O
lymphangiogenesis	O
by	O
suppression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
.	O

We	O
have	O
previously	O
reported	O
that	O
dihydroartemisinin	O
is	O
found	O
to	O
have	O
a	O
potent	O
ability	O
in	O
influencing	O
lymphatic	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
artemisinin	O
on	O
tumor	O
growth	O
,	O
lymphangiogenesis	O
,	O
metastasis	O
and	O
survival	O
in	O
mouse	O
Lewis	O
lung	O
carcinoma	O
(	O
LLC	O
)	O
models	O
.	O

We	O
found	O
that	O
orally	O
administered	O
artemisinin	O
inhibited	O
lymph	O
node	O
and	O
lung	O
metastasis	O
and	O
prolonged	O
survival	O
without	O
retarding	O
tumor	O
growth	O
.	O

Consistent	O
with	O
the	O
decrease	O
in	O
lymph	O
node	O
metastasis	O
,	O
tumor	O
lymphangiogenesis	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
was	O
significantly	O
decreased	O
in	O
artemisinin	O
-	O
treated	O
mice	O
,	O
as	O
compared	O
to	O
control	O
mice	O
.	O

Furthermore	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
and	O
upregulation	O
of	O
VEGF	O
-	O
C	O
mRNA	O
and	O
protein	O
in	O
LLC	O
cells	O
was	O
also	O
suppressed	O
by	O
artemisinin	O
or	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB	O
-	O
203580	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
could	O
serve	O
as	O
a	O
mediator	O
of	O
proinflammatory	O
cytokine	O
-	O
induced	O
VEGF	O
-	O
C	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
artemisinin	O
may	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
lymph	O
node	O
metastasis	O
by	O
downregulating	O
VEGF	O
-	O
C	O
and	O
reducing	O
tumor	O
lymphangiogenesis	O
.	O

Allogeneic	O
injection	O
of	O
fetal	O
membrane	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
induces	O
therapeutic	O
angiogenesis	O
in	O
a	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
.	O

Bone	O
marrow	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
(	O
BM	O
-	O
MSC	O
)	O
have	O
been	O
demonstrated	O
to	O
be	O
an	O
attractive	O
therapeutic	O
cell	O
source	O
for	O
tissue	O
regeneration	O
and	O
repair	O
.	O

However	O
,	O
it	O
remains	O
unknown	O
whether	O
or	O
not	O
allogeneic	O
transplantation	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
derived	O
from	O
fetal	O
membranes	O
(	O
FM	O
)	O
,	O
which	O
are	O
generally	O
discarded	O
as	O
medical	O
waste	O
after	O
delivery	O
,	O
has	O
therapeutic	O
potential	O
.	O

FM	O
-	O
MSC	O
were	O
obtained	O
from	O
Lewis	O
rats	O
and	O
had	O
surface	O
antigen	O
expression	O
and	O
multipotent	O
potential	O
partly	O
similar	O
to	O
those	O
of	O
BM	O
-	O
MSC	O
.	O

Compared	O
with	O
BM	O
-	O
MSC	O
,	O
FM	O
-	O
MSC	O
secreted	O
a	O
comparable	O
amount	O
of	O
hepatocyte	O
growth	O
factor	O
despite	O
a	O
small	O
amount	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
.	O

FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
both	O
expressed	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
but	O
not	O
MHC	O
class	O
II	O
antigens	O
and	O
did	O
not	O
elicit	O
allogeneic	O
lymphocyte	O
proliferation	O
in	O
mixed	O
lymphocyte	O
culture	O
.	O

FM	O
-	O
MSC	O
or	O
BM	O
-	O
MSC	O
obtained	O
from	O
Lewis	O
rats	O
were	O
injected	O
into	O
a	O
MHC	O
-	O
mismatched	O
August	O
-	O
Copenhagen	O
-	O
Irish	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
.	O

Three	O
weeks	O
after	O
injection	O
,	O
blood	O
perfusion	O
and	O
capillary	O
density	O
were	O
significantly	O
higher	O
in	O
the	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
groups	O
than	O
in	O
the	O
phosphate	O
-	O
buffered	O
saline	O
group	O
,	O
and	O
allogeneic	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
were	O
still	O
observed	O
.	O

In	O
nonischemic	O
hind	O
limb	O
tissues	O
,	O
allogeneic	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
injection	O
were	O
associated	O
with	O
a	O
comparatively	O
small	O
amount	O
of	O
T	O
lymphocyte	O
infiltration	O
,	O
compared	O
with	O
the	O
injection	O
of	O
allogeneic	O
splenic	O
lymphocytes	O
.	O

In	O
conclusion	O
,	O
allogeneic	O
FM	O
-	O
MSC	O
injection	O
did	O
not	O
elicit	O
a	O
lymphocyte	O
proliferative	O
response	O
and	O
provided	O
significant	O
improvement	O
in	O
a	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
,	O
comparable	O
to	O
the	O
response	O
to	O
BM	O
-	O
MSC	O
.	O

Thus	O
,	O
allogeneic	O
injection	O
of	O
FM	O
-	O
MSC	O
may	O
be	O
a	O
new	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
severe	O
peripheral	O
vascular	O
disease	O
.	O

Disclosure	O
of	O
potential	O
conflicts	O
of	O
interest	O
is	O
found	O
at	O
the	O
end	O
of	O
this	O
article	O
.	O

Regulation	O
of	O
the	O
Warburg	O
effect	O
in	O
early	O
-	O
passage	O
breast	O
cancer	O
cells	O
.	O

Malignancy	O
in	O
cancer	O
is	O
associated	O
with	O
aerobic	O
glycolysis	O
(	O
Warburg	O
effect	O
)	O
evidenced	O
by	O
increased	O
trapping	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
(	O
FdG	O
)	O
in	O
patients	O
imaged	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
uptake	O
correlates	O
with	O
glucose	O
transporter	O
(	O
GLUT	O
-	O
1	O
)	O
expression	O
,	O
which	O
can	O
be	O
regulated	O
by	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O

We	O
have	O
previously	O
reported	O
in	O
established	O
breast	O
lines	O
that	O
HIF	O
-	O
1alpha	O
levels	O
in	O
the	O
presence	O
of	O
oxygen	O
leads	O
to	O
the	O
Warburg	O
effect	O
.	O

However	O
,	O
glycolysis	O
and	O
GLUT	O
-	O
1	O
can	O
also	O
be	O
induced	O
independent	O
of	O
HIF	O
-	O
1alpha	O
by	O
other	O
factors	O
,	O
such	O
as	O
c	O
-	O
Myc	O
and	O
phosphorylated	O
Akt	O
(	O
pAkt	O
)	O
.	O

This	O
study	O
investigates	O
HIF	O
-	O
1alpha	O
,	O
c	O
-	O
Myc	O
,	O
pAkt	O
,	O
and	O
aerobic	O
glycolysis	O
in	O
low	O
-	O
passage	O
breast	O
cancer	O
cells	O
under	O
the	O
assumption	O
that	O
these	O
represent	O
the	O
in	O
vivo	O
condition	O
better	O
than	O
established	O
lines	O
.	O

Similar	O
to	O
in	O
vivo	O
FdG	O
-	O
PET	O
or	O
primary	O
breast	O
cancers	O
,	O
rates	O
of	O
glycolysis	O
were	O
diverse	O
,	O
being	O
higher	O
in	O
cells	O
expressing	O
both	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
and	O
lower	O
in	O
cell	O
lines	O
low	O
or	O
negative	O
in	O
both	O
transcription	O
factors	O
.	O

No	O
correlations	O
were	O
observed	O
between	O
glycolytic	O
rates	O
and	O
pAkt	O
levels	O
.	O

Two	O
of	O
12	O
cell	O
lines	O
formed	O
xenografts	O
in	O
mice	O
.	O

Both	O
were	O
positive	O
for	O
HIF	O
-	O
1alpha	O
and	O
phosphorylated	O
c	O
-	O
Myc	O
,	O
and	O
only	O
one	O
was	O
positive	O
for	O
pAkt	O
.	O

Glycolysis	O
was	O
affected	O
by	O
pharmacological	O
regulation	O
of	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
.	O

These	O
findings	O
suggest	O
that	O
c	O
-	O
Myc	O
and	O
/	O
or	O
HIF	O
-	O
1alpha	O
activities	O
are	O
both	O
involved	O
in	O
the	O
regulation	O
of	O
glycolysis	O
in	O
breast	O
cancers	O
.	O

Bevacizumab	O
and	O
irinotecan	O
therapy	O
in	O
glioblastoma	O
multiforme	O
:	O
a	O
series	O
of	O
13	O
cases	O
.	O

OBJECT	O
:	O
Endothelial	O
proliferation	O
has	O
been	O
recognized	O
as	O
a	O
marker	O
of	O
high	O
-	O
grade	O
or	O
aggressive	O
glioma	O
.	O

Bevacizumab	O
is	O
a	O
humanized	O
immunoglobulin	O
G1	O
monoclonal	O
antibody	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
that	O
has	O
been	O
shown	O
to	O
have	O
activity	O
in	O
malignant	O
gliomas	O
when	O
combined	O
with	O
irinotecan	O
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
series	O
of	O
13	O
patients	O
with	O
recurrent	O
heavily	O
pretreated	O
malignant	O
glioma	O
that	O
was	O
treated	O
with	O
the	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
.	O

METHODS	O
:	O
Standard	O
therapy	O
with	O
primary	O
resection	O
followed	O
by	O
adjuvant	O
chemotherapy	O
and	O
radiation	O
had	O
failed	O
in	O
all	O
patients	O
.	O

The	O
median	O
number	O
of	O
therapies	O
applied	O
,	O
including	O
initial	O
surgery	O
,	O
was	O
5	O
(	O
range	O
3	O
-	O
7	O
therapies	O
)	O
.	O

Nine	O
patients	O
were	O
started	O
on	O
bevacizumab	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
m2	O
every	O
2	O
weeks	O
.	O

Four	O
patients	O
received	O
bevacizumab	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
m2	O
;	O
irinotecan	O
was	O
given	O
at	O
a	O
dose	O
of	O
125	O
mg	O
/	O
m2	O
every	O
week	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
Of	O
the	O
13	O
treated	O
patients	O
,	O
10	O
(	O
77	O
%	O
)	O
had	O
a	O
radiologically	O
demonstrated	O
partial	O
response	O
and	O
3	O
(	O
23	O
%	O
)	O
had	O
stable	O
disease	O
.	O

Six	O
patients	O
(	O
46	O
%	O
)	O
had	O
a	O
clinical	O
response	O
.	O

The	O
median	O
time	O
to	O
disease	O
progression	O
while	O
on	O
treatment	O
was	O
24	O
weeks	O
.	O

The	O
median	O
overall	O
survival	O
was	O
27	O
weeks	O
.	O

The	O
disease	O
progressed	O
in	O
8	O
patients	O
,	O
despite	O
an	O
initial	O
response	O
.	O

Five	O
patients	O
are	O
still	O
responding	O
to	O
therapy	O
.	O

Six	O
of	O
the	O
8	O
patients	O
whose	O
disease	O
progressed	O
have	O
died	O
.	O

Bevacizumab	O
was	O
discontinued	O
in	O
2	O
patients	O
because	O
of	O
nonfatal	O
intracranial	O
bleeding	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
is	O
safe	O
and	O
has	O
excellent	O
activity	O
even	O
in	O
this	O
relapsed	O
,	O
heavily	O
pretreated	O
population	O
of	O
patients	O
with	O
high	O
-	O
grade	O
malignant	O
glioma	O
,	O
most	O
of	O
whom	O
would	O
not	O
be	O
candidates	O
for	O
clinical	O
trials	O
.	O

Intracerebral	O
grafting	O
of	O
cultured	O
autologous	O
skin	O
fibroblasts	O
into	O
the	O
rat	O
striatum	O
:	O
an	O
assessment	O
of	O
graft	O
size	O
and	O
ultrastructure	O
.	O

To	O
identify	O
a	O
suitable	O
donor	O
cell	O
population	O
for	O
gene	O
therapy	O
applications	O
to	O
the	O
central	O
nervous	O
system	O
,	O
primary	O
fibroblasts	O
isolated	O
from	O
skin	O
biopsies	O
and	O
maintained	O
in	O
culture	O
are	O
employed	O
as	O
autologous	O
cells	O
for	O
intracerebral	O
grafting	O
within	O
the	O
adult	O
rat	O
striatum	O
.	O

Results	O
from	O
the	O
present	O
investigation	O
reveal	O
that	O
cultured	O
primary	O
skin	O
fibroblasts	O
cease	O
to	O
proliferate	O
once	O
they	O
reach	O
confluence	O
;	O
these	O
cells	O
are	O
thus	O
contact	O
inhibited	O
in	O
vitro	O
.	O

Following	O
implantation	O
within	O
the	O
striatum	O
,	O
the	O
volume	O
of	O
the	O
primary	O
fibroblast	O
grafts	O
,	O
stained	O
immunohistochemically	O
for	O
fibronectin	O
,	O
does	O
not	O
differ	O
significantly	O
at	O
3	O
and	O
8	O
weeks	O
.	O

The	O
graft	O
size	O
is	O
dependent	O
on	O
the	O
density	O
of	O
the	O
cell	O
suspension	O
,	O
but	O
not	O
dependent	O
on	O
either	O
the	O
number	O
of	O
passages	O
the	O
cells	O
are	O
taken	O
through	O
in	O
culture	O
prior	O
to	O
grafting	O
or	O
on	O
the	O
postoperative	O
survival	O
period	O
.	O

Ultrastructural	O
evidence	O
reveals	O
that	O
at	O
8	O
weeks	O
the	O
grafts	O
are	O
composed	O
primarily	O
of	O
collagen	O
and	O
fibroblasts	O
with	O
rough	O
endoplasmic	O
reticulum	O
and	O
vesicles	O
.	O

Reactive	O
astrocytic	O
processes	O
and	O
phagocytic	O
cells	O
are	O
also	O
present	O
in	O
the	O
grafts	O
.	O

The	O
grafts	O
are	O
extensively	O
vascularized	O
with	O
capillaries	O
composed	O
of	O
nonfenestrated	O
endothelium	O
;	O
intercellular	O
junctions	O
are	O
evident	O
at	O
sites	O
of	O
apposition	O
between	O
endothelial	O
cells	O
.	O

It	O
is	O
concluded	O
that	O
primary	O
skin	O
fibroblasts	O
are	O
able	O
to	O
survive	O
for	O
at	O
least	O
8	O
weeks	O
following	O
intracerebral	O
implantation	O
and	O
continue	O
to	O
synthesize	O
collagen	O
and	O
fibronectin	O
in	O
vivo	O
.	O

Also	O
,	O
the	O
grafts	O
maintain	O
a	O
constant	O
volume	O
between	O
3	O
and	O
8	O
weeks	O
,	O
thereby	O
indicating	O
that	O
primary	O
skin	O
fibroblasts	O
do	O
not	O
produce	O
tumors	O
.	O

Finally	O
,	O
dynamic	O
host	O
-	O
to	O
-	O
graft	O
interactions	O
-	O
-	O
including	O
phagocytic	O
migration	O
,	O
astrocytic	O
hypertrophy	O
and	O
infiltration	O
within	O
the	O
grafts	O
,	O
and	O
angiogenesis	O
-	O
-	O
are	O
features	O
that	O
constitute	O
the	O
structural	O
integration	O
of	O
primary	O
skin	O
fibroblasts	O
grafted	O
within	O
the	O
adult	O
rat	O
central	O
nervous	O
system	O
.	O

[	O
TESE	O
and	O
mTESE	O
.	O
Therapeutic	O
options	O
in	O
male	O
infertility	O
due	O
to	O
testicular	O
azoospermia	O
]	O
.	O

Modern	O
techniques	O
of	O
testicular	O
sperm	O
extraction	O
(	O
TESE	O
)	O
make	O
it	O
possible	O
for	O
an	O
infertile	O
man	O
to	O
father	O
a	O
child	O
.	O

The	O
operations	O
are	O
standardized	O
to	O
a	O
large	O
extent	O
and	O
the	O
underlying	O
morphological	O
alterations	O
of	O
spermatogenesis	O
also	O
appear	O
to	O
be	O
sufficiently	O
known	O
.	O

Current	O
research	O
is	O
focused	O
on	O
prognostic	O
factors	O
for	O
the	O
testicular	O
material	O
that	O
determine	O
the	O
sperm	O
retrieval	O
rate	O
and	O
success	O
rates	O
after	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	O
injection	O
(	O
IVF	O
-	O
ICSI	O
)	O
.	O
TESE	O
and	O
microTESE	O
are	O
accepted	O
standard	O
operations	O
for	O
testicular	O
sperm	O
retrieval	O
for	O
IVF	O
/	O
ICSI	O
.	O

Predictions	O
for	O
effective	O
sperm	O
recovery	O
are	O
addressed	O
.	O

Demographic	O
consequences	O
of	O
terrestrial	O
habitat	O
loss	O
for	O
pool	O
-	O
breeding	O
amphibians	O
:	O
predicting	O
extinction	O
risks	O
associated	O
with	O
inadequate	O
size	O
of	O
buffer	O
zones	O
.	O

Much	O
of	O
the	O
biodiversity	O
associated	O
with	O
isolated	O
wetlands	O
requires	O
aquatic	O
and	O
terrestrial	O
habitat	O
to	O
maintain	O
viable	O
populations	O
.	O

Current	O
federal	O
wetland	O
regulations	O
in	O
the	O
United	O
States	O
do	O
not	O
protect	O
isolated	O
wetlands	O
or	O
extend	O
protection	O
to	O
surrounding	O
terrestrial	O
habitat	O
.	O

Consequently	O
,	O
some	O
land	O
managers	O
,	O
city	O
planners	O
,	O
and	O
policy	O
makers	O
at	O
the	O
state	O
and	O
local	O
levels	O
are	O
making	O
an	O
effort	O
to	O
protect	O
these	O
wetland	O
and	O
neighboring	O
upland	O
habitats	O
.	O

Balancing	O
human	O
land	O
-	O
use	O
and	O
habitat	O
conservation	O
is	O
challenging	O
,	O
and	O
well	O
-	O
informed	O
land	O
-	O
use	O
policy	O
is	O
hindered	O
by	O
a	O
lack	O
of	O
knowledge	O
of	O
the	O
specific	O
risks	O
of	O
varying	O
amounts	O
of	O
habitat	O
loss	O
.	O

Using	O
projections	O
of	O
wood	O
frog	O
(	O
Rana	O
sylvatica	O
)	O
and	O
spotted	O
salamander	O
(	O
Ambystoma	O
maculatum	O
)	O
populations	O
,	O
we	O
related	O
the	O
amount	O
of	O
high	O
-	O
quality	O
terrestrial	O
habitat	O
surrounding	O
isolated	O
wetlands	O
to	O
the	O
decline	O
and	O
risk	O
of	O
extinction	O
of	O
local	O
amphibian	O
populations	O
.	O

These	O
simulations	O
showed	O
that	O
current	O
state	O
-	O
level	O
wetland	O
regulations	O
protecting	O
30	O
m	O
or	O
less	O
of	O
surrounding	O
terrestrial	O
habitat	O
are	O
inadequate	O
to	O
support	O
viable	O
populations	O
of	O
pool	O
-	O
breeding	O
amphibians	O
.	O

We	O
also	O
found	O
that	O
species	O
with	O
different	O
life	O
-	O
history	O
strategies	O
responded	O
differently	O
to	O
the	O
loss	O
and	O
degradation	O
of	O
terrestrial	O
habitat	O
.	O

The	O
wood	O
frog	O
,	O
with	O
a	O
short	O
life	O
span	O
and	O
high	O
fecundity	O
,	O
was	O
most	O
sensitive	O
to	O
habitat	O
loss	O
and	O
isolation	O
,	O
whereas	O
the	O
longer	O
-	O
lived	O
spotted	O
salamander	O
with	O
lower	O
fecundity	O
was	O
most	O
sensitive	O
to	O
habitat	O
degradation	O
that	O
lowered	O
adult	O
survival	O
rates	O
.	O

Our	O
model	O
results	O
demonstrate	O
that	O
a	O
high	O
probability	O
of	O
local	O
amphibian	O
population	O
persistence	O
requires	O
sufficient	O
terrestrial	O
habitat	O
,	O
the	O
maintenance	O
of	O
habitat	O
quality	O
,	O
and	O
connectivity	O
among	O
local	O
populations	O
.	O

Our	O
results	O
emphasize	O
the	O
essential	O
role	O
of	O
adequate	O
terrestrial	O
habitat	O
to	O
the	O
maintenance	O
of	O
wetland	O
biodiversity	O
and	O
ecosystem	O
function	O
and	O
offer	O
a	O
means	O
of	O
quantifying	O
the	O
risks	O
associated	O
with	O
terrestrial	O
habitat	O
loss	O
and	O
degradation	O
.	O

Endosialin	O
/	O
TEM	O
1	O
/	O
CD248	O
is	O
a	O
pericyte	O
marker	O
of	O
embryonic	O
and	O
tumor	O
neovascularization	O
.	O

The	O
formation	O
of	O
functional	O
,	O
mature	O
blood	O
vessels	O
depends	O
on	O
the	O
interaction	O
between	O
endothelial	O
cells	O
and	O
pericytes	O
.	O

Commonality	O
exists	O
in	O
the	O
processes	O
involved	O
in	O
vasculature	O
development	O
between	O
tissues	O
whether	O
healthy	O
or	O
diseased	O
.	O

Endosialin	O
/	O
TEM	O
1	O
is	O
a	O
cell	O
membrane	O
protein	O
that	O
is	O
expressed	O
in	O
blood	O
vessels	O
during	O
embryogenesis	O
and	O
tumorigenesis	O
but	O
not	O
in	O
normal	O
mature	O
vessels	O
.	O

Antibodies	O
developed	O
to	O
human	O
endosialin	O
were	O
used	O
to	O
investigate	O
endosialin	O
expression	O
and	O
function	O
in	O
human	O
prenatal	O
brain	O
pericytes	O
and	O
pericytes	O
residing	O
in	O
tumors	O
.	O

Anti	O
-	O
endosialin	O
was	O
capable	O
of	O
preventing	O
pericyte	O
tube	O
formation	O
in	O
culture	O
and	O
inhibited	O
migration	O
.	O

Brain	O
pericytes	O
in	O
culture	O
had	O
higher	O
levels	O
of	O
endosialin	O
/	O
TEM	O
1	O
than	O
TEMs	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4	O
,	O
-	O
5	O
,	O
-	O
7	O
,	O
and	O
-	O
8	O
.	O

Immunocytochemistry	O
revealed	O
that	O
endosialin	O
was	O
present	O
in	O
the	O
cytoplasmic	O
body	O
and	O
in	O
the	O
elongated	O
extensions	O
essential	O
to	O
pericyte	O
function	O
.	O

Transgenic	O
mice	O
engineered	O
to	O
express	O
human	O
endosialin	O
bred	O
on	O
an	O
immunocompromised	O
background	O
allowed	O
the	O
growth	O
of	O
human	O
tumor	O
xenografts	O
.	O

In	O
human	O
colon	O
carcinoma	O
Colo205	O
and	O
HT29	B
xenografts	O
grown	O
in	O
human	O
endosialin	O
-	O
transgenic	O
mice	O
,	O
endosialin	O
expression	O
was	O
largely	O
confined	O
to	O
NG2	O
-	O
expressing	O
perivascular	O
cells	O
and	O
not	O
CD31	O
-	O
positive	O
endothelial	O
cells	O
.	O

Similar	O
methods	O
applied	O
to	O
human	O
ovarian	O
and	O
colon	O
tumors	O
confirmed	O
endosialin	O
expression	O
by	O
pericytes	O
.	O

The	O
data	O
indicate	O
that	O
endosialin	O
is	O
strongly	O
expressed	O
by	O
pericytes	O
during	O
periods	O
of	O
active	O
angiogenesis	O
during	O
embryonic	O
and	O
tumor	O
development	O
.	O

Anti	O
-	O
endosialin	O
antibodies	O
may	O
have	O
value	O
in	O
identifying	O
vasculature	O
in	O
malignant	O
tissues	O
.	O

With	O
the	O
appropriate	O
agent	O
,	O
targeting	O
endosialin	O
may	O
interfere	O
with	O
blood	O
vessel	O
growth	O
during	O
tumor	O
development	O
.	O

The	O
role	O
of	O
p53	O
in	O
pigmentation	O
,	O
tanning	O
and	O
melanoma	O
.	O

p53	O
has	O
a	O
central	O
role	O
in	O
skin	O
pigmentation	O
and	O
may	O
impact	O
on	O
melanoma	O
at	O
all	O
stages	O
,	O
however	O
,	O
as	O
it	O
'	O
s	O
mutation	O
frequency	O
in	O
melanoma	O
is	O
low	O
,	O
it	O
'	O
s	O
role	O
has	O
been	O
somewhat	O
under	O
-	O
appreciated	O
.	O

During	O
normal	O
skin	O
function	O
,	O
p53	O
in	O
the	O
keratinocyte	O
is	O
a	O
transducer	O
of	O
the	O
skin	O
tanning	O
signal	O
and	O
an	O
essential	O
component	O
of	O
what	O
is	O
effectively	O
a	O
keratinocyte	O
-	O
melanocyte	O
signaling	O
cycle	O
that	O
regulates	O
skin	O
pigmentation	O
.	O

It	O
is	O
clear	O
that	O
this	O
cycle	O
functions	O
optimally	O
in	O
skin	O
of	O
dark	O
pigmentation	O
.	O

When	O
melanin	O
biosynthesis	O
is	O
genetically	O
disrupted	O
in	O
skin	O
of	O
white	O
complexion	O
,	O
we	O
propose	O
that	O
this	O
cycle	O
operates	O
as	O
a	O
promoter	O
of	O
melanocyte	O
proliferation	O
.	O

The	O
cell	O
autonomous	O
function	O
of	O
p53	O
in	O
melanocytes	O
is	O
not	O
well	O
described	O
,	O
however	O
,	O
the	O
balance	O
of	O
the	O
evidence	O
suggests	O
that	O
p53	O
is	O
an	O
effective	O
tumor	O
suppressor	O
and	O
the	O
myriad	O
of	O
mechanisms	O
by	O
which	O
the	O
p53	O
pathway	O
may	O
be	O
dysregulated	O
in	O
tumors	O
attests	O
to	O
it	O
importance	O
as	O
a	O
tumor	O
suppressor	O
.	O

In	O
this	O
review	O
,	O
we	O
outline	O
the	O
known	O
mechanisms	O
that	O
impair	O
p53	O
itself	O
and	O
its	O
immediate	O
regulators	O
or	O
target	O
genes	O
during	O
melanomagenesis	O
.	O

Due	O
to	O
the	O
importance	O
of	O
this	O
pathway	O
,	O
it	O
is	O
clear	O
that	O
p53	O
disruptions	O
may	O
relate	O
directly	O
to	O
a	O
patient	O
'	O
s	O
prognosis	O
.	O

This	O
pathway	O
will	O
continue	O
to	O
be	O
a	O
focus	O
of	O
investigation	O
,	O
particularly	O
with	O
respect	O
to	O
targeted	O
experimental	O
chemotherapeutics	O
.	O

Quantitative	O
retention	O
-	O
biological	O
activity	O
relationship	O
study	O
by	O
micellar	O
liquid	O
chromatography	O
.	O

In	O
a	O
previous	O
paper	O
,	O
the	O
usefulness	O
of	O
micellar	O
liquid	O
chromatography	O
(	O
MLC	O
)	O
in	O
predicting	O
octanol	O
-	O
water	O
partition	O
coefficients	O
of	O
organic	O
compounds	O
was	O
reported	O
.	O

This	O
paper	O
is	O
the	O
first	O
successful	O
report	O
of	O
a	O
quantitative	O
retention	O
-	O
activity	O
relationship	O
study	O
using	O
the	O
retention	O
factor	O
in	O
MLC	O
for	O
predicting	O
the	O
biological	O
activity	O
of	O
a	O
group	O
of	O
phenolic	O
compounds	O
.	O

Excellent	O
correlation	O
was	O
obtained	O
between	O
the	O
capacity	O
factor	O
in	O
MLC	O
and	O
the	O
bioactivity	O
(	O
measured	O
as	O
log	O
1	O
/	O
C	O
,	O
where	O
C	O
is	O
the	O
50	O
%	O
inhibitory	O
growth	O
concentration	O
)	O
of	O
26	O
para	O
-	O
substituted	O
phenols	O
.	O

A	O
single	O
MLC	O
retention	O
parameter	O
is	O
capable	O
of	O
describing	O
the	O
bioactivity	O
of	O
phenols	O
,	O
while	O
three	O
conventional	O
molecular	O
descriptors	O
(	O
log	O
P	O
(	O
ow	O
)	O
,	O
pKa	O
,	O
and	O
R	O
)	O
are	O
needed	O
to	O
achieve	O
a	O
similar	O
correlation	O
.	O

This	O
indicates	O
that	O
both	O
hydrophobic	O
and	O
electronic	O
interactions	O
are	O
incorporated	O
in	O
a	O
single	O
MLC	O
retention	O
parameter	O
,	O
which	O
is	O
due	O
to	O
the	O
amphiphilic	O
nature	O
of	O
surfactants	O
in	O
the	O
system	O
.	O

In	O
situations	O
like	O
this	O
,	O
QRAR	O
is	O
a	O
suitable	O
alternative	O
to	O
QSAR	O
since	O
measuring	O
MLC	O
retention	O
is	O
much	O
easier	O
than	O
measuring	O
different	O
molecular	O
descriptors	O
needed	O
to	O
build	O
the	O
QSAR	O
model	O
.	O

Addition	O
of	O
10	O
%	O
2	O
-	O
propanol	O
to	O
a	O
micellar	O
system	O
(	O
hybrid	O
system	O
)	O
proved	O
to	O
be	O
the	O
best	O
chromatographic	O
system	O
for	O
the	O
best	O
estimation	O
of	O
the	O
phenols	O
bioactivity	O
.	O

Other	O
chromatographic	O
factors	O
such	O
as	O
pH	O
and	O
stationary	O
phase	O
also	O
showed	O
significant	O
effect	O
on	O
the	O
correlation	O
between	O
capacity	O
factor	O
k	O
'	O
and	O
log	O
1	O
/	O
C	O
.	O

Enhancement	O
of	O
docetaxel	O
-	O
induced	O
cytotoxicity	O
and	O
apoptosis	O
by	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
through	O
downregulation	O
of	O
survivin	O
(	O
BIRC5	O
)	O
,	O
MCL	O
-	O
1	O
and	O
LTbeta	O
-	O
R	O
in	O
hormone	O
-	O
and	O
drug	O
resistant	O
prostate	O
cancer	O
cell	O
line	O
,	O
DU	B
-	I
145	I
.	O

BACKGROUND	O
:	O
The	O
management	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
still	O
remains	O
as	O
an	O
important	O
challenge	O
of	O
daily	O
oncology	O
practice	O
.	O

Docetaxel	O
has	O
proved	O
to	O
be	O
a	O
first	O
line	O
treatment	O
choice	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
could	O
potently	O
inhibit	O
the	O
growth	O
of	O
prostate	O
cancer	O
cells	O
in	O
vitro	O
and	O
its	O
combination	O
with	O
various	O
anticancer	O
agents	O
results	O
in	O
increased	O
cytotoxicity	O
.	O

Based	O
on	O
these	O
data	O
,	O
our	O
aim	O
was	O
to	O
examine	O
the	O
synergistic	O
/	O
additive	O
cytotoxic	O
and	O
apoptotic	O
effects	O
of	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
,	O
in	O
hormone	O
-	O
and	O
drug	O
refractory	O
human	O
DU	B
-	I
145	I
prostate	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
we	O
have	O
searched	O
for	O
the	O
underlying	O
mechanisms	O
of	O
apoptosis	O
by	O
demonstrating	O
apoptosis	O
-	O
related	O
genes	O
.	O

METHODS	O
:	O
XTT	O
cell	O
proliferation	O
assay	O
was	O
used	O
for	O
showing	O
cytotoxicity	O
.	O

For	O
verifying	O
apoptosis	O
,	O
both	O
DNA	O
Fragmentation	O
by	O
ELISA	O
assay	O
and	O
caspase	O
3	O
/	O
7	O
activity	O
measurement	O
were	O
used	O
.	O

For	O
detecting	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
docetaxel	O
-	O
ATRA	O
combination	O
,	O
OligoGeArray	O
which	O
consists	O
of	O
112	O
apoptosis	O
related	O
genes	O
was	O
used	O
.	O

RESULTS	O
:	O
Our	O
results	O
revealed	O
that	O
docetaxel	O
and	O
ATRA	O
were	O
synergistically	O
cytotoxic	O
and	O
apoptotic	O
in	O
DU	B
-	I
145	I
cells	O
,	O
in	O
a	O
dose	O
-	O
and	O
time	O
dependent	O
manner	O
.	O

It	O
was	O
also	O
shown	O
by	O
our	O
studies	O
that	O
apoptosis	O
was	O
induced	O
in	O
DU	B
-	I
145	I
prostate	O
carcinoma	O
cells	O
with	O
significant	O
cytotoxicity	O
,	O
no	O
matter	O
which	O
agent	O
applied	O
first	O
.	O

We	O
have	O
found	O
out	O
that	O
docetaxel	O
-	O
ATRA	O
combination	O
significantly	O
downregulates	O
survivin	O
(	O
BIRC5	O
)	O
,	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
MCL	O
-	O
1	O
)	O
and	O
lymphotoxin	O
beta	O
-	O
receptor	O
(	O
LTbetaR	O
)	O
genes	O
,	O
which	O
all	O
three	O
have	O
pivotal	O
roles	O
in	O
regulation	O
of	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
we	O
strongly	O
suggest	O
that	O
docetaxel	O
and	O
ATRA	O
combination	O
is	O
a	O
good	O
candidate	O
for	O
this	O
challenging	O
era	O
of	O
daily	O
oncologic	O
practice	O
.	O

Also	O
,	O
the	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
might	O
allow	O
a	O
reduction	O
in	O
docetaxel	O
doses	O
and	O
by	O
this	O
way	O
may	O
diminish	O
docetaxel	O
adverse	O
effects	O
while	O
maintaining	O
the	O
therapeutic	O
effect	O
in	O
patients	O
with	O
HRPC	O
.	O

Thermostability	O
and	O
molecular	O
encapsulation	O
within	O
an	O
engineered	O
caged	O
protein	O
scaffold	O
.	O

Self	O
-	O
assembling	O
biological	O
complexes	O
such	O
as	O
viral	O
capsids	O
have	O
been	O
manipulated	O
to	O
function	O
in	O
innovative	O
nanotechnology	O
applications	O
.	O

The	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
from	O
Bacillus	O
stearothermophilus	O
forms	O
a	O
dodecahedral	O
complex	O
and	O
potentially	O
provides	O
another	O
platform	O
for	O
these	O
purposes	O
.	O

In	O
this	O
investigation	O
,	O
we	O
show	O
that	O
this	O
protein	O
assembly	O
exhibits	O
unusual	O
stability	O
and	O
can	O
be	O
modified	O
to	O
encapsulate	O
model	O
drug	O
molecules	O
.	O

To	O
distill	O
the	O
E2	O
protein	O
down	O
to	O
its	O
structural	O
scaffold	O
core	O
,	O
we	O
synthesized	O
a	O
truncated	O
gene	O
optimized	O
for	O
expression	O
in	O
Escherichia	O
coli	O
.	O

The	O
correct	O
assembly	O
and	O
dodecahedral	O
structure	O
of	O
the	O
resulting	O
scaffold	O
was	O
confirmed	O
with	O
dynamic	O
light	O
scattering	O
and	O
transmission	O
electron	O
microscopy	O
.	O

Using	O
circular	O
dichroism	O
and	O
differential	O
scanning	O
calorimetry	O
,	O
we	O
found	O
the	O
thermostability	O
of	O
the	O
complex	O
to	O
be	O
unusually	O
high	O
,	O
with	O
an	O
onset	O
temperature	O
of	O
unfolding	O
at	O
81	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
degrees	O
C	O
and	O
an	O
apparent	O
midpoint	O
unfolding	O
temperature	O
of	O
91	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
degrees	O
C	O
.	O

To	O
evaluate	O
the	O
potential	O
of	O
this	O
scaffold	O
for	O
encapsulation	O
of	O
guest	O
molecules	O
,	O
we	O
made	O
variants	O
at	O
residues	O
381	O
and	O
239	O
which	O
altered	O
the	O
physicochemical	O
properties	O
of	O
the	O
hollow	O
internal	O
cavity	O
.	O

These	O
mutants	O
,	O
yielding	O
60	O
and	O
120	O
mutations	O
within	O
this	O
cavity	O
,	O
assembled	O
into	O
the	O
correct	O
architecture	O
and	O
exhibited	O
high	O
thermostability	O
that	O
was	O
comparable	O
to	O
the	O
wild	O
-	O
type	O
scaffold	O
.	O

To	O
show	O
the	O
applicability	O
of	O
this	O
scaffold	O
,	O
two	O
different	O
fluorescent	O
dye	O
molecules	O
were	O
covalently	O
coupled	O
to	O
the	O
cysteine	O
mutant	O
at	O
site	O
381	O
.	O

We	O
demonstrate	O
that	O
these	O
mutations	O
can	O
introduce	O
non	O
-	O
native	O
functionality	O
and	O
enable	O
molecular	O
encapsulation	O
within	O
the	O
cavity	O
while	O
still	O
retaining	O
the	O
dodecahedral	O
structure	O
.	O

The	O
unusually	O
robust	O
nature	O
of	O
this	O
scaffold	O
and	O
its	O
amenability	O
to	O
internal	O
changes	O
reveal	O
its	O
potential	O
for	O
nanoscale	O
applications	O
.	O

Efficient	O
inhibition	O
of	O
ovarian	O
cancer	O
growth	O
and	O
prolonged	O
survival	O
by	O
transfection	O
with	O
a	O
novel	O
pro	O
-	O
apoptotic	O
gene	O
,	O
hPNAS	O
-	O
4	O
,	O
in	O
a	O
mouse	O
model	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
.	O

OBJECTIVE	O
:	O
We	O
transfected	O
ovarian	O
cancer	O
cells	O
and	O
administered	O
recombinant	O
plasmid	O
encoding	O
hPNAS	O
-	O
4	O
to	O
nude	O
mice	O
bearing	O
ovarian	O
cancer	O
,	O
aiming	O
to	O
evaluate	O
the	O
effect	O
of	O
hPNAS	O
-	O
4	O
against	O
ovarian	O
cancer	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
Ovarian	O
cancer	O
SKOV3	B
cells	O
were	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
plasmid	O
,	O
and	O
cell	O
proliferation	O
was	O
evaluated	O
by	O
MTT	O
assay	O
;	O
apoptosis	O
was	O
examined	O
by	O
DNA	O
ladder	O
,	O
Hoechst33258	O
staining	O
and	O
flow	O
-	O
cytometric	O
assays	O
.	O

Nude	O
mice	O
bearing	O
ovarian	O
cancers	O
were	O
treated	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
/	O
liposome	O
.	O

Tumor	O
growth	O
was	O
determined	O
and	O
survival	O
was	O
recorded	O
.	O

TUNEL	O
assay	O
and	O
microvessel	O
density	O
was	O
assessed	O
to	O
evaluate	O
apoptosis	O
and	O
angiogenesis	O
.	O

RESULTS	O
:	O
Both	O
inhibition	O
of	O
proliferation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
induction	O
of	O
apoptosis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
SKOV3	B
cells	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
in	O
vitro	O
.	O

In	O
hPNAS	O
-	O
4	O
-	O
p	O
-	O
treated	O
tumor	O
cells	O
in	O
vivo	O
,	O
tumor	O
growth	O
significantly	O
decreased	O
,	O
while	O
the	O
survival	O
time	O
of	O
tumor	O
-	O
bearing	O
mice	O
was	O
prolonged	O
compared	O
with	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
apoptosis	O
of	O
tumor	O
cells	O
and	O
decreased	O
angiogenesis	O
in	O
tumor	O
tissue	O
were	O
also	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
promising	O
results	O
on	O
the	O
potential	O
antitumor	O
effects	O
of	O
hPNAS	O
-	O
4	O
on	O
ovarian	O
cancer	O
in	O
vitro	O
and	O
in	O
vivo	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
.	O

Consequently	O
,	O
hPNAS	O
-	O
4	O
has	O
potential	O
as	O
a	O
new	O
gene	O
therapy	O
for	O
human	O
ovarian	O
cancer	O
.	O

Diverse	O
cell	O
signaling	O
events	O
modulated	O
by	O
perlecan	O
.	O

Perlecan	O
is	O
a	O
ubiquitous	O
pericellular	O
proteoglycan	O
ideally	O
placed	O
to	O
mediate	O
cell	O
signaling	O
events	O
controlling	O
migration	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O

Its	O
control	O
of	O
growth	O
factor	O
signaling	O
usually	O
involves	O
interactions	O
with	O
the	O
heparan	O
sulfate	O
chains	O
covalently	O
coupled	O
to	O
the	O
protein	O
core	O
'	O
s	O
N	O
-	O
terminus	O
.	O

However	O
,	O
this	O
modular	O
protein	O
core	O
also	O
binds	O
with	O
relatively	O
high	O
affinity	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
surface	O
receptors	O
,	O
thereby	O
stabilizing	O
cell	O
-	O
matrix	O
links	O
.	O

This	O
review	O
will	O
focus	O
on	O
perlecan	O
-	O
growth	O
factor	O
interactions	O
and	O
describe	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
this	O
highly	O
conserved	O
proteoglycan	O
during	O
development	O
,	O
cancer	O
growth	O
,	O
and	O
angiogenesis	O
.	O

The	O
pro	O
-	O
angiogenic	O
capacities	O
of	O
perlecan	O
that	O
involve	O
proliferative	O
and	O
migratory	O
signals	O
in	O
response	O
to	O
bound	O
growth	O
factors	O
will	O
be	O
explored	O
,	O
as	O
well	O
as	O
the	O
anti	O
-	O
angiogenic	O
signals	O
resulting	O
from	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
known	O
as	O
endorepellin	O
and	O
integrins	O
that	O
control	O
adhesion	O
of	O
cells	O
to	O
the	O
extracellular	O
matrix	O
.	O

These	O
two	O
somewhat	O
diametrically	O
opposed	O
roles	O
will	O
be	O
discussed	O
in	O
light	O
of	O
new	O
data	O
emerging	O
from	O
various	O
fields	O
which	O
converge	O
on	O
perlecan	O
as	O
a	O
key	O
regulator	O
of	O
cell	O
growth	O
and	O
angiogenesis	O
.	O

Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
through	O
a	O
phosphomimetic	O
serine	O
727	O
promotes	O
prostate	O
tumorigenesis	O
independent	O
of	O
tyrosine	O
705	O
phosphorylation	O
.	O

Aberrantly	O
activated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
is	O
implicated	O
in	O
the	O
development	O
of	O
various	O
human	O
cancers	O
.	O

Y705	O
phosphorylation	O
is	O
conventionally	O
thought	O
to	O
be	O
required	O
for	O
Stat3	O
signal	O
-	O
dependent	O
activation	O
and	O
seems	O
to	O
play	O
an	O
essential	O
role	O
in	O
some	O
malignancies	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
Stat3	O
is	O
activated	O
through	O
novel	O
and	O
noncanonical	O
mechanisms	O
,	O
including	O
phosphorylation	O
at	O
S727	O
.	O

Here	O
,	O
we	O
investigate	O
S727	O
phosphorylation	O
of	O
Stat3	O
and	O
its	O
subsequent	O
effects	O
in	O
prostate	O
cancer	O
development	O
,	O
independent	O
of	O
Y705	O
phosphorylation	O
,	O
using	O
mutated	O
Stat3	O
in	O
the	O
human	O
prostate	O
cancer	O
cell	O
line	O
LNCaP	B
.	O

We	O
show	O
mutation	O
of	O
S727	O
to	O
the	O
phosphomimetic	O
residue	O
Glu	O
,	O
and	O
inactivation	O
of	O
Y705	O
(	O
Y705F	O
/	O
S727E	O
)	O
resulted	O
in	O
a	O
remarkable	O
growth	O
advantage	O
in	O
low	O
-	O
serum	O
,	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
,	O
and	O
increased	O
tumorigenicity	O
in	O
nonobese	O
diabetic	O
/	O
severe	O
combined	O
immunodeficient	O
(	O
NOD	O
/	O
SCID	O
)	O
mice	O
,	O
possibly	O
by	O
direct	O
activation	O
of	O
downstream	O
proto	O
-	O
oncogenes	O
c	O
-	O
myc	O
,	O
mcl	O
-	O
1	O
,	O
and	O
survivin	O
.	O

Y705F	O
/	O
S727E	O
mutant	O
cells	O
were	O
more	O
invasive	O
than	O
Y705F	O
/	O
S727A	O
(	O
inactivation	O
of	O
Y705	O
and	O
S727	O
)	O
mutant	O
cells	O
,	O
and	O
more	O
Y705F	O
/	O
S727E	O
mutant	O
Stat3	O
was	O
localized	O
in	O
the	O
nuclei	O
relative	O
to	O
Y705F	O
/	O
S727A	O
mutant	O
Stat3	O
at	O
the	O
steady	O
state	O
.	O

Furthermore	O
,	O
the	O
Y705F	O
/	O
S727E	O
but	O
not	O
the	O
Y705F	O
/	O
S727A	O
mutant	O
induced	O
anchorage	O
-	O
independent	O
growth	O
of	O
noncancerous	O
prostate	O
epithelial	O
cells	O
(	O
RWPE	B
-	I
1	I
)	O
.	O

We	O
further	O
show	O
that	O
Stat3	O
is	O
phosphorylated	O
at	O
S727	O
in	O
65	O
%	O
of	O
malignant	O
prostate	O
tissues	O
(	O
n	O
=	O
20	O
)	O
relative	O
to	O
25	O
%	O
of	O
normal	O
prostate	O
tissues	O
(	O
n	O
=	O
4	O
)	O
.	O

Moreover	O
,	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
phosphoS727	O
-	O
Stat3	O
expression	O
and	O
Gleason	O
score	O
in	O
these	O
prostate	O
cancer	O
tissues	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
S727	O
phosphorylation	O
is	O
sufficient	O
to	O
activate	O
Stat3	O
,	O
thereby	O
driving	O
prostate	O
tumorigenesis	O
independent	O
of	O
Y705	O
phosphorylation	O
.	O

Angiogenesis	O
associated	O
with	O
visceral	O
and	O
subcutaneous	O
adipose	O
tissue	O
in	O
severe	O
human	O
obesity	O
.	O

OBJECTIVE	O
:	O
The	O
expansion	O
of	O
adipose	O
tissue	O
is	O
linked	O
to	O
the	O
development	O
of	O
its	O
vasculature	O
.	O

However	O
,	O
the	O
regulation	O
of	O
adipose	O
tissue	O
angiogenesis	O
in	O
humans	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
angiogenesis	O
associated	O
with	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
)	O
and	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
from	O
the	O
same	O
obese	O
patients	O
in	O
an	O
in	O
vivo	O
model	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
Adipose	O
tissue	O
samples	O
from	O
visceral	O
(	O
VAT	O
)	O
and	O
subcutaneous	O
(	O
SAT	O
)	O
sites	O
,	O
obtained	O
from	O
36	O
obese	O
patients	O
(	O
mean	O
BMI	O
46	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
during	O
bariatric	O
surgery	O
,	O
were	O
layered	O
on	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
.	O

RESULTS	O
:	O
Both	O
SAT	O
and	O
VAT	O
expressed	O
angiogenic	O
factors	O
without	O
significant	O
difference	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
.	O

Adipose	O
tissue	O
layered	O
on	O
CAM	O
stimulated	O
angiogenesis	O
.	O

Angiogenic	O
stimulation	O
was	O
macroscopically	O
detectable	O
,	O
with	O
engulfment	O
of	O
the	O
samples	O
,	O
in	O
39	O
%	O
and	O
was	O
evidenced	O
by	O
angiography	O
in	O
59	O
%	O
of	O
the	O
samples	O
.	O

A	O
connection	O
between	O
CAM	O
and	O
adipose	O
tissue	O
vessels	O
was	O
evidenced	O
by	O
immunohistochemistry	O
,	O
with	O
recruitment	O
of	O
both	O
avian	O
and	O
human	O
endothelial	O
cells	O
.	O

The	O
angiogenic	O
potency	O
of	O
adipose	O
tissue	O
was	O
not	O
related	O
to	O
its	O
localization	O
(	O
with	O
an	O
angiogenic	O
stimulation	O
in	O
60	O
%	O
of	O
SAT	O
samples	O
and	O
61	O
%	O
of	O
VAT	O
samples	O
)	O
or	O
to	O
adipocyte	O
size	O
or	O
inflammatory	O
infiltrate	O
assessed	O
in	O
adipose	O
samples	O
before	O
the	O
graft	O
on	O
CAM	O
.	O

Stimulation	O
of	O
angiogenesis	O
by	O
adipose	O
tissue	O
was	O
nearly	O
abolished	O
by	O
bevacizumab	O
,	O
which	O
specifically	O
targets	O
human	O
VEGF	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
established	O
a	O
model	O
to	O
study	O
the	O
regulation	O
of	O
angiogenesis	O
by	O
human	O
adipose	O
tissue	O
.	O

This	O
model	O
highlighted	O
the	O
role	O
of	O
VEGF	O
in	O
angiogenesis	O
in	O
both	O
SAT	O
and	O
VAT	O
.	O

The	O
in	O
vivo	O
properties	O
of	O
STX243	O
:	O
a	O
potent	O
angiogenesis	O
inhibitor	O
in	O
breast	O
cancer	O
.	O

The	O
steroidal	O
-	O
based	O
drug	O
2	O
-	O
ethyloestradiol	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX243	O
)	O
has	O
been	O
developed	O
as	O
a	O
potent	O
antiangiogenic	O
and	O
antitumour	O
compound	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
STX243	O
is	O
more	O
active	O
in	O
vivo	O
than	O
the	O
clinically	O
relevant	O
drug	O
2	O
-	O
methoxyoestradiol	O
(	O
2	O
-	O
MeOE2	O
)	O
and	O
the	O
structurally	O
similar	O
compound	O
2	O
-	O
MeOE2	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX140	O
)	O
.	O

The	O
tumour	O
growth	O
inhibition	O
efficacy	O
,	O
antiangiogenic	O
potential	O
and	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
using	O
four	O
in	O
vivo	O
models	O
.	O

Both	O
STX243	O
and	O
STX140	O
were	O
capable	O
of	O
retarding	O
the	O
growth	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
xenograft	O
tumours	O
(	O
72	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
no	O
inhibition	O
was	O
observed	O
for	O
animals	O
treated	O
with	O
2	O
-	O
MeOE2	O
.	O

Further	O
tumour	O
inhibition	O
studies	O
showed	O
that	O
STX243	O
was	O
also	O
active	O
against	O
MCF	B
-	I
7	I
paclitaxel	O
-	O
resistant	O
tumours	O
.	O

Using	O
a	O
Matrigel	O
plug	O
-	O
based	O
model	O
,	O
in	O
vivo	O
angiogenesis	O
was	O
restricted	O
with	O
STX243	O
and	O
STX140	O
(	O
50	O
and	O
72	O
%	O
,	O
respectively	O
,	O
using	O
a	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
oral	O
dose	O
)	O
,	O
thereby	O
showing	O
the	O
antiangiogenic	O
activity	O
of	O
both	O
compounds	O
.	O

The	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
at	O
two	O
different	O
doses	O
using	O
adult	O
female	O
rats	O
.	O

The	O
compound	O
was	O
orally	O
bioavailable	O
(	O
31	O
%	O
after	O
a	O
single	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dose	O
)	O
and	O
resistant	O
to	O
metabolism	O
.	O

These	O
results	O
show	O
that	O
STX243	O
is	O
a	O
potent	O
in	O
vivo	O
drug	O
and	O
could	O
be	O
clinically	O
effective	O
at	O
treating	O
a	O
number	O
of	O
oncological	O
conditions	O
.	O

M	O
-	O
CSF	O
signals	O
through	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
via	O
Sp1	O
to	O
induce	O
VEGF	O
production	O
and	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O

BACKGROUND	O
:	O
M	O
-	O
CSF	O
recruits	O
mononuclear	O
phagocytes	O
which	O
regulate	O
processes	O
such	O
as	O
angiogenesis	O
and	O
metastases	O
in	O
tumors	O
.	O

VEGF	O
is	O
a	O
potent	O
activator	O
of	O
angiogenesis	O
as	O
it	O
promotes	O
endothelial	O
cell	O
proliferation	O
and	O
new	O
blood	O
vessel	O
formation	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
in	O
vitro	O
M	O
-	O
CSF	O
induces	O
the	O
expression	O
of	O
biologically	O
-	O
active	O
VEGF	O
from	O
human	O
monocytes	O
.	O

METHODOLOGY	O
AND	O
RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
molecular	O
mechanism	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
production	O
.	O

Using	O
a	O
construct	O
containing	O
the	O
VEGF	O
promoter	O
linked	O
to	O
a	O
luciferase	O
reporter	O
,	O
we	O
found	O
that	O
a	O
mutation	O
reducing	O
HIF	O
binding	O
to	O
the	O
VEGF	O
promoter	O
had	O
no	O
significant	O
effect	O
on	O
luciferase	O
production	O
induced	O
by	O
M	O
-	O
CSF	O
stimulation	O
.	O

Further	O
analysis	O
revealed	O
that	O
M	O
-	O
CSF	O
induced	O
VEGF	O
through	O
the	O
MAPK	O
/	O
ERK	O
signaling	O
pathway	O
via	O
the	O
transcription	O
factor	O
,	O
Sp1	O
.	O

Thus	O
,	O
inhibition	O
of	O
either	O
ERK	O
or	O
Sp1	O
suppressed	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

M	O
-	O
CSF	O
also	O
induced	O
the	O
nuclear	O
localization	O
of	O
Sp1	O
,	O
which	O
was	O
blocked	O
by	O
ERK	O
inhibition	O
.	O

Finally	O
,	O
mutating	O
the	O
Sp1	O
binding	O
sites	O
within	O
the	O
VEGF	O
promoter	O
or	O
inhibiting	O
ERK	O
decreased	O
VEGF	O
promoter	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
treated	O
human	O
monocytes	O
.	O

To	O
evaluate	O
the	O
biological	O
significance	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
,	O
we	O
used	O
an	O
in	O
vivo	O
angiogenesis	O
model	O
to	O
illustrate	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
recruit	O
mononuclear	O
phagocytes	O
,	O
increase	O
VEGF	O
levels	O
,	O
and	O
enhance	O
angiogenesis	O
.	O

Importantly	O
,	O
the	O
addition	O
of	O
a	O
neutralizing	O
VEGF	O
antibody	O
abolished	O
M	O
-	O
CSF	O
-	O
induced	O
blood	O
vessel	O
formation	O
.	O

CONCLUSION	O
:	O
These	O
data	O
delineate	O
an	O
ERK	O
-	O
and	O
Sp1	O
-	O
dependent	O
mechanism	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
and	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
induce	O
angiogenesis	O
via	O
VEGF	O
in	O
vivo	O
.	O

Allergic	O
pulmonary	O
inflammation	O
promotes	O
the	O
recruitment	O
of	O
circulating	O
tumor	O
cells	O
to	O
the	O
lung	O
.	O

Allergen	O
-	O
induced	O
respiratory	O
inflammation	O
facilitates	O
and	O
/	O
or	O
elicits	O
the	O
extravasation	O
of	O
proinflammatory	O
leukocytes	O
by	O
well	O
-	O
understood	O
mechanisms	O
that	O
mediate	O
the	O
movement	O
of	O
multiple	O
cell	O
types	O
.	O

The	O
nonspecific	O
character	O
of	O
these	O
pathways	O
led	O
us	O
to	O
hypothesize	O
that	O
circulating	O
cancer	O
cells	O
use	O
similar	O
mechanisms	O
,	O
promoting	O
secondary	O
tumor	O
formation	O
at	O
distal	O
sites	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
frequency	O
of	O
metastasis	O
to	O
the	O
lung	O
as	O
a	O
function	O
of	O
allergic	O
pulmonary	O
inflammation	O
was	O
assessed	O
following	O
the	O
i	O
.	O
v	O
.	O
injection	O
of	O
B16	B
-	I
F10	I
melanoma	O
cells	O
in	O
mice	O
.	O

These	O
studies	O
showed	O
that	O
allergen	O
-	O
induced	O
pulmonary	O
inflammation	O
resulted	O
in	O
a	O
>	O
3	O
-	O
fold	O
increase	O
in	O
lung	O
metastases	O
.	O

This	O
increase	O
was	O
dependent	O
on	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
activities	O
;	O
however	O
,	O
it	O
occurred	O
independent	O
of	O
the	O
induced	O
eosinophilia	O
associated	O
with	O
allergen	O
provocation	O
.	O

Interventional	O
strategies	O
showed	O
that	O
existing	O
therapeutic	O
modalities	O
for	O
asthma	O
,	O
such	O
as	O
inhaled	O
corticosteroids	O
,	O
were	O
sufficient	O
to	O
block	O
the	O
enhanced	O
pulmonary	O
recruitment	O
of	O
cancer	O
cells	O
from	O
circulation	O
.	O

Additional	O
mechanistic	O
studies	O
further	O
suggested	O
that	O
the	O
ability	O
of	O
circulating	O
cancer	O
cells	O
to	O
extravasate	O
to	O
surrounding	O
lung	O
tissues	O
was	O
linked	O
to	O
the	O
activation	O
of	O
the	O
vascular	O
endothelium	O
via	O
one	O
or	O
more	O
Galpha	O
(	O
i	O
)	O
-	O
coupled	O
receptors	O
.	O

Interestingly	O
,	O
a	O
survey	O
of	O
a	O
clinical	O
breast	O
cancer	O
surgical	O
database	O
showed	O
that	O
the	O
incidence	O
of	O
asthma	O
was	O
higher	O
among	O
patients	O
with	O
lung	O
metastases	O
.	O

Thus	O
,	O
our	O
data	O
show	O
that	O
allergic	O
respiratory	O
inflammation	O
may	O
represent	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
lung	O
metastases	O
and	O
suggest	O
that	O
amelioration	O
of	O
the	O
pulmonary	O
inflammation	O
associated	O
with	O
asthma	O
will	O
have	O
a	O
direct	O
and	O
immediate	O
benefit	O
to	O
the	O
7	O
%	O
to	O
8	O
%	O
of	O
breast	O
cancer	O
patients	O
with	O
this	O
lung	O
disease	O
.	O

PI3	O
K	O
/	O
Akt	O
-	O
dependent	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
by	O
NF	O
-	O
kappaB	O
in	O
metastatic	O
prostate	O
cancer	O
cells	O
.	O

BACKGROUND	O
:	O
Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
exert	O
osteoinductive	O
effects	O
in	O
prostate	O
cancer	O
(	O
PC	O
)	O
via	O
uncharacterized	O
mechanisms	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
implicated	O
in	O
PC	O
metastasis	O
,	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
or	O
BMP	O
-	O
4	O
/	O
Smad	O
signaling	O
in	O
PC	O
cells	O
.	O

METHODS	O
:	O
NF	O
-	O
kappaB	O
inhibition	O
was	O
achieved	O
by	O
IkappaBalpha	O
super	O
-	O
repressor	O
adenoviral	O
vector	O
and	O
activation	O
was	O
monitored	O
by	O
EMSA	O
and	O
reporter	O
assays	O
.	O

BMP	O
expression	O
and	O
activation	O
was	O
measured	O
by	O
PCR	O
and	O
reporter	O
assays	O
.	O

Promoter	O
binding	O
assay	O
was	O
performed	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O

Smad1	O
/	O
5	O
/	O
8	O
phosphorylation	O
was	O
measured	O
by	O
Western	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
PCR	O
and	O
chimeric	O
BMP	O
-	O
2	O
and	O
BMP	O
-	O
4	O
luciferase	O
assays	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
confers	O
robust	O
and	O
selective	O
activation	O
of	O
BMP	O
-	O
2	O
in	O
p65	O
overexpressing	O
or	O
rhTNF	O
-	O
alpha	O
-	O
stimulated	O
PC	O
cells	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
significantly	O
reduced	O
transcript	O
levels	O
and	O
autocrine	O
production	O
of	O
BMP	O
-	O
2	O
by	O
rhTNF	O
-	O
alpha	O
stimulated	O
C4	B
-	I
2B	I
cells	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
the	O
parental	O
LNCaP	B
cells	O
.	O

Selective	O
inhibition	O
of	O
PI3	O
K	O
/	O
Akt	O
suppressed	O
the	O
NF	O
-	O
kappaB	O
-	O
induced	O
BMP	O
-	O
2	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreased	O
the	O
transcript	O
levels	O
and	O
BMP	O
-	O
2	O
-	O
induced	O
phosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
,	O
critical	O
downstream	O
targets	O
of	O
BMP	O
-	O
2	O
signaling	O
in	O
PC	O
cells	O
.	O

Notably	O
,	O
the	O
activation	O
of	O
BMPRII	O
by	O
BMP	O
-	O
2	O
is	O
required	O
for	O
modulation	O
of	O
Smad	O
activation	O
by	O
NF	O
-	O
kappaB	O
in	O
PC	O
cells	O
.	O

Based	O
on	O
ChIP	O
analysis	O
,	O
the	O
transcriptional	O
regulation	O
of	O
BMP	O
-	O
2	O
gene	O
by	O
NF	O
-	O
kappaB	O
may	O
be	O
partially	O
attributed	O
to	O
binding	O
to	O
kappab	O
site	O
on	O
the	O
BMP	O
-	O
2	O
promoter	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
PI3	O
K	O
/	O
Akt	O
-	O
NF	O
-	O
kappaB	O
axis	O
may	O
promote	O
PC	O
bone	O
metastasis	O
in	O
part	O
by	O
regulating	O
transcription	O
and	O
activation	O
of	O
the	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
cascade	O
in	O
osteotropic	O
PC	O
cells	O
.	O

Inhibition	O
of	O
energy	O
-	O
producing	O
pathways	O
of	O
HepG2	B
cells	O
by	O
3	O
-	O
bromopyruvate	O
.	O

3	O
-	O
BrPA	O
(	O
3	O
-	O
bromopyruvate	O
)	O
is	O
an	O
alkylating	O
agent	O
with	O
anti	O
-	O
tumoral	O
activity	O
on	O
hepatocellular	O
carcinoma	O
.	O

This	O
compound	O
inhibits	O
cellular	O
ATP	O
production	O
owing	O
to	O
its	O
action	O
on	O
glycolysis	O
and	O
oxidative	O
phosphorylation	O
;	O
however	O
,	O
the	O
specific	O
metabolic	O
steps	O
and	O
mechanisms	O
of	O
3	O
-	O
BrPA	O
action	O
in	O
human	O
hepatocellular	O
carcinomas	O
,	O
particularly	O
its	O
effects	O
on	O
mitochondrial	O
energetics	O
,	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
it	O
was	O
found	O
that	O
incubation	O
of	O
HepG2	B
cells	O
with	O
a	O
low	O
concentration	O
of	O
3	O
-	O
BrPA	O
for	O
a	O
short	O
period	O
(	O
150	O
microM	O
for	O
30	O
min	O
)	O
significantly	O
affected	O
both	O
glycolysis	O
and	O
mitochondrial	O
respiratory	O
functions	O
.	O

The	O
activity	O
of	O
mitochondrial	O
hexokinase	O
was	O
not	O
inhibited	O
by	O
150	O
microM	O
3	O
-	O
BrPA	O
,	O
but	O
this	O
concentration	O
caused	O
more	O
than	O
70	O
%	O
inhibition	O
of	O
GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
and	O
3	O
-	O
phosphoglycerate	O
kinase	O
activities	O
.	O

Additionally	O
,	O
3	O
-	O
BrPA	O
treatment	O
significantly	O
impaired	O
lactate	O
production	O
by	O
HepG2	B
cells	O
,	O
even	O
when	O
glucose	O
was	O
withdrawn	O
from	O
the	O
incubation	O
medium	O
.	O

Oxygen	O
consumption	O
of	O
HepG2	B
cells	O
supported	O
by	O
either	O
pyruvate	O
/	O
malate	O
or	O
succinate	O
was	O
inhibited	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
3	O
-	O
BrPA	O
in	O
glucose	O
-	O
free	O
medium	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
oxygen	O
consumption	O
was	O
affected	O
only	O
when	O
succinate	O
was	O
used	O
as	O
the	O
oxidizable	O
substrate	O
.	O

An	O
increase	O
in	O
oligomycin	O
-	O
independent	O
respiration	O
was	O
observed	O
in	O
HepG2	B
cells	O
treated	O
with	O
3	O
-	O
BrPA	O
only	O
when	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
indicating	O
that	O
3	O
-	O
BrPA	O
induces	O
mitochondrial	O
proton	O
leakage	O
as	O
well	O
as	O
blocking	O
the	O
electron	O
transport	O
system	O
.	O

The	O
activity	O
of	O
succinate	O
dehydrogenase	O
was	O
inhibited	O
by	O
70	O
%	O
by	O
3	O
-	O
BrPA	O
treatment	O
.	O

These	O
results	O
suggest	O
that	O
the	O
combined	O
action	O
of	O
3	O
-	O
BrPA	O
on	O
succinate	O
dehydrogenase	O
and	O
on	O
glycolysis	O
,	O
inhibiting	O
steps	O
downstream	O
of	O
the	O
phosphorylation	O
of	O
glucose	O
,	O
play	O
an	O
important	O
role	O
in	O
HepG2	B
cell	O
death	O
.	O

[	O
Retinochoroidopathy	O
after	O
intravitreal	O
anti	O
-	O
VEGF	O
treatment	O
]	O

A	O
74	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
metamorphopsias	O
of	O
the	O
right	O
eye	O
2	O
weeks	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
to	O
treat	O
choroidal	O
neovascularization	O
due	O
to	O
exudative	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

The	O
diagnosis	O
reached	O
was	O
retinochoroiditis	O
as	O
an	O
occult	O
manifestation	O
of	O
sarcoidosis	O
,	O
possibly	O
resulting	O
from	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	O
.	O

The	O
patient	O
received	O
a	O
prescription	O
for	O
100	O
mg	O
Ultralan	O
to	O
be	O
taken	O
daily	O
for	O
3	O
days	O
and	O
then	O
tapered	O
in	O
3	O
day	O
steps	O
.	O

During	O
the	O
further	O
course	O
no	O
deterioration	O
of	O
the	O
condition	O
was	O
observed	O
.	O

[	O
The	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
:	O
an	O
analysis	O
of	O
513	O
cases	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

METHODS	O
:	O

513	O
APL	O
patients	O
in	O
the	O
last	O
two	O
decades	O
were	O
retrospectively	O
analyzed	O
in	O
this	O
research	O
.	O

We	O
investigated	O
the	O
clinical	O
features	O
including	O
age	O
,	O
sex	O
,	O
abnormality	O
of	O
peripheral	O
hemogram	O
before	O
treatment	O
,	O
therapeutic	O
effect	O
and	O
follow	O
-	O
up	O
and	O
laboratory	O
data	O
such	O
as	O
morphology	O
,	O
immunology	O
,	O
cytogenetics	O
and	O
molecular	O
biology	O
(	O
MICM	O
)	O
.	O

RESULTS	O
:	O

The	O
median	O
age	O
of	O
the	O
APL	O
patients	O
was	O
33	O
years	O
old	O
and	O
the	O
ratio	O
of	O
male	O
and	O
female	O
was	O
1	O
.	O
21	O
:	O
1	O
.	O

Before	O
treatment	O
,	O
the	O
median	O
level	O
of	O
WBC	O
was	O
4	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
the	O
detection	O
rate	O
of	O
abnormal	O
promyelocyte	O
on	O
blood	O
film	O
was	O
85	O
.	O
8	O
%	O
;	O
with	O
immunophenotypic	O
detection	O
,	O
the	O
expression	O
levels	O
of	O
CD117	O
,	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD7	O
,	O
CD14	O
and	O
CD19	O
in	O
APL	O
were	O
found	O
to	O
be	O
lower	O
and	O
the	O
expression	O
levels	O
of	O
CD2	O
,	O
CD33	O
and	O
MPO	O
higher	O
than	O
those	O
in	O
other	O
subtypes	O
of	O
acute	O
myelocytic	O
leukemia	O
(	O
AML	O
)	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Specific	O
abnormal	O
chromosome	O
t	O
(	O
15	O
;	O
17	O
)	O
was	O
detected	O
in	O
91	O
.	O
7	O
%	O
of	O
the	O
patients	O
,	O
of	O
whom	O
75	O
.	O
9	O
%	O
had	O
standard	O
translocation	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
being	O
the	O
most	O
common	O
one	O
and	O
15	O
.	O
8	O
%	O
of	O
the	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
additional	O
abnormal	O
chromosome	O
.	O

There	O
was	O
only	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
with	O
normal	O
karyotype	O
.	O

However	O
,	O
the	O
presence	O
of	O
both	O
simple	O
translocation	O
and	O
complex	O
translocation	O
was	O
seldom	O
seen	O
.	O

With	O
molecular	O
biological	O
detection	O
,	O
PML	O
/	O
RARalpha	O
fusion	O
gene	O
positive	O
rate	O
was	O
99	O
.	O
6	O
%	O
.	O

In	O
a	O
relatively	O
long	O
clinical	O
follow	O
-	O
up	O
,	O
we	O
found	O
that	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
in	O
APL	O
patients	O
was	O
84	O
.	O
7	O
%	O
,	O
incidence	O
of	O
DIC	O
was	O
13	O
.	O
4	O
%	O
and	O
five	O
-	O
year	O
survival	O
rate	O
was	O
30	O
.	O
7	O
%	O
.	O

The	O
median	O
count	O
of	O
WBC	O
in	O
CR	O
group	O
was	O
lower	O
than	O
that	O
non	O
-	O
remission	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
on	O
expressions	O
of	O
CD34	O
and	O
CD2	O
and	O
changes	O
of	O
cytogenetics	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

Comprehensive	O
evaluation	O
of	O
MICM	O
could	O
be	O
of	O
important	O
significance	O
in	O
the	O
diagnosis	O
and	O
prognosis	O
judgment	O
for	O
APL	O
patients	O
.	O

The	O
CR	O
rate	O
in	O
these	O
patients	O
with	O
high	O
WBC	O
count	O
was	O
considerable	O
low	O
.	O

The	O
detection	O
of	O
macrosomia	O
at	O
a	O
teaching	O
hospital	O
.	O

We	O
sought	O
to	O
determine	O
the	O
detection	O
(	O
clinical	O
or	O
sonographic	O
)	O
rate	O
of	O
macrosomic	O
newborns	O
(	O
at	O
least	O
4000	O
g	O
)	O
and	O
the	O
peripartum	O
factors	O
among	O
those	O
who	O
were	O
or	O
were	O
not	O
identified	O
accurately	O
.	O

We	O
retrospectively	O
reviewed	O
all	O
deliveries	O
over	O
1	O
year	O
and	O
all	O
maternal	O
and	O
neonatal	O
charts	O
of	O
macrosomic	O
newborns	O
delivered	O
during	O
that	O
year	O
.	O

Odds	O
ratio	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
.	O

Over	O
a	O
12	O
-	O
month	O
period	O
,	O
the	O
rate	O
of	O
macrosomia	O
was	O
10	O
%	O
(	O
421	O
/	O
4194	O
)	O
and	O
of	O
those	O
,	O
only	O
11	O
%	O
(	O
95	O
%	O
CI	O
8	O
to	O
14	O
%	O
)	O
were	O
suspected	O
clinically	O
or	O
sonographically	O
.	O

None	O
of	O
the	O
newborns	O
weighing	O
4500	O
g	O
or	O
more	O
were	O
recognized	O
before	O
birth	O
(	O
0	O
/	O
57	O
;	O
95	O
%	O
CI	O
0	O
to	O
6	O
%	O
)	O
.	O

The	O
rate	O
of	O
cesarean	O
delivery	O
was	O
significantly	O
higher	O
among	O
newborns	O
correctly	O
identified	O
as	O
macrosomic	O
(	O
58	O
%	O
)	O
versus	O
those	O
missed	O
(	O
36	O
%	O
;	O
OR	O
2	O
.	O
76	O
,	O
95	O
%	O
CI	O
1	O
.	O
46	O
,	O
5	O
.	O
16	O
)	O
.	O

The	O
incidence	O
of	O
newborns	O
weighing	O
in	O
excess	O
of	O
4000	O
g	O
is	O
10	O
%	O
,	O
and	O
approximately	O
90	O
%	O
of	O
these	O
macrosomic	O
newborns	O
were	O
unsuspected	O
before	O
birth	O
.	O

Silencing	O
of	O
directional	O
migration	O
in	O
roundabout4	O
knockdown	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Roundabouts	O
are	O
axon	O
guidance	O
molecules	O
that	O
have	O
recently	O
been	O
identified	O
to	O
play	O
a	O
role	O
in	O
vascular	O
guidance	O
as	O
well	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
gene	O
knockdown	O
analysis	O
of	O
endothelial	O
Robos	O
,	O
in	O
particular	O
roundabout	O
4	O
(	O
robo4	O
)	O
,	O
the	O
predominant	O
Robo	O
in	O
endothelial	O
cells	O
using	O
small	O
interfering	O
RNA	O
technology	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Robo1	O
and	O
Robo4	O
knockdown	O
cells	O
display	O
distinct	O
activity	O
in	O
endothelial	O
cell	O
migration	O
assay	O
.	O

The	O
knockdown	O
of	O
robo4	O
abrogated	O
the	O
chemotactic	O
response	O
of	O
endothelial	O
cells	O
to	O
serum	O
but	O
enhanced	O
a	O
chemokinetic	O
response	O
to	O
Slit2	O
,	O
while	O
robo1	O
knockdown	O
cells	O
do	O
not	O
display	O
chemotactic	O
response	O
to	O
serum	O
or	O
VEGF	O
.	O

Robo4	O
knockdown	O
endothelial	O
cells	O
unexpectedly	O
show	O
up	O
regulation	O
of	O
Rho	O
GTPases	O
.	O

Zebrafish	O
Robo4	O
rescues	O
both	O
Rho	O
GTPase	O
homeostasis	O
and	O
serum	O
reduced	O
chemotaxis	O
in	O
robo4	O
knockdown	O
cells	O
.	O

Robo1	O
and	O
Robo4	O
interact	O
and	O
share	O
molecules	O
such	O
as	O
Slit2	O
,	O
Mena	O
and	O
Vilse	O
,	O
a	O
Cdc42	O
-	O
GAP	O
.	O

In	O
addition	O
,	O
this	O
study	O
mechanistically	O
implicates	O
IRSp53	O
in	O
the	O
signaling	O
nexus	O
between	O
activated	O
Cdc42	O
and	O
Mena	O
,	O
both	O
of	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
involved	O
with	O
Robo4	O
signaling	O
in	O
endothelial	O
cells	O
.	O

CONCLUSION	O
:	O
This	O
study	O
identifies	O
specific	O
components	O
of	O
the	O
Robo	O
signaling	O
apparatus	O
that	O
work	O
together	O
to	O
guide	O
directional	O
migration	O
of	O
endothelial	O
cells	O
.	O

Atypical	O
mycobacteriosis	O
of	O
the	O
larynx	O
:	O
an	O
unusual	O
clinical	O
presentation	O
secondary	O
to	O
steroids	O
inhalation	O
.	O

Vocal	O
cords	O
stiffness	O
can	O
be	O
associated	O
with	O
a	O
variety	O
of	O
etiologic	O
agents	O
,	O
but	O
it	O
is	O
rarely	O
seen	O
with	O
atypical	O
mycobacteria	O
,	O
for	O
example	O
,	O
Mycobacterium	O
avium	O
complex	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
white	O
woman	O
who	O
is	O
and	O
was	O
maintained	O
on	O
inhaled	O
steroids	O
.	O

She	O
presented	O
with	O
hoarseness	O
and	O
low	O
-	O
grade	O
fever	O
,	O
but	O
her	O
medical	O
history	O
was	O
otherwise	O
unremarkable	O
.	O

Laryngoscopy	O
revealed	O
bilateral	O
scarring	O
of	O
the	O
vocal	O
cords	O
.	O

Vocal	O
cord	O
biopsies	O
were	O
performed	O
.	O

Histologic	O
examination	O
revealed	O
unremarkable	O
laryngeal	O
mucosa	O
,	O
except	O
for	O
abundant	O
subepithelial	O
non	O
-	O
necrotizing	O
granulomata	O
.	O

The	O
differential	O
diagnosis	O
included	O
sarcoid	O
,	O
Klebsiella	O
scleroma	O
,	O
and	O
tuberculosis	O
.	O

Special	O
stains	O
reviewed	O
abundant	O
acid	O
-	O
fast	O
bacilli	O
,	O
later	O
confirmed	O
by	O
a	O
DNA	O
assay	O
on	O
induced	O
deep	O
sputum	O
,	O
consistent	O
with	O
M	O
avium	O
complex	O
.	O

Subsequently	O
,	O
steroids	O
were	O
withdrawn	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
a	O
multiple	O
-	O
drug	O
antituberculous	O
regimen	O
and	O
had	O
a	O
full	O
recovery	O
.	O

This	O
unusual	O
clinical	O
presentation	O
of	O
the	O
atypical	O
mycobacteriosis	O
may	O
be	O
encountered	O
by	O
otolaryngologists	O
and	O
pathologists	O
,	O
and	O
it	O
is	O
critical	O
to	O
recognize	O
it	O
in	O
patients	O
immunocompromised	O
because	O
of	O
steroids	O
.	O

A	O
novel	O
integrin	O
alpha5beta1	O
antagonistic	O
peptide	O
,	O
A5	O
-	O
1	O
,	O
screened	O
by	O
Protein	O
Chip	O
system	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

Integrin	O
alpha5beta1	O
immobilized	O
on	O
a	O
ProteoChip	O
was	O
used	O
to	O
screen	O
new	O
antagonistic	O
peptides	O
from	O
multiple	O
hexapeptide	O
sub	O
-	O
libraries	O
of	O
the	O
positional	O
scanning	O
synthetic	O
peptide	O
combinatorial	O
library	O
(	O
PS	O
-	O
SPCL	O
)	O
.	O

The	O
integrin	O
alpha5beta1	O
-	O
Fibronectin	O
interaction	O
was	O
demonstrated	O
on	O
the	O
chip	O
.	O

A	O
novel	O
peptide	O
ligand	O
,	O
A5	O
-	O
1	O
(	O
VILVLF	O
)	O
,	O
with	O
high	O
affinity	O
to	O
integrin	O
alpha5beta1	O
was	O
identified	O
from	O
the	O
hexapeptide	O
libraries	O
with	O
this	O
chip	O
-	O
based	O
screening	O
method	O
on	O
the	O
basis	O
of	O
a	O
competitive	O
inhibition	O
assay	O
.	O

A5	O
-	O
1	O
inhibits	O
the	O
integrin	O
-	O
fibronectin	O
interaction	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
;	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
28	O
microM	O
.	O

In	O
addition	O
,	O
it	O
inhibits	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
,	O
tubular	O
network	O
formation	O
,	O
and	O
bFGF	O
-	O
induced	O
neovascularization	O
in	O
a	O
chick	O
chorioallantoic	O
membrane	O
.	O

These	O
results	O
suggest	O
that	O
A5	O
-	O
1	O
will	O
be	O
a	O
potent	O
inhibitor	O
of	O
neovascularization	O
.	O

Are	O
former	O
female	O
elite	O
athletes	O
more	O
likely	O
to	O
experience	O
urinary	O
incontinence	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
?	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
former	O
female	O
elite	O
athletes	O
are	O
more	O
likely	O
to	O
experience	O
urinary	O
incontinence	O
(	O
UI	O
)	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
and	O
to	O
assess	O
possible	O
risk	O
factors	O
for	O
UI	O
in	O
athletes	O
.	O

Three	O
hundred	O
and	O
thirty	O
-	O
one	O
former	O
elite	O
athletes	O
(	O
response	O
rate	O
81	O
%	O
)	O
and	O
640	O
controls	O
replied	O
to	O
a	O
postal	O
questionnaire	O
including	O
validated	O
questions	O
on	O
UI	O
.	O

While	O
competing	O
in	O
sport	O
,	O
10	O
.	O
9	O
%	O
and	O
2	O
.	O
7	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
reported	O
stress	O
urinary	O
incontinence	O
(	O
SUI	O
)	O
and	O
urge	O
incontinence	O
,	O
respectively	O
.	O

Presently	O
,	O
36	O
.	O
5	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
and	O
36	O
.	O
9	O
%	O
of	O
the	O
controls	O
reported	O
SUI	O
.	O

9	O
.	O
1	O
%	O
and	O
9	O
.	O
4	O
%	O
reported	O
urge	O
incontinence	O
.	O

Among	O
former	O
elite	O
athletes	O
,	O
those	O
with	O
two	O
or	O
three	O
children	O
were	O
more	O
likely	O
than	O
nulliparous	O
women	O
to	O
have	O
UI	O
now	O
.	O

Also	O
,	O
among	O
former	O
athletes	O
,	O
UI	O
was	O
more	O
common	O
in	O
women	O
with	O
vs	O
those	O
without	O
UI	O
while	O
competing	O
(	O
odds	O
ratio	O
8	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
55	O
-	O
20	O
.	O
71	O
)	O
.	O

Age	O
,	O
menopause	O
and	O
being	O
regularly	O
physically	O
active	O
now	O
were	O
not	O
associated	O
with	O
UI	O
in	O
either	O
group	O
.	O

Based	O
on	O
this	O
study	O
,	O
the	O
prevalence	O
of	O
UI	O
does	O
not	O
seem	O
to	O
be	O
higher	O
in	O
former	O
athletes	O
than	O
in	O
controls	O
.	O

However	O
,	O
the	O
results	O
indicate	O
that	O
UI	O
early	O
in	O
life	O
,	O
as	O
reported	O
during	O
elite	O
sport	O
,	O
is	O
a	O
strong	O
predictor	O
of	O
UI	O
later	O
in	O
life	O
.	O

Evaluation	O
of	O
electrical	O
stimulation	O
for	O
ischemic	O
wound	O
therapy	O
:	O
a	O
feasibility	O
study	O
using	O
the	O
lapine	O
wound	O
model	O
.	O

Chronic	O
wounds	O
are	O
a	O
major	O
secondary	O
complication	O
for	O
many	O
people	O
with	O
impaired	O
mobility	O
.	O

Electrical	O
stimulation	O
(	O
ES	O
)	O
has	O
been	O
recommended	O
as	O
a	O
adjunctive	O
therapy	O
,	O
however	O
optimal	O
treatment	O
paradigms	O
have	O
not	O
been	O
established	O
.	O

Our	O
group	O
seeks	O
to	O
determine	O
the	O
basic	O
mechanisms	O
underlying	O
ES	O
wound	O
therapy	O
,	O
an	O
area	O
where	O
understanding	O
is	O
currently	O
limited	O
.	O

A	O
feasibility	O
study	O
was	O
carried	O
out	O
to	O
develop	O
the	O
Ahn	O
/	O
Mustoe	O
lapine	O
wound	O
model	O
for	O
systematic	O
investigation	O
of	O
the	O
effects	O
of	O
electrical	O
stimulation	O
on	O
ischemic	O
wound	O
therapy	O
.	O

A	O
standardized	O
surgical	O
procedure	O
incorporated	O
a	O
hybrid	O
stimulation	O
system	O
comprising	O
an	O
implantable	O
mini	O
-	O
stimulator	O
and	O
surface	O
electrodes	O
,	O
with	O
creation	O
of	O
repeatable	O
ischemic	O
wounds	O
.	O

Twenty	O
mature	O
male	O
New	O
Zealand	O
white	O
rabbits	O
(	O
3	O
kg	O
weight	O
)	O
were	O
employed	O
to	O
evaluate	O
the	O
effects	O
of	O
two	O
empirically	O
selected	O
stimulation	O
paradigms	O
applied	O
continuously	O
for	O
7	O
-	O
21	O
days	O
,	O
using	O
each	O
animal	O
as	O
its	O
own	O
control	O
.	O

Outcomes	O
measures	O
included	O
transcutaneous	O
blood	O
gas	O
levels	O
,	O
histology	O
,	O
total	O
RNA	O
content	O
and	O
analysis	O
of	O
alpha2	O
(	O
I	O
)	O
collagen	O
(	O
COL	O
-	O
I	O
)	O
,	O
type	O
IV	O
collagen	O
(	O
COL	O
-	O
IV	O
)	O
,	O
alpha1	O
(	O
V	O
)	O
collagen	O
(	O
COL	O
-	O
V	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

All	O
markers	O
for	O
stimulated	O
wounds	O
showed	O
increased	O
activity	O
relative	O
to	O
non	O
-	O
stimulated	O
control	O
wounds	O
between	O
7	O
and	O
14	O
days	O
following	O
injury	O
,	O
with	O
peak	O
activity	O
at	O
14	O
days	O
.	O

By	O
21	O
days	O
post	O
-	O
injury	O
,	O
all	O
activity	O
had	O
returned	O
to	O
near	O
baseline	O
level	O
.	O

VEGF	O
and	O
COL	O
-	O
IV	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
for	O
pattern	O
A	O
(	O
110	O
mus	O
pulse	O
width	O
)	O
compared	O
to	O
pattern	O
B	O
(	O
5	O
mus	O
pulse	O
width	O
)	O
at	O
14	O
days	O
,	O
implying	O
that	O
pattern	O
A	O
may	O
be	O
more	O
effective	O
at	O
promoting	O
angiogenesis	O
.	O

All	O
wounds	O
were	O
fully	O
re	O
-	O
epithelialized	O
by	O
10	O
days	O
post	O
-	O
injury	O
.	O

Both	O
COL	O
-	O
I	O
and	O
COL	O
-	O
V	O
showed	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
activity	O
between	O
day	O
7	O
and	O
day	O
14	O
for	O
pattern	O
A	O
,	O
potentially	O
indicating	O
a	O
continued	O
effect	O
on	O
matrix	O
remodeling	O
.	O

The	O
early	O
closure	O
of	O
all	O
wounds	O
implies	O
that	O
the	O
rabbit	O
ear	O
model	O
may	O
not	O
be	O
valid	O
for	O
chronic	O
wound	O
studies	O
.	O

VEGF	O
,	O
angiopoietin	O
-	O
1	O
and	O
-	O
2	O
in	O
bronchial	O
asthma	O
:	O
new	O
molecular	O
targets	O
in	O
airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
.	O

Airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
are	O
known	O
features	O
of	O
bronchial	O
asthma	O
,	O
but	O
the	O
mechanisms	O
of	O
these	O
structural	O
alterations	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
angiogenic	O
factors	O
,	O
stimulates	O
endothelial	O
cell	O
proliferation	O
and	O
induces	O
the	O
angiogenesis	O
.	O

Recently	O
,	O
considerable	O
attentions	O
have	O
been	O
devoted	O
to	O
the	O
physiological	O
roles	O
of	O
angiopoietin	O
(	O
Ang	O
)	O
-	O
1	O
and	O
-	O
2	O
as	O
regulatory	O
factors	O
of	O
VEGF	O
.	O

Ang	O
-	O
1	O
has	O
been	O
shown	O
to	O
induce	O
the	O
migration	O
and	O
sprouting	O
of	O
endothelial	O
cells	O
,	O
and	O
coexpression	O
of	O
Ang	O
-	O
1	O
and	O
VEGF	O
enhanced	O
angiogenesis	O
.	O

In	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
,	O
Ang	O
-	O
2	O
also	O
promotes	O
rapid	O
increase	O
in	O
capillary	O
diameter	O
,	O
remodeling	O
of	O
the	O
basal	O
lamina	O
,	O
proliferation	O
and	O
migration	O
of	O
endothelial	O
cells	O
,	O
and	O
stimulates	O
sprouting	O
of	O
new	O
blood	O
vessels	O
.	O

Thus	O
,	O
VEGF	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
may	O
play	O
complementary	O
and	O
coordinated	O
roles	O
in	O
airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
,	O
and	O
these	O
structural	O
changes	O
are	O
potentially	O
reversible	O
by	O
therapeutic	O
intervention	O
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
discuss	O
from	O
a	O
clinical	O
point	O
of	O
view	O
the	O
potential	O
interactions	O
between	O
VEGF	O
and	O
angiopoietins	O
in	O
the	O
asthmatic	O
airways	O
,	O
and	O
focus	O
on	O
the	O
therapeutic	O
implications	O
targeting	O
for	O
these	O
angiogenic	O
factors	O
.	O

Recently	O
,	O
there	O
is	O
an	O
increasing	O
number	O
of	O
patents	O
which	O
have	O
been	O
focused	O
on	O
the	O
inhibitors	O
of	O
VEGF	O
action	O
.	O

These	O
inhibitors	O
are	O
directed	O
towards	O
the	O
receptors	O
of	O
VEGF	O
or	O
intracellular	O
substrates	O
for	O
the	O
receptors	O
.	O

We	O
will	O
also	O
discuss	O
several	O
patents	O
regarding	O
inhibitors	O
of	O
VEGF	O
action	O
in	O
the	O
present	O
review	O
.	O

Effect	O
of	O
transplanted	O
mesenchymal	O
stem	O
cells	O
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	O
function	O
after	O
acute	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
transplantation	O
is	O
of	O
therapeutic	O
potential	O
after	O
ischemic	O
injury	O
in	O
both	O
experimental	O
and	O
clinical	O
studies	O
.	O

Clinically	O
,	O
elderly	O
patients	O
are	O
more	O
vulnerable	O
to	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

But	O
little	O
is	O
known	O
about	O
the	O
characteristics	O
of	O
young	O
donor	O
-	O
derived	O
MSCs	O
transplanted	O
to	O
old	O
patients	O
with	O
AMI	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
transplanted	O
MSCs	O
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	O
function	O
after	O
AMI	O
.	O

METHODS	O
:	O
MSCs	O
from	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
isolated	O
and	O
cultured	O
in	O
vitro	O
.	O

The	O
apoptosis	O
characteristics	O
of	O
MSCs	O
were	O
observed	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
.	O

SD	O
rats	O
underwent	O
MI	O
received	O
intramyocardial	O
injection	O
of	O
MSCs	O
from	O
young	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
old	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O

AMI	O
control	O
group	O
received	O
equal	O
volume	O
physiological	O
saline	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
observe	O
the	O
differentiation	O
of	O
the	O
grafted	O
cells	O
into	O
cardiomyocytes	O
.	O

Four	O
weeks	O
after	O
cell	O
transplantation	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
VIII	O
-	O
factor	O
immunohistochemistry	O
for	O
vessel	O
density	O
,	O
TUNEL	O
,	O
caspase	O
-	O
3	O
for	O
cardiomyocyte	O
apoptosis	O
,	O
echocardiography	O
and	O
hemodynamic	O
detection	O
for	O
heart	O
function	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
apoptosis	O
rate	O
of	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	O
group	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Engrafted	O
MSCs	O
survived	O
,	O
proliferated	O
and	O
differentiated	O
into	O
myocardium	O
-	O
like	O
cells	O
.	O

VEGF	O
gene	O
expression	O
and	O
capillary	O
density	O
in	O
the	O
old	O
donor	O
-	O
derived	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
young	O
donor	O
-	O
derived	O
group	O
but	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
transplantation	O
of	O
old	O
donor	O
-	O
derived	O
MSCs	O
attenuated	O
apoptosis	O
of	O
cardiomyocytes	O
in	O
the	O
peri	O
-	O
infarct	O
region	O
compared	O
with	O
the	O
control	O
group	O
and	O
the	O
effect	O
was	O
elevated	O
in	O
young	O
donor	O
-	O
derived	O
MSCs	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
heart	O
functions	O
(	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
left	O
ventricle	O
fractional	O
shortening	O
(	O
LVFS	O
)	O
)	O
were	O
improved	O
more	O
significantly	O
in	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	O
group	O
than	O
in	O
the	O
control	O
group	O
and	O
the	O
heart	O
function	O
in	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	O
group	O
further	O
improved	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Young	O
donor	O
-	O
derived	O
MSCs	O
can	O
improve	O
heart	O
function	O
significantly	O
through	O
angiogenesis	O
and	O
decreasing	O
cardiomyocyte	O
apoptosis	O
when	O
transplanted	O
to	O
the	O
infarcted	O
area	O
.	O

Clinical	O
significance	O
of	O
chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
expression	O
in	O
human	O
colorectal	O
cancer	O
.	O

Chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
(	O
COUP	O
-	O
TFII	O
)	O
plays	O
an	O
essential	O
role	O
in	O
angiogenesis	O
and	O
development	O
.	O

A	O
previous	O
study	O
showed	O
that	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
enhanced	O
invasiveness	O
of	O
human	O
lung	O
carcinoma	O
cells	O
.	O

However	O
,	O
no	O
published	O
data	O
are	O
available	O
concerning	O
the	O
biological	O
and	O
clinical	O
significance	O
of	O
COUP	O
-	O
TFII	O
expression	O
in	O
colorectal	O
cancer	O
.	O

Thus	O
,	O
our	O
objective	O
was	O
to	O
explore	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
in	O
colorectal	O
cancer	O
as	O
well	O
as	O
its	O
association	O
with	O
clinicopathological	O
features	O
,	O
and	O
to	O
evaluate	O
the	O
role	O
of	O
COUP	O
-	O
TFII	O
as	O
a	O
prognostic	O
indicator	O
in	O
colorectal	O
cancer	O
.	O

We	O
investigated	O
the	O
presence	O
of	O
COUP	O
-	O
TFII	O
in	O
human	O
colorectal	O
cancer	O
tissues	O
and	O
adjacent	O
normal	O
tissues	O
from	O
95	O
primary	O
colorectal	O
cancer	O
patients	O
by	O
immunohistochemistry	O
.	O

The	O
correlation	O
between	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
and	O
clinicopathologic	O
features	O
was	O
investigated	O
.	O

The	O
3	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
tumors	O
expressing	O
different	O
levels	O
of	O
COUP	O
-	O
TFII	O
were	O
evaluated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
COUP	O
-	O
TFII	O
expression	O
and	O
age	O
at	O
surgery	O
,	O
gender	O
,	O
histopathologic	O
differentiation	O
,	O
vessel	O
invasion	O
,	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
,	O
or	O
nodal	O
involvement	O
.	O

However	O
,	O
survival	O
analysis	O
showed	O
that	O
the	O
COUP	O
-	O
TFII	O
-	O
positive	O
group	O
had	O
a	O
significantly	O
better	O
OS	O
compared	O
to	O
COUP	O
-	O
TFII	O
-	O
negative	O
group	O
(	O
80	O
.	O
4	O
%	O
vs	O
.	O
57	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
0491	O
)	O
.	O

Based	O
on	O
our	O
results	O
,	O
COUP	O
-	O
TFII	O
may	O
represent	O
a	O
biomarker	O
for	O
good	O
prognosis	O
in	O
colorectal	O
cancer	O
.	O

p53	O
hot	O
-	O
spot	O
mutants	O
increase	O
tumor	O
vascularization	O
via	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
HIF1	O
/	O
VEGF	O
-	O
A	O
pathway	O
.	O

The	O
function	O
of	O
p53	O
tumor	O
suppressor	O
is	O
often	O
altered	O
in	O
various	O
human	O
tumors	O
predominantly	O
through	O
missense	O
-	O
mutations	O
resulting	O
in	O
accumulation	O
of	O
mutant	O
proteins	O
.	O

We	O
revealed	O
that	O
expression	O
of	O
p53	O
proteins	O
with	O
amino	O
-	O
acid	O
substitutions	O
at	O
codons	O
175	O
(	O
R175H	O
)	O
,	O
248	O
(	O
R248W	O
)	O
,	O
and	O
273	O
(	O
R273H	O
)	O
,	O
representing	O
the	O
hot	O
-	O
spots	O
of	O
mutations	O
in	O
various	O
human	O
tumors	O
,	O
increased	O
the	O
number	O
of	O
vessels	O
in	O
HCT116	B
human	O
colon	O
carcinoma	O
xenografts	O
and	O
,	O
as	O
a	O
result	O
,	O
accelerated	O
their	O
growth	O
.	O

Stimulation	O
of	O
tumor	O
angiogenesis	O
was	O
connected	O
with	O
about	O
2	O
-	O
fold	O
increase	O
in	O
intracellular	O
level	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

Antioxidant	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
aspartate	O
(	O
NAC	O
)	O
decreased	O
vessels	O
number	O
in	O
tumors	O
formed	O
by	O
cells	O
with	O
inactivated	O
p53	O
and	O
inhibited	O
their	O
growth	O
.	O

Effect	O
of	O
ROS	O
on	O
angiogenesis	O
in	O
tumors	O
expressing	O
hot	O
-	O
spot	O
p53	O
mutants	O
was	O
correlated	O
with	O
their	O
ability	O
to	O
increase	O
a	O
content	O
of	O
HIF1	O
transcriptional	O
factor	O
responsible	O
for	O
up	O
-	O
regulation	O
of	O
VEGF	O
-	O
A	O
mRNAs	O
.	O

The	O
Akt	O
/	O
mTOR	O
pathway	O
assures	O
the	O
synthesis	O
of	O
HIF	O
-	O
1alpha	O
protein	O
in	O
a	O
glucose	O
-	O
and	O
reoxygenation	O
-	O
dependent	O
manner	O
in	O
irradiated	O
tumors	O
.	O

Transcriptional	O
activity	O
of	O
HIF	O
-	O
1	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
)	O
has	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
solid	O
tumors	O
after	O
ionizing	O
radiation	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
response	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
series	O
of	O
molecular	O
imaging	O
experiments	O
using	O
a	O
HIF	O
-	O
1	O
-	O
dependent	O
reporter	O
gene	O
,	O
5HREp	O
-	O
ODD	O
-	O
luc	O
,	O
and	O
found	O
an	O
essential	O
role	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
.	O

Hypoxic	O
tumor	O
cells	O
distant	O
from	O
blood	O
vessels	O
were	O
dramatically	O
reoxygenated	O
at	O
24	O
h	O
postirradiation	O
,	O
and	O
HIF	O
-	O
1	O
activity	O
increased	O
as	O
HIF	O
-	O
1alpha	O
accumulated	O
in	O
the	O
reoxygenated	O
regions	O
.	O

The	O
accumulation	O
was	O
inhibited	O
with	O
a	O
nonmetabolizable	O
glucose	O
analog	O
,	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
,	O
through	O
the	O
suppression	O
of	O
radiation	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
in	O
the	O
reoxygenated	O
regions	O
.	O

Akt	O
knockdown	O
and	O
an	O
mTOR	O
inhibitor	O
revealed	O
the	O
importance	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
the	O
postirradiation	O
accumulation	O
of	O
HIF	O
-	O
1alpha	O
.	O

In	O
vitro	O
experiments	O
confirmed	O
that	O
an	O
increase	O
in	O
glucose	O
availability	O
induced	O
Akt	O
phosphorylation	O
under	O
reoxygenated	O
conditions	O
and	O
consequently	O
up	O
-	O
regulated	O
HIF	O
-	O
1alpha	O
translation	O
.	O

Moreover	O
,	O
both	O
the	O
accelerated	O
translation	O
and	O
the	O
previously	O
reported	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
stabilization	O
of	O
HIF	O
-	O
1alpha	O
protein	O
were	O
essential	O
to	O
the	O
activation	O
of	O
HIF	O
-	O
1	O
.	O

All	O
of	O
these	O
results	O
indicate	O
that	O
Akt	O
/	O
mTOR	O
-	O
dependent	O
translation	O
of	O
HIF	O
-	O
1alpha	O
plays	O
a	O
critical	O
role	O
in	O
the	O
postirradiation	O
up	O
-	O
regulation	O
of	O
intratumoral	O
HIF	O
-	O
1	O
activity	O
in	O
response	O
to	O
radiation	O
-	O
induced	O
alterations	O
of	O
glucose	O
and	O
oxygen	O
availability	O
in	O
a	O
solid	O
tumor	O
.	O

Homeostatic	O
functions	O
of	O
the	O
p53	O
tumor	O
suppressor	O
:	O
regulation	O
of	O
energy	O
metabolism	O
and	O
antioxidant	O
defense	O
.	O

The	O
p53	O
tumor	O
suppressor	O
plays	O
pivotal	O
role	O
in	O
the	O
organism	O
by	O
supervising	O
strict	O
compliance	O
of	O
individual	O
cells	O
to	O
needs	O
of	O
the	O
whole	O
organisms	O
.	O

It	O
has	O
been	O
widely	O
accepted	O
that	O
p53	O
acts	O
in	O
response	O
to	O
stresses	O
and	O
abnormalities	O
in	O
cell	O
physiology	O
by	O
mobilizing	O
the	O
repair	O
processes	O
or	O
by	O
removing	O
the	O
diseased	O
cells	O
through	O
initiating	O
the	O
cell	O
death	O
programs	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
indicate	O
that	O
even	O
under	O
normal	O
physiological	O
conditions	O
certain	O
activities	O
of	O
p53	O
participate	O
in	O
homeostatic	O
regulation	O
of	O
metabolic	O
processes	O
and	O
that	O
these	O
activities	O
are	O
important	O
for	O
prevention	O
of	O
cancer	O
.	O

These	O
novel	O
functions	O
of	O
p53	O
help	O
to	O
align	O
metabolic	O
processes	O
with	O
the	O
proliferation	O
and	O
energy	O
status	O
,	O
to	O
maintain	O
optimal	O
mode	O
of	O
glucose	O
metabolism	O
and	O
to	O
boost	O
the	O
energy	O
efficient	O
mitochondrial	O
respiration	O
in	O
response	O
to	O
ATP	O
deficiency	O
.	O

Additional	O
activities	O
of	O
p53	O
in	O
non	O
-	O
stressed	O
cells	O
tune	O
up	O
the	O
antioxidant	O
defense	O
mechanisms	O
reducing	O
the	O
probability	O
of	O
mutations	O
caused	O
by	O
DNA	O
oxidation	O
under	O
conditions	O
of	O
daily	O
stresses	O
.	O

The	O
deficiency	O
in	O
the	O
p53	O
-	O
mediated	O
regulation	O
of	O
glycolysis	O
and	O
mitochondrial	O
respiration	O
greatly	O
accounts	O
for	O
the	O
deficient	O
respiration	O
of	O
the	O
predominance	O
of	O
aerobic	O
glycolysis	O
in	O
cancer	O
cells	O
(	O
the	O
Warburg	O
effect	O
)	O
,	O
while	O
the	O
deficiency	O
in	O
the	O
p53	O
-	O
modulated	O
antioxidant	O
defense	O
mechanisms	O
contributes	O
to	O
mutagenesis	O
and	O
additionally	O
boosts	O
the	O
carcinogenesis	O
process	O
.	O

Estradiol	O
increases	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
human	O
breast	O
tissue	O
and	O
breast	O
cancer	O
in	O
vivo	O
.	O

IL	O
-	O
8	O
or	O
CXCL8	O
has	O
been	O
associated	O
with	O
tumor	O
angiogenesis	O
,	O
metastasis	O
,	O
and	O
poor	O
prognosis	O
in	O
breast	O
cancer	O
.	O

Estrogen	O
is	O
crucial	O
in	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O

Whether	O
sex	O
steroids	O
affect	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
breast	O
tissue	O
or	O
breast	O
cancer	O
is	O
not	O
known	O
.	O

Several	O
cell	O
types	O
in	O
a	O
tissue	O
secrete	O
IL	O
-	O
8	O
.	O

Hence	O
,	O
regulatory	O
mechanisms	O
of	O
IL	O
-	O
8	O
need	O
to	O
be	O
investigated	O
in	O
whole	O
tissue	O
.	O

We	O
used	O
microdialysis	O
to	O
sample	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	O
tissue	O
in	O
situ	O
in	O
pre	O
-	O
and	O
postmenopausal	O
women	O
,	O
preoperatively	O
in	O
breast	O
cancers	O
of	O
women	O
,	O
and	O
in	O
experimental	O
breast	O
cancer	O
in	O
mice	O
.	O

We	O
found	O
a	O
significant	O
positive	O
correlation	O
between	O
IL	O
-	O
8	O
and	O
estradiol	O
in	O
normal	O
breast	O
tissue	O
and	O
hormone	O
-	O
dependent	O
breast	O
cancer	O
in	O
vivo	O
.	O

Ex	O
vivo	O
,	O
estradiol	O
exposure	O
increased	O
the	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
whole	O
breast	O
tissue	O
in	O
culture	O
.	O

In	O
experimental	O
breast	O
cancer	O
,	O
estradiol	O
increased	O
IL	O
-	O
8	O
whereas	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
inhibited	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
both	O
in	O
vitro	O
and	O
extracellularly	O
in	O
vivo	O
in	O
tumors	O
of	O
nude	O
mice	O
.	O

An	O
anti	O
-	O
IL	O
-	O
8	O
Ab	O
inhibited	O
endothelial	O
cell	O
proliferation	O
induced	O
by	O
cancer	O
cell	O
produced	O
IL	O
-	O
8	O
and	O
tumors	O
with	O
low	O
IL	O
-	O
8	O
levels	O
exhibited	O
decreased	O
angiogenesis	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
estradiol	O
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	O
tissue	O
and	O
human	O
breast	O
cancer	O
.	O

IL	O
-	O
8	O
may	O
present	O
a	O
novel	O
therapeutic	O
target	O
for	O
estrogen	O
driven	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O

Involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
cerebral	O
cavernous	O
malformations	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	O
cavernous	O
malformations	O
(	O
CCMs	O
)	O
are	O
prevalent	O
cerebral	O
vascular	O
lesions	O
involving	O
aberrant	O
angiogenesis	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

Phosphatase	O
and	O
tension	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
,	O
a	O
tumor	O
suppressor	O
,	O
is	O
frequently	O
deficient	O
in	O
various	O
pathologies	O
due	O
to	O
mutation	O
or	O
epigenetic	O
alterations	O
.	O

PTEN	O
promoter	O
hypermethylation	O
is	O
a	O
major	O
epigenetic	O
silencing	O
mechanism	O
leading	O
to	O
activation	O
of	O
angiogenesis	O
in	O
tumors	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
PTEN	O
promoter	O
methylation	O
was	O
involved	O
in	O
CCMs	O
.	O

METHODS	O
:	O
PTEN	O
promoter	O
methylation	O
was	O
detected	O
in	O
surgical	O
specimens	O
of	O
CCMs	O
(	O
n	O
=	O
69	O
)	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

The	O
methylation	O
status	O
was	O
correlated	O
to	O
the	O
clinical	O
manifestations	O
and	O
to	O
PTEN	O
expression	O
,	O
which	O
was	O
analyzed	O
by	O
both	O
Western	O
blot	O
and	O
immunohistochemistry	O
.	O

To	O
investigate	O
the	O
endothelial	O
proliferation	O
and	O
the	O
potential	O
signaling	O
pathways	O
affected	O
by	O
PTEN	O
methylation	O
,	O
proliferating	O
cell	O
nuclear	O
antigen	O
as	O
well	O
as	O
phosphor	O
-	O
Akt	O
and	O
phosphor	O
-	O
Erk1	O
,	O
2	O
were	O
detected	O
by	O
immunofluorescence	O
and	O
Western	O
blot	O
,	O
respectively	O
,	O
in	O
CCM	O
specimens	O
.	O

RESULTS	O
:	O
Methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
revealed	O
PTEN	O
promoter	O
methylation	O
in	O
15	O
.	O
9	O
%	O
CCMs	O
.	O

Strikingly	O
,	O
5	O
of	O
6	O
familial	O
CCMs	O
showed	O
PTEN	O
promoter	O
methylation	O
(	O
83	O
.	O
3	O
%	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
sporadic	O
cases	O
(	O
9	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
promoter	O
methylation	O
appeared	O
more	O
frequently	O
in	O
multiple	O
CCMs	O
,	O
including	O
familial	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
,	O
than	O
that	O
in	O
single	O
-	O
lesioned	O
CCMs	O
(	O
11	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Immunostaining	O
and	O
Western	O
blot	O
revealed	O
a	O
more	O
significant	O
PTEN	O
downregulation	O
in	O
PTEN	O
-	O
methylated	O
CCMs	O
in	O
comparison	O
to	O
PTEN	O
-	O
unmethylated	O
CCMs	O
.	O

Reduced	O
PTEN	O
expression	O
was	O
inversely	O
correlated	O
to	O
the	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
and	O
to	O
the	O
activation	O
of	O
Erk1	O
,	O
2	O
,	O
but	O
not	O
of	O
Akt	O
.	O

CONCLUSIONS	O
:	O
We	O
reported	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
CCMs	O
,	O
particularly	O
in	O
familial	O
CCMs	O
,	O
suggesting	O
this	O
epigenetic	O
alteration	O
as	O
a	O
potential	O
pathomechanism	O
of	O
CCMs	O
.	O

The	O
identification	O
of	O
Erk1	O
,	O
2	O
as	O
triggered	O
signaling	O
in	O
the	O
lesions	O
may	O
be	O
valuable	O
for	O
the	O
development	O
of	O
effective	O
therapy	O
for	O
this	O
disease	O
.	O

Grape	O
seed	O
extract	O
inhibits	O
angiogenesis	O
via	O
suppression	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Blockade	O
of	O
angiogenesis	O
is	O
an	O
important	O
approach	O
for	O
cancer	O
treatment	O
and	O
prevention	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
critical	O
factors	O
that	O
induce	O
angiogenesis	O
and	O
has	O
thus	O
become	O
an	O
attractive	O
target	O
for	O
antiangiogenesis	O
treatment	O
.	O

However	O
,	O
most	O
current	O
anti	O
-	O
VEGF	O
agents	O
often	O
cause	O
some	O
side	O
effects	O
when	O
given	O
chronically	O
.	O

Identification	O
of	O
naturally	O
occurring	O
VEGF	O
inhibitors	O
derived	O
from	O
diet	O
would	O
be	O
one	O
alternative	O
approach	O
with	O
an	O
advantage	O
of	O
known	O
safety	O
.	O

Grape	O
seed	O
extract	O
(	O
GSE	O
)	O
,	O
a	O
widely	O
used	O
dietary	O
supplement	O
,	O
is	O
known	O
to	O
have	O
antitumor	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
activity	O
of	O
GSE	O
on	O
VEGF	O
receptor	O
and	O
angiogenesis	O
.	O

We	O
found	O
that	O
GSE	O
could	O
directly	O
inhibit	O
the	O
kinase	O
activity	O
of	O
purified	O
VEGF	O
receptor	O
2	O
,	O
a	O
novel	O
activity	O
of	O
GSE	O
that	O
has	O
not	O
been	O
characterized	O
.	O

GSE	O
could	O
also	O
inhibit	O
the	O
VEGF	O
receptor	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
mediated	O
signaling	O
pathway	O
in	O
endothelial	O
cells	O
.	O

As	O
a	O
result	O
,	O
GSE	O
could	O
inhibit	O
VEGF	O
-	O
induced	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
as	O
well	O
as	O
sprout	O
formation	O
from	O
aorta	O
ring	O
.	O

In	O
vivo	O
assay	O
further	O
showed	O
that	O
GSE	O
could	O
inhibit	O
tumor	O
growth	O
and	O
tumor	O
angiogenesis	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
breast	O
cancer	O
cells	O
in	O
mice	O
.	O

Consistent	O
with	O
the	O
in	O
vitro	O
data	O
,	O
GSE	O
treatment	O
of	O
tumor	O
-	O
bearing	O
mice	O
led	O
to	O
concomitant	O
reduction	O
of	O
blood	O
vessel	O
density	O
and	O
phosphorylation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Depletion	O
of	O
polyphenol	O
with	O
polyvinylpyrrolidone	O
abolished	O
the	O
antiangiogenic	O
activity	O
of	O
GSE	O
,	O
suggesting	O
a	O
water	O
-	O
soluble	O
fraction	O
of	O
polyphenol	O
in	O
GSE	O
is	O
responsible	O
for	O
the	O
antiangiogenic	O
activity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
GSE	O
is	O
a	O
well	O
-	O
tolerated	O
and	O
inexpensive	O
natural	O
VEGF	O
inhibitor	O
and	O
could	O
potentially	O
be	O
useful	O
in	O
cancer	O
prevention	O
or	O
treatment	O
.	O

Chemokine	O
receptor	O
CXCR4	O
expression	O
,	O
function	O
,	O
and	O
clinical	O
implications	O
in	O
gastric	O
cancer	O
.	O

The	O
chemokine	O
receptor	O
CXCR4	O
is	O
associated	O
with	O
the	O
biological	O
behavior	O
of	O
cancer	O
,	O
but	O
few	O
studies	O
have	O
addressed	O
the	O
expression	O
and	O
function	O
of	O
CXCR4	O
in	O
human	O
gastric	O
cancer	O
and	O
its	O
impact	O
on	O
disease	O
prognosis	O
.	O

We	O
studied	O
the	O
expression	O
of	O
CXCR4	O
using	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
,	O
flow	O
cytometry	O
,	O
and	O
confocal	O
microscopy	O
in	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O

We	O
also	O
examined	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
anti	O
-	O
apoptotic	O
activity	O
in	O
response	O
to	O
stromal	O
cell	O
-	O
derived	O
factor	O
(	O
SDF	O
)	O
-	O
1alpha	O
and	O
evaluated	O
SDF	O
-	O
1alpha	O
/	O
CXCR4	O
signaling	O
pathways	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
correlation	O
between	O
CXCR4	O
expression	O
and	O
the	O
clinical	O
features	O
of	O
221	O
gastric	O
cancer	O
tissue	O
samples	O
.	O

CXCR4	O
transcripts	O
and	O
proteins	O
were	O
detectable	O
in	O
all	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O

However	O
,	O
MKN	B
-	I
28	I
,	O
MKN	B
-	I
45	I
,	O
MKN	B
-	I
74	I
,	O
and	O
SNU16	B
cells	O
did	O
not	O
express	O
membrane	O
CXCR4	O
.	O

In	O
contrast	O
,	O
KATO	B
III	I
cells	O
expressed	O
membrane	O
CXCR4	O
.	O

In	O
these	O
cells	O
,	O
SDF	O
-	O
1alpha	O
-	O
induced	O
migration	O
was	O
observed	O
and	O
was	O
blocked	O
by	O
AMD3100	O
,	O
a	O
specific	O
inhibitor	O
of	O
CXCR4	O
.	O

SDF	O
-	O
1alpha	O
induced	O
rapid	O
phosphorylation	O
of	O
Erk1	O
/	O
2	O
MAPK	O
but	O
did	O
not	O
promote	O
phosphorylation	O
of	O
Stat3	O
or	O
Akt	O
.	O

Gastric	O
cancer	O
tissue	O
samples	O
expressed	O
CXCR4	O
with	O
variable	O
intensities	O
.	O

Strong	O
CXCR4	O
expression	O
was	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastases	O
(	O
P	O
=	O
0	O
.	O
028	O
)	O
and	O
higher	O
stages	O
III	O
/	O
IV	O
(	O
P	O
=	O
0	O
.	O
047	O
)	O
,	O
and	O
further	O
tended	O
to	O
be	O
correlated	O
with	O
a	O
reduced	O
5	O
-	O
year	O
survival	O
rate	O
(	O
42	O
.	O
6	O
%	O
vs	O
.	O
53	O
.	O
9	O
%	O
;	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

In	O
conclusion	O
,	O
CXCR4	O
expression	O
is	O
associated	O
with	O
gastric	O
cancer	O
cell	O
migration	O
in	O
vitro	O
,	O
and	O
strong	O
expression	O
of	O
CXCR4	O
by	O
gastric	O
cancer	O
cells	O
is	O
significantly	O
associated	O
with	O
lymphatic	O
metastasis	O
in	O
patients	O
with	O
gastric	O
cancer	O
,	O
suggesting	O
that	O
CXCR4	O
plays	O
an	O
important	O
role	O
during	O
gastric	O
cancer	O
progression	O
.	O

Effect	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
wound	O
healing	O
.	O

Age	O
-	O
related	O
impaired	O
wound	O
healing	O
leads	O
to	O
substantial	O
morbidity	O
and	O
mortality	O
along	O
with	O
a	O
large	O
financial	O
burden	O
to	O
health	O
services	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
the	O
tissue	O
damage	O
associated	O
with	O
chronic	O
wounds	O
is	O
initiated	O
and	O
propagated	O
by	O
an	O
inappropriately	O
excessive	O
inflammatory	O
response	O
.	O

Research	O
on	O
age	O
-	O
related	O
impaired	O
wound	O
healing	O
suggests	O
that	O
the	O
decline	O
in	O
sex	O
steroid	O
hormones	O
with	O
age	O
may	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
vivo	O
.	O

Topical	O
and	O
systemic	O
estrogen	O
treatments	O
have	O
shown	O
an	O
increased	O
rate	O
of	O
healing	O
by	O
reducing	O
inflammation	O
,	O
however	O
the	O
underlying	O
mechanisms	O
are	O
little	O
understood	O
.	O

In	O
vitro	O
studies	O
also	O
suggest	O
progesterone	O
may	O
play	O
a	O
role	O
in	O
modulating	O
inflammation	O
.	O

Macrophages	O
are	O
essential	O
mediators	O
of	O
inflammation	O
and	O
wound	O
healing	O
.	O

Macrophages	O
can	O
be	O
activated	O
in	O
a	O
classical	O
or	O
alternative	O
manner	O
in	O
parallel	O
with	O
the	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
dichotomy	O
,	O
respectively	O
.	O

Using	O
a	O
murine	O
incisional	O
wound	O
healing	O
model	O
this	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
roles	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
the	O
wound	O
healing	O
response	O
.	O

Our	O
findings	O
suggest	O
with	O
a	O
reduction	O
of	O
steroid	O
hormones	O
following	O
ovariectomy	O
,	O
alternatively	O
activated	O
macrophage	O
markers	O
(	O
Fizz1	O
and	O
Ym1	O
)	O
were	O
reduced	O
,	O
with	O
this	O
effect	O
being	O
reversed	O
with	O
the	O
administration	O
of	O
estrogen	O
or	O
progesterone	O
;	O
suggesting	O
that	O
with	O
the	O
reduction	O
of	O
steroid	O
hormones	O
macrophages	O
are	O
activated	O
in	O
a	O
classical	O
manner	O
,	O
promoting	O
inflammation	O
,	O
whereas	O
estrogen	O
or	O
progesterone	O
are	O
contributing	O
toward	O
macrophage	O
activation	O
in	O
an	O
alternative	O
manner	O
,	O
driving	O
wound	O
repair	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O

Heart	O
sound	O
and	O
electrocardiogram	O
recording	O
devices	O
for	O
telemedicine	O
environments	O
.	O

There	O
is	O
currently	O
a	O
worldwide	O
trend	O
to	O
bring	O
healthcare	O
services	O
as	O
close	O
as	O
possible	O
to	O
the	O
patient	O
,	O
either	O
through	O
home	O
healthcare	O
systems	O
,	O
or	O
telemedicine	O
.	O

There	O
is	O
thus	O
a	O
general	O
need	O
for	O
equipment	O
that	O
can	O
capture	O
patient	O
data	O
electronically	O
for	O
automated	O
review	O
or	O
analysis	O
by	O
a	O
medical	O
practitioner	O
.	O

This	O
paper	O
presents	O
prototype	O
systems	O
that	O
were	O
developed	O
with	O
the	O
ultimate	O
aim	O
for	O
use	O
in	O
telemedicine	O
settings	O
in	O
rural	O
Africa	O
.	O

These	O
devices	O
can	O
be	O
used	O
to	O
electronically	O
capture	O
data	O
on	O
patients	O
from	O
several	O
sensors	O
in	O
a	O
quick	O
an	O
easy	O
manner	O
.	O

In	O
our	O
presented	O
cases	O
we	O
focus	O
on	O
cardiovascular	O
information	O
.	O

One	O
of	O
the	O
main	O
advantages	O
of	O
the	O
proposed	O
systems	O
is	O
that	O
the	O
data	O
are	O
captured	O
simultaneously	O
from	O
multiple	O
sensors	O
.	O

The	O
data	O
can	O
be	O
stored	O
and	O
sent	O
electronically	O
for	O
review	O
and	O
analysis	O
,	O
and	O
knowledge	O
-	O
based	O
systems	O
or	O
neural	O
network	O
type	O
models	O
can	O
be	O
used	O
in	O
the	O
future	O
for	O
semi	O
-	O
autonomous	O
screening	O
of	O
the	O
recordings	O
,	O
before	O
a	O
patient	O
is	O
referred	O
to	O
a	O
specialist	O
.	O

Effect	O
of	O
platelet	O
-	O
rich	O
plasma	O
and	O
fibrin	O
glue	O
on	O
healing	O
of	O
critical	O
-	O
size	O
calvarial	O
bone	O
defects	O
.	O

Despite	O
the	O
insufficient	O
number	O
of	O
experimental	O
studies	O
,	O
platelet	O
-	O
rich	O
plasma	O
(	O
PRP	O
)	O
including	O
high	O
amounts	O
of	O
growth	O
factors	O
is	O
introduced	O
to	O
clinical	O
use	O
rapidly	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
PRP	O
and	O
platelet	O
-	O
poor	O
plasma	O
(	O
PPP	O
)	O
on	O
healing	O
of	O
critical	O
-	O
size	O
bone	O
defects	O
.	O
Bilateral	O
full	O
-	O
thickness	O
,	O
critical	O
-	O
size	O
bone	O
defects	O
were	O
created	O
in	O
the	O
parietal	O
bones	O
of	O
32	O
rabbits	O
,	O
which	O
had	O
been	O
studied	O
in	O
4	O
groups	O
.	O

Saline	O
,	O
thrombin	O
solution	O
,	O
PPP	O
,	O
and	O
PRP	O
were	O
applied	O
to	O
the	O
created	O
defects	O
before	O
closure	O
.	O

Radiologic	O
defect	O
area	O
measurement	O
results	O
at	O
0	O
,	O
4	O
,	O
and	O
16	O
weeks	O
were	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
densities	O
of	O
the	O
newly	O
formed	O
bones	O
at	O
16th	O
week	O
were	O
studied	O
.	O

Histologic	O
parameters	O
(	O
primary	O
and	O
secondary	O
bone	O
trabecula	O
,	O
neovascularization	O
,	O
and	O
bone	O
marrow	O
and	O
connective	O
tissue	O
formation	O
)	O
were	O
compared	O
between	O
4	O
-	O
and	O
16	O
-	O
week	O
groups	O
.	O
More	O
rapid	O
decrease	O
in	O
defect	O
size	O
was	O
observed	O
in	O
groups	O
3	O
and	O
4	O
than	O
in	O
groups	O
1	O
and	O
2	O
,	O
both	O
in	O
the	O
4th	O
and	O
16th	O
weeks	O
.	O

Newly	O
formed	O
bone	O
densities	O
were	O
also	O
found	O
to	O
be	O
higher	O
in	O
these	O
2	O
groups	O
.	O

New	O
bone	O
formation	O
was	O
detected	O
to	O
be	O
more	O
rapid	O
considering	O
histologic	O
parameters	O
,	O
in	O
groups	O
3	O
and	O
4	O
at	O
4th	O
and	O
16th	O
weeks	O
.	O
Study	O
demonstrates	O
that	O
PRP	O
and	O
PPP	O
might	O
have	O
favorable	O
effects	O
on	O
bone	O
healing	O
.	O

Although	O
we	O
can	O
not	O
reveal	O
any	O
statistical	O
difference	O
between	O
these	O
2	O
substances	O
considering	O
osteoinductive	O
potential	O
,	O
PRP	O
group	O
has	O
demonstrated	O
superior	O
results	O
compared	O
with	O
fibrin	O
glue	O
group	O
.	O

Higher	O
platelet	O
concentrations	O
may	O
expose	O
beneficial	O
effects	O
of	O
PRP	O
.	O

Host	O
-	O
derived	O
angiopoietin	O
-	O
2	O
affects	O
early	O
stages	O
of	O
tumor	O
development	O
and	O
vessel	O
maturation	O
but	O
is	O
dispensable	O
for	O
later	O
stages	O
of	O
tumor	O
growth	O
.	O

The	O
angiopoietin	O
/	O
Tie2	O
system	O
has	O
been	O
identified	O
as	O
the	O
second	O
vascular	O
-	O
specific	O
receptor	O
tyrosine	O
kinase	O
system	O
controlling	O
vessel	O
assembly	O
,	O
maturation	O
,	O
and	O
quiescence	O
.	O

Angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
is	O
prominently	O
up	O
-	O
regulated	O
in	O
the	O
host	O
-	O
derived	O
vasculature	O
of	O
most	O
tumors	O
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
antiangiogenic	O
intervention	O
.	O

Yet	O
,	O
the	O
net	O
outcome	O
of	O
Ang	O
-	O
2	O
functions	O
on	O
tumor	O
angiogenesis	O
is	O
believed	O
to	O
be	O
contextual	O
depending	O
on	O
the	O
local	O
cytokine	O
milieu	O
.	O

Correspondingly	O
,	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
have	O
been	O
shown	O
to	O
exert	O
protumorigenic	O
as	O
well	O
as	O
antitumorigenic	O
effects	O
.	O

To	O
clarify	O
the	O
role	O
of	O
Ang	O
-	O
2	O
for	O
angiogenesis	O
and	O
tumor	O
growth	O
in	O
a	O
definite	O
genetic	O
experimental	O
setting	O
,	O
the	O
present	O
study	O
was	O
aimed	O
at	O
comparatively	O
studying	O
the	O
growth	O
of	O
different	O
tumors	O
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O

Lewis	O
lung	O
carcinomas	O
,	O
MT	O
-	O
ret	O
melanomas	O
,	O
and	O
B16F10	B
melanomas	O
all	O
grew	O
slower	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O

Yet	O
,	O
tumor	O
growth	O
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
dissociated	O
during	O
early	O
stages	O
of	O
tumor	O
development	O
,	O
whereas	O
tumor	O
growth	O
rates	O
during	O
later	O
stages	O
of	O
primary	O
tumor	O
progression	O
were	O
similar	O
.	O

Analysis	O
of	O
the	O
intratumoral	O
vascular	O
architecture	O
revealed	O
no	O
major	O
differences	O
in	O
microvessel	O
density	O
and	O
perfusion	O
characteristics	O
.	O

However	O
,	O
diameters	O
of	O
intratumoral	O
microvessels	O
were	O
smaller	O
in	O
tumors	O
grown	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
,	O
and	O
the	O
vasculature	O
had	O
an	O
altered	O
pattern	O
of	O
pericyte	O
recruitment	O
and	O
maturation	O
.	O

Ang	O
-	O
2	O
-	O
deficient	O
tumor	O
vessels	O
had	O
higher	O
pericyte	O
coverage	O
indices	O
.	O

Recruited	O
pericytes	O
were	O
desmin	O
and	O
NG2	O
positive	O
and	O
predominately	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
negative	O
,	O
indicative	O
of	O
a	O
more	O
mature	O
pericyte	O
phenotype	O
.	O

Collectively	O
,	O
the	O
experiments	O
define	O
the	O
role	O
of	O
Ang	O
-	O
2	O
during	O
tumor	O
angiogenesis	O
and	O
establish	O
a	O
better	O
rationale	O
for	O
combination	O
therapies	O
involving	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
.	O

Liposomal	O
honokiol	O
inhibits	O
VEGF	O
-	O
D	O
-	O
induced	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
xenograft	O
tumor	O
model	O
.	O

Lymph	O
nodes	O
metastasis	O
of	O
tumor	O
could	O
be	O
a	O
crucial	O
early	O
step	O
in	O
the	O
metastatic	O
process	O
.	O

Induction	O
of	O
tumor	O
lymphangiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
D	O
may	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumor	O
metastasis	O
to	O
regional	O
lymph	O
nodes	O
and	O
these	O
processes	O
can	O
be	O
inhibited	O
by	O
inactivation	O
of	O
the	O
VEGFR	O
-	O
3	O
signaling	O
pathway	O
.	O

Honokiol	O
has	O
been	O
reported	O
to	O
possess	O
potent	O
antiangiogenesis	O
and	O
antitumor	O
properties	O
in	O
several	O
cell	O
lines	O
and	O
xenograft	O
tumor	O
models	O
.	O

However	O
,	O
its	O
role	O
in	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
lymphatic	O
metastasis	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
established	O
lymph	O
node	O
metastasis	O
models	O
by	O
injecting	O
overexpressing	O
VEGF	O
-	O
D	O
Lewis	O
lung	O
carcinoma	O
cells	O
into	O
C57BL	O
/	O
6	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
honokiol	O
on	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
related	O
lymph	O
node	O
metastasis	O
.	O

The	O
underlying	O
mechanisms	O
were	O
systematically	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
in	O
vivo	O
study	O
,	O
liposomal	O
honokiol	O
significantly	O
inhibited	O
the	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
Lewis	O
lung	O
carcinoma	O
model	O
.	O

A	O
remarkable	O
delay	O
of	O
tumor	O
growth	O
and	O
prolonged	O
life	O
span	O
were	O
also	O
observed	O
.	O

In	O
in	O
vitro	O
study	O
,	O
honokiol	O
inhibited	O
VEGF	O
-	O
D	O
-	O
induced	O
survival	O
,	O
proliferation	O
and	O
tube	O
-	O
formation	O
of	O
both	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
lymphatic	O
vascular	O
endothelial	O
cells	O
(	O
HLECs	B
)	O
.	O

Western	O
blotting	O
analysis	O
showed	O
that	O
liposomal	O
honokiol	O
-	O
inhibited	O
Akt	O
and	O
MAPK	O
phosphorylation	O
in	O
2	O
endothelial	O
cells	O
,	O
and	O
downregulated	O
expressions	O
of	O
VEGFR	O
-	O
2	O
of	O
human	O
vascular	O
endothelial	O
cells	O
and	O
VEGFR	O
-	O
3	O
of	O
lymphatic	O
endothelial	O
cells	O
.	O

Thus	O
,	O
we	O
identified	O
for	O
the	O
first	O
time	O
that	O
honokiol	O
provided	O
therapeutic	O
benefit	O
not	O
only	O
by	O
direct	O
effects	O
on	O
tumor	O
cells	O
and	O
antiangiogenesis	O
but	O
also	O
by	O
inhibiting	O
lymphangiogenesis	O
and	O
metastasis	O
via	O
the	O
VEGFR	O
-	O
3	O
pathway	O
.	O

The	O
present	O
findings	O
may	O
be	O
of	O
importance	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
spread	O
of	O
cancer	O
via	O
the	O
lymphatics	O
and	O
explore	O
the	O
therapeutical	O
strategy	O
of	O
honokiol	O
on	O
antilymphangiogenesis	O
and	O
antimetastasis	O
.	O

Short	O
pigment	O
epithelial	O
-	O
derived	O
factor	O
-	O
derived	O
peptide	O
inhibits	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

PURPOSE	O
:	O
Pigment	O
epithelial	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	O
tumor	O
growth	O
.	O

Our	O
previous	O
studies	O
mapped	O
PEDF	O
antiangiogenic	O
and	O
prosurvival	O
activities	O
to	O
distinct	O
epitopes	O
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	O
,	O
which	O
maintains	O
antiangiogenic	O
and	O
antitumor	O
efficacy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	O
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	O
,	O
P18	O
,	O
and	O
P23	O
.	O

We	O
analyzed	O
their	O
ability	O
to	O
block	O
endothelial	O
cell	O
chemotaxis	O
and	O
induce	O
apoptosis	O
in	O
vitro	O
and	O
their	O
antiangiogenic	O
activity	O
in	O
vivo	O
.	O

The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	O
activity	O
against	O
mildly	O
aggressive	O
xenografted	O
prostate	O
carcinoma	O
and	O
highly	O
aggressive	O
renal	O
cell	O
carcinoma	O
.	O

To	O
verify	O
that	O
P18	O
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
and	O
CD95	O
ligand	O
expression	O
in	O
P18	O
-	O
treated	O
vasculature	O
.	O

RESULTS	O
:	O
P14	O
and	O
P18	O
blocked	O
endothelial	O
cell	O
chemotaxis	O
;	O
P18	O
and	O
P23	O
induced	O
apoptosis	O
.	O

P18	O
showed	O
the	O
highest	O
IC50	O
and	O
blocked	O
angiogenesis	O
in	O
vivo	O
:	O
P23	O
was	O
inactive	O
and	O
P14	O
was	O
proangiogenic	O
.	O

P18	O
increased	O
the	O
production	O
of	O
CD95	O
ligand	O
and	O
reduced	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
by	O
the	O
endothelial	O
cells	O
in	O
vivo	O
.	O

In	O
tumor	O
studies	O
,	O
P18	O
was	O
more	O
effective	O
in	O
blocking	O
the	O
angiogenesis	O
and	O
growth	O
of	O
the	O
prostate	O
cancer	O
than	O
parental	O
34	O
-	O
mer	O
;	O
in	O
the	O
renal	O
cell	O
carcinoma	O
,	O
P18	O
strongly	O
decreased	O
angiogenesis	O
and	O
halted	O
the	O
progression	O
of	O
established	O
tumors	O
.	O

CONCLUSIONS	O
:	O
P18	O
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	O
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
prostate	O
and	O
renal	O
cancer	O
.	O

An	O
introduction	O
to	O
evidence	O
-	O
based	O
practice	O
for	O
hand	O
surgeons	O
and	O
therapists	O
.	O

Evidence	O
-	O
based	O
practice	O
is	O
a	O
methodical	O
approach	O
to	O
clinical	O
practice	O
where	O
experience	O
,	O
best	O
research	O
evidence	O
,	O
and	O
patient	O
goals	O
and	O
values	O
are	O
integrated	O
to	O
make	O
optimal	O
decisions	O
when	O
making	O
a	O
diagnosis	O
,	O
selecting	O
a	O
diagnostic	O
test	O
,	O
picking	O
an	O
intervention	O
or	O
determining	O
prognosis	O
.	O

There	O
are	O
five	O
steps	O
in	O
this	O
process	O
.	O

Hand	O
surgeons	O
and	O
therapists	O
can	O
use	O
the	O
evidence	O
-	O
based	O
process	O
to	O
attain	O
optimal	O
management	O
of	O
individual	O
patients	O
,	O
manage	O
their	O
overall	O
practice	O
,	O
guide	O
the	O
ongoing	O
professional	O
development	O
,	O
and	O
deal	O
with	O
funding	O
and	O
policy	O
makers	O
.	O

Aflibercept	O
(	O
AVE0005	O
)	O
:	O
an	O
alternative	O
strategy	O
for	O
inhibiting	O
tumour	O
angiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factors	O
.	O

BACKGROUND	O
:	O
Aberrant	O
angiogenesis	O
is	O
a	O
landmark	O
feature	O
in	O
cancer	O
,	O
which	O
is	O
important	O
for	O
proliferation	O
,	O
growth	O
and	O
metastasis	O
,	O
and	O
is	O
mediated	O
by	O
various	O
pro	O
-	O
angiogenic	O
factors	O
.	O

The	O
VEGF	O
pathway	O
is	O
one	O
of	O
the	O
most	O
important	O
and	O
best	O
-	O
studied	O
angiogenic	O
pathways	O
.	O

Inhibition	O
of	O
this	O
pathway	O
may	O
provide	O
clinical	O
benefits	O
to	O
cancer	O
patients	O
.	O

OBJECTIVES	O
:	O
Strategies	O
to	O
inhibit	O
the	O
VEGF	O
pathway	O
,	O
including	O
antibodies	O
to	O
VEGF	O
,	O
antibodies	O
to	O
the	O
extracellular	O
domain	O
of	O
VEGFR	O
-	O
1	O
or	O
VEGFR	O
-	O
2	O
,	O
decoy	O
receptors	O
for	O
VEGF	O
and	O
tyrosine	O
kinase	O
inhibitors	O
of	O
VEGFRs	O
,	O
are	O
summarized	O
.	O

METHODS	O
:	O
This	O
review	O
outlines	O
and	O
compares	O
the	O
latest	O
development	O
of	O
these	O
strategies	O
,	O
with	O
emphasis	O
on	O
aflibercept	O
,	O
a	O
novel	O
decoy	O
fusion	O
protein	O
of	O
domain	O
2	O
of	O
VEGFR	O
-	O
1	O
and	O
domain	O
3	O
of	O
VEGFR	O
-	O
2	O
with	O
the	O
Fc	O
fragment	O
of	O
IgG1	O
.	O

RESULTS	O
:	O
Aflibercept	O
was	O
shown	O
to	O
have	O
early	O
clinical	O
activity	O
.	O

Multiple	O
studies	O
are	O
ongoing	O
to	O
determine	O
the	O
clinical	O
benefits	O
of	O
aflibercept	O
in	O
cancer	O
patients	O
.	O

Prolonged	O
control	O
of	O
patterned	O
biofilm	O
formation	O
by	O
bio	O
-	O
inert	O
surface	O
chemistry	O
.	O

A	O
bio	O
-	O
inert	O
surface	O
chemistry	O
was	O
developed	O
that	O
can	O
confine	O
biofilm	O
formation	O
in	O
designed	O
patterns	O
for	O
at	O
least	O
26	O
days	O
.	O

Handling	O
within	O
run	O
retention	O
time	O
shifts	O
in	O
two	O
-	O
dimensional	O
chromatography	O
data	O
using	O
shift	O
correction	O
and	O
modeling	O
.	O

The	O
use	O
of	O
PARAFAC	O
for	O
modeling	O
GC	O
x	O
GC	O
-	O
TOFMS	O
peaks	O
is	O
well	O
documented	O
.	O

This	O
success	O
is	O
due	O
to	O
the	O
trilinear	O
structure	O
of	O
these	O
data	O
under	O
ideal	O
,	O
or	O
sufficiently	O
close	O
to	O
ideal	O
,	O
chromatographic	O
conditions	O
.	O

However	O
,	O
using	O
temperature	O
programming	O
to	O
cope	O
with	O
the	O
general	O
elution	O
problem	O
,	O
deviations	O
from	O
trilinearity	O
within	O
a	O
run	O
are	O
more	O
likely	O
to	O
be	O
seen	O
for	O
the	O
following	O
three	O
cases	O
:	O
(	O
1	O
)	O
compounds	O
(	O
i	O
.	O
e	O
.	O
,	O
analytes	O
)	O
severely	O
broadened	O
on	O
the	O
first	O
column	O
hence	O
defined	O
by	O
many	O
modulation	O
periods	O
,	O
(	O
2	O
)	O
analytes	O
with	O
a	O
very	O
high	O
retention	O
factor	O
on	O
the	O
second	O
column	O
and	O
likely	O
wrapped	O
around	O
in	O
that	O
dimension	O
,	O
or	O
(	O
3	O
)	O
with	O
fast	O
temperature	O
program	O
rates	O
.	O

This	O
deviation	O
from	O
trilinearity	O
is	O
seen	O
as	O
retention	O
time	O
-	O
shifted	O
peak	O
profiles	O
in	O
subsequent	O
modulation	O
periods	O
(	O
first	O
column	O
fractions	O
)	O
.	O

In	O
this	O
report	O
,	O
a	O
relaxed	O
yet	O
powerful	O
version	O
of	O
PARAFAC	O
,	O
known	O
as	O
PARAFAC2	O
has	O
been	O
applied	O
to	O
handle	O
this	O
shift	O
within	O
the	O
model	O
step	O
by	O
allowing	O
generation	O
of	O
individual	O
peak	O
profiles	O
in	O
subsequent	O
first	O
column	O
fractions	O
.	O

An	O
alternative	O
approach	O
was	O
also	O
studied	O
,	O
utilizing	O
a	O
standard	O
retention	O
time	O
shift	O
correction	O
to	O
restore	O
the	O
data	O
trilinearity	O
structure	O
followed	O
by	O
PARAFAC	O
.	O

These	O
two	O
approaches	O
are	O
compared	O
when	O
identifying	O
and	O
quantifying	O
a	O
known	O
analyte	O
over	O
a	O
large	O
concentration	O
series	O
where	O
a	O
certain	O
shift	O
is	O
simulated	O
in	O
the	O
successive	O
first	O
column	O
fractions	O
.	O

Finally	O
,	O
the	O
methods	O
are	O
applied	O
to	O
real	O
chromatographic	O
data	O
showing	O
severely	O
shifted	O
peak	O
profiles	O
.	O

The	O
pros	O
and	O
cons	O
of	O
the	O
presented	O
approaches	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
model	O
parameters	O
,	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
degree	O
of	O
shift	O
.	O

Women	O
'	O
s	O
attitudes	O
,	O
preferences	O
,	O
and	O
perceived	O
barriers	O
to	O
treatment	O
for	O
perinatal	O
depression	O
.	O

BACKGROUND	O
:	O

Perinatal	O
depression	O
is	O
associated	O
with	O
potential	O
negative	O
consequences	O
for	O
the	O
mother	O
and	O
infant	O
,	O
and	O
therefore	O
efforts	O
to	O
improve	O
treatment	O
access	O
and	O
efficacy	O
are	O
warranted	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
pregnant	O
women	O
'	O
s	O
preferences	O
and	O
attitudes	O
about	O
treatment	O
for	O
depression	O
,	O
and	O
perceived	O
potential	O
barriers	O
to	O
accessing	O
treatment	O
.	O

METHODS	O
:	O

Data	O
were	O
collected	O
by	O
means	O
of	O
a	O
questionnaire	O
from	O
a	O
convenience	O
sample	O
of	O
509	O
predominantly	O
well	O
-	O
educated	O
,	O
high	O
-	O
income	O
,	O
married	O
women	O
in	O
the	O
northeastern	O
United	O
States	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O

Participants	O
were	O
queried	O
as	O
to	O
treatment	O
modalities	O
in	O
which	O
they	O
would	O
most	O
likely	O
participate	O
if	O
they	O
wanted	O
help	O
for	O
depression	O
,	O
their	O
attitudes	O
toward	O
psychotherapeutic	O
and	O
pharmacological	O
treatments	O
,	O
and	O
perceived	O
barriers	O
to	O
receiving	O
help	O
.	O

RESULTS	O
:	O

Most	O
women	O
(	O
92	O
%	O
)	O
indicated	O
that	O
would	O
likely	O
participate	O
in	O
individual	O
therapy	O
if	O
help	O
was	O
needed	O
.	O

Only	O
35	O
percent	O
stated	O
that	O
they	O
would	O
likely	O
take	O
medication	O
if	O
recommended	O
,	O
and	O
14	O
percent	O
indicated	O
that	O
they	O
would	O
participate	O
in	O
group	O
therapy	O
.	O

The	O
greatest	O
perceived	O
potential	O
barriers	O
to	O
treatment	O
were	O
lack	O
of	O
time	O
(	O
65	O
%	O
)	O
,	O
stigma	O
(	O
43	O
%	O
)	O
,	O
and	O
childcare	O
issues	O
(	O
33	O
%	O
)	O
.	O

Most	O
women	O
indicated	O
a	O
preference	O
to	O
receive	O
mental	O
health	O
care	O
at	O
the	O
obstetrics	O
clinic	O
,	O
either	O
from	O
their	O
obstetrics	O
practitioner	O
or	O
from	O
a	O
mental	O
health	O
practitioner	O
located	O
at	O
the	O
clinic	O
.	O

Factors	O
associated	O
with	O
acceptability	O
of	O
various	O
depression	O
treatments	O
are	O
presented	O
.	O

CONCLUSIONS	O
:	O

Understanding	O
what	O
prevents	O
women	O
from	O
seeking	O
or	O
obtaining	O
help	O
for	O
depression	O
and	O
determining	O
what	O
they	O
prefer	O
in	O
the	O
way	O
of	O
treatment	O
may	O
lead	O
to	O
improved	O
depression	O
treatment	O
rates	O
and	O
hold	O
promise	O
for	O
improving	O
the	O
overall	O
health	O
of	O
childbearing	O
women	O
.	O

The	O
effect	O
of	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carriers	O
on	O
tissue	O
-	O
engineered	O
trachea	O
.	O

The	O
biological	O
effect	O
of	O
the	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carrier	O
(	O
Oxygent	O
)	O
was	O
investigated	O
in	O
tissue	O
-	O
engineered	O
trachea	O
(	O
TET	O
)	O
construction	O
.	O

Media	O
supplemented	O
with	O
and	O
without	O
10	O
%	O
Oxygent	O
were	O
compared	O
in	O
all	O
assessments	O
.	O

Partial	O
tissue	O
oxygen	O
tension	O
(	O
PtO	O
(	O
2	O
)	O
)	O
was	O
measured	O
with	O
polarographic	O
microprobes	O
;	O
epithelial	O
metabolism	O
was	O
monitored	O
by	O
microdialysis	O
inside	O
the	O
TET	O
epithelium	O
perfused	O
with	O
the	O
medium	O
underneath	O
.	O

Chondrocyte	O
-	O
DegraPol	O
constructs	O
were	O
cultured	O
for	O
1	O
month	O
with	O
the	O
medium	O
before	O
glycosaminoglycan	O
assessment	O
and	O
histology	O
.	O

Tissue	O
reaction	O
of	O
TET	O
epithelial	O
scaffolds	O
immersed	O
with	O
the	O
medium	O
was	O
evaluated	O
on	O
the	O
chick	O
embryo	O
chorioallantoic	O
membrane	O
.	O

Oxygent	O
perfusion	O
medium	O
increased	O
the	O
TET	O
epithelial	O
PtO	O
(	O
2	O
)	O
(	O
51	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
vs	O
.	O
33	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
at	O
200	O
microm	O
thickness	O
;	O
12	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
vs	O
.	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
at	O
400	O
microm	O
thickness	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
decreased	O
the	O
lactate	O
concentration	O
(	O
0	O
.	O
63	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
80	O
+	O
/	O
-	O
0	O
.	O
06	O
mmol	O
/	O
L	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
lactate	O
/	O
pyruvate	O
(	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
26	O
vs	O
.	O
3	O
.	O
36	O
+	O
/	O
-	O
10	O
.	O
13	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
lactate	O
/	O
glucose	O
ratios	O
(	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
14	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Chondrocyte	O
-	O
DegraPol	O
in	O
Oxygent	O
group	O
presented	O
lower	O
glycosaminoglycan	O
value	O
(	O
0	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
00	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
histology	O
slides	O
showed	O
poor	O
acid	O
mucopolysaccharides	O
formation	O
.	O

Orthogonal	O
polarization	O
spectral	O
imaging	O
showed	O
no	O
difference	O
in	O
functional	O
capillary	O
density	O
between	O
the	O
scaffolds	O
cultured	O
on	O
chorioallantoic	O
membranes	O
.	O

The	O
foreign	O
body	O
reaction	O
was	O
similar	O
in	O
both	O
groups	O
.	O

We	O
conclude	O
that	O
Oxygent	O
increases	O
TET	O
epithelial	O
PtO	O
(	O
2	O
)	O
,	O
improves	O
epithelial	O
metabolism	O
,	O
does	O
not	O
impair	O
angiogenesis	O
,	O
and	O
tends	O
to	O
slow	O
cartilage	O
tissue	O
formation	O
.	O

Distinct	O
role	O
of	O
PLCbeta3	O
in	O
VEGF	O
-	O
mediated	O
directional	O
migration	O
and	O
vascular	O
sprouting	O
.	O

Endothelial	O
cell	O
proliferation	O
and	O
migration	O
is	O
essential	O
to	O
angiogenesis	O
.	O

Typically	O
,	O
proliferation	O
and	O
chemotaxis	O
of	O
endothelial	O
cells	O
is	O
driven	O
by	O
growth	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O

VEGF	O
activates	O
phospholipases	O
(	O
PLCs	O
)	O
-	O
specifically	O
PLCgamma1	O
-	O
that	O
are	O
important	O
for	O
tubulogenesis	O
,	O
differentiation	O
and	O
DNA	O
synthesis	O
.	O

However	O
,	O
we	O
show	O
here	O
that	O
VEGF	O
,	O
specifically	O
through	O
VEGFR2	O
,	O
induces	O
phosphorylation	O
of	O
two	O
serine	O
residues	O
on	O
PLCbeta3	O
,	O
and	O
this	O
was	O
confirmed	O
in	O
an	O
ex	O
vivo	O
embryoid	O
body	O
model	O
.	O

Knockdown	O
of	O
PLCbeta3	O
in	O
HUVEC	O
cells	O
affects	O
IP3	O
production	O
,	O
actin	O
reorganization	O
,	O
migration	O
and	O
proliferation	O
;	O
whereas	O
migration	O
is	O
inhibited	O
,	O
proliferation	O
is	O
enhanced	O
.	O

Our	O
data	O
suggest	O
that	O
enhanced	O
proliferation	O
is	O
precipitated	O
by	O
an	O
accelerated	O
cell	O
cycle	O
,	O
and	O
decreased	O
migration	O
by	O
an	O
inability	O
to	O
activate	O
CDC42	O
.	O

Given	O
that	O
PLCbeta3	O
is	O
typically	O
known	O
as	O
an	O
effector	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
,	O
our	O
data	O
demonstrate	O
a	O
unique	O
crosstalk	O
between	O
the	O
G	O
-	O
protein	O
and	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
axes	O
and	O
reveal	O
a	O
novel	O
molecular	O
mechanism	O
of	O
VEGF	O
signaling	O
and	O
,	O
thus	O
,	O
angiogenesis	O
.	O

The	O
semaphorin	O
7A	O
receptor	O
Plexin	O
C1	O
is	O
lost	O
during	O
melanoma	O
metastasis	O
.	O

The	O
transformation	O
of	O
normal	O
melanocytes	O
,	O
or	O
melanocyte	O
stem	O
cells	O
,	O
to	O
melanoma	O
,	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
mechanisms	O
.	O

Loss	O
of	O
tumor	O
suppressor	O
proteins	O
,	O
which	O
function	O
as	O
brakes	O
on	O
cell	O
growth	O
,	O
migration	O
,	O
or	O
cell	O
survival	O
,	O
was	O
recognized	O
early	O
on	O
as	O
an	O
important	O
mechanism	O
for	O
initiation	O
and	O
progression	O
of	O
melanoma	O
.	O

Semaphorins	O
and	O
their	O
cognate	O
receptors	O
,	O
Plexins	O
and	O
neuropilins	O
,	O
are	O
involved	O
in	O
neuronal	O
pathfinding	O
,	O
immune	O
function	O
,	O
and	O
tumor	O
progression	O
through	O
effects	O
on	O
blood	O
vessel	O
growth	O
and	O
cell	O
migration	O
.	O

Semaphorin	O
7A	O
(	O
Sema7A	O
)	O
is	O
a	O
membrane	O
-	O
linked	O
semaphorin	O
that	O
is	O
expressed	O
by	O
human	O
keratinocytes	O
,	O
and	O
we	O
have	O
shown	O
that	O
Sema7A	O
binds	O
to	O
human	O
melanocytes	O
through	O
beta1	O
-	O
integrins	O
and	O
the	O
Plexin	O
C1	O
receptor	O
.	O

Functional	O
studies	O
showed	O
that	O
Sema7A	O
stimulates	O
cytoskeletal	O
reorganization	O
in	O
human	O
melanocytes	O
,	O
resulting	O
in	O
adhesion	O
and	O
dendrite	O
formation	O
.	O

Downstream	O
targets	O
of	O
Plexin	O
C1	O
signaling	O
in	O
human	O
melanocytes	O
include	O
cofilin	O
and	O
LIM	O
kinase	O
II	O
,	O
both	O
of	O
which	O
are	O
critical	O
mediators	O
of	O
cell	O
adhesion	O
and	O
migration	O
.	O

In	O
this	O
report	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
Plexin	O
C1	O
using	O
immunohistochemistry	O
on	O
sections	O
of	O
primary	O
and	O
matched	O
metastatic	O
lesions	O
from	O
19	O
subjects	O
and	O
in	O
a	O
large	O
melanoma	O
tumor	O
microarray	O
.	O

Our	O
data	O
show	O
a	O
significant	O
loss	O
of	O
Plexin	O
C1	O
in	O
metastatic	O
melanoma	O
compared	O
with	O
primary	O
melanoma	O
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
Plexin	O
C1	O
receptor	O
is	O
a	O
tumor	O
suppressor	O
protein	O
for	O
melanoma	O
.	O

Coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
.	O

BACKGROUND	O
:	O
The	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
is	O
abnormal	O
and	O
the	O
reason	O
is	O
not	O
very	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
.	O

METHODS	O
:	O
From	O
June	O
2004	O
to	O
December	O
2007	O
,	O
132	O
patients	O
received	O
diagnosis	O
and	O
treatment	O
in	O
our	O
hospital	O
.	O

The	O
coagulative	O
parameters	O
including	O
the	O
prothrombin	O
time	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
and	O
fibrinogen	O
levels	O
were	O
collected	O
and	O
studied	O
retrospectively	O
.	O

RESULTS	O
:	O
The	O
average	O
fibrinogen	O
levels	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
,	O
(	O
476	O
.	O
21	O
+	O
/	O
-	O
142	O
.	O
05	O
)	O
mg	O
/	O
dl	O
,	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
with	O
cholangiolithiasis	O
,	O
(	O
403	O
.	O
28	O
+	O
/	O
-	O
126	O
.	O
41	O
)	O
mg	O
/	O
dl	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	O
with	O
pancreatic	O
carcinoma	O
,	O
the	O
levels	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
jaundice	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
without	O
jaundice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	O
who	O
received	O
Pancreaticoduodenectomy	O
,	O
Whipple	O
'	O
s	O
operation	O
,	O
the	O
level	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
local	O
invasiveness	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
without	O
invasiveness	O
.	O

The	O
group	O
with	O
lymphatic	O
metastasis	O
had	O
higher	O
levels	O
than	O
the	O
group	O
without	O
lymphatic	O
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
of	O
intraoperative	O
blood	O
loss	O
between	O
patients	O
with	O
vitamin	O
K	O
,	O
(	O
748	O
.	O
27	O
+	O
/	O
-	O
448	O
.	O
51	O
)	O
ml	O
,	O
and	O
those	O
without	O
vitamin	O
K	O
,	O
(	O
767	O
.	O
31	O
+	O
/	O
-	O
547	O
.	O
89	O
)	O
ml	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
level	O
of	O
fibrinogen	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
was	O
elevated	O
.	O

The	O
elevated	O
fibrinogen	O
level	O
may	O
be	O
associated	O
with	O
invasiveness	O
and	O
lymphatic	O
metastasis	O
.	O

Using	O
vitamin	O
K	O
in	O
perioperation	O
management	O
did	O
not	O
reduce	O
intraoperative	O
blood	O
loss	O
.	O

Role	O
of	O
the	O
interferon	O
-	O
inducible	O
IFI16	O
gene	O
in	O
the	O
induction	O
of	O
ICAM	O
-	O
1	O
by	O
TNF	O
-	O
alpha	O
.	O

The	O
Interferon	O
-	O
inducible	O
gene	O
IFI16	O
,	O
a	O
member	O
of	O
the	O
HIN200	O
family	O
,	O
is	O
activated	O
by	O
oxidative	O
stress	O
and	O
cell	O
density	O
,	O
in	O
addition	O
to	O
Interferons	O
,	O
and	O
it	O
is	O
implicated	O
in	O
the	O
regulation	O
of	O
endothelial	O
cell	O
proliferation	O
and	O
vessel	O
formation	O
in	O
vitro	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IFI16	O
is	O
required	O
for	O
proinflammatory	O
gene	O
stimulation	O
by	O
IFN	O
-	O
gamma	O
through	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

To	O
examine	O
whether	O
IFI16	O
induction	O
might	O
be	O
extended	O
to	O
other	O
proinflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
we	O
used	O
the	O
strategy	O
of	O
the	O
RNA	O
interference	O
to	O
knock	O
down	O
IFI16	O
expression	O
,	O
and	O
analyze	O
the	O
capability	O
of	O
TNF	O
-	O
alpha	O
to	O
stimulate	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
or	O
CD54	O
)	O
expression	O
in	O
the	O
absence	O
of	O
functional	O
IFI16	O
.	O

Our	O
studies	O
demonstrate	O
that	O
IFI16	O
mediates	O
ICAM	O
-	O
1	O
stimulation	O
by	O
TNF	O
-	O
alpha	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
thus	O
reinforcing	O
the	O
role	O
of	O
the	O
IFI16	O
molecule	O
in	O
the	O
inflammation	O
process	O
.	O

Molecular	O
analysis	O
of	O
genetic	O
instability	O
caused	O
by	O
chronic	O
inflammation	O
.	O

Genetic	O
instability	O
is	O
a	O
hallmark	O
of	O
human	O
cancers	O
.	O

It	O
is	O
the	O
driving	O
force	O
for	O
tumor	O
development	O
as	O
it	O
facilitates	O
the	O
accumulation	O
of	O
mutations	O
in	O
genes	O
that	O
regulate	O
cell	O
death	O
and	O
proliferation	O
and	O
therefore	O
promotes	O
malignant	O
transformation	O
.	O

Chronic	O
inflammation	O
is	O
a	O
common	O
underlying	O
condition	O
for	O
human	O
tumor	O
development	O
,	O
accounting	O
for	O
approximately	O
20	O
%	O
of	O
human	O
cancers	O
.	O

TNFalpha	O
is	O
an	O
important	O
inflammation	O
cytokine	O
and	O
is	O
crucial	O
to	O
the	O
development	O
of	O
inflammation	O
-	O
associated	O
cancers	O
.	O

We	O
have	O
shown	O
that	O
TNFalpha	O
can	O
cause	O
DNA	O
damages	O
through	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

TNFalpha	O
treatment	O
in	O
cultured	O
cells	O
resulted	O
in	O
increased	O
gene	O
mutations	O
,	O
gene	O
amplification	O
,	O
micronuclei	O
formation	O
and	O
chromosomal	O
instability	O
.	O

Antioxidants	O
significantly	O
reduced	O
TNFalpha	O
-	O
induced	O
genetic	O
damage	O
.	O

In	O
addition	O
,	O
TNFalpha	O
treatment	O
alone	O
led	O
to	O
increased	O
malignant	O
transformation	O
of	O
mouse	O
embryo	O
fibroblasts	O
,	O
which	O
could	O
be	O
partially	O
suppressed	O
by	O
antioxidants	O
.	O

Therefore	O
,	O
genetic	O
instability	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
-	O
associated	O
cancers	O
.	O

The	O
impact	O
of	O
tracheal	O
intubation	O
on	O
host	O
defenses	O
and	O
risks	O
for	O
nosocomial	O
pneumonia	O
.	O

Nosocomial	O
pneumonia	O
remains	O
a	O
common	O
complication	O
in	O
patients	O
treated	O
with	O
endotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
and	O
continues	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
mortality	O
rate	O
of	O
these	O
patients	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
that	O
the	O
risk	O
of	O
pneumonia	O
increases	O
with	O
the	O
duration	O
of	O
intubation	O
but	O
that	O
the	O
period	O
of	O
highest	O
risk	O
is	O
the	O
first	O
2	O
weeks	O
of	O
therapy	O
.	O

Gram	O
-	O
negative	O
bacteria	O
account	O
for	O
most	O
nosocomial	O
pneumonias	O
in	O
intubated	O
patients	O
,	O
but	O
Staphylococcus	O
aureus	O
may	O
also	O
play	O
a	O
role	O
in	O
what	O
may	O
be	O
a	O
polymicrobial	O
infection	O
.	O

In	O
the	O
most	O
seriously	O
ill	O
individuals	O
,	O
and	O
in	O
those	O
treated	O
with	O
long	O
-	O
term	O
mechanical	O
ventilation	O
,	O
Pseudomonas	O
aeruginosa	O
is	O
a	O
common	O
pathogen	O
.	O

Endotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
predispose	O
to	O
pneumonia	O
for	O
a	O
variety	O
of	O
reasons	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O

The	O
endotracheal	O
tube	O
can	O
have	O
direct	O
effects	O
on	O
the	O
airway	O
that	O
result	O
in	O
a	O
reduction	O
in	O
local	O
host	O
defenses	O
.	O

Thus	O
,	O
mucosal	O
injury	O
can	O
reduce	O
mucociliary	O
function	O
,	O
while	O
upper	O
airway	O
defenses	O
are	O
bypassed	O
and	O
the	O
effectiveness	O
of	O
cough	O
is	O
reduced	O
.	O

Indirectly	O
,	O
intubation	O
can	O
result	O
in	O
an	O
enhanced	O
capacity	O
of	O
tracheobronchial	O
cells	O
to	O
bind	O
gram	O
-	O
negative	O
bacteria	O
,	O
an	O
effect	O
that	O
favors	O
airway	O
colonization	O
and	O
pneumonia	O
.	O

The	O
injury	O
to	O
the	O
airway	O
can	O
create	O
binding	O
sites	O
for	O
bacteria	O
in	O
the	O
basement	O
membrane	O
of	O
the	O
bronchial	O
tree	O
and	O
the	O
stimulation	O
of	O
the	O
secretion	O
of	O
mucus	O
,	O
which	O
then	O
stagnates	O
and	O
can	O
create	O
potential	O
sites	O
for	O
bacterial	O
adherence	O
.	O

The	O
endotracheal	O
tube	O
also	O
enhances	O
bacterial	O
entry	O
to	O
the	O
lung	O
by	O
serving	O
as	O
a	O
reservoir	O
for	O
bacteria	O
to	O
remain	O
sequestered	O
,	O
safe	O
from	O
host	O
defenses	O
.	O

Respiratory	O
therapy	O
devices	O
can	O
allow	O
bacteria	O
to	O
proliferate	O
and	O
can	O
then	O
introduce	O
them	O
into	O
the	O
patient	O
if	O
not	O
handled	O
properly	O
.	O

Finally	O
,	O
patients	O
who	O
are	O
ill	O
enough	O
to	O
require	O
intubation	O
also	O
have	O
disease	O
-	O
associated	O
impairments	O
in	O
systemic	O
host	O
defense	O
,	O
which	O
add	O
to	O
the	O
impairments	O
caused	O
by	O
the	O
use	O
of	O
an	O
artificial	O
airway	O
.	O

The	O
host	O
defense	O
impairments	O
that	O
occur	O
in	O
mechanically	O
ventilated	O
patients	O
can	O
lead	O
to	O
respiratory	O
tract	O
infection	O
in	O
the	O
form	O
of	O
either	O
febrile	O
tracheobronchitis	O
or	O
pneumonia	O
.	O

The	O
diagnosis	O
of	O
pneumonia	O
in	O
intubated	O
patients	O
is	O
difficult	O
and	O
controversial	O
.	O

It	O
can	O
be	O
made	O
by	O
either	O
clinical	O
criteria	O
or	O
microbiologic	O
criteria	O
,	O
the	O
latter	O
by	O
using	O
a	O
bronchoscopically	O
directed	O
protected	O
specimen	O
brush	O
.	O

Therapy	O
of	O
pneumonia	O
in	O
mechanically	O
ventilated	O
patients	O
is	O
not	O
always	O
successful	O
,	O
and	O
systemic	O
antibiotics	O
may	O
need	O
to	O
be	O
supplemented	O
by	O
topical	O
antimicrobials	O
.	O

No	O
clearly	O
effective	O
prophylactic	O
strategy	O
currently	O
exists	O
,	O
but	O
our	O
understanding	O
of	O
pneumonia	O
pathogenesis	O
has	O
led	O
to	O
some	O
promising	O
directions	O
.	O

As	O
more	O
data	O
are	O
collected	O
,	O
inhaled	O
antibiotics	O
,	O
selective	O
digestive	O
decontamination	O
,	O
and	O
enhancement	O
of	O
host	O
defenses	O
by	O
cytokines	O
and	O
pre	O
-	O
formed	O
antibodies	O
may	O
emerge	O
as	O
useful	O
approaches	O
.	O

Antivascular	O
actions	O
of	O
microtubule	O
-	O
binding	O
drugs	O
.	O

Microtubule	O
-	O
binding	O
drugs	O
(	O
MBD	O
)	O
are	O
widely	O
used	O
in	O
cancer	O
chemotherapy	O
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	O
and	O
vascular	O
-	O
disrupting	O
properties	O
.	O

These	O
antivascular	O
actions	O
are	O
due	O
in	O
part	O
to	O
direct	O
effects	O
on	O
endothelial	O
cells	O
,	O
and	O
all	O
MBDs	O
(	O
both	O
microtubule	O
-	O
stabilizing	O
and	O
microtubule	O
-	O
destabilizing	O
)	O
inhibit	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
tube	O
formation	O
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	O
actions	O
.	O

In	O
addition	O
,	O
the	O
microtubule	O
-	O
destabilizing	O
agents	O
cause	O
prominent	O
changes	O
in	O
endothelial	O
cell	O
morphology	O
,	O
an	O
action	O
associated	O
with	O
rapid	O
vascular	O
collapse	O
in	O
vivo	O
.	O

The	O
effects	O
on	O
endothelial	O
cells	O
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	O
microtubule	O
gross	O
morphology	O
,	O
do	O
not	O
cause	O
microtubule	O
bundling	O
or	O
microtubule	O
loss	O
and	O
do	O
not	O
induce	O
cell	O
cycle	O
arrest	O
,	O
apoptosis	O
,	O
or	O
cell	O
death	O
.	O

Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	O
produce	O
more	O
subtle	O
effects	O
on	O
microtubule	O
dynamics	O
,	O
block	O
critical	O
cell	O
signaling	O
pathways	O
,	O
and	O
prevent	O
the	O
microtubules	O
from	O
properly	O
interacting	O
with	O
transient	O
subcellular	O
assemblies	O
(	O
focal	O
adhesions	O
and	O
adherens	O
junctions	O
)	O
whose	O
subsequent	O
stabilization	O
and	O
/	O
or	O
maturation	O
are	O
required	O
for	O
cell	O
motility	O
and	O
cell	O
-	O
cell	O
interactions	O
.	O

This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	O
actions	O
of	O
the	O
MBDs	O
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	O
the	O
tumor	O
vasculature	O
.	O

PTTG	O
overexpression	O
promotes	O
lymph	O
node	O
metastasis	O
in	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

Human	O
pituitary	O
tumor	O
transforming	O
gene	O
(	O
PTTG	O
)	O
overexpression	O
correlates	O
with	O
metastasis	O
in	O
multiple	O
tumors	O
,	O
and	O
yet	O
its	O
molecular	O
mechanisms	O
of	O
action	O
remain	O
elusive	O
.	O

We	O
detected	O
PTTG	O
overexpression	O
in	O
66	O
%	O
(	O
111	O
of	O
169	O
)	O
of	O
primary	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
tumor	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

PTTG	O
overexpression	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Ectopic	O
PTTG	O
overexpression	O
in	O
a	O
representative	O
ESCC	O
cell	O
line	O
,	O
EC9706	B
,	O
increased	O
in	O
vitro	O
cell	O
migration	O
and	O
invasion	O
and	O
promoted	O
in	O
vivo	O
lymph	O
node	O
metastasis	O
.	O

Suppressing	O
PTTG	O
expression	O
by	O
siRNA	O
decreased	O
cell	O
motility	O
in	O
both	O
PTTG	O
-	O
HA	O
/	O
EC9706	B
and	O
KYSE150	B
cells	O
.	O

By	O
using	O
mass	O
spectrometric	O
analysis	O
,	O
we	O
identified	O
that	O
PTTG	O
up	O
-	O
regulated	O
S100A4	O
and	O
galectin	O
-	O
1	O
secretion	O
and	O
down	O
-	O
regulated	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
2	O
secretion	O
to	O
the	O
culture	O
media	O
.	O

PTTG	O
induced	O
S100A4	O
and	O
galectin	O
-	O
1	O
mRNA	O
and	O
protein	O
expression	O
as	O
assessed	O
by	O
Western	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Attenuating	O
galectin	O
-	O
1	O
expression	O
by	O
siRNA	O
constrained	O
PTTG	O
-	O
HA	O
/	O
EC9706	B
cell	O
motility	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

PTTG	O
activated	O
E	O
-	O
box	O
transcription	O
and	O
induced	O
c	O
-	O
Myc	O
protein	O
expression	O
in	O
EC9706	B
cells	O
,	O
which	O
in	O
turn	O
may	O
act	O
on	O
an	O
E	O
-	O
box	O
motif	O
within	O
the	O
galectin	O
-	O
1	O
promoter	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
further	O
confirmed	O
specific	O
c	O
-	O
Myc	O
binding	O
to	O
galectin	O
-	O
1	O
promoter	O
.	O

PTTG	O
-	O
induced	O
galectin	O
-	O
1	O
transactivation	O
and	O
expression	O
were	O
mediated	O
by	O
c	O
-	O
Myc	O
,	O
and	O
both	O
inductions	O
were	O
suppressed	O
by	O
c	O
-	O
Myc	O
RNAi	O
cotranfection	O
.	O

These	O
findings	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
PTTG	O
overexpression	O
in	O
promoting	O
tumor	O
metastasis	O
,	O
whereby	O
up	O
-	O
regulated	O
PTTG	O
modulates	O
expression	O
and	O
secretion	O
of	O
metastasis	O
-	O
related	O
factors	O
to	O
facilitate	O
cell	O
motility	O
.	O

Neurovascular	O
effects	O
of	O
CD47	O
signaling	O
:	O
promotion	O
of	O
cell	O
death	O
,	O
inflammation	O
,	O
and	O
suppression	O
of	O
angiogenesis	O
in	O
brain	O
endothelial	O
cells	O
in	O
vitro	O
.	O

The	O
concept	O
of	O
the	O
neurovascular	O
unit	O
emphasizes	O
that	O
common	O
signals	O
and	O
substrates	O
underlie	O
the	O
physiology	O
and	O
pathophysiology	O
of	O
neuronal	O
and	O
endothelial	O
compartments	O
in	O
brain	O
.	O

Recent	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
integrin	O
-	O
associated	O
protein	O
CD47	O
promotes	O
neuronal	O
cell	O
death	O
.	O

Is	O
it	O
possible	O
that	O
CD47	O
may	O
also	O
negatively	O
affect	O
cerebral	O
endothelial	O
cells	O
?	O

Exposure	O
of	O
wild	O
-	O
type	O
primary	O
mouse	O
cerebral	O
endothelial	O
cells	O
to	O
the	O
CD47	O
ligand	O
thrombospondin	O
1	O
(	O
TSP	O
-	O
1	O
)	O
induced	O
an	O
increasing	O
amount	O
of	O
cell	O
death	O
,	O
whereas	O
cytotoxicity	O
was	O
significantly	O
decreased	O
in	O
cerebral	O
endothelial	O
cells	O
derived	O
from	O
CD47	O
knockout	O
mice	O
.	O

The	O
specific	O
CD47	O
-	O
activating	O
peptide	O
,	O
4N1	O
K	O
,	O
similarly	O
induced	O
cell	O
death	O
in	O
human	O
brain	O
microvascular	O
endothelial	O
cells	O
.	O

Promotion	O
of	O
inflammation	O
was	O
also	O
involved	O
because	O
lower	O
TSP	O
-	O
1	O
was	O
able	O
to	O
up	O
-	O
regulate	O
the	O
adhesion	O
molecules	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
.	O

Finally	O
,	O
CD47	O
signaling	O
may	O
suppress	O
angiogenesis	O
because	O
4N1	O
K	O
significantly	O
inhibited	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
CD47	O
signaling	O
can	O
negatively	O
affect	O
the	O
viability	O
and	O
function	O
of	O
cerebral	O
endothelial	O
cells	O
,	O
further	O
supporting	O
the	O
notion	O
that	O
CD47	O
may	O
be	O
a	O
potential	O
neurovascular	O
target	O
for	O
stroke	O
and	O
brain	O
injury	O
.	O

Characterization	O
of	O
the	O
metabolic	O
changes	O
underlying	O
growth	O
factor	O
angiogenic	O
activation	O
:	O
identification	O
of	O
new	O
potential	O
therapeutic	O
targets	O
.	O

Angiogenesis	O
is	O
a	O
fundamental	O
process	O
to	O
normal	O
and	O
abnormal	O
tissue	O
growth	O
and	O
repair	O
,	O
which	O
consists	O
of	O
recruiting	O
endothelial	O
cells	O
toward	O
an	O
angiogenic	O
stimulus	O
.	O

The	O
cells	O
subsequently	O
proliferate	O
and	O
differentiate	O
to	O
form	O
endothelial	O
tubes	O
and	O
capillary	O
-	O
like	O
structures	O
.	O

Little	O
is	O
known	O
about	O
the	O
metabolic	O
adaptation	O
of	O
endothelial	O
cells	O
through	O
such	O
a	O
transformation	O
.	O

We	O
studied	O
the	O
metabolic	O
changes	O
of	O
endothelial	O
cell	O
activation	O
by	O
growth	O
factors	O
using	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
and	O
mass	O
isotopomer	O
distribution	O
analysis	O
.	O

The	O
metabolism	O
of	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
by	O
HUVEC	O
allows	O
us	O
to	O
trace	O
many	O
of	O
the	O
main	O
glucose	O
metabolic	O
pathways	O
,	O
including	O
glycogen	O
synthesis	O
,	O
the	O
pentose	O
cycle	O
and	O
the	O
glycolytic	O
pathways	O
.	O

So	O
we	O
established	O
that	O
these	O
pathways	O
were	O
crucial	O
to	O
endothelial	O
cell	O
proliferation	O
under	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
stimulation	O
.	O

A	O
specific	O
VEGF	O
receptor	O
-	O
2	O
inhibitor	O
demonstrated	O
the	O
importance	O
of	O
glycogen	O
metabolism	O
and	O
pentose	O
cycle	O
pathway	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
glycogen	O
was	O
depleted	O
in	O
a	O
low	O
glucose	O
medium	O
,	O
but	O
conserved	O
under	O
hypoxic	O
conditions	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
direct	O
inhibition	O
of	O
key	O
enzymes	O
to	O
glycogen	O
metabolism	O
and	O
pentose	O
phosphate	O
pathways	O
reduced	O
HUVEC	O
viability	O
and	O
migration	O
.	O

In	O
this	O
regard	O
,	O
inhibitors	O
of	O
these	O
pathways	O
have	O
been	O
shown	O
to	O
be	O
effective	O
antitumoral	O
agents	O
.	O

To	O
sum	O
up	O
,	O
our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
metabolic	O
pathways	O
offers	O
a	O
novel	O
and	O
powerful	O
therapeutic	O
approach	O
,	O
which	O
simultaneously	O
inhibits	O
tumor	O
cell	O
proliferation	O
and	O
tumor	O
-	O
induced	O
angiogenesis	O
.	O

Rab	O
GTPase	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
in	O
endothelial	O
cells	O
.	O

OBJECTIVE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
VEGFR2	O
)	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
that	O
regulates	O
vascular	O
physiology	O
.	O

However	O
,	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
VEGFR2	O
signaling	O
and	O
trafficking	O
is	O
coordinated	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
have	O
tested	O
endocytic	O
Rab	O
GTPases	O
for	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
linked	O
to	O
endothelial	O
cell	O
migration	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Quiescent	O
VEGFR2	O
displays	O
endosomal	O
localization	O
and	O
colocalization	O
with	O
the	O
Rab5a	O
GTPase	O
,	O
an	O
early	O
endosome	O
fusion	O
regulator	O
.	O

Expression	O
of	O
GTP	O
or	O
GDP	O
-	O
bound	O
Rab5a	O
mutants	O
block	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O

Manipulation	O
of	O
Rab7a	O
GTPase	O
activity	O
associated	O
with	O
late	O
endosomes	O
using	O
overexpression	O
of	O
wild	O
-	O
type	O
or	O
mutant	O
proteins	O
blocks	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O

Depletion	O
of	O
Rab7a	O
decreased	O
VEGFR2	O
Y1175	O
phosphorylation	O
but	O
increased	O
p42	O
/	O
44	O
(	O
pERK1	O
/	O
2	O
)	O
MAPK	O
phosphorylation	O
.	O

Endothelial	O
cell	O
migration	O
was	O
increased	O
by	O
Rab5a	O
depletion	O
but	O
decreased	O
by	O
Rab7a	O
depletion	O
.	O

CONCLUSIONS	O
:	O
Rab5a	O
and	O
Rab7a	O
regulate	O
VEGFR2	O
trafficking	O
toward	O
early	O
and	O
late	O
endosomes	O
.	O

Our	O
data	O
suggest	O
that	O
VEGFR2	O
-	O
mediated	O
regulation	O
of	O
endothelial	O
function	O
is	O
dependent	O
on	O
different	O
but	O
specific	O
Rab	O
-	O
mediated	O
GTP	O
hydrolysis	O
activity	O
required	O
for	O
endosomal	O
trafficking	O
.	O

FOXO3a	O
elicits	O
a	O
pro	O
-	O
apoptotic	O
transcription	O
program	O
and	O
cellular	O
response	O
to	O
human	O
lung	O
carcinogen	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
.	O

Long	O
-	O
term	O
carcinogen	O
exposure	O
exerts	O
continuous	O
pressure	O
on	O
key	O
mechanisms	O
that	O
repair	O
or	O
eliminate	O
carcinogen	O
-	O
damaged	O
cells	O
giving	O
rise	O
to	O
selective	O
failures	O
that	O
contribute	O
to	O
lung	O
cancer	O
.	O

FOXO3a	O
is	O
a	O
transcription	O
factor	O
that	O
elicits	O
a	O
protective	O
response	O
to	O
diverse	O
cellular	O
stresses	O
.	O

Although	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
,	O
its	O
role	O
in	O
sporadic	O
cancer	O
is	O
uncertain	O
.	O

We	O
recently	O
observed	O
that	O
FOXO3a	O
gene	O
inactivation	O
occurs	O
frequently	O
in	O
carcinogen	O
-	O
induced	O
lung	O
adenocarcinoma	O
(	O
LAC	O
)	O
.	O

This	O
suggests	O
that	O
FOXO3a	O
may	O
play	O
a	O
role	O
in	O
LAC	O
suppression	O
by	O
eliciting	O
a	O
protective	O
response	O
to	O
carcinogenic	O
stress	O
.	O

Here	O
we	O
investigated	O
this	O
possibility	O
by	O
examining	O
the	O
role	O
of	O
FOXO3a	O
in	O
the	O
cellular	O
response	O
to	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
,	O
a	O
lung	O
carcinogen	O
implicated	O
as	O
a	O
cause	O
of	O
human	O
LAC	O
.	O

We	O
show	O
that	O
restoration	O
of	O
FOXO3a	O
in	O
FOXO3a	O
-	O
deficient	O
LAC	O
cells	O
increases	O
sensitivity	O
to	O
apoptosis	O
caused	O
by	O
a	O
DNA	O
-	O
damaging	O
intermediate	O
of	O
NNK	O
.	O

Prior	O
to	O
this	O
cellular	O
outcome	O
,	O
FOXO3a	O
is	O
functionally	O
activated	O
and	O
mediates	O
a	O
large	O
-	O
scale	O
transcription	O
program	O
in	O
response	O
to	O
this	O
damage	O
involving	O
a	O
significant	O
modulation	O
of	O
440	O
genes	O
.	O

Genes	O
most	O
significantly	O
represented	O
in	O
this	O
program	O
are	O
those	O
with	O
roles	O
in	O
cell	O
growth	O
and	O
proliferation	O
>	O
protein	O
synthesis	O
>	O
gene	O
expression	O
>	O
cell	O
death	O
>	O
cell	O
cycle	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
FOXO3a	O
directs	O
an	O
anti	O
-	O
carcinogenic	O
transcription	O
program	O
that	O
culminates	O
in	O
the	O
elimination	O
of	O
carcinogen	O
-	O
damaged	O
cells	O
.	O

This	O
suggests	O
that	O
FOXO3a	O
is	O
a	O
potential	O
suppressor	O
of	O
carcinogenic	O
damage	O
in	O
LAC	O
.	O

Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
neural	O
stem	O
/	O
progenitor	O
cells	O
increases	O
proliferation	O
and	O
neurogenesis	O
in	O
culture	O
but	O
has	O
little	O
effect	O
on	O
these	O
functions	O
in	O
vivo	O
.	O

The	O
polycomb	O
gene	O
Bmi	O
-	O
1	O
is	O
required	O
for	O
the	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
from	O
diverse	O
tissues	O
,	O
including	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Bmi	O
-	O
1	O
expression	O
is	O
elevated	O
in	O
most	O
human	O
gliomas	O
,	O
irrespective	O
of	O
grade	O
,	O
raising	O
the	O
question	O
of	O
whether	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
is	O
sufficient	O
to	O
promote	O
self	O
-	O
renewal	O
or	O
tumorigenesis	O
by	O
CNS	O
stem	O
/	O
progenitor	O
cells	O
.	O

To	O
test	O
this	O
we	O
generated	O
Nestin	O
-	O
Bmi	O
-	O
1	O
-	O
GFP	O
transgenic	O
mice	O
.	O

Analysis	O
of	O
two	O
independent	O
lines	O
with	O
expression	O
in	O
the	O
fetal	O
and	O
adult	O
CNS	O
demonstrated	O
that	O
transgenic	O
neural	O
stem	O
cells	O
formed	O
larger	O
colonies	O
,	O
more	O
self	O
-	O
renewing	O
divisions	O
,	O
and	O
more	O
neurons	O
in	O
culture	O
.	O

However	O
,	O
in	O
vivo	O
,	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
had	O
little	O
effect	O
on	O
CNS	O
stem	O
cell	O
frequency	O
,	O
subventricular	O
zone	O
proliferation	O
,	O
olfactory	O
bulb	O
neurogenesis	O
,	O
or	O
neurogenesis	O
/	O
gliogenesis	O
during	O
development	O
.	O

Bmi	O
-	O
1	O
transgenic	O
mice	O
were	O
born	O
with	O
enlarged	O
lateral	O
ventricles	O
and	O
a	O
minority	O
developed	O
idiopathic	O
hydrocephalus	O
as	O
adults	O
,	O
but	O
none	O
of	O
the	O
transgenic	O
mice	O
formed	O
detectable	O
CNS	O
tumors	O
,	O
even	O
when	O
aged	O
.	O

The	O
more	O
pronounced	O
effects	O
of	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
culture	O
were	O
largely	O
attributable	O
to	O
the	O
attenuated	O
induction	O
of	O
p16	O
(	O
Ink4a	O
)	O
and	O
p19	O
(	O
Arf	O
)	O
in	O
culture	O
,	O
proteins	O
that	O
are	O
generally	O
not	O
expressed	O
by	O
neural	O
stem	O
/	O
progenitor	O
cells	O
in	O
young	O
mice	O
in	O
vivo	O
.	O

Bmi	O
-	O
1	O
over	O
-	O
expression	O
therefore	O
has	O
more	O
pronounced	O
effects	O
in	O
culture	O
and	O
does	O
not	O
appear	O
to	O
be	O
sufficient	O
to	O
induce	O
tumorigenesis	O
in	O
vivo	O
.	O

Erbb2	O
suppresses	O
DNA	O
damage	O
-	O
induced	O
checkpoint	O
activation	O
and	O
UV	O
-	O
induced	O
mouse	O
skin	O
tumorigenesis	O
.	O

The	O
Erbb2	O
receptor	O
is	O
activated	O
by	O
UV	O
irradiation	O
,	O
the	O
primary	O
cause	O
of	O
non	O
-	O
melanoma	O
skin	O
cancer	O
.	O

We	O
hypothesized	O
that	O
Erbb2	O
activation	O
contributes	O
to	O
UV	O
-	O
induced	O
skin	O
tumorigenesis	O
by	O
suppressing	O
cell	O
cycle	O
arrest	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
inhibition	O
of	O
Erbb2	O
in	O
v	O
-	O
ras	O
(	O
Ha	O
)	O
transgenic	O
mice	O
before	O
UV	O
exposure	O
resulted	O
in	O
both	O
56	O
%	O
fewer	O
skin	O
tumors	O
and	O
tumors	O
that	O
were	O
70	O
%	O
smaller	O
.	O

Inhibition	O
of	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
Erbb2	O
also	O
resulted	O
in	O
milder	O
epidermal	O
hyperplasia	O
,	O
S	O
-	O
phase	O
accumulation	O
,	O
and	O
decreased	O
levels	O
of	O
the	O
cell	O
cycle	O
regulator	O
Cdc25a	O
,	O
suggesting	O
altered	O
cell	O
cycle	O
regulation	O
on	O
inhibition	O
of	O
Erbb2	O
.	O

Further	O
investigation	O
using	O
inhibition	O
or	O
genetic	O
deletion	O
of	O
Erbb2	O
in	O
vitro	O
revealed	O
reduced	O
Cdc25a	O
levels	O
and	O
increased	O
S	O
-	O
phase	O
arrest	O
in	O
UV	O
-	O
irradiated	O
cells	O
lacking	O
Erbb2	O
activity	O
.	O

Ectopic	O
expression	O
of	O
Cdc25a	O
prevented	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
in	O
keratinocytes	O
lacking	O
Erbb2	O
activity	O
,	O
demonstrating	O
that	O
maintenance	O
of	O
Cdc25a	O
by	O
Erbb2	O
suppresses	O
cell	O
cycle	O
arrest	O
.	O

Examination	O
of	O
checkpoint	O
pathway	O
activation	O
upstream	O
of	O
Cdc25a	O
revealed	O
Erbb2	O
activation	O
did	O
not	O
alter	O
Ataxia	O
Telangiectasia	O
and	O
Rad3	O
-	O
related	O
/	O
Ataxia	O
Telangiectasia	O
Mutated	O
activity	O
but	O
increased	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
.	O

Since	O
Akt	O
phosphorylates	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
,	O
the	O
effect	O
of	O
Erbb2	O
on	O
phosphatidyl	O
inositol	O
-	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
/	O
Akt	O
signaling	O
during	O
UV	O
-	O
induced	O
cell	O
cycle	O
arrest	O
was	O
determined	O
.	O

Erbb2	O
ablation	O
reduced	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
PI3	O
K	O
while	O
inhibition	O
of	O
PI3	O
K	O
/	O
Akt	O
increased	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
.	O

Thus	O
,	O
UV	O
-	O
induced	O
Erbb2	O
activation	O
increases	O
skin	O
tumorigenesis	O
through	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
,	O
Cdc25a	O
maintenance	O
,	O
and	O
suppression	O
of	O
S	O
-	O
phase	O
arrest	O
via	O
a	O
PI3	O
K	O
/	O
Akt	O
-	O
dependent	O
mechanism	O
.	O

The	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
signaling	O
pathway	O
specific	O
to	O
breast	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

Tumors	O
are	O
tissue	O
-	O
specific	O
diseases	O
,	O
and	O
their	O
mechanisms	O
of	O
invasion	O
and	O
metastasis	O
are	O
highly	O
diverse	O
.	O

In	O
breast	O
cancer	O
,	O
biomarkers	O
that	O
specifically	O
correlate	O
with	O
the	O
invasive	O
phenotypes	O
have	O
not	O
been	O
clearly	O
identified	O
.	O

A	O
small	O
GTPase	O
Arf6	O
primarily	O
regulates	O
recycling	O
of	O
plasma	O
membrane	O
components	O
.	O

We	O
have	O
shown	O
that	O
Arf6	O
and	O
its	O
effector	O
AMAP1	O
(	O
DDEF1	O
,	O
DEF1	O
,	O
ASAP1	O
and	O
centaurin	O
beta4	O
)	O
are	O
abnormally	O
overexpressed	O
in	O
some	O
breast	O
cancers	O
and	O
used	O
for	O
their	O
invasion	O
and	O
metastasis	O
.	O

Overexpression	O
of	O
these	O
proteins	O
is	O
independent	O
of	O
the	O
transcriptional	O
upregulation	O
of	O
their	O
genes	O
,	O
and	O
occurs	O
only	O
in	O
highly	O
malignant	O
breast	O
cancer	O
cells	O
.	O

We	O
recently	O
identified	O
GEP100	O
(	O
BRAG2	O
)	O
to	O
be	O
responsible	O
for	O
the	O
Arf6	O
activation	O
to	O
induce	O
invasion	O
and	O
metastasis	O
,	O
by	O
directly	O
binding	O
to	O
ligand	O
-	O
activated	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

A	O
series	O
of	O
our	O
studies	O
revealed	O
that	O
for	O
activation	O
of	O
the	O
invasion	O
pathway	O
of	O
EGFR	O
,	O
it	O
is	O
prerequisite	O
that	O
Arf6	O
and	O
AMAP1	O
both	O
are	O
highly	O
overexpressed	O
,	O
and	O
that	O
EGFR	O
is	O
activated	O
by	O
ligands	O
.	O

Pathological	O
analyses	O
indicate	O
that	O
a	O
significant	O
large	O
population	O
of	O
human	O
ductal	O
cancers	O
may	O
utilize	O
the	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
pathway	O
for	O
their	O
malignancy	O
.	O

Microenvironments	O
have	O
been	O
highly	O
implicated	O
in	O
the	O
malignancy	O
of	O
mammary	O
tumors	O
.	O

Our	O
results	O
reveal	O
an	O
aspect	O
of	O
the	O
precise	O
molecular	O
mechanisms	O
of	O
some	O
breast	O
cancers	O
,	O
in	O
which	O
full	O
invasiveness	O
is	O
not	O
acquired	O
just	O
by	O
intracellular	O
alterations	O
of	O
cancer	O
cells	O
,	O
but	O
extracellular	O
factors	O
from	O
microenvironments	O
may	O
also	O
be	O
necessary	O
.	O

Possible	O
translation	O
of	O
our	O
knowledge	O
to	O
cancer	O
therapeutics	O
will	O
also	O
be	O
discussed	O
.	O

Met	O
amplification	O
and	O
tumor	O
progression	O
in	O
Cdkn2a	O
-	O
deficient	O
melanocytes	O
.	O

While	O
many	O
genetic	O
alterations	O
have	O
been	O
identified	O
in	O
melanoma	O
,	O
the	O
relevant	O
molecular	O
events	O
that	O
contribute	O
to	O
disease	O
progression	O
are	O
poorly	O
understood	O
.	O

Most	O
primary	O
human	O
melanomas	O
exhibit	O
loss	O
of	O
expression	O
of	O
the	O
CDKN2A	O
locus	O
in	O
addition	O
to	O
activation	O
of	O
the	O
canonical	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
Cdkn2a	O
-	O
deficient	O
mouse	O
melanocyte	O
cell	O
line	O
to	O
screen	O
for	O
secondary	O
genetic	O
events	O
in	O
melanoma	O
tumor	O
progression	O
.	O

Upon	O
investigation	O
,	O
intrachromosomal	O
gene	O
amplification	O
of	O
Met	O
,	O
a	O
receptor	O
tyrosine	O
kinase	O
implicated	O
in	O
melanoma	O
progression	O
,	O
was	O
identified	O
in	O
Cdkn2a	O
-	O
deficient	O
tumors	O
.	O

RNA	O
interference	O
targeting	O
Met	O
in	O
these	O
tumor	O
cells	O
resulted	O
in	O
a	O
significant	O
delay	O
in	O
tumor	O
growth	O
in	O
vivo	O
compared	O
with	O
the	O
control	O
cells	O
.	O

MET	O
expression	O
is	O
rarely	O
detected	O
in	O
primary	O
human	O
melanoma	O
but	O
is	O
frequently	O
observed	O
in	O
metastatic	O
disease	O
.	O

This	O
study	O
validates	O
a	O
role	O
for	O
Met	O
activation	O
in	O
melanoma	O
tumor	O
progression	O
in	O
the	O
context	O
of	O
Cdkn2a	O
deficiency	O
.	O

Activated	O
platelets	O
enhance	O
ovarian	O
cancer	O
cell	O
invasion	O
in	O
a	O
cellular	O
model	O
of	O
metastasis	O
.	O

Increased	O
platelet	O
counts	O
and	O
systemic	O
coagulation	O
activation	O
are	O
associated	O
with	O
ovarian	O
cancer	O
progression	O
.	O

Platelet	O
activation	O
occurs	O
in	O
the	O
tumor	O
microenvironment	O
and	O
may	O
influence	O
local	O
invasion	O
and	O
metastasis	O
.	O

We	O
used	O
a	O
cellular	O
model	O
of	O
tumor	O
invasion	O
to	O
investigate	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
the	O
human	O
ovarian	O
cancer	O
cell	O
line	O
,	O
SKOV3	B
.	O

SKOV3	B
cells	O
were	O
exposed	O
to	O
washed	O
,	O
thrombin	O
receptor	O
activating	O
peptide	O
(	O
TRAP	O
)	O
-	O
activated	O
or	O
TRAP	O
-	O
naive	O
platelets	O
under	O
various	O
experimental	O
conditions	O
,	O
and	O
tumor	O
cell	O
invasion	O
was	O
assayed	O
in	O
Matrigel	O
chambers	O
.	O

The	O
effect	O
of	O
platelets	O
on	O
the	O
content	O
of	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
and	O
VEGF	O
in	O
SKOV3	B
cell	O
conditioned	O
medium	O
was	O
measured	O
using	O
an	O
ELISA	O
assay	O
.	O

TRAP	O
-	O
activated	O
platelets	O
stimulated	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
SKOV3	B
cell	O
invasion	O
.	O

Exposure	O
to	O
activated	O
platelet	O
membranes	O
and	O
to	O
soluble	O
proteins	O
contained	O
in	O
activated	O
platelet	O
releasate	O
both	O
contributed	O
to	O
the	O
observed	O
increase	O
in	O
invasion	O
.	O

The	O
inhibition	O
of	O
platelet	O
activation	O
with	O
prostaglandin	O
E1	O
(	O
PGE	O
(	O
1	O
)	O
)	O
attenuated	O
the	O
invasive	O
capacity	O
of	O
SKOV3	B
cells	O
.	O

Exposure	O
to	O
platelets	O
resulted	O
in	O
significantly	O
increased	O
uPA	O
and	O
VEGF	O
content	O
of	O
SKOV3	B
cell	O
conditioned	O
medium	O
.	O

Activated	O
platelets	O
enhance	O
SKOV3	B
human	O
ovarian	O
cancer	O
cell	O
invasion	O
through	O
Matrigel	O
and	O
increase	O
the	O
amount	O
of	O
uPA	O
and	O
VEGF	O
secreted	O
into	O
SKOV3	B
cell	O
conditioned	O
medium	O
.	O

If	O
generalizable	O
to	O
additional	O
cell	O
lines	O
and	O
human	O
disease	O
,	O
this	O
observation	O
may	O
partially	O
explain	O
the	O
adverse	O
prognosis	O
associated	O
with	O
thrombocytosis	O
in	O
ovarian	O
cancer	O
.	O

Platelets	O
,	O
therefore	O
,	O
may	O
represent	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
human	O
ovarian	O
cancer	O
.	O

AngiomiRs	O
-	O
-	O
key	O
regulators	O
of	O
angiogenesis	O
.	O

The	O
formation	O
of	O
new	O
blood	O
vessels	O
through	O
the	O
process	O
of	O
angiogenesis	O
is	O
critical	O
in	O
vascular	O
development	O
and	O
homeostasis	O
.	O

Aberrant	O
angiogenesis	O
leads	O
to	O
a	O
variety	O
of	O
diseases	O
,	O
such	O
as	O
ischemia	O
and	O
cancer	O
.	O

Recent	O
studies	O
have	O
revealed	O
important	O
roles	O
for	O
miRNAs	O
in	O
regulating	O
endothelial	O
cell	O
(	O
EC	O
)	O
function	O
,	O
especially	O
angiogenesis	O
.	O

Mice	O
with	O
EC	O
-	O
specific	O
deletion	O
of	O
Dicer	O
,	O
a	O
key	O
enzyme	O
for	O
generating	O
miRNAs	O
,	O
display	O
defective	O
postnatal	O
angiogenesis	O
.	O

Specific	O
miRNAs	O
(	O
angiomiRs	O
)	O
have	O
recently	O
been	O
shown	O
to	O
regulate	O
angiogenesis	O
in	O
vivo	O
.	O

miRNA	O
-	O
126	O
,	O
an	O
EC	O
-	O
restricted	O
miRNA	O
,	O
regulates	O
vascular	O
integrity	O
and	O
developmental	O
angiogenesis	O
.	O

miR	O
-	O
378	O
,	O
miR	O
-	O
296	O
,	O
and	O
the	O
miR	O
-	O
17	O
-	O
92	O
cluster	O
contribute	O
to	O
tumor	O
angiogenesis	O
.	O

Manipulating	O
angiomiRs	O
in	O
the	O
settings	O
of	O
pathological	O
vascularization	O
represents	O
a	O
new	O
therapeutic	O
approach	O
.	O

[	O
Incidence	O
of	O
fungal	O
infection	O
in	O
surgical	O
diseases	O
of	O
the	O
pancreas	O
]	O
.	O

Recently	O
the	O
number	O
of	O
mycotic	O
infections	O
has	O
increased	O
significantly	O
.	O

Authors	O
have	O
observed	O
13	O
mycotic	O
infections	O
on	O
operated	O
patients	O
suffering	O
pancreatic	O
diseases	O
between	O
1984	O
and	O
1990	O
.	O

9	O
of	O
13	O
patients	O
had	O
pancreatic	O
abscesses	O
as	O
well	O
.	O

The	O
risk	O
factors	O
of	O
fungal	O
infections	O
are	O
analysed	O
.	O

It	O
is	O
important	O
to	O
take	O
differentiation	O
between	O
fungal	O
colonisation	O
and	O
septicaemia	O
caused	O
by	O
yeasts	O
.	O

Repeated	O
microbiological	O
examinations	O
can	O
promote	O
recognising	O
of	O
the	O
fungal	O
invasion	O
.	O

The	O
base	O
of	O
the	O
therapy	O
is	O
to	O
avoid	O
risk	O
factors	O
of	O
infections	O
and	O
to	O
use	O
antifungal	O
medication	O
in	O
time	O
.	O

Cisplatin	O
reduces	O
endothelial	O
cell	O
migration	O
via	O
regulation	O
of	O
type	O
2	O
-	O
matrix	O
metalloproteinase	O
activity	O
.	O

AIMS	O
:	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	O
on	O
endothelial	O
cell	O
migration	O
,	O
an	O
essential	O
process	O
for	O
vascular	O
remodeling	O
and	O
regeneration	O
in	O
several	O
physiological	O
and	O
pathological	O
situations	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
were	O
treated	O
with	O
cisplatin	O
and	O
endothelial	O
cell	O
migration	O
analyzed	O
by	O
fluorescence	O
and	O
scratch	O
-	O
wound	O
migration	O
assay	O
.	O

MMP2	O
and	O
MMP9	O
activity	O
were	O
determined	O
by	O
zymographic	O
assay	O
,	O
and	O
MAPK	O
activation	O
by	O
Western	O
blotting	O
analysis	O
.	O

RESULTS	O
:	O
We	O
demonstrated	O
that	O
cisplatin	O
provoked	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
decrease	O
of	O
HUVEC	O
migration	O
;	O
this	O
effect	O
was	O
clearly	O
independent	O
from	O
its	O
well	O
known	O
cytotoxic	O
activity	O
.	O

In	O
addition	O
,	O
cisplatin	O
markedly	O
reduced	O
MMP2	O
activity	O
in	O
both	O
conditioned	O
media	O
and	O
cell	O
lysates	O
,	O
increased	O
p38	O
MAPK	O
and	O
JNK	O
phosphorylation	O
,	O
but	O
did	O
not	O
affect	O
ERK	O
phosphorylation	O
.	O

Endothelial	O
cell	O
migration	O
was	O
attenuated	O
by	O
treatment	O
of	O
cells	O
with	O
GM6001	O
,	O
a	O
non	O
-	O
specific	O
inhibitor	O
of	O
MMPs	O
,	O
or	O
by	O
a	O
selective	O
anti	O
-	O
MMP2	O
antibody	O
.	O

However	O
,	O
treatment	O
of	O
cells	O
with	O
SB202190	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
p38	O
MAPK	O
and	O
JNK	O
respectively	O
,	O
did	O
not	O
affect	O
HUVEC	O
migration	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggested	O
that	O
cisplatin	O
induced	O
a	O
reduction	O
of	O
endothelial	O
cell	O
migration	O
through	O
an	O
inhibition	O
of	O
MMP2	O
activity	O
by	O
downstream	O
signal	O
transduction	O
pathways	O
independent	O
of	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
.	O

Promoting	O
angiogenesis	O
via	O
manipulation	O
of	O
VEGF	O
responsiveness	O
with	O
notch	O
signaling	O
.	O

Promoting	O
angiogenesis	O
via	O
delivery	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
other	O
angiogenic	O
factors	O
is	O
both	O
a	O
potential	O
therapy	O
for	O
cardiovascular	O
diseases	O
and	O
a	O
critical	O
aspect	O
for	O
tissue	O
regeneration	O
.	O

The	O
recent	O
demonstration	O
that	O
VEGF	O
signaling	O
is	O
modulated	O
by	O
the	O
Notch	O
signaling	O
pathway	O
,	O
however	O
,	O
suggests	O
that	O
inhibiting	O
Notch	O
signaling	O
may	O
enhance	O
regional	O
neovascularization	O
,	O
by	O
altering	O
the	O
responsiveness	O
of	O
local	O
endothelial	O
cells	O
to	O
angiogenic	O
stimuli	O
.	O

We	O
tested	O
this	O
possibility	O
with	O
in	O
vitro	O
assays	O
using	O
human	O
endothelial	O
cells	O
,	O
as	O
well	O
as	O
in	O
a	O
rodent	O
hindlimb	O
ischemia	O
model	O
.	O

Treatment	O
of	O
cultured	O
human	O
endothelial	O
cells	O
with	O
DAPT	O
,	O
a	O
gamma	O
secretase	O
inhibitor	O
,	O
increased	O
cell	O
migration	O
and	O
sprout	O
formation	O
in	O
response	O
to	O
VEGF	O
stimulation	O
with	O
a	O
biphasic	O
dependence	O
on	O
DAPT	O
concentration	O
.	O

Further	O
,	O
delivery	O
of	O
an	O
appropriate	O
combination	O
of	O
DAPT	O
and	O
VEGF	O
from	O
an	O
injectable	O
alginate	O
hydrogel	O
system	O
into	O
ischemic	O
hindlimbs	O
led	O
to	O
a	O
faster	O
recovery	O
of	O
blood	O
flow	O
than	O
VEGF	O
or	O
DAPT	O
alone	O
;	O
perfusion	O
levels	O
reached	O
80	O
%	O
of	O
the	O
normal	O
level	O
by	O
week	O
4	O
with	O
combined	O
DAPT	O
and	O
VEGF	O
delivery	O
.	O

Direct	O
intramuscular	O
or	O
intraperitoneal	O
injection	O
of	O
DAPT	O
did	O
not	O
result	O
in	O
the	O
same	O
level	O
of	O
improvement	O
,	O
suggesting	O
that	O
appropriate	O
presentation	O
of	O
DAPT	O
(	O
gel	O
delivery	O
)	O
is	O
important	O
for	O
its	O
activity	O
.	O

DAPT	O
delivery	O
from	O
the	O
hydrogels	O
also	O
did	O
not	O
lead	O
to	O
any	O
adverse	O
side	O
effects	O
,	O
in	O
contrast	O
to	O
systemic	O
introduction	O
of	O
DAPT	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
a	O
new	O
approach	O
to	O
promote	O
angiogenesis	O
by	O
controlling	O
Notch	O
signaling	O
,	O
and	O
may	O
provide	O
new	O
options	O
to	O
treat	O
patients	O
with	O
diseases	O
that	O
diminish	O
angiogenic	O
responsiveness	O
.	O

[	O
Activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
and	O
its	O
involvement	O
in	O
endothelial	O
cell	O
migration	O
]	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
(	O
SREBP	O
)	O
and	O
its	O
critical	O
role	O
in	O
endothelial	O
cell	O
migration	O
.	O

METHODS	O
:	O
Bovine	O
aortic	O
endothelial	O
cells	O
(	O
ECs	O
)	O
were	O
cultured	O
.	O

The	O
expression	O
of	O
SREBP	O
and	O
Cdc42	O
were	O
determined	O
by	O
Western	O
blot	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Moreover	O
,	O
outward	O
growth	O
migration	O
model	O
and	O
transwell	O
chamber	O
assay	O
were	O
used	O
to	O
detect	O
ECs	O
migration	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
SREBP	O
was	O
activated	O
during	O
ECs	O
migration	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
increased	O
active	O
form	O
SREBP	O
in	O
migrating	O
as	O
compared	O
to	O
non	O
-	O
migrating	O
ECs	O
population	O
.	O

SREBP	O
activation	O
decreased	O
as	O
ECs	O
migration	O
slowed	O
;	O
(	O
2	O
)	O
Coincidental	O
with	O
SREBP	O
activation	O
,	O
mRNA	O
expression	O
of	O
its	O
target	O
genes	O
such	O
as	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
HMG	O
-	O
CoA	O
reductase	O
,	O
and	O
fatty	O
acid	O
synthase	O
also	O
increased	O
in	O
migrating	O
ECs	O
population	O
as	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
;	O
(	O
3	O
)	O
Migration	O
induced	O
SREBP	O
activation	O
in	O
ECs	O
was	O
inhibited	O
by	O
SREBP	O
-	O
acting	O
protein	O
RNAi	O
and	O
pharmacologically	O
by	O
25	O
-	O
hydroxycholesterol	O
;	O
(	O
4	O
)	O
Inhibition	O
of	O
SREBP	O
led	O
to	O
decreased	O
ECs	O
migration	O
in	O
various	O
models	O
;	O
(	O
5	O
)	O
Cells	O
genetically	O
deficient	O
in	O
SREBP	O
-	O
acting	O
protein	O
,	O
S1P	O
,	O
or	O
S2P	O
,	O
phenotypically	O
exhibited	O
impaired	O
migration	O
;	O
(	O
6	O
)	O
SREBP	O
inhibition	O
in	O
ECs	O
suppressed	O
the	O
activity	O
of	O
small	O
GTPase	O
Cdc42	O
,	O
a	O
key	O
molecule	O
for	O
ECs	O
motility	O
.	O

CONCLUSIONS	O
:	O
SREBP	O
is	O
activated	O
during	O
and	O
plays	O
a	O
critical	O
role	O
in	O
ECs	O
migration	O
.	O

Targeting	O
SREBP	O
could	O
become	O
a	O
novel	O
approach	O
in	O
fighting	O
diseases	O
involving	O
abnormal	O
ECs	O
migration	O
.	O

Fibroblast	O
growth	O
factor	O
receptor	O
2	O
-	O
positive	O
fibroblasts	O
provide	O
a	O
suitable	O
microenvironment	O
for	O
tumor	O
development	O
and	O
progression	O
in	O
esophageal	O
carcinoma	O
.	O

PURPOSE	O
:	O
Tumor	O
fibroblasts	O
(	O
TF	O
)	O
have	O
been	O
suggested	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
complex	O
process	O
of	O
tumor	O
-	O
stroma	O
interactions	O
and	O
tumorigenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
specific	O
role	O
of	O
TF	O
in	O
the	O
esophageal	O
cancer	O
microenvironment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
An	O
Affymetrix	O
expression	O
microarray	O
was	O
used	O
to	O
compare	O
gene	O
expression	O
profiles	O
between	O
six	O
pairs	O
of	O
TFs	O
and	O
normal	O
fibroblasts	O
from	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
.	O

Differentially	O
expressed	O
genes	O
were	O
identified	O
,	O
and	O
a	O
subset	O
was	O
evaluated	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
About	O
43	O
%	O
(	O
126	O
of	O
292	O
)	O
of	O
known	O
deregulated	O
genes	O
in	O
TFs	O
were	O
associated	O
with	O
cell	O
proliferation	O
,	O
extracellular	O
matrix	O
remodeling	O
,	O
and	O
immune	O
response	O
.	O

Up	O
-	O
regulation	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
FGFR2	O
)	O
,	O
which	O
showed	O
the	O
most	O
significant	O
change	O
,	O
was	O
detected	O
in	O
all	O
six	O
tested	O
TFs	O
compared	O
with	O
their	O
paired	O
normal	O
fibroblasts	O
.	O

A	O
further	O
study	O
found	O
that	O
FGFR2	O
-	O
positive	O
fibroblasts	O
were	O
only	O
observed	O
inside	O
the	O
tumor	O
tissues	O
and	O
not	O
in	O
tumor	O
-	O
surrounding	O
stromal	O
tissues	O
,	O
suggesting	O
that	O
FGFR2	O
could	O
be	O
used	O
as	O
a	O
TF	O
-	O
specific	O
marker	O
in	O
ESCC	O
.	O

Moreover	O
,	O
the	O
conditioned	O
medium	O
from	O
TFs	O
was	O
found	O
to	O
be	O
able	O
to	O
promote	O
ESCC	O
tumor	O
cell	O
growth	O
,	O
migration	O
,	O
and	O
invasion	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
provides	O
new	O
candidate	O
genes	O
for	O
the	O
esophageal	O
cancer	O
microenvironment	O
.	O

Based	O
on	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
FGFR2	O
(	O
+	O
)	O
-	O
TFs	O
might	O
provide	O
cancer	O
cells	O
with	O
a	O
suitable	O
microenvironment	O
via	O
secretion	O
of	O
proteins	O
that	O
could	O
promote	O
cancer	O
development	O
and	O
progression	O
through	O
stimulation	O
of	O
cancer	O
cell	O
proliferation	O
,	O
induction	O
of	O
angiogenesis	O
,	O
inhibition	O
of	O
cell	O
adhesion	O
,	O
enhancement	O
of	O
cell	O
mobility	O
,	O
and	O
promotion	O
of	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
.	O

[	O
Role	O
of	O
the	O
tumor	O
suppressor	O
ARF	O
in	O
oncogenesis	O
]	O

The	O
paper	O
reviews	O
the	O
data	O
available	O
in	O
the	O
literature	O
on	O
a	O
role	O
of	O
the	O
tumor	O
suppressor	O
ARF	O
in	O
oncogenesis	O
and	O
considers	O
the	O
structure	O
of	O
a	O
gene	O
encoding	O
ARF	O
protein	O
.	O

The	O
p53	O
-	O
dependent	O
and	O
p	O
-	O
53	O
-	O
independent	O
functions	O
of	O
this	O
protein	O
are	O
under	O
many	O
studies	O
.	O

There	O
is	O
evidence	O
for	O
the	O
implication	O
of	O
ARF	O
in	O
angiogenesis	O
.	O

There	O
is	O
more	O
and	O
more	O
information	O
on	O
the	O
role	O
of	O
ARF	O
in	O
the	O
regulation	O
of	O
a	O
cell	O
cycle	O
,	O
apoptosis	O
,	O
and	O
autophagy	O
.	O

The	O
importance	O
of	O
this	O
tumor	O
suppressor	O
in	O
the	O
mechanisms	O
of	O
carcinogenesis	O
is	O
beyond	O
question	O
as	O
the	O
inactivation	O
of	O
ARF	O
suppressor	O
activity	O
leads	O
to	O
the	O
rapid	O
growth	O
of	O
neoplasia	O
.	O

However	O
,	O
the	O
exact	O
mechanisms	O
of	O
ARF	O
action	O
yet	O
remain	O
unclear	O
and	O
require	O
further	O
studies	O
by	O
different	O
specialists	O
at	O
both	O
the	O
molecular	O
genetic	O
and	O
other	O
levels	O
of	O
investigation	O
.	O

Impact	O
of	O
tumor	O
cell	O
VEGF	O
expression	O
on	O
the	O
in	O
vivo	O
efficacy	O
of	O
vandetanib	O
(	O
ZACTIMA	O
;	O
ZD6474	O
)	O
.	O

VEGF	O
is	O
the	O
key	O
player	O
in	O
tumor	O
angiogenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
impact	O
of	O
VEGF	O
expression	O
on	O
the	O
response	O
of	O
tumors	O
to	O
the	O
VEGFR2	O
associated	O
tyrosine	O
kinase	O
inhibitor	O
vandetanib	O
was	O
evaluated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
colon	O
carcinoma	O
(	O
HT29	B
)	O
and	O
murine	O
squamous	O
carcinoma	O
(	O
SCCVII	B
)	O
clonal	O
cell	O
lines	O
expressing	O
varying	O
levels	O
of	O
VEGF	O
were	O
established	O
and	O
their	O
response	O
to	O
vandetanib	O
was	O
assessed	O
in	O
tissue	O
culture	O
and	O
as	O
solid	O
tumors	O
.	O

RESULTS	O
:	O
Vandetanib	O
treatment	O
had	O
no	O
effect	O
on	O
tumor	O
cell	O
clonogenic	O
cell	O
survival	O
in	O
vitro	O
but	O
doses	O
>	O
or	O
=	O
10	O
nM	O
significantly	O
reduced	O
endothelial	O
cell	O
migration	O
.	O

In	O
vivo	O
,	O
tumors	O
derived	O
from	O
cell	O
clones	O
expressing	O
high	O
levels	O
of	O
VEGF	O
displayed	O
significantly	O
enhanced	O
angiogenesis	O
and	O
more	O
aggressive	O
growth	O
.	O

An	O
intradermal	O
angiogenesis	O
assay	O
was	O
used	O
to	O
demonstrate	O
that	O
a	O
4	O
-	O
day	O
treatment	O
with	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
able	O
to	O
significantly	O
inhibit	O
blood	O
vessel	O
growth	O
induced	O
by	O
both	O
parental	O
and	O
high	O
VEGF	O
-	O
expressing	O
tumor	O
cell	O
clones	O
.	O

In	O
the	O
HT29	B
tumor	O
model	O
,	O
treatment	O
response	O
to	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
Monday	O
-	O
Friday	O
for	O
2	O
weeks	O
)	O
was	O
greatest	O
in	O
xenografts	O
derived	O
from	O
the	O
highest	O
VEGF	O
-	O
expressing	O
cell	O
clones	O
.	O

A	O
similar	O
trend	O
was	O
noted	O
in	O
the	O
SCCVII	B
tumor	O
model	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
vandetanib	O
therapy	O
effectively	O
counteracted	O
the	O
aggressive	O
feature	O
of	O
tumor	O
growth	O
resulting	O
from	O
VEGF	O
over	O
-	O
expressing	O
tumor	O
cells	O
and	O
suggest	O
that	O
such	O
tumors	O
may	O
be	O
particularly	O
well	O
suited	O
for	O
anti	O
-	O
VEGF	O
interventions	O
.	O

The	O
modulation	O
of	O
platelet	O
and	O
endothelial	O
cell	O
adhesion	O
to	O
vascular	O
graft	O
materials	O
by	O
perlecan	O
.	O

Controlled	O
neo	O
-	O
endothelialisation	O
is	O
critical	O
to	O
the	O
patency	O
of	O
small	O
diameter	O
vascular	O
grafts	O
.	O

Endothelialisation	O
and	O
platelet	O
adhesion	O
to	O
purified	O
endothelial	O
cell	O
-	O
derived	O
perlecan	O
,	O
the	O
major	O
heparan	O
sulfate	O
(	O
HS	O
)	O
proteoglycan	O
in	O
basement	O
membranes	O
,	O
were	O
investigated	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O

Expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
were	O
coated	O
with	O
perlecan	O
and	O
tested	O
in	O
an	O
ovine	O
carotid	O
interposition	O
model	O
for	O
a	O
period	O
of	O
6	O
weeks	O
and	O
assessed	O
using	O
light	O
and	O
scanning	O
microscopy	O
.	O

Enhanced	O
endothelial	O
cell	O
growth	O
and	O
reduced	O
platelet	O
adhesion	O
were	O
observed	O
on	O
the	O
perlecan	O
coated	O
grafts	O
when	O
compared	O
to	O
uncoated	O
controls	O
implanted	O
in	O
the	O
same	O
sheep	O
(	O
n	O
=	O
5	O
)	O
.	O

Perlecan	O
was	O
also	O
found	O
to	O
stimulate	O
endothelial	O
cell	O
proliferation	O
in	O
vitro	O
over	O
a	O
period	O
of	O
6	O
days	O
in	O
the	O
presence	O
of	O
plasma	O
proteins	O
and	O
fibroblastic	O
growth	O
factor	O
2	O
(	O
FGF	O
-	O
2	O
)	O
,	O
however	O
in	O
the	O
absence	O
of	O
FGF	O
-	O
2	O
endothelial	O
cell	O
growth	O
could	O
not	O
be	O
maintained	O
during	O
this	O
period	O
.	O

Perlecan	O
was	O
found	O
to	O
be	O
anti	O
-	O
adhesive	O
for	O
platelets	O
,	O
however	O
after	O
removal	O
of	O
the	O
HS	O
chains	O
attached	O
to	O
perlecan	O
,	O
platelet	O
adhesion	O
and	O
aggregation	O
were	O
supported	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
HS	O
chains	O
of	O
perlecan	O
in	O
improving	O
graft	O
patency	O
by	O
selectively	O
promoting	O
endothelial	O
cell	O
proliferation	O
while	O
modulating	O
platelet	O
adhesion	O
.	O

Mechanical	O
regulation	O
of	O
the	O
proangiogenic	O
factor	O
CCN1	O
/	O
CYR61	O
gene	O
requires	O
the	O
combined	O
activities	O
of	O
MRTF	O
-	O
A	O
and	O
CREB	O
-	O
binding	O
protein	O
histone	O
acetyltransferase	O
.	O

Smooth	O
muscle	O
-	O
rich	O
tissues	O
respond	O
to	O
mechanical	O
overload	O
by	O
an	O
adaptive	O
hypertrophic	O
growth	O
combined	O
with	O
activation	O
of	O
angiogenesis	O
,	O
which	O
potentiates	O
their	O
mechanical	O
overload	O
-	O
bearing	O
capabilities	O
.	O

Neovascularization	O
is	O
associated	O
with	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
angiogenic	O
factors	O
such	O
as	O
CCN1	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
-	O
encoded	O
matricellular	O
molecule	O
critical	O
for	O
vascular	O
development	O
and	O
repair	O
.	O

Here	O
we	O
have	O
demonstrated	O
that	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
the	O
CCN1	O
gene	O
involves	O
signaling	O
cascades	O
through	O
RhoA	O
-	O
mediated	O
actin	O
remodeling	O
and	O
the	O
p38	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
.	O

Actin	O
signaling	O
controls	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
activity	O
via	O
SRF	O
interaction	O
with	O
the	O
myocardin	O
-	O
related	O
transcriptional	O
activator	O
(	O
MRTF	O
)	O
-	O
A	O
and	O
tethering	O
to	O
a	O
single	O
CArG	O
box	O
sequence	O
within	O
the	O
CCN1	O
promoter	O
.	O

Such	O
activity	O
was	O
abolished	O
in	O
mechanically	O
stimulated	O
mouse	O
MRTF	O
-	O
A	O
(	O
-	O
/	O
-	O
)	O
cells	O
or	O
upon	O
inhibition	O
of	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
either	O
pharmacologically	O
or	O
by	O
siRNAs	O
.	O

Mechanical	O
strain	O
induced	O
CBP	O
-	O
mediated	O
acetylation	O
of	O
histones	O
3	O
and	O
4	O
at	O
the	O
SRF	O
-	O
binding	O
site	O
and	O
within	O
the	O
CCN1	O
gene	O
coding	O
region	O
.	O

Inhibition	O
of	O
p38	O
SAPK	O
reduced	O
CBP	O
HAT	O
activity	O
and	O
its	O
recruitment	O
to	O
the	O
SRF	O
.	O
MRTF	O
-	O
A	O
complex	O
,	O
whereas	O
enforced	O
induction	O
of	O
p38	O
by	O
upstream	O
activators	O
(	O
e	O
.	O
g	O
.	O
MKK3	O
and	O
MKK6	O
)	O
enhanced	O
both	O
CBP	O
HAT	O
and	O
CCN1	O
promoter	O
activities	O
.	O

Similarly	O
,	O
mechanical	O
overload	O
-	O
induced	O
CCN1	O
gene	O
expression	O
in	O
vivo	O
was	O
associated	O
with	O
nuclear	O
localization	O
of	O
MRTF	O
-	O
A	O
and	O
enrichment	O
of	O
the	O
CCN1	O
promoter	O
with	O
both	O
MRTF	O
-	O
A	O
and	O
acetylated	O
histone	O
H3	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
signal	O
-	O
controlled	O
activation	O
of	O
SRF	O
,	O
MRTF	O
-	O
A	O
,	O
and	O
CBP	O
provides	O
a	O
novel	O
connection	O
between	O
mechanical	O
stimuli	O
and	O
angiogenic	O
gene	O
expression	O
.	O

Tumour	O
angiogenesis	O
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	O
gliomas	O
.	O

Angiogenesis	O
is	O
a	O
key	O
event	O
in	O
the	O
progression	O
of	O
malignant	O
gliomas	O
.	O

The	O
presence	O
of	O
microvascular	O
proliferation	O
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	O
multiforme	O
.	O

Tumour	O
angiogenesis	O
involves	O
multiple	O
cellular	O
processes	O
including	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
reorganisation	O
of	O
extracellular	O
matrix	O
and	O
tube	O
formation	O
.	O

These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
growth	O
factors	O
.	O

Angiogenesis	O
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	O
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	O
kinase	O
levels	O
.	O

Other	O
anti	O
-	O
angiogenic	O
therapies	O
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	O
inhibitor	O
levels	O
.	O

Most	O
anti	O
-	O
angiogenic	O
therapies	O
for	O
malignant	O
gliomas	O
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O

The	O
greatest	O
potential	O
for	O
angiogenesis	O
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Regulation	O
of	O
thrombospondin	O
-	O
1	O
by	O
natural	O
and	O
synthetic	O
progestins	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

Our	O
recent	O
studies	O
show	O
that	O
progestins	O
induce	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
breast	O
cancer	O
cells	O
that	O
express	O
mutant	O
p53	O
protein	O
.	O

Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	O
also	O
induce	O
thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
mRNA	O
and	O
protein	O
in	O
T47	B
-	I
D	I
and	O
BT	B
-	I
474	I
breast	O
cancer	O
cells	O
.	O

Antiprogestin	O
RU	O
-	O
486	O
inhibits	O
the	O
induction	O
of	O
VEGF	O
and	O
TSP	O
-	O
1	O
by	O
progestins	O
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	O
is	O
mediated	O
by	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
.	O

Actinomycin	O
-	O
D	O
,	O
but	O
not	O
puromycin	O
,	O
also	O
blocks	O
progestin	O
-	O
dependent	O
induction	O
of	O
TSP	O
-	O
1	O
.	O

A	O
putative	O
progestin	O
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	O
TSP	O
-	O
1	O
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	O
-	O
PR	O
complex	O
might	O
directly	O
regulate	O
transcription	O
of	O
the	O
TSP	O
-	O
1	O
gene	O
in	O
human	O
cells	O
.	O

Conditioned	O
medium	O
from	O
progestin	O
-	O
treated	O
breast	O
cancer	O
cells	O
stimulates	O
endothelial	O
cell	O
proliferation	O
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	O
to	O
TSP	O
-	O
1	O
,	O
indicating	O
that	O
TSP	O
-	O
1	O
secreted	O
by	O
breast	O
cancer	O
cells	O
could	O
be	O
pro	O
-	O
angiogenic	O
.	O

Since	O
tumor	O
cell	O
-	O
derived	O
TSP	O
-	O
1	O
has	O
the	O
potential	O
to	O
promote	O
angiogenesis	O
in	O
the	O
tumor	O
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
therapy	O
.	O

Angiogenesis	O
in	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
-	O
null	O
mice	O
.	O

Platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
PECAM	O
)	O
-	O
1	O
has	O
been	O
previously	O
implicated	O
in	O
endothelial	O
cell	O
migration	O
;	O
additionally	O
,	O
anti	O
-	O
PECAM	O
-	O
1	O
antibodies	O
have	O
been	O
shown	O
to	O
inhibit	O
in	O
vivo	O
angiogenesis	O
.	O

Studies	O
were	O
therefore	O
performed	O
with	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
to	O
further	O
define	O
the	O
involvement	O
of	O
PECAM	O
-	O
1	O
in	O
blood	O
vessel	O
formation	O
.	O

Vascularization	O
of	O
subcutaneous	O
Matrigel	O
implants	O
as	O
well	O
as	O
tumor	O
angiogenesis	O
were	O
both	O
inhibited	O
in	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
.	O

Reciprocal	O
bone	O
marrow	O
transplants	O
that	O
involved	O
both	O
wild	O
-	O
type	O
and	O
PECAM	O
-	O
1	O
-	O
deficient	O
mice	O
revealed	O
that	O
the	O
impaired	O
angiogenic	O
response	O
resulted	O
from	O
a	O
loss	O
of	O
endothelial	O
,	O
but	O
not	O
leukocyte	O
,	O
PECAM	O
-	O
1	O
.	O

In	O
vitro	O
wound	O
migration	O
and	O
single	O
-	O
cell	O
motility	O
by	O
PECAM	O
-	O
1	O
-	O
null	O
endothelial	O
cells	O
were	O
also	O
compromised	O
.	O

In	O
addition	O
,	O
filopodia	O
formation	O
,	O
a	O
feature	O
of	O
motile	O
cells	O
,	O
was	O
inhibited	O
in	O
PECAM	O
-	O
1	O
-	O
null	O
endothelial	O
cells	O
as	O
well	O
as	O
in	O
human	O
endothelial	O
cells	O
treated	O
with	O
either	O
anti	O
-	O
PECAM	O
-	O
1	O
antibody	O
or	O
PECAM	O
-	O
1	O
siRNA	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
PECAM	O
-	O
1	O
promoted	O
filopodia	O
formation	O
and	O
increased	O
the	O
protein	O
expression	O
levels	O
of	O
Cdc42	O
,	O
a	O
Rho	O
GTPase	O
that	O
is	O
known	O
to	O
promote	O
the	O
formation	O
of	O
filopodia	O
.	O

In	O
the	O
developing	O
retinal	O
vasculature	O
,	O
numerous	O
,	O
long	O
filamentous	O
filopodia	O
,	O
emanating	O
from	O
endothelial	O
cells	O
at	O
the	O
tips	O
of	O
angiogenic	O
sprouts	O
,	O
were	O
observed	O
in	O
wild	O
-	O
type	O
animals	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
.	O

Together	O
,	O
these	O
data	O
further	O
establish	O
the	O
involvement	O
of	O
endothelial	O
PECAM	O
-	O
1	O
in	O
angiogenesis	O
and	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
PECAM	O
-	O
1	O
may	O
stimulate	O
endothelial	O
cell	O
motility	O
by	O
promoting	O
the	O
formation	O
of	O
filopodia	O
.	O

Desipramine	O
inhibits	O
the	O
growth	O
of	O
a	O
mouse	O
skin	O
squamous	O
cell	O
carcinoma	O
cell	O
line	O
and	O
affects	O
glucocorticoid	O
receptor	O
-	O
mediated	O
transcription	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
tricyclic	O
antidepressant	O
desipramine	O
(	O
DMI	O
)	O
on	O
the	O
growth	O
inhibition	O
and	O
translocation	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
cancerous	O
and	O
noncancerous	O
cell	O
lines	O
and	O
the	O
effect	O
of	O
DMI	O
on	O
GR	O
-	O
mediated	O
transcription	O
.	O

Nontumorigenic	O
,	O
immortalized	O
keratinocytes	O
cell	O
line	O
(	O
3PC	B
)	O
,	O
papilloma	O
(	O
MT1	B
/	I
2	I
)	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
(	O
Ca3	B
/	I
7	I
)	O
cell	O
lines	O
were	O
initially	O
used	O
to	O
study	O
the	O
cell	O
growth	O
inhibition	O
by	O
DMI	O
.	O

Although	O
,	O
the	O
growth	O
of	O
all	O
three	O
cell	O
lines	O
was	O
suppressed	O
by	O
DMI	O
,	O
it	O
was	O
more	O
effective	O
in	O
Ca3	B
/	I
7	I
cells	O
.	O

Therefore	O
,	O
we	O
next	O
examined	O
the	O
effect	O
of	O
DMI	O
on	O
Ca3	B
/	I
7	I
cells	O
,	O
resistant	O
to	O
growth	O
inhibition	O
by	O
the	O
synthetic	O
glucocorticoid	O
fluocinolone	O
acetonide	O
(	O
FA	O
)	O
.	O

DMI	O
inhibited	O
cell	O
proliferation	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
translocation	O
of	O
GR	O
was	O
induced	O
by	O
FA	O
alone	O
,	O
DMI	O
alone	O
,	O
and	O
combination	O
of	O
both	O
agents	O
.	O

FA	O
induced	O
GR	O
-	O
mediated	O
transcription	O
in	O
Ca3	B
/	I
7	I
cells	O
transfected	O
with	O
a	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
,	O
but	O
DMI	O
alone	O
did	O
not	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O

However	O
,	O
DMI	O
inhibited	O
FA	O
-	O
induced	O
,	O
GR	O
-	O
mediated	O
transcription	O
when	O
both	O
agents	O
were	O
given	O
together	O
.	O

Pretreatment	O
with	O
DMI	O
followed	O
by	O
combination	O
of	O
DMI	O
and	O
FA	O
decreased	O
GR	O
-	O
mediated	O
transcription	O
more	O
than	O
pretreatment	O
with	O
FA	O
.	O

The	O
expression	O
of	O
metallothionein	O
-	O
1	O
(	O
Mt	O
-	O
1	O
)	O
gene	O
,	O
which	O
is	O
regulated	O
by	O
GR	O
,	O
was	O
induced	O
significantly	O
by	O
the	O
combination	O
of	O
DMI	O
and	O
FA	O
,	O
and	O
enhanced	O
significantly	O
by	O
pretreatment	O
with	O
FA	O
but	O
not	O
DMI	O
.	O

DMI	O
is	O
suggested	O
to	O
inhibit	O
the	O
growth	O
of	O
Ca3	B
/	I
7	I
cells	O
and	O
to	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O

WNT	O
/	O
TCF	O
signaling	O
through	O
LEF1	O
and	O
HOXB9	O
mediates	O
lung	O
adenocarcinoma	O
metastasis	O
.	O

Metastasis	O
from	O
lung	O
adenocarcinoma	O
can	O
occur	O
swiftly	O
to	O
multiple	O
organs	O
within	O
months	O
of	O
diagnosis	O
.	O

The	O
mechanisms	O
that	O
confer	O
this	O
rapid	O
metastatic	O
capacity	O
to	O
lung	O
tumors	O
are	O
unknown	O
.	O

Activation	O
of	O
the	O
canonical	O
WNT	O
/	O
TCF	O
pathway	O
is	O
identified	O
here	O
as	O
a	O
determinant	O
of	O
metastasis	O
to	O
brain	O
and	O
bone	O
during	O
lung	O
adenocarcinoma	O
progression	O
.	O

Gene	O
expression	O
signatures	O
denoting	O
WNT	O
/	O
TCF	O
activation	O
are	O
associated	O
with	O
relapse	O
to	O
multiple	O
organs	O
in	O
primary	O
lung	O
adenocarcinoma	O
.	O

Metastatic	O
subpopulations	O
isolated	O
from	O
independent	O
lymph	O
node	O
-	O
derived	O
lung	O
adenocarcinoma	O
cell	O
lines	O
harbor	O
a	O
hyperactive	O
WNT	O
/	O
TCF	O
pathway	O
.	O

Reduction	O
of	O
TCF	O
activity	O
in	O
these	O
cells	O
attenuates	O
their	O
ability	O
to	O
form	O
brain	O
and	O
bone	O
metastases	O
in	O
mice	O
,	O
independently	O
of	O
effects	O
on	O
tumor	O
growth	O
in	O
the	O
lungs	O
.	O

The	O
WNT	O
/	O
TCF	O
target	O
genes	O
HOXB9	O
and	O
LEF1	O
are	O
identified	O
as	O
mediators	O
of	O
chemotactic	O
invasion	O
and	O
colony	O
outgrowth	O
.	O

Thus	O
,	O
a	O
distinct	O
WNT	O
/	O
TCF	O
signaling	O
program	O
through	O
LEF1	O
and	O
HOXB9	O
enhances	O
the	O
competence	O
of	O
lung	O
adenocarcinoma	O
cells	O
to	O
colonize	O
the	O
bones	O
and	O
the	O
brain	O
.	O

For	O
a	O
video	O
summary	O
of	O
this	O
article	O
,	O
see	O
the	O
PaperFlick	O
file	O
available	O
with	O
the	O
online	O
Supplemental	O
Data	O
.	O

c	O
-	O
Ski	O
overexpression	O
promotes	O
tumor	O
growth	O
and	O
angiogenesis	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
in	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
.	O

c	O
-	O
Ski	O
,	O
originally	O
identified	O
as	O
a	O
proto	O
-	O
oncogene	O
product	O
,	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
family	O
signaling	O
through	O
interaction	O
with	O
Smad2	O
,	O
Smad3	O
,	O
and	O
Smad4	O
.	O

High	O
expression	O
of	O
c	O
-	O
Ski	O
has	O
been	O
found	O
in	O
some	O
cancers	O
,	O
including	O
gastric	O
cancer	O
.	O

We	O
previously	O
showed	O
that	O
disruption	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
in	O
a	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
model	O
accelerated	O
tumor	O
growth	O
through	O
induction	O
of	O
tumor	O
angiogenesis	O
by	O
decreased	O
expression	O
of	O
the	O
anti	O
-	O
angiogenic	O
factor	O
thrombospondin	O
(	O
TSP	O
)	O
-	O
1	O
.	O

Here	O
,	O
we	O
examined	O
the	O
function	O
of	O
c	O
-	O
Ski	O
in	O
human	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
OCUM	B
-	I
2MLN	I
cells	O
.	O

Overexpression	O
of	O
c	O
-	O
Ski	O
inhibited	O
TGF	O
-	O
beta	O
signaling	O
in	O
OCUM	B
-	I
2MLN	I
cells	O
.	O

Interestingly	O
,	O
c	O
-	O
Ski	O
overexpression	O
resulted	O
in	O
extensive	O
acceleration	O
of	O
the	O
growth	O
of	O
subcutaneous	O
xenografts	O
in	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
female	O
mice	O
(	O
6	O
weeks	O
of	O
age	O
)	O
.	O

Similar	O
to	O
tumors	O
expressing	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
,	O
histochemical	O
studies	O
revealed	O
less	O
fibrosis	O
and	O
increased	O
angiogenesis	O
in	O
xenografted	O
tumors	O
expressing	O
c	O
-	O
Ski	O
compared	O
to	O
control	O
tumors	O
.	O

Induction	O
of	O
TSP	O
-	O
1	O
mRNA	O
by	O
TGF	O
-	O
beta	O
was	O
attenuated	O
by	O
c	O
-	O
Ski	O
in	O
vitro	O
,	O
and	O
expression	O
of	O
TSP	O
-	O
1	O
mRNA	O
was	O
decreased	O
in	O
tumors	O
expressing	O
c	O
-	O
Ski	O
in	O
vivo	O
.	O

These	O
findings	O
suggest	O
that	O
c	O
-	O
Ski	O
overexpression	O
promotes	O
the	O
growth	O
of	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
through	O
induction	O
of	O
angiogenesis	O
.	O

[	O
Quantitative	O
analysis	O
of	O
regional	O
cerebral	O
blood	O
flow	O
in	O
elderly	O
with	O
white	O
matter	O
lesions	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
observe	O
whether	O
the	O
severity	O
of	O
white	O
matter	O
lesions	O
(	O
WML	O
)	O
is	O
related	O
to	O
ischemia	O
in	O
elderly	O
.	O

METHODS	O
:	O

WML	O
were	O
divided	O
into	O
2	O
categories	O
(	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
)	O
and	O
four	O
grades	O
(	O
grade	O
0	O
,	O
grade	O
1	O
,	O
grade	O
2	O
and	O
grade	O
3	O
)	O
according	O
to	O
the	O
severity	O
of	O
WML	O
showing	O
on	O
the	O
FLAIR	O
sequence	O
of	O
MRI	O
using	O
modified	O
Fazekas	O
scale	O
.	O

The	O
values	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
within	O
WML	O
and	O
other	O
brain	O
regions	O
were	O
measured	O
using	O
Xenon	O
contrast	O
CT	O
.	O

RESULTS	O
:	O

Mean	O
rCBF	O
(	O
ml	O
x	O
100	O
g	O
(	O
-	O
1	O
)	O
x	O
min	O
(	O
-	O
1	O
)	O
)	O
within	O
lesions	O
around	O
periventricular	O
areas	O
,	O
in	O
right	O
and	O
left	O
centrum	O
semiovale	O
were	O
20	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
8	O
,	O
22	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
and	O
22	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
1	O
in	O
grade	O
0	O
;	O
20	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
,	O
21	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
and	O
21	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
8	O
in	O
grade1	O
;	O
16	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
15	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7	O
and	O
15	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
in	O
grade	O
2	O
;	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
6	O
,	O
14	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
2	O
and	O
14	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
in	O
grade	O
3	O
respectively	O
.	O

The	O
severity	O
of	O
WML	O
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	O
both	O
in	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
rCBF	O
values	O
between	O
grade	O
0	O
and	O
1	O
,	O
but	O
significant	O
differences	O
existed	O
between	O
grade	O
0	O
and	O
grades	O
2	O
and	O
3	O
,	O
between	O
grade	O
1	O
and	O
grades	O
2	O
and	O
3	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Statistical	O
significance	O
also	O
existed	O
between	O
the	O
severity	O
of	O
white	O
matter	O
lesions	O
and	O
rCBF	O
in	O
bilateral	O
temporal	O
lobes	O
and	O
lentiform	O
nucleases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
severity	O
of	O
WML	O
both	O
in	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	O
.	O

MEK5	O
/	O
ERK5	O
signaling	O
modulates	O
endothelial	O
cell	O
migration	O
and	O
focal	O
contact	O
turnover	O
.	O

The	O
formation	O
of	O
new	O
blood	O
vessels	O
from	O
pre	O
-	O
existing	O
ones	O
requires	O
highly	O
coordinated	O
restructuring	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
and	O
the	O
surrounding	O
extracellular	O
matrix	O
.	O

Directed	O
EC	O
migration	O
is	O
a	O
central	O
step	O
in	O
this	O
process	O
and	O
depends	O
on	O
cellular	O
signaling	O
cascades	O
that	O
initiate	O
and	O
control	O
the	O
structural	O
rearrangements	O
.	O

On	O
the	O
basis	O
of	O
earlier	O
findings	O
that	O
ERK5	O
deficiency	O
in	O
mouse	O
EC	O
results	O
in	O
massive	O
defects	O
in	O
vessel	O
architecture	O
,	O
we	O
focused	O
on	O
the	O
impact	O
of	O
the	O
MEK5	O
/	O
ERK5	O
signaling	O
pathway	O
on	O
EC	O
migration	O
.	O

Using	O
a	O
retroviral	O
gene	O
transfer	O
approach	O
,	O
we	O
found	O
that	O
constitutive	O
activation	O
of	O
MEK5	O
/	O
ERK5	O
signaling	O
strongly	O
inhibits	O
EC	O
migration	O
and	O
results	O
in	O
massive	O
morphological	O
changes	O
.	O

The	O
area	O
covered	O
by	O
spread	O
EC	O
was	O
dramatically	O
enlarged	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
focal	O
contacts	O
and	O
altered	O
organization	O
of	O
actin	O
filaments	O
.	O

Consequently	O
,	O
cells	O
were	O
more	O
rigid	O
and	O
show	O
reduced	O
motility	O
.	O

This	O
phenotype	O
was	O
most	O
likely	O
based	O
on	O
decreased	O
focal	O
contact	O
turnover	O
caused	O
by	O
reduced	O
expression	O
of	O
p130Cas	O
,	O
a	O
key	O
player	O
in	O
directed	O
cell	O
migration	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
ERK5	O
signaling	O
not	O
only	O
is	O
involved	O
in	O
EC	O
survival	O
and	O
stress	O
response	O
but	O
also	O
controls	O
migration	O
and	O
morphology	O
of	O
EC	O
.	O

The	O
Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
short	O
variant	O
promoters	O
direct	O
vascular	O
bed	O
-	O
specific	O
gene	O
expression	O
during	O
inflammation	O
in	O
mice	O
.	O

Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
(	O
DSCR	O
-	O
1	O
)	O
short	O
variant	O
(	O
DSCR	O
-	O
1s	O
)	O
is	O
an	O
inhibitor	O
of	O
calcineurin	O
/	O
NFAT	O
signaling	O
encoded	O
by	O
exons	O
4	O
-	O
7	O
of	O
DSCR1	O
.	O

We	O
previously	O
reported	O
that	O
VEGF	O
induces	O
DSCR	O
-	O
1s	O
expression	O
in	O
endothelial	O
cells	O
,	O
which	O
in	O
turn	O
negatively	O
feeds	O
back	O
to	O
attenuate	O
endothelial	O
cell	O
activation	O
.	O

Here	O
,	O
in	O
order	O
to	O
characterize	O
the	O
role	O
of	O
the	O
promoter	O
that	O
drives	O
DSCR	O
-	O
1s	O
expression	O
in	O
mediating	O
inducible	O
expression	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
functional	O
relevance	O
of	O
DSCR	O
-	O
1s	O
in	O
inflammation	O
,	O
we	O
targeted	O
a	O
DNA	O
construct	O
containing	O
1	O
.	O
7	O
kb	O
of	O
the	O
human	O
DSCR1s	O
promoter	O
coupled	O
to	O
the	O
lacZ	O
reporter	O
to	O
the	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
Hprt	O
)	O
locus	O
of	O
mice	O
.	O

We	O
determined	O
that	O
lacZ	O
was	O
uniformly	O
expressed	O
in	O
the	O
endothelium	O
of	O
transgenic	O
embryos	O
but	O
was	O
markedly	O
downregulated	O
postnatally	O
.	O

Systemic	O
administration	O
of	O
VEGF	O
or	O
LPS	O
in	O
adult	O
mice	O
resulted	O
in	O
cyclosporine	O
A	O
-	O
sensitive	O
reactivation	O
of	O
the	O
DSCR1s	O
promoter	O
and	O
endogenous	O
gene	O
expression	O
in	O
a	O
subset	O
of	O
organs	O
,	O
including	O
the	O
heart	O
and	O
brain	O
.	O

The	O
DSCR1s	O
promoter	O
was	O
similarly	O
induced	O
in	O
the	O
endothelium	O
of	O
tumor	O
xenografts	O
.	O

In	O
a	O
mouse	O
model	O
of	O
endotoxemia	O
,	O
DSCR	O
-	O
1s	O
-	O
deficient	O
mice	O
demonstrated	O
increased	O
sepsis	O
mortality	O
,	O
whereas	O
adenovirus	O
-	O
mediated	O
DSCR	O
-	O
1s	O
overexpression	O
protected	O
against	O
LPS	O
-	O
induced	O
lethality	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
DSCR1s	O
promoter	O
directs	O
vascular	O
bed	O
-	O
specific	O
expression	O
in	O
activated	O
endothelium	O
and	O
that	O
DSCR	O
-	O
1s	O
serves	O
to	O
dampen	O
the	O
host	O
response	O
to	O
infection	O
.	O

[	O
The	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
by	O
cognitive	O
,	O
behavioral	O
,	O
and	O
temperamental	O
variables	O
in	O
a	O
six	O
-	O
month	O
time	O
interval	O
]	O
.	O

Several	O
models	O
have	O
been	O
proposed	O
to	O
explain	O
the	O
depressive	O
phenomenon	O
,	O
such	O
as	O
the	O
theory	O
of	O
dysfunctional	O
attitudes	O
,	O
the	O
hopelessness	O
theory	O
,	O
the	O
behavioral	O
model	O
of	O
activity	O
level	O
,	O
or	O
temperamental	O
models	O
.	O

This	O
article	O
presents	O
data	O
about	O
the	O
role	O
of	O
those	O
models	O
in	O
the	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
in	O
a	O
sample	O
of	O
414	O
college	O
students	O
,	O
assessed	O
over	O
a	O
temporal	O
interval	O
of	O
six	O
months	O
.	O

Dysfunctional	O
attitudes	O
,	O
attributional	O
styles	O
,	O
the	O
level	O
of	O
activity	O
,	O
and	O
the	O
five	O
-	O
factors	O
of	O
personality	O
were	O
assessed	O
.	O

The	O
BDI	O
-	O
II	O
was	O
the	O
depression	O
level	O
measure	O
.	O

The	O
results	O
showed	O
that	O
these	O
variables	O
predict	O
depression	O
levels	O
,	O
but	O
with	O
low	O
coefficients	O
.	O

The	O
dimensions	O
of	O
Need	O
of	O
Achievement	O
(	O
a	O
dysfunctional	O
attitude	O
)	O
and	O
Neuroticism	O
had	O
particularly	O
greater	O
weight	O
in	O
the	O
prediction	O
,	O
but	O
only	O
Neuroticism	O
seems	O
to	O
behave	O
like	O
a	O
vulnerability	O
element	O
.	O

Attributional	O
styles	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
prediction	O
of	O
depression	O
.	O

Activity	O
level	O
lost	O
its	O
predictive	O
role	O
during	O
the	O
6	O
-	O
month	O
interval	O
.	O

These	O
results	O
are	O
discussed	O
according	O
to	O
the	O
role	O
of	O
the	O
proposed	O
models	O
and	O
the	O
need	O
for	O
a	O
deeper	O
explanation	O
of	O
the	O
variance	O
of	O
depression	O
scores	O
.	O

EPOX	O
inhibits	O
angiogenesis	O
by	O
degradation	O
of	O
Mcl	O
-	O
1	O
through	O
ERK	O
inactivation	O
.	O

PURPOSE	O
:	O
Antiangiogenic	O
therapy	O
is	O
considered	O
as	O
an	O
effective	O
strategy	O
for	O
controlling	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	O
.	O

Among	O
a	O
myriad	O
of	O
biological	O
activities	O
described	O
for	O
xanthone	O
derivatives	O
,	O
the	O
anticancer	O
activity	O
is	O
quite	O
remarkable	O
,	O
but	O
the	O
molecular	O
mechanism	O
is	O
not	O
clearly	O
resolved	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
antiangiogenic	O
mechanism	O
of	O
3	O
,	O
6	O
-	O
di	O
(	O
2	O
,	O
3	O
-	O
epoxypropoxy	O
)	O
xanthone	O
(	O
EPOX	O
)	O
,	O
a	O
novel	O
Mcl	O
-	O
1	O
targeting	O
drug	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
To	O
evaluate	O
the	O
antiangiogenic	O
activity	O
of	O
EPOX	O
,	O
we	O
did	O
cell	O
viability	O
,	O
cell	O
cycle	O
,	O
tube	O
formation	O
assay	O
in	O
vitro	O
,	O
and	O
Matrigel	O
plug	O
assay	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
EPOX	O
on	O
the	O
endothelial	O
signaling	O
pathway	O
,	O
we	O
did	O
immunoblotting	O
,	O
immunoprecipitation	O
,	O
and	O
immunofluorescence	O
analysis	O
.	O

Intracellular	O
glutathione	O
levels	O
were	O
determined	O
with	O
the	O
use	O
of	O
monochlorobimane	O
,	O
a	O
glutathione	O
-	O
specific	O
probe	O
.	O

RESULTS	O
:	O
EPOX	O
induced	O
endothelial	O
cell	O
apoptosis	O
in	O
association	O
with	O
proteasome	O
-	O
dependent	O
Mcl	O
-	O
1	O
degradation	O
.	O

Down	O
-	O
regulation	O
of	O
Mcl	O
-	O
1	O
resulted	O
in	O
an	O
increase	O
in	O
Mcl	O
-	O
1	O
-	O
free	O
Bim	O
,	O
activation	O
of	O
Bax	O
,	O
and	O
then	O
signaling	O
of	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Additionally	O
,	O
glutathione	O
depletion	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
inactivation	O
was	O
observed	O
in	O
EPOX	O
-	O
treated	O
cells	O
.	O

Glutathione	O
supplementation	O
reversed	O
the	O
inhibitory	O
effects	O
of	O
EPOX	O
on	O
ERK	O
,	O
which	O
increases	O
the	O
phosphorylation	O
of	O
Mcl	O
-	O
1	O
at	O
T	O
(	O
163	O
.	O
)	O
Overexpression	O
of	O
mitogen	O
-	O
activated	O
protein	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
partially	O
reversed	O
the	O
effect	O
of	O
EPOX	O
on	O
Mcl	O
-	O
1	O
dephosphorylation	O
,	O
ubiquitination	O
,	O
and	O
degradation	O
,	O
further	O
implicating	O
ERK	O
in	O
the	O
regulation	O
of	O
Mcl	O
-	O
1	O
stability	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
EPOX	O
induces	O
glutathione	O
depletion	O
,	O
ERK	O
inactivation	O
,	O
and	O
Mcl	O
-	O
1	O
degradation	O
on	O
endothelial	O
cells	O
,	O
which	O
leads	O
to	O
inhibition	O
of	O
angiogenesis	O
.	O

Our	O
results	O
suggest	O
that	O
EPOX	O
is	O
a	O
novel	O
antiangiogenic	O
agent	O
,	O
making	O
it	O
a	O
promising	O
lead	O
compound	O
for	O
further	O
development	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
pathologies	O
.	O

Angiogenesis	O
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	O
disease	O
.	O

Angiogenesis	O
is	O
the	O
biologic	O
process	O
of	O
forming	O
new	O
blood	O
vessels	O
.	O

Undoubtedly	O
,	O
blood	O
vessels	O
growth	O
regulation	O
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O

Under	O
physiological	O
conditions	O
,	O
angiogenesis	O
is	O
regulated	O
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O

In	O
many	O
diseases	O
state	O
body	O
loses	O
control	O
over	O
angiogenesis	O
.	O

Angiogenesis	O
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	O
vessels	O
either	O
grow	O
excessively	O
or	O
insufficiently	O
.	O

Insufficient	O
angiogenesis	O
occurs	O
in	O
diseases	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	O
.	O

Myocardial	O
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	O
angiogenesis	O
in	O
many	O
experimental	O
models	O
.	O

Therapeutic	O
angiogenesis	O
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	O
the	O
growth	O
of	O
new	O
blood	O
vessels	O
.	O

Traditional	O
coronary	O
revascularization	O
therapies	O
such	O
as	O
coronary	O
angioplasty	O
or	O
bypass	O
graft	O
surgery	O
,	O
act	O
by	O
restoring	O
blood	O
flow	O
through	O
the	O
preexisting	O
coronary	O
vessels	O
.	O

One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	O
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	O
disease	O
.	O

In	O
contrast	O
,	O
therapeutic	O
angiogenesis	O
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	O
collateral	O
development	O
may	O
be	O
stimulated	O
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	O
ischemia	O
.	O

Studies	O
,	O
both	O
in	O
human	O
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	O
growth	O
factors	O
and	O
progenitor	O
cells	O
can	O
enhance	O
new	O
blood	O
vessels	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
,	O
recombinant	O
proteins	O
and	O
bone	O
marrow	O
stem	O
cells	O
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	O
.	O

As	O
coronary	O
artery	O
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	O
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	O
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O

Nicked	O
{	O
beta	O
}	O
2	O
-	O
glycoprotein	O
I	O
binds	O
angiostatin	O
4	O
.	O
5	O
(	O
plasminogen	O
kringle	O
1	O
-	O
5	O
)	O
and	O
attenuates	O
its	O
antiangiogenic	O
property	O
.	O

Angiostatin	O
was	O
first	O
discovered	O
as	O
a	O
plasminogen	O
fragment	O
with	O
antitumor	O
/	O
antiangiogenic	O
property	O
.	O

One	O
of	O
the	O
angiostatin	O
isoforms	O
,	O
that	O
is	O
,	O
angiostatin	O
4	O
.	O
5	O
(	O
AS4	O
.	O
5	O
)	O
,	O
consisting	O
of	O
plasminogen	O
kringle	O
1	O
to	O
4	O
and	O
a	O
most	O
part	O
of	O
kringle	O
5	O
,	O
is	O
produced	O
by	O
autoproteolysis	O
and	O
present	O
in	O
human	O
plasma	O
.	O

beta2	O
-	O
glycoprotein	O
I	O
(	O
beta2GPI	O
)	O
is	O
proteolytically	O
cleaved	O
by	O
plasmin	O
in	O
its	O
domain	O
V	O
(	O
nicked	O
beta2GPI	O
)	O
,	O
resulting	O
in	O
binding	O
to	O
plasminogen	O
.	O

Antiangiogenic	O
properties	O
have	O
been	O
recently	O
reported	O
in	O
nicked	O
beta2GPI	O
as	O
well	O
as	O
in	O
intact	O
beta2GPI	O
at	O
higher	O
concentrations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
significant	O
binding	O
of	O
nicked	O
beta2GPI	O
to	O
AS4	O
.	O
5	O
(	O
K	O
(	O
D	O
)	O
=	O
3	O
.	O
27	O
x	O
10	O
(	O
6	O
)	O
M	O
(	O
-	O
1	O
)	O
)	O
.	O

Via	O
this	O
binding	O
,	O
nicked	O
beta2GPI	O
attenuates	O
the	O
antiangiogenic	O
functions	O
of	O
AS4	O
.	O
5	O
in	O
the	O
proliferation	O
of	O
arterial	O
/	O
venous	O
endothelial	O
cells	O
,	O
in	O
the	O
extracellular	O
matrix	O
invasion	O
and	O
the	O
tube	O
formation	O
of	O
venous	O
endothelial	O
cells	O
,	O
and	O
in	O
vivo	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
intact	O
beta2GPI	O
does	O
not	O
bind	O
to	O
AS4	O
.	O
5	O
or	O
inhibit	O
its	O
antiangiogenic	O
activity	O
.	O

Thus	O
,	O
nicked	O
beta2GPI	O
exerts	O
dual	O
effects	O
on	O
angiogenesis	O
,	O
that	O
is	O
,	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
in	O
the	O
presence	O
of	O
AS4	O
.	O
5	O
,	O
whereas	O
nicked	O
beta2GPI	O
inhibits	O
angiogenesis	O
at	O
concentrations	O
high	O
enough	O
to	O
neutralize	O
AS4	O
.	O
5	O
.	O

Our	O
data	O
suggest	O
that	O
plasmin	O
-	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
by	O
interacting	O
with	O
plasmin	O
-	O
generated	O
AS4	O
.	O
5	O
in	O
sites	O
of	O
increased	O
fibrinolysis	O
such	O
as	O
thrombus	O
.	O

Use	O
of	O
uteroglobin	O
for	O
the	O
engineering	O
of	O
polyvalent	O
,	O
polyspecific	O
fusion	O
proteins	O
.	O

We	O
report	O
a	O
novel	O
strategy	O
to	O
engineer	O
and	O
express	O
stable	O
and	O
soluble	O
human	O
recombinant	O
polyvalent	O
/	O
polyspecific	O
fusion	O
proteins	O
.	O

The	O
procedure	O
is	O
based	O
on	O
the	O
use	O
of	O
a	O
central	O
skeleton	O
of	O
uteroglobin	O
,	O
a	O
small	O
and	O
very	O
soluble	O
covalently	O
linked	O
homodimeric	O
protein	O
that	O
is	O
very	O
resistant	O
to	O
proteolytic	O
enzymes	O
and	O
to	O
pH	O
variations	O
.	O

Using	O
a	O
human	O
recombinant	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
angiogenesis	O
marker	O
domain	O
B	O
of	O
fibronectin	O
,	O
interleukin	O
2	O
,	O
and	O
an	O
scFv	O
able	O
to	O
neutralize	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
we	O
expressed	O
various	O
biologically	O
active	O
uteroglobin	O
fusion	O
proteins	O
.	O

The	O
results	O
demonstrate	O
the	O
possibility	O
to	O
generate	O
monospecific	O
divalent	O
and	O
tetravalent	O
antibodies	O
,	O
immunocytokines	O
,	O
and	O
dual	O
specificity	O
tetravalent	O
antibodies	O
.	O

Furthermore	O
,	O
compared	O
with	O
similar	O
fusion	O
proteins	O
in	O
which	O
uteroglobin	O
was	O
not	O
used	O
,	O
the	O
use	O
of	O
uteroglobin	O
improved	O
properties	O
of	O
solubility	O
and	O
stability	O
.	O

Indeed	O
,	O
in	O
the	O
reported	O
cases	O
it	O
was	O
possible	O
to	O
vacuum	O
dry	O
and	O
reconstitute	O
the	O
proteins	O
without	O
any	O
aggregation	O
or	O
loss	O
in	O
protein	O
and	O
biological	O
activity	O
.	O

Targeting	O
angiogenesis	O
:	O
progress	O
with	O
anti	O
-	O
VEGF	O
treatment	O
with	O
large	O
molecules	O
.	O

Angiogenesis	O
-	O
-	O
one	O
of	O
the	O
hallmarks	O
of	O
cancer	O
-	O
-	O
has	O
emerged	O
as	O
a	O
valid	O
therapeutic	O
target	O
in	O
oncology	O
.	O

The	O
VEGF	O
system	O
represents	O
a	O
key	O
mediator	O
of	O
tumor	O
-	O
initiated	O
angiogenesis	O
and	O
the	O
first	O
target	O
of	O
antiangiogenesis	O
agents	O
introduced	O
in	O
clinical	O
practice	O
.	O

Although	O
anti	O
-	O
VEGF	O
therapies	O
have	O
clearly	O
demonstrated	O
antitumor	O
efficacy	O
in	O
various	O
malignancies	O
,	O
especially	O
when	O
combined	O
with	O
conventional	O
cytotoxic	O
chemotherapy	O
,	O
their	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
.	O

This	O
Review	O
will	O
discuss	O
the	O
rationale	O
for	O
using	O
antiangiogenic	O
compounds	O
and	O
will	O
focus	O
on	O
large	O
molecules	O
,	O
such	O
as	O
antibodies	O
,	O
that	O
target	O
the	O
VEGF	O
system	O
.	O

Clinical	O
data	O
on	O
bevacizumab	O
is	O
discussed	O
in	O
detail	O
.	O

Predictive	O
markers	O
for	O
anti	O
-	O
VEGF	O
agents	O
have	O
not	O
yet	O
been	O
identified	O
and	O
questions	O
regarding	O
the	O
usefulness	O
of	O
bevacizumab	O
in	O
the	O
adjuvant	O
setting	O
as	O
well	O
as	O
its	O
continued	O
use	O
beyond	O
progression	O
remain	O
unanswered	O
,	O
in	O
spite	O
of	O
negative	O
data	O
on	O
bevacizumab	O
in	O
treating	O
patients	O
with	O
adjuvant	O
colon	O
cancer	O
.	O

Nonetheless	O
,	O
anti	O
-	O
VEGF	O
therapy	O
has	O
enhanced	O
the	O
arsenal	O
of	O
anticancer	O
therapies	O
and	O
has	O
provided	O
new	O
insights	O
into	O
the	O
biology	O
of	O
malignancy	O
.	O

[	O
An	O
experimental	O
study	O
on	O
angiogenesis	O
of	O
non	O
-	O
vascularized	O
autogenous	O
bone	O
graft	O
with	O
vascular	O
bundle	O
implantation	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
vascular	O
bundle	O
implantation	O
in	O
autogenous	O
bone	O
graft	O
on	O
angiogenesis	O
.	O

METHODS	O
:	O
Thirty	O
-	O
six	O
New	O
Zealand	O
white	O
rabbits	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

A	O
portion	O
of	O
bilateral	O
radial	O
bones	O
of	O
a	O
rabbit	O
were	O
removed	O
as	O
free	O
bone	O
grafts	O
,	O
whose	O
periostea	O
were	O
peeled	O
off	O
.	O

In	O
test	O
group	O
,	O
the	O
external	O
maxillary	O
artery	O
bundle	O
was	O
passed	O
through	O
the	O
marrow	O
cavity	O
of	O
the	O
bone	O
.	O

In	O
control	O
group	O
,	O
there	O
was	O
no	O
vascular	O
bundle	O
implantation	O
.	O

Each	O
bone	O
was	O
placed	O
in	O
masseter	O
muscle	O
separately	O
.	O

The	O
rabbits	O
were	O
sacrificed	O
and	O
the	O
specimens	O
were	O
procured	O
at	O
3	O
days	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
6	O
weeks	O
after	O
surgery	O
for	O
histological	O
observation	O
,	O
Chinese	O
ink	O
perfusion	O
and	O
CD34	O
immunohistochemistry	O
.	O

Microvessel	O
density	O
(	O
MVD	O
)	O
was	O
assessed	O
in	O
order	O
to	O
evaluate	O
angiogenesis	O
of	O
autogenous	O
bone	O
grafts	O
.	O

RESULTS	O
:	O
The	O
bone	O
grafts	O
were	O
found	O
revascularization	O
in	O
3	O
days	O
after	O
surgery	O
in	O
the	O
test	O
group	O
,	O
whereas	O
at	O
2	O
weeks	O
in	O
the	O
control	O
group	O
.	O

In	O
3	O
days	O
,	O
1	O
week	O
,	O
2	O
weeks	O
,	O
3	O
weeks	O
and	O
4	O
weeks	O
after	O
surgery	O
,	O
the	O
MVD	O
of	O
test	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

In	O
4	O
weeks	O
after	O
surgery	O
,	O
angiogenesis	O
of	O
test	O
group	O
reached	O
to	O
peak	O
.	O

CONCLUSION	O
:	O
Vascular	O
bundle	O
implantation	O
improved	O
angiogenesis	O
in	O
non	O
-	O
vascularized	O
autogenous	O
bone	O
graft	O
in	O
this	O
study	O
.	O

[	O
Ambiguity	O
role	O
of	O
neutrophils	O
in	O
oncogenesis	O
]	O

The	O
review	O
is	O
focused	O
on	O
the	O
participation	O
of	O
polymorphonuclear	O
granulocytes	O
(	O
neutrophils	O
)	O
in	O
development	O
and	O
spreading	O
of	O
a	O
tumor	O
.	O

We	O
consider	O
both	O
the	O
well	O
known	O
functions	O
of	O
neutrophils	O
(	O
degranulation	O
,	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
)	O
and	O
the	O
recently	O
shown	O
one	O
(	O
presentation	O
of	O
an	O
antigene	O
)	O
.	O

The	O
special	O
attention	O
is	O
focused	O
on	O
the	O
ambiguity	O
of	O
the	O
neutrophil	O
role	O
in	O
oncogenesis	O
.	O

The	O
dominant	O
view	O
is	O
that	O
neutrophils	O
display	O
exclusively	O
antitumor	O
properties	O
.	O

The	O
update	O
information	O
testifies	O
about	O
protumoral	O
activity	O
of	O
neutrophils	O
:	O
they	O
migrate	O
to	O
a	O
tumor	O
and	O
promote	O
angiogenesis	O
and	O
metastasis	O
at	O
late	O
stages	O
of	O
the	O
tumor	O
.	O

It	O
is	O
interesting	O
that	O
certain	O
components	O
of	O
neutrophil	O
cytotoxic	O
arsenal	O
(	O
ROS	O
,	O
cytokines	O
,	O
specific	O
enzymes	O
)	O
participate	O
both	O
in	O
antitumoral	O
defenses	O
of	O
an	O
organism	O
and	O
protumoral	O
activity	O
.	O

Targeting	O
glucose	O
consumption	O
and	O
autophagy	O
in	O
myeloma	O
with	O
the	O
novel	O
nucleoside	O
analogue	O
8	O
-	O
aminoadenosine	O
.	O

Multiple	O
myeloma	O
,	O
an	O
incurable	O
plasma	O
cell	O
malignancy	O
,	O
is	O
characterized	O
by	O
altered	O
cellular	O
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
.	O

Recent	O
connections	O
between	O
glucose	O
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
provide	O
a	O
compelling	O
rationale	O
for	O
targeting	O
metabolic	O
changes	O
in	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
the	O
purine	O
analogue	O
8	O
-	O
aminoadenosine	O
to	O
acutely	O
reduce	O
glucose	O
consumption	O
by	O
regulating	O
localization	O
and	O
expression	O
of	O
key	O
glucose	O
transporters	O
.	O

Myeloma	O
cells	O
counteracted	O
the	O
metabolic	O
stress	O
by	O
activating	O
autophagy	O
.	O

Co	O
-	O
treatment	O
with	O
inhibitors	O
of	O
autophagy	O
results	O
in	O
marked	O
enhancement	O
of	O
cell	O
death	O
.	O

Glucose	O
consumption	O
by	O
drug	O
-	O
resistant	O
myeloma	O
cells	O
was	O
unaffected	O
by	O
8	O
-	O
aminoadenosine	O
,	O
and	O
accordingly	O
,	O
no	O
activation	O
of	O
autophagy	O
was	O
observed	O
.	O

However	O
,	O
these	O
cells	O
can	O
be	O
sensitized	O
to	O
8	O
-	O
aminoadenosine	O
under	O
glucose	O
-	O
limiting	O
conditions	O
.	O

The	O
prosurvival	O
autophagic	O
response	O
of	O
myeloma	O
to	O
nutrient	O
deprivation	O
or	O
to	O
nucleoside	O
analogue	O
treatment	O
has	O
not	O
been	O
described	O
previously	O
.	O

This	O
study	O
establishes	O
the	O
potential	O
of	O
metabolic	O
targeting	O
as	O
a	O
broader	O
means	O
to	O
kill	O
and	O
sensitize	O
myeloma	O
and	O
identifies	O
a	O
compound	O
that	O
can	O
achieve	O
this	O
goal	O
.	O

Endothelial	O
cell	O
migration	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
are	O
the	O
result	O
of	O
loss	O
of	O
breast	O
tissue	O
polarity	O
.	O

Recruiting	O
a	O
new	O
blood	O
supply	O
is	O
a	O
rate	O
-	O
limiting	O
step	O
in	O
tumor	O
progression	O
.	O

In	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
breast	O
carcinogenesis	O
,	O
disorganized	O
,	O
proliferative	O
transformed	O
breast	O
epithelial	O
cells	O
express	O
significantly	O
higher	O
expression	O
of	O
angiogenic	O
genes	O
compared	O
with	O
their	O
polarized	O
,	O
growth	O
-	O
arrested	O
nonmalignant	O
counterparts	O
.	O

Elevated	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
by	O
malignant	O
cells	O
enhanced	O
recruitment	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
in	O
heterotypic	O
cocultures	O
.	O

Significantly	O
,	O
phenotypic	O
reversion	O
of	O
malignant	O
cells	O
via	O
reexpression	O
of	O
HoxD10	O
,	O
which	O
is	O
lost	O
in	O
malignant	O
progression	O
,	O
significantly	O
attenuated	O
VEGF	O
expression	O
in	O
a	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
-	O
independent	O
fashion	O
and	O
reduced	O
EC	O
migration	O
.	O

This	O
was	O
due	O
primarily	O
to	O
restoring	O
polarity	O
:	O
forced	O
proliferation	O
of	O
polarized	O
,	O
nonmalignant	O
cells	O
did	O
not	O
induce	O
VEGF	O
expression	O
and	O
EC	O
recruitment	O
,	O
whereas	O
disrupting	O
the	O
architecture	O
of	O
growth	O
-	O
arrested	O
,	O
reverted	O
cells	O
did	O
.	O

These	O
data	O
show	O
that	O
disrupting	O
cytostructure	O
activates	O
the	O
angiogenic	O
switch	O
even	O
in	O
the	O
absence	O
of	O
proliferation	O
and	O
/	O
or	O
hypoxia	O
and	O
restoring	O
organization	O
of	O
malignant	O
clusters	O
reduces	O
VEGF	O
expression	O
and	O
EC	O
activation	O
to	O
levels	O
found	O
in	O
quiescent	O
nonmalignant	O
epithelium	O
.	O

These	O
data	O
confirm	O
the	O
importance	O
of	O
tissue	O
architecture	O
and	O
polarity	O
in	O
malignant	O
progression	O
.	O

Aging	O
affects	O
the	O
cardiovascular	O
responses	O
to	O
cold	O
stress	O
in	O
humans	O
.	O

Cardiovascular	O
-	O
related	O
mortality	O
peaks	O
during	O
cold	O
winter	O
months	O
,	O
particularly	O
in	O
older	O
adults	O
.	O

Acute	O
physiological	O
responses	O
,	O
such	O
as	O
increases	O
in	O
blood	O
pressure	O
,	O
in	O
response	O
to	O
cold	O
exposure	O
may	O
contribute	O
to	O
these	O
associations	O
.	O

To	O
determine	O
whether	O
the	O
blood	O
pressure	O
-	O
raising	O
effect	O
(	O
pressor	O
response	O
)	O
of	O
non	O
-	O
internal	O
body	O
temperature	O
-	O
reducing	O
cold	O
stress	O
is	O
greater	O
with	O
age	O
,	O
we	O
measured	O
physiological	O
responses	O
to	O
20	O
min	O
of	O
superficial	O
skin	O
cooling	O
,	O
via	O
water	O
-	O
perfused	O
suit	O
,	O
in	O
12	O
younger	O
[	O
25	O
+	O
/	O
-	O
1	O
(	O
SE	O
)	O
yr	O
old	O
]	O
and	O
12	O
older	O
(	O
65	O
+	O
/	O
-	O
2	O
yr	O
old	O
)	O
adults	O
.	O

We	O
found	O
that	O
superficial	O
skin	O
cooling	O
elicited	O
an	O
increase	O
in	O
blood	O
pressure	O
from	O
resting	O
levels	O
(	O
pressor	O
response	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
and	O
older	O
adults	O
.	O

However	O
,	O
the	O
magnitude	O
of	O
this	O
pressor	O
response	O
(	O
systolic	O
and	O
mean	O
blood	O
pressure	O
)	O
was	O
more	O
than	O
twofold	O
higher	O
in	O
older	O
adults	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
younger	O
adults	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
pressor	O
response	O
was	O
similar	O
at	O
peripheral	O
(	O
brachial	O
)	O
and	O
central	O
(	O
estimated	O
in	O
the	O
aorta	O
)	O
measurement	O
sites	O
.	O

Regression	O
analysis	O
revealed	O
that	O
aortic	O
pulse	O
wave	O
velocity	O
,	O
a	O
measure	O
of	O
central	O
arterial	O
stiffness	O
obtained	O
before	O
cooling	O
,	O
was	O
the	O
best	O
predictor	O
of	O
the	O
increased	O
pressor	O
response	O
to	O
superficial	O
skin	O
cooling	O
in	O
older	O
adults	O
,	O
explaining	O
approximately	O
63	O
%	O
of	O
its	O
variability	O
.	O

These	O
results	O
indicate	O
that	O
there	O
is	O
a	O
greater	O
pressor	O
response	O
to	O
non	O
-	O
internal	O
body	O
temperature	O
-	O
reducing	O
cold	O
stress	O
with	O
age	O
in	O
humans	O
that	O
may	O
be	O
mediated	O
by	O
increased	O
levels	O
of	O
central	O
arterial	O
stiffness	O
.	O

Metronomic	O
5	O
-	O
fluorouracil	O
,	O
oxaliplatin	O
and	O
irinotecan	O
in	O
colorectal	O
cancer	O
.	O

Metronomic	O
chemotherapy	O
(	O
the	O
frequent	O
,	O
long	O
term	O
,	O
low	O
dose	O
administration	O
of	O
chemotherapeutic	O
drugs	O
)	O
is	O
a	O
promising	O
therapy	O
because	O
it	O
enhances	O
the	O
anti	O
-	O
endothelial	O
activity	O
of	O
conventional	O
chemotherapeutics	O
,	O
but	O
with	O
lower	O
or	O
no	O
toxic	O
effects	O
compared	O
to	O
maximum	O
tolerated	O
dose	O
administration	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
compare	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
antiangiogenic	O
and	O
antitumor	O
activities	O
of	O
metronomic	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
,	O
oxaliplatin	O
(	O
L	O
-	O
OHP	O
)	O
and	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
in	O
colorectal	O
cancer	O
and	O
to	O
investigate	O
the	O
metronomic	O
combination	O
of	O
these	O
drugs	O
.	O

In	O
vitro	O
cell	O
proliferation	O
,	O
combination	O
studies	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
analyses	O
were	O
performed	O
on	O
endothelial	O
(	O
HMVEC	B
-	I
d	I
)	O
and	O
colorectal	O
cancer	O
(	O
HT	B
-	I
29	I
)	O
cells	O
exposed	O
for	O
144	O
h	O
to	O
metronomic	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
the	O
active	O
metabolite	O
of	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
and	O
5	O
-	O
FU	O
.	O

HT	B
-	I
29	I
human	O
colorectal	O
cancer	O
xenograft	O
model	O
was	O
used	O
and	O
tumour	O
growth	O
,	O
microvessel	O
density	O
and	O
VEGF	O
quantification	O
were	O
performed	O
in	O
tumours	O
after	O
the	O
administration	O
of	O
metronomic	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
,	O
5	O
-	O
FU	O
and	O
their	O
simultaneous	O
combination	O
.	O

Low	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
preferentially	O
inhibited	O
endothelial	O
cell	O
proliferation	O
.	O

Simultaneous	O
and	O
continuous	O
exposure	O
of	O
HT	B
-	I
29	I
and	O
HMVEC	B
-	I
d	I
cells	O
to	O
low	O
concentrations	O
SN	O
-	O
38	O
+	O
L	O
-	O
OHP	O
+	O
5	O
-	O
FU	O
for	O
144	O
h	O
showed	O
a	O
strong	O
antagonism	O
and	O
an	O
unfavorable	O
dose	O
-	O
reduction	O
index	O
.	O

Moreover	O
,	O
the	O
ternary	O
combination	O
resulted	O
in	O
a	O
significant	O
increase	O
of	O
VEGF	O
secretion	O
in	O
HT	B
-	I
29	I
cancer	O
cells	O
.	O

In	O
a	O
xenograft	O
model	O
metronomic	O
CPT	O
-	O
11	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
significantly	O
inhibits	O
HT	B
-	I
29	I
tumor	O
growth	O
and	O
microvessel	O
density	O
in	O
the	O
absence	O
of	O
toxicity	O
.	O

On	O
the	O
contrary	O
,	O
metronomic	O
5	O
-	O
FU	O
+	O
L	O
-	O
OHP	O
+	O
CPT	O
-	O
11	O
therapy	O
did	O
not	O
affect	O
the	O
microvascular	O
count	O
.	O

The	O
metronomic	O
concept	O
might	O
not	O
universally	O
apply	O
to	O
every	O
cytotoxic	O
drug	O
in	O
colorectal	O
cancer	O
and	O
metronomic	O
combination	O
regimens	O
should	O
be	O
used	O
with	O
caution	O
.	O

A	O
key	O
role	O
for	O
the	O
integrin	O
alpha2beta1	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O

The	O
alpha2beta1	O
integrin	O
receptor	O
plays	O
a	O
key	O
role	O
in	O
angiogenesis	O
.	O

Here	O
we	O
investigated	O
the	O
effects	O
of	O
small	O
molecule	O
inhibitors	O
(	O
SMIs	O
)	O
designed	O
to	O
disrupt	O
integrin	O
alpha2	O
I	O
or	O
beta1	O
I	O
-	O
like	O
domain	O
function	O
on	O
angiogenesis	O
.	O

In	O
unchallenged	O
endothelial	O
cells	O
,	O
fibrillar	O
collagen	O
induced	O
robust	O
capillary	O
morphogenesis	O
.	O

In	O
contrast	O
,	O
tube	O
formation	O
was	O
significantly	O
reduced	O
by	O
SMI496	O
,	O
a	O
beta1	O
I	O
-	O
like	O
domain	O
inhibitor	O
and	O
by	O
function	O
-	O
blocking	O
anti	O
-	O
alpha2beta1	O
but	O
not	O
-	O
alpha1beta1	O
antibodies	O
.	O

Endothelial	O
cells	O
bound	O
fluorescein	O
-	O
labeled	O
collagen	O
I	O
fibrils	O
,	O
an	O
interaction	O
specifically	O
inhibited	O
by	O
SMI496	O
.	O

Moreover	O
,	O
SMI496	O
caused	O
cell	O
retraction	O
and	O
cytoskeletal	O
collapse	O
of	O
endothelial	O
cells	O
as	O
well	O
as	O
delayed	O
endothelial	O
cell	O
wound	O
healing	O
.	O

SMI	O
activities	O
were	O
examined	O
in	O
vivo	O
by	O
supplementing	O
the	O
growth	O
medium	O
of	O
zebrafish	O
embryos	O
expressing	O
green	O
fluorescent	O
protein	O
under	O
the	O
control	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
promoter	O
.	O

SMI496	O
,	O
but	O
not	O
a	O
control	O
compound	O
,	O
interfered	O
with	O
angiogenesis	O
in	O
vivo	O
by	O
reversibly	O
inhibiting	O
sprouting	O
from	O
the	O
axial	O
vessels	O
.	O

We	O
further	O
characterized	O
zebrafish	O
alpha2	O
integrin	O
and	O
discovered	O
that	O
this	O
integrin	O
is	O
highly	O
conserved	O
,	O
especially	O
the	O
I	O
domain	O
.	O

Notably	O
,	O
a	O
similar	O
vascular	O
phenotype	O
was	O
induced	O
by	O
morpholino	O
-	O
mediated	O
knockdown	O
of	O
the	O
integrin	O
alpha2	O
subunit	O
.	O

By	O
live	O
videomicroscopy	O
,	O
we	O
confirmed	O
that	O
the	O
vessels	O
were	O
largely	O
nonfunctional	O
in	O
the	O
absence	O
of	O
alpha2beta1	O
integrin	O
.	O

Collectively	O
,	O
our	O
results	O
provide	O
strong	O
biochemical	O
and	O
genetic	O
evidence	O
of	O
a	O
central	O
role	O
for	O
alpha2beta1	O
integrin	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O

Mapping	O
of	O
the	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
gene	O
to	O
mouse	O
chromosome	O
17	O
.	O

In	O
humans	O
,	O
methylmalonyl	O
acidemia	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
(	O
MUT	O
)	O
controlled	O
by	O
a	O
gene	O
that	O
has	O
been	O
mapped	O
to	O
chromosome	O
6	O
.	O

The	O
mouse	O
homolog	O
of	O
this	O
gene	O
has	O
now	O
been	O
mapped	O
to	O
mouse	O
chromosome	O
17	O
.	O

Recombinant	O
inbred	O
and	O
congenic	O
strains	O
place	O
the	O
mouse	O
Mut	O
locus	O
1	O
.	O
06	O
cM	O
distal	O
to	O
H	O
-	O
2	O
,	O
between	O
Pgk	O
-	O
2	O
and	O
Ce	O
-	O
2	O
.	O

The	O
relative	O
order	O
of	O
syntenic	O
probes	O
flanking	O
H	O
-	O
2	O
on	O
mouse	O
chromosome	O
17	O
and	O
HLA	O
on	O
human	O
chromosome	O
6	O
is	O
shown	O
to	O
be	O
different	O
.	O

Dopamine	O
regulates	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
by	O
engaging	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
2	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
receptor	O
phosphorylation	O
is	O
the	O
crucial	O
step	O
for	O
initiating	O
downstream	O
signaling	O
pathways	O
that	O
lead	O
to	O
angiogenesis	O
or	O
related	O
pathophysiological	O
outcomes	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
neurotransmitter	O
dopamine	O
could	O
inhibit	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
(	O
VEGFR	O
-	O
2	O
)	O
,	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
microvascular	O
permeability	O
,	O
and	O
thus	O
,	O
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
address	O
the	O
mechanism	O
by	O
which	O
VEGFR	O
-	O
2	O
phosphorylation	O
is	O
regulated	O
by	O
dopamine	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
D2	O
dopamine	O
receptor	O
(	O
D2DR	O
)	O
colocalizes	O
with	O
VEGFR	O
-	O
2	O
at	O
the	O
cell	O
surface	O
.	O

Dopamine	O
pretreatment	O
increases	O
the	O
translocation	O
and	O
colocalization	O
of	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
(	O
SHP	O
-	O
2	O
)	O
with	O
D2DR	O
at	O
the	O
cell	O
surface	O
.	O

Dopamine	O
administration	O
leads	O
to	O
increased	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
SHP	O
-	O
2	O
and	O
this	O
increased	O
phosphorylation	O
parallels	O
the	O
increased	O
phosphatase	O
activity	O
of	O
SHP	O
-	O
2	O
.	O

Active	O
SHP	O
-	O
2	O
then	O
dephosphorylates	O
VEGFR	O
-	O
2	O
at	O
Y951	O
,	O
Y996	O
and	O
Y1059	O
,	O
but	O
not	O
Y1175	O
.	O

We	O
also	O
observe	O
that	O
SHP	O
-	O
2	O
knockdown	O
impairs	O
the	O
dopamine	O
-	O
regulated	O
inhibition	O
of	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
,	O
subsequently	O
,	O
Src	O
phosphorylation	O
and	O
migration	O
.	O

Our	O
data	O
establish	O
a	O
novel	O
role	O
for	O
SHP	O
-	O
2	O
phosphatase	O
in	O
the	O
dopamine	O
-	O
mediated	O
regulation	O
of	O
VEGFR	O
-	O
2	O
phosphorylation	O
.	O

[	O
The	O
value	O
of	O
intermittent	O
ultrasound	O
treatment	O
in	O
subacromial	O
impingement	O
syndrome	O
]	O
.	O

OBJECTIVES	O
:	O

The	O
role	O
of	O
intermittent	O
ultrasound	O
in	O
the	O
conservative	O
treatment	O
of	O
subacromial	O
impingement	O
syndrome	O
(	O
SIS	O
)	O
has	O
not	O
been	O
clarified	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	O
treatment	O
in	O
SIS	O
.	O

METHODS	O
:	O

Thirty	O
-	O
six	O
patients	O
(	O
29	O
females	O
,	O
7	O
males	O
;	O
mean	O
age	O
51	O
years	O
;	O
range	O
40	O
to	O
69	O
years	O
)	O
with	O
type	O
II	O
SIS	O
were	O
randomized	O
to	O
two	O
groups	O
to	O
receive	O
intermittent	O
ultrasound	O
(	O
group	O
1	O
,	O
n	O
=	O
20	O
)	O
and	O
placebo	O
ultrasound	O
(	O
group	O
2	O
,	O
n	O
=	O
16	O
)	O
for	O
three	O
weeks	O
(	O
15	O
sessions	O
)	O
.	O

All	O
the	O
patients	O
received	O
the	O
same	O
standard	O
physical	O
therapy	O
and	O
rehabilitation	O
modalities	O
besides	O
ultrasound	O
treatment	O
.	O

Evaluations	O
were	O
made	O
before	O
and	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
.	O

Functional	O
results	O
were	O
assessed	O
by	O
the	O
Constant	O
score	O
,	O
pain	O
was	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
and	O
range	O
of	O
motion	O
was	O
measured	O
.	O

RESULTS	O
:	O

Within	O
-	O
group	O
comparisons	O
showed	O
significant	O
improvements	O
in	O
both	O
groups	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Comparison	O
between	O
pretreatment	O
and	O
6	O
-	O
week	O
values	O
were	O
as	O
follows	O
:	O
the	O
mean	O
flexion	O
increased	O
from	O
148	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
4	O
degrees	O
to	O
175	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
0	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
165	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
1	O
degrees	O
to	O
177	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
4	O
degrees	O
in	O
group	O
2	O
;	O
internal	O
and	O
external	O
rotation	O
increased	O
from	O
66	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
7	O
degrees	O
and	O
61	O
.	O
9	O
+	O
/	O
-	O
22	O
.	O
9	O
degrees	O
to	O
83	O
.	O
2	O
+	O
/	O
-	O
10	O
.	O
9	O
degrees	O
and	O
84	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
6	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
75	O
.	O
0	O
+	O
/	O
-	O
17	O
.	O
3	O
degrees	O
and	O
70	O
.	O
0	O
+	O
/	O
-	O
19	O
.	O
8	O
degrees	O
to	O
87	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
8	O
degrees	O
and	O
84	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
4	O
degrees	O
in	O
group	O
2	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
the	O
range	O
of	O
motion	O
at	O
the	O
end	O
of	O
six	O
weeks	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
Constant	O
score	O
improved	O
from	O
43	O
.	O
7	O
+	O
/	O
-	O
12	O
.	O
9	O
to	O
65	O
.	O
7	O
+	O
/	O
-	O
7	O
.	O
7	O
in	O
group	O
1	O
,	O
and	O
from	O
43	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
7	O
.	O
6	O
in	O
group	O
2	O
.	O

Pain	O
scores	O
decreased	O
from	O
5	O
.	O
5	O
to	O
2	O
and	O
from	O
5	O
to	O
1	O
in	O
group	O
1	O
and	O
2	O
,	O
respectively	O
.	O

Improvements	O
in	O
Constant	O
scores	O
and	O
pain	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O

Our	O
findings	O
suggest	O
that	O
intermittent	O
ultrasound	O
added	O
to	O
conservative	O
treatment	O
of	O
SIS	O
do	O
not	O
provide	O
an	O
additional	O
benefit	O
to	O
the	O
patients	O
.	O

Netrin	O
-	O
1	O
up	O
-	O
regulation	O
in	O
inflammatory	O
bowel	O
diseases	O
is	O
required	O
for	O
colorectal	O
cancer	O
progression	O
.	O

Chronic	O
inflammation	O
and	O
cancer	O
are	O
intimately	O
associated	O
.	O

This	O
is	O
particularly	O
true	O
for	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
,	O
such	O
as	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
,	O
which	O
show	O
a	O
major	O
increased	O
risk	O
for	O
colorectal	O
cancer	O
.	O

While	O
the	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
IBD	O
has	O
recently	O
improved	O
,	O
the	O
mechanisms	O
that	O
link	O
these	O
chronic	O
inflammatory	O
states	O
to	O
colorectal	O
cancer	O
development	O
are	O
in	O
large	O
part	O
unknown	O
.	O

One	O
of	O
these	O
mechanisms	O
is	O
NF	O
-	O
kappaB	O
pathway	O
activation	O
which	O
in	O
turn	O
may	O
contribute	O
to	O
tumor	O
formation	O
by	O
providing	O
anti	O
-	O
apoptotic	O
survival	O
signals	O
to	O
the	O
epithelial	O
cells	O
.	O

Based	O
on	O
the	O
observation	O
that	O
netrin	O
-	O
1	O
,	O
the	O
anti	O
-	O
apoptotic	O
ligand	O
for	O
the	O
dependence	O
receptors	O
DCC	O
and	O
UNC5H	O
is	O
up	O
-	O
regulated	O
in	O
colonic	O
crypts	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
,	O
we	O
show	O
here	O
that	O
colorectal	O
cancers	O
from	O
inflammatory	O
bowel	O
diseases	O
patients	O
have	O
selected	O
up	O
-	O
regulation	O
of	O
netrin	O
-	O
1	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inflammation	O
-	O
driven	O
netrin	O
-	O
1	O
up	O
-	O
regulation	O
is	O
causal	O
for	O
colorectal	O
cancer	O
development	O
as	O
interference	O
with	O
netrin	O
-	O
1	O
autocrine	O
loop	O
in	O
a	O
mouse	O
model	O
for	O
ulcerative	O
colitis	O
-	O
associated	O
colorectal	O
cancer	O
,	O
while	O
showing	O
no	O
effect	O
on	O
inflammation	O
,	O
inhibits	O
colorectal	O
cancer	O
progression	O
.	O

Pseudohypoaldosteronism	O
in	O
eight	O
families	O
:	O
different	O
forms	O
of	O
inheritance	O
are	O
evidence	O
for	O
various	O
genetic	O
defects	O
.	O

Pseudohypoaldosteronism	O
is	O
a	O
rare	O
hereditary	O
disorder	O
presenting	O
in	O
early	O
infancy	O
with	O
renal	O
salt	O
loss	O
leading	O
to	O
hyponatremia	O
and	O
hyperkalemia	O
despite	O
high	O
levels	O
of	O
plasma	O
aldosterone	O
.	O

The	O
patients	O
are	O
insensitive	O
to	O
mineralocorticoids	O
;	O
however	O
,	O
sodium	O
supplementation	O
is	O
able	O
to	O
correct	O
electrolyte	O
abnormalities	O
.	O

Absent	O
or	O
greatly	O
diminished	O
type	O
I	O
aldosterone	O
receptors	O
in	O
peripheral	O
mononuclear	O
leucocytes	O
have	O
been	O
recently	O
demonstrated	O
and	O
explain	O
the	O
lack	O
of	O
response	O
to	O
mineralocorticoids	O
.	O

We	O
have	O
studied	O
the	O
mode	O
of	O
inheritance	O
in	O
eight	O
families	O
with	O
a	O
total	O
of	O
nine	O
patients	O
.	O

There	O
was	O
evidence	O
for	O
an	O
autosomal	O
recessive	O
form	O
of	O
inheritance	O
in	O
four	O
families	O
,	O
while	O
the	O
other	O
four	O
families	O
appeared	O
to	O
have	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
.	O

In	O
three	O
families	O
the	O
autosomal	O
recessive	O
form	O
was	O
characterized	O
by	O
normal	O
receptor	O
as	O
well	O
as	O
hormone	O
data	O
in	O
both	O
parents	O
,	O
while	O
in	O
one	O
family	O
receptor	O
levels	O
in	O
both	O
parents	O
were	O
greatly	O
reduced	O
,	O
but	O
hormone	O
levels	O
were	O
normal	O
.	O

In	O
the	O
four	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
transmission	O
there	O
was	O
always	O
one	O
parent	O
with	O
reduced	O
receptor	O
binding	O
in	O
peripheral	O
mononuclear	O
leucocytes	O
and	O
elevated	O
serum	O
hormone	O
levels	O
.	O

These	O
parents	O
were	O
entirely	O
asymptomatic	O
.	O

In	O
an	O
extended	O
family	O
we	O
were	O
able	O
to	O
study	O
an	O
aunt	O
and	O
her	O
newborn	O
daughter	O
,	O
who	O
were	O
both	O
also	O
biochemically	O
affected	O
but	O
clinically	O
asymptomatic	O
.	O

It	O
,	O
therefore	O
,	O
appears	O
that	O
this	O
dual	O
pattern	O
of	O
genetic	O
transmission	O
may	O
indicate	O
differing	O
genetic	O
defects	O
which	O
cause	O
the	O
same	O
clinical	O
picture	O
of	O
pseudohypoaldosteronism	O
.	O

Risk	O
factors	O
for	O
breast	O
recurrence	O
in	O
premenopausal	O
and	O
postmenopausal	O
patients	O
with	O
ductal	O
cancers	O
treated	O
by	O
conservation	O
therapy	O
.	O

Risk	O
factors	O
for	O
local	O
failure	O
were	O
evaluated	O
for	O
496	O
clinical	O
Stage	O
I	O
-	O
II	O
patients	O
with	O
infiltrating	O
ductal	O
carcinomas	O
(	O
median	O
follow	O
-	O
up	O
,	O
71	O
months	O
)	O
treated	O
by	O
conservative	O
surgery	O
and	O
radiotherapy	O
.	O

Monofactorial	O
analysis	O
identified	O
the	O
following	O
factors	O
to	O
be	O
correlated	O
with	O
increased	O
risk	O
:	O
moderate	O
/	O
marked	O
mononuclear	O
cell	O
reaction	O
(	O
MCR	O
)	O
,	O
high	O
histologic	O
grade	O
(	O
G	O
)	O
,	O
extensive	O
intraductal	O
component	O
(	O
EIC	O
)	O
,	O
tumor	O
necrosis	O
,	O
macroscopic	O
multiplicity	O
,	O
estrogen	O
receptor	O
negativity	O
,	O
anatomic	O
tumor	O
size	O
,	O
age	O
younger	O
than	O
40	O
years	O
,	O
and	O
vascular	O
invasion	O
.	O

Only	O
MCR	O
,	O
G	O
,	O
and	O
EIC	O
proved	O
significant	O
in	O
Cox	O
multivariate	O
analysis	O
.	O

These	O
risk	O
factors	O
were	O
highly	O
age	O
dependent	O
,	O
with	O
EIC	O
markedly	O
more	O
prevalent	O
in	O
women	O
younger	O
than	O
50	O
,	O
MCR	O
and	O
G	O
in	O
women	O
younger	O
than	O
40	O
.	O

Separate	O
Cox	O
analysis	O
for	O
premenopausal	O
patients	O
showed	O
that	O
MCR	O
/	O
EIC	O
determined	O
risk	O
independent	O
of	O
resection	O
margins	O
:	O
tumors	O
with	O
MCR	O
had	O
a	O
28	O
%	O
,	O
and	O
with	O
EIC	O
a	O
22	O
%	O
probability	O
of	O
recurring	O
locally	O
by	O
5	O
years	O
.	O

Premenopausal	O
patients	O
with	O
neither	O
risk	O
factor	O
had	O
a	O
very	O
low	O
failure	O
rate	O
(	O
2.6	O
%	O
at	O
5	O
years	O
)	O
,	O
regardless	O
of	O
age	O
.	O

For	O
postmenopausal	O
patients	O
risk	O
of	O
breast	O
recurrence	O
was	O
determined	O
both	O
by	O
adequacy	O
of	O
resection	O
margins	O
and	O
grade	O
,	O
with	O
a	O
high	O
local	O
failure	O
rate	O
for	O
patients	O
having	O
G3	O
tumors	O
with	O
positive	O
or	O
indeterminate	O
margins	O
(	O
31	O
%	O
at	O
5	O
years	O
)	O
.	O

The	O
authors	O
conclude	O
that	O
the	O
microscopic	O
examination	O
is	O
the	O
only	O
useful	O
tool	O
for	O
assessing	O
the	O
risk	O
of	O
local	O
failure	O
,	O
which	O
is	O
quite	O
low	O
for	O
the	O
majority	O
of	O
patients	O
treated	O
with	O
breast	O
conservation	O
.	O

High	O
-	O
risk	O
patients	O
can	O
be	O
recognized	O
morphologically	O
.	O

The	O
age	O
dependence	O
of	O
morphologic	O
risk	O
factors	O
appears	O
to	O
explain	O
the	O
high	O
local	O
failure	O
rate	O
seen	O
in	O
patients	O
younger	O
than	O
40	O
.	O

Human	O
immunodeficiency	O
virus	O
vpr	O
product	O
is	O
a	O
virion	O
-	O
associated	O
regulatory	O
protein	O
.	O

The	O
vpr	O
product	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
acts	O
in	O
trans	O
to	O
accelerate	O
virus	O
replication	O
and	O
cytopathic	O
effect	O
in	O
T	O
cells	O
.	O

Here	O
it	O
is	O
shown	O
that	O
the	O
HIV-1	O
viral	O
particle	O
contains	O
multiple	O
copies	O
of	O
the	O
vpr	O
protein	O
.	O

The	O
vpr	O
product	O
is	O
the	O
first	O
regulatory	O
protein	O
of	O
HIV-1	O
to	O
be	O
found	O
in	O
the	O
virus	O
particle	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
vpr	O
acts	O
to	O
facilitate	O
the	O
early	O
steps	O
of	O
infection	O
before	O
de	O
novo	O
viral	O
protein	O
synthesis	O
occurs	O
.	O

Steroid	O
dose	O
sparing	O
:	O
pharmacodynamic	O
responses	O
to	O
single	O
versus	O
divided	O
doses	O
of	O
methylprednisolone	O
in	O
man	O
.	O

Inhibitory	O
drug	O
interactions	O
affecting	O
the	O
metabolism	O
of	O
methylprednisolone	O
(	O
MP	O
)	O
may	O
produce	O
either	O
steroid	O
sparing	O
or	O
adverse	O
effects	O
partly	O
by	O
increasing	O
the	O
exposure	O
time	O
to	O
the	O
steroid	O
.	O

This	O
phenomenon	O
can	O
be	O
mimicked	O
by	O
administering	O
MP	O
in	O
divided	O
doses	O
.	O

Two	O
types	O
of	O
responses	O
were	O
compared	O
after	O
a	O
single	O
MP	O
dose	O
(	O
40	O
mg	O
bolus	O
)	O
and	O
a	O
divided	O
regimen	O
(	O
20	O
mg	O
bolus	O
and	O
a	O
5	O
mg	O
bolus	O
8	O
hours	O
later	O
)	O
in	O
six	O
healthy	O
male	O
volunteers	O
.	O

The	O
suppression	O
of	O
basophils	O
measured	O
as	O
whole	O
blood	O
histamine	O
and	O
plasma	O
cortisol	O
concentrations	O
was	O
assessed	O
during	O
32	O
hours	O
.	O

The	O
37.5	O
%	O
reduction	O
in	O
dose	O
produced	O
a	O
23	O
%	O
overall	O
decreased	O
blood	O
histamine	O
response	O
.	O

A	O
pharmacodynamic	O
model	O
for	O
basophil	O
cell	O
distribution	O
to	O
and	O
from	O
an	O
extravascular	O
compartment	O
describes	O
the	O
effects	O
of	O
MP	O
after	O
both	O
regimens	O
.	O

A	O
slower	O
initial	O
decline	O
in	O
blood	O
histamine	O
after	O
the	O
divided	O
regimen	O
may	O
be	O
related	O
to	O
incomplete	O
suppression	O
of	O
basophil	O
cell	O
return	O
to	O
blood	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
of	O
about	O
5	O
ng	O
/	O
ml	O
were	O
similar	O
for	O
both	O
regimens	O
.	O

The	O
decline	O
and	O
return	O
of	O
cortisol	O
concentrations	O
were	O
similar	O
between	O
MP	O
treatments	O
with	O
suppression	O
continuing	O
for	O
24	O
hours	O
.	O

The	O
50	O
%	O
inhibitory	O
concentrations	O
of	O
MP	O
values	O
for	O
adrenal	O
suppression	O
were	O
about	O
1	O
ng	O
/	O
ml	O
.	O

Pharmacodynamic	O
modeling	O
is	O
useful	O
in	O
quantitating	O
corticosteroid	O
responses	O
and	O
generally	O
predicted	O
the	O
`	O
`	O
dose	O
-	O
sparing	O
''	O
effects	O
that	O
were	O
achieved	O
by	O
prolonging	O
MP	O
plasma	O
concentrations	O
.	O

This	O
study	O
supports	O
previous	O
clinical	O
observations	O
that	O
patients	O
may	O
require	O
morning	O
through	O
evening	O
exposure	O
to	O
MP	O
to	O
optimize	O
efficacy	O
while	O
adrenal	O
suppression	O
is	O
being	O
minimized	O
.	O

The	O
internal	O
methionine	O
codons	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
II	O
rex	O
gene	O
are	O
not	O
required	O
for	O
p24rex	O
production	O
or	O
virus	O
replication	O
and	O
transformation	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
types	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
and	O
II	O
(	O
HTLV	O
-	O
II	O
)	O
have	O
two	O
nonstructural	O
trans	O
-	O
acting	O
regulatory	O
genes	O
,	O
tax	O
and	O
rex	O
,	O
located	O
in	O
the	O
3	O
'	O
region	O
of	O
the	O
viral	O
genome	O
.	O

The	O
tax	O
gene	O
product	O
(	O
HTLV	O
-	O
I	O
p40tax	O
and	O
HTLV	O
-	O
II	O
p37tax	O
)	O
is	O
the	O
transcriptional	O
activator	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
.	O

The	O
rex	O
gene	O
encodes	O
two	O
protein	O
products	O
,	O
p27rex	O
/	O
p21rex	O
and	O
p26rex	O
/	O
p24rex	O
in	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
,	O
respectively	O
.	O

Rex	O
acts	O
posttranscriptionally	O
to	O
facilitate	O
accumulation	O
of	O
full	O
-	O
length	O
gag	O
/	O
pol	O
and	O
singly	O
spliced	O
env	O
mRNA	O
in	O
the	O
cytoplasm	O
of	O
HTLV	O
-	O
infected	O
cells	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
first	O
ATG	O
of	O
the	O
rex	O
gene	O
is	O
critical	O
for	O
Rex	O
production	O
and	O
function	O
.	O

The	O
importance	O
of	O
the	O
internal	O
ATGs	O
to	O
Rex	O
function	O
is	O
not	O
known	O
.	O

However	O
,	O
in	O
vitro	O
mutagenesis	O
of	O
the	O
HTLV	O
-	O
I	O
rex	O
gene	O
has	O
provided	O
indirect	O
evidence	O
which	O
suggests	O
that	O
p21rex	O
,	O
and	O
by	O
analogy	O
HTLV	O
-	O
II	O
p24rex	O
,	O
results	O
from	O
initiation	O
at	O
an	O
internal	O
AUG	O
of	O
the	O
tax	O
/	O
rex	O
mRNA	O
.	O

By	O
using	O
an	O
infectious	O
molecular	O
clone	O
of	O
HTLV	O
-	O
II	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
the	O
internal	O
ATGs	O
of	O
the	O
rex	O
gene	O
on	O
Rex	O
protein	O
production	O
and	O
function	O
.	O

Our	O
results	O
indicate	O
that	O
p24rex	O
of	O
HTLV	O
-	O
II	O
is	O
not	O
initiated	O
at	O
an	O
internal	O
AUG	O
and	O
that	O
the	O
internal	O
methionine	O
codons	O
are	O
not	O
crucial	O
to	O
the	O
function	O
of	O
the	O
rex	O
gene	O
and	O
,	O
ultimately	O
,	O
the	O
transforming	O
properties	O
of	O
the	O
virus	O
.	O

[	O
Glucocorticoid	O
receptors	O
on	O
human	O
peripheral	O
mononuclear	O
and	O
polymorphonuclear	O
leucocytes	O
:	O
changes	O
in	O
patients	O
with	O
yang	O
-	O
deficiency	O
]	O

It	O
was	O
found	O
that	O
,	O
in	O
former	O
works	O
,	O
the	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
on	O
peripheral	O
mixed	O
leucocytes	O
in	O
patients	O
with	O
Yang	O
-	O
deficiency	O
were	O
decreased	O
.	O

In	O
this	O
work	O
,	O
the	O
mixed	O
leucocytes	O
were	O
further	O
separated	O
into	O
mononuclear	O
(	O
MNL	O
)	O
and	O
polymorphonuclear	O
(	O
PML	O
)	O
leucocytes	O
,	O
and	O
GCR	O
were	O
determined	O
in	O
each	O
part	O
of	O
leucocytes	O
.	O

GCR	O
on	O
MNL	O
and	O
PML	O
in	O
6	O
Yang	O
deficient	O
patients	O
were	O
3473	O
+	O
/-	O
413	O
and	O
4433	O
+	O
/-	O
651	O
sites	O
/	O
cell	O
respectively	O
,	O
statistically	O
significant	O
from	O
the	O
normal	O
control	O
group	O
(	O
4462	O
+	O
/-	O
962	O
and	O
5622	O
+	O
/-	O
782	O
sites	O
/	O
cell	O
respectively	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

GCR	O
on	O
MNL	O
,	O
PML	O
and	O
mixed	O
leucocytes	O
in	O
5	O
patients	O
were	O
determined	O
simultaneously	O
,	O
and	O
all	O
lowered	O
from	O
the	O
control	O
group	O
.	O

The	O
results	O
were	O
3369	O
+	O
/-	O
370	O
,	O
4986	O
+	O
/-	O
419	O
and	O
4524	O
+	O
/-	O
852	O
sites	O
/	O
cell	O
respectively	O
,	O
with	O
the	O
lowest	O
GCR	O
on	O
MNL	O
and	O
highest	O
on	O
PML	O
.	O

Type	O
-	O
II	O
estrogen	O
binding	O
sites	O
in	O
a	O
lymphoblastoid	B
cell	I
line	I
and	O
growth	O
-	O
inhibitory	O
effect	O
of	O
estrogen	O
,	O
anti	O
-	O
estrogen	O
and	O
bioflavonoids	O
.	O

Type	O
-	O
II	O
estrogen	O
-	O
binding	O
sites	O
(	O
type	O
-	O
II	O
EBS	O
)	O
have	O
been	O
demonstrated	O
in	O
the	O
human	B
lymphoblastoid	I
cell	I
line	I
IM-9	B
using	O
a	O
whole	O
-	O
cell	O
assay	O
with	O
(	O
6	O
,	O
7	O
-	O
3H	O
)	O
estradiol	O
(	O
3H	O
-	O
E2	O
)	O
as	O
tracer	O
.	O

Competition	O
analysis	O
showed	O
that	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
and	O
the	O
flavonoids	O
quercetin	O
and	O
rutin	O
competed	O
for	O
(	O
3H	O
)	O
-E2	O
binding	O
to	O
type	O
-	O
II	O
EBS	O
.	O

Growth	O
experiments	O
demonstrated	O
that	O
diethylstilbestrol	O
(	O
DES	O
)	O
tamoxifen	O
(	O
TAM	O
)	O
,	O
quercetin	O
and	O
rutin	O
exerted	O
a	O
reversible	O
dose	O
-	O
dependent	O
inhibition	O
of	O
cell	O
proliferation	O
in	O
the	O
range	O
of	O
concentrations	O
between	O
10	O
nM	O
and	O
10	O
microM	O
.	O

The	O
relative	O
binding	O
affinity	O
of	O
quercetin	O
,	O
rutin	O
,	O
DES	O
and	O
TAM	O
for	O
type	O
-	O
II	O
EBS	O
correlated	O
well	O
with	O
their	O
potency	O
as	O
cell	O
growth	O
inhibitors	O
.	O

Moreover	O
,	O
hesperidin	O
,	O
a	O
flavonoid	O
which	O
does	O
not	O
bind	O
to	O
type	O
-	O
II	O
EBS	O
,	O
was	O
ineffective	O
in	O
inhibiting	O
cell	O
growth	O
.	O

Cell	O
-	O
cycle	O
analysis	O
showed	O
that	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
DES	O
,	O
TAM	O
or	O
quercetin	O
was	O
due	O
to	O
a	O
blocking	O
effect	O
in	O
the	O
G0-G1	O
phases	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
estrogen	O
and	O
anti	O
-	O
estrogen	O
concentrations	O
and	O
flavonoids	O
may	O
regulate	O
IM-9	B
cell	O
growth	O
through	O
a	O
common	O
mechanism	O
involving	O
a	O
binding	O
interaction	O
with	O
type	O
-	O
II	O
EBS	O
.	O

Synthesis	O
of	O
4	O
,	O
19-disubstituted	O
derivatives	O
of	O
DOC	O
.	O

Radioreceptor	O
assay	O
of	O
some	O
corticosteroid	O
derivatives	O
in	O
human	O
mononuclear	O
leukocytes	O
.	O

Several	O
new	O
4	O
,	O
19-substituted	O
steroids	O
and	O
previously	O
synthesized	O
corticosteroids	O
were	O
assayed	O
for	O
affinity	O
to	O
type	O
1	O
receptors	O
in	O
human	O
mononuclear	O
leukocytes	O
.	O

11	O
beta	O
,	O
19-epoxy-4	O
,	O
21-dihydroxypregn-4-ene-3	O
,	O
20-dione	O
(	O
2	O
)	O
was	O
hydrogenated	O
with	O
Pd	O
-	O
C	O
to	O
yield	O
a	O
mixture	O
of	O
all	O
four	O
dihydro	O
derivatives	O
5	O
,	O
accompanied	O
by	O
4	O
,	O
21-diacetoxy-11	O
beta	O
,	O
19-epoxy-3-hydroxypregnan-20-one	O
(	O
6	O
)	O
and	O
21-acetoxy-11	O
beta	O
,	O
19-epoxy-4-hydroxypregnane-3	O
,	O
20-dione	O
(	O
7	O
)	O
.	O

With	O
hot	O
acetic	O
+	O
p	O
-	O
toluenesulfonic	O
acid	O
5	O
underwent	O
rearrangement	O
to	O
21-acetoxy-11	O
beta	O
,	O
19-epoxypregn-5-ene-4	O
,	O
20-dione	O
(	O
8	O
)	O
Pd	O
-	O
C	O
hydrogenation	O
of	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregna-2	O
,	O
9	O
(	O
11	O
)	O
-diene-4	O
,	O
20-dione	O
(	O
10	O
)	O
gave	O
3	O
,	O
21-diacetoxy-5	O
beta	O
,	O
19-cyclopregn-5-ene-4	O
,	O
20-dione	O
(	O
11	O
)	O
and	O
the	O
9	O
,	O
11-dihydro	O
derivative	O
of	O
the	O
latter	O
.	O

Treatment	O
of	O
10	O
with	O
warm	O
HCl	O
furnished	O
19-chloro-4	O
,	O
21-dihydroxypregna-4	O
,	O
9	O
(	O
11	O
)	O
-diene-3	O
,	O
20-dione	O
(	O
13	O
)	O
.	O

Pd	O
-	O
C	O
hydrogenation	O
of	O
its	O
diacetate	O
14	O
afforded	O
the	O
4	O
,	O
5-dihydro	O
derivative	O
18	O
,	O
19-chloro-21-acetoxypregn-9	O
(	O
11	O
)	O
-en-20-one	O
(	O
15	O
)	O
,	O
its	O
4-acetoxy	O
derivative	O
16	O
and	O
the	O
3	O
,	O
4-diacetoxy	O
derivative	O
17	O
.	O

When	O
tested	O
in	O
a	O
radioreceptor	O
assay	O
in	O
human	O
mononuclear	O
leukocytes	O
the	O
synthesized	O
compounds	O
showed	O
only	O
low	O
relative	O
binding	O
affinities	O
(	O
RBA	O
)	O
to	O
type	O
1	O
receptor	O
,	O
the	O
highest	O
being	O
0.72	O
%	O
for	O
13	O
(	O
aldosterone	O
=	O
100	O
%	O
)	O
.	O

For	O
comparison	O
,	O
other	O
RBA	O
in	O
this	O
system	O
were	O
:	O
19-noraldosterone	O
,	O
20	O
%	O
;	O
18-deoxyaldosterone	O
,	O
5.8	O
%	O
;	O
18-deoxy-19-noraldosterone	O
,	O
4.7	O
%	O
;	O
18	O
,	O
21-anhydroaldosterone	O
,	O
0.37	O
%	O
;	O
17-isoaldosterone	O
,	O
7.6	O
%	O
and	O
apoaldosterone	O
,	O
4.3	O
%	O

Specific	O
depletion	O
of	O
the	O
B	B
-	I
cell	I
population	I
induced	O
by	O
aberrant	O
expression	O
of	O
human	O
interferon	O
regulatory	O
factor	O
1	O
gene	O
in	O
transgenic	O
mice	O
.	O

Interferons	O
(	O
IFNs	O
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	O
proteins	O
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	O
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	O
factor	O
,	O
IRF-1	O
(	O
interferon	O
regulatory	O
factor	O
1	O
)	O
,	O
which	O
binds	O
to	O
type	O
I	O
IFN	O
and	O
some	O
IFN	O
-	O
inducible	O
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	O
gene	O
is	O
both	O
virus	O
and	O
IFN	O
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	O
gene	O
is	O
functioning	O
in	O
IFN	O
-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	O
IRF-1	O
gene	O
linked	O
to	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B	O
-	O
cell	O
population	O
.	O

In	O
fact	O
,	O
transgenic	B
bone	I
marrow	I
cells	I
cocultured	O
with	O
a	O
bone	B
marrow	I
-	I
derived	I
stromal	I
cell	I
line	I
revealed	O
an	O
altered	O
B	O
-	O
cell	O
maturation	O
pattern	O
.	O

Functional	O
analysis	O
of	O
cis	O
-	O
linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	O
proteins	O
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA	O
-	O
DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell	O
-	O
specific	O
transcription	O
.	O

This	O
`	O
`	O
octamer	O
`	O
`	O
in	O
the	O
context	O
of	O
DRA	O
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	O
(	O
OTF-1	O
)	O
and	O
lymphoid	O
-	O
specific	O
(	O
OTF-2	O
)	O
`	O
`	O
octamer	O
''	O
binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
`	O
`	O
octamer	O
''	O
complex	O
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis	O
-	O
acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	B
II	I
-	I
negative	I
HeLa	I
cells	I
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	O
the	O
Y	O
box	O
,	O
but	O
retained	O
the	O
`	O
`	O
octamer	O
''	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	O
linear	O
templates	O
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	O
or	O
disrupting	O
the	O
X	O
consensus	O
element	O
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
`	O
`	O
octamer	O
''	O
does	O
not	O
utilize	O
OTF-2	O
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Inhibition	O
of	O
protein	O
phosphatases	O
by	O
okadaic	O
acid	O
induces	O
AP1	O
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	O
phosphatases	O
in	O
T	O
cell	O
activation	O
,	O
Jurkat	B
cells	I
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
phosphatases	O
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	O
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	O
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto	O
-	O
oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	O
further	O
enhanced	O
the	O
induction	O
of	O
AP1	O
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto	O
-	O
oncogenes	O
including	O
c	O
-	O
jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c	O
-	O
fos	O
and	O
fra-1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	B
cells	I
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c	O
-	O
jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c	O
-	O
jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c	O
-	O
jun	O
transcription	O
.	O

The	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	O
phosphatases	O
1	O
and	O
2A	O
(	O
PP1	O
and	O
PP2A	O
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	O
factor	O
AP1	O
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T	O
-	O
cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T	O
-	O
cell	O
-	O
specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T	O
-	O
cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T	O
-	O
cell	O
phenotype	O
by	O
functioning	O
as	O
'	O
master	O
regulators	O
of	O
T	O
-	O
cell	O
differentiation	O
'	O
.	O

HTLV-1	O
Tax	O
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
T	B
-	I
cell	I
lines	I
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	O
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	O
proteins	O
,	O
c	O
-	O
Fos	O
,	O
Fra-1	O
,	O
c	O
-	O
Jun	O
,	O
JunB	O
,	O
and	O
JunD	O
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	O
.	O

By	O
using	O
the	O
human	B
T	I
-	I
cell	I
line	I
(	O
JPX-9	B
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	O
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	O
,	O
c	O
-	O
Jun	O
,	O
and	O
JunD	O
was	O
also	O
transactivated	O
by	O
Tax1	O
.	O

Moreover	O
,	O
Tax1	O
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	O
finger	O
motifs	O
,	O
Egr-1	O
and	O
Egr-2	O
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	O
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	O
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	O
difference	O
in	O
glucocorticoid	O
receptor	O
number	O
or	O
affinity	O
between	O
depressed	O
patients	O
and	O
recovered	O
or	O
control	O
subjects	O
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
three	O
groups	O
.	O

No	O
relationship	O
could	O
be	O
established	O
between	O
glucocorticoid	O
receptor	O
binding	O
and	O
antidepressant	O
medication	O
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand	O
-	O
induced	O
plasticity	O
of	O
glucocorticoid	O
receptor	O
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	O
receptor	O
numbers	O
during	O
depression	O
.	O

Glucocorticoid	O
receptors	O
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age	O
-	O
related	O
decrease	O
in	O
the	O
number	O
of	O
GR	O
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O
there	O
was	O
no	O
apparent	O
seasonal	O
variation	O
in	O
GR	O
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	O
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	O
.	O

Eight	O
patients	O
with	O
dermatomyositis	O
/	O
polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	O
in	O
MNL	O
could	O
be	O
down	O
-	O
regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	O
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	O
in	O
MNL	O
did	O
not	O
demonstrate	O
circadian	O
variation	O
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0	O
/	O
G1	O
switch	O
gene	O
containing	O
a	O
CpG	O
-	O
rich	O
island	O
encodes	O
a	O
small	O
basic	O
protein	O
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
(	O
G0S	O
genes	O
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin	O
-induced	O
switch	O
of	O
lymphocytes	O
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	O
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	O
genes	O
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	O
mRNA	O
increases	O
transiently	O
within	O
1	O
-	O
2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	O
or	O
cycloheximide	O
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full	O
-	O
length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino	O
-	O
acid	O
basic	O
protein	O
has	O
two	O
potential	O
alpha	O
-	O
helical	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
region	O
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta	O
-	O
sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0	O
/	O
G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	O
kinase	O
C	O
and	O
casein	O
kinase	O
II	O
.	O

The	O
gene	O
contains	O
a	O
CpG	O
-	O
rich	O
island	O
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19	O
/	O
(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	O
sites	O
for	O
CCAAT	O
-	O
box	O
binding	O
factors	O
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	O
sites	O
for	O
transcription	O
factors	O
AP1	O
,	O
AP2	O
,	O
and	O
AP3	O
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	O
receptor	O
alpha	O
chain	O
in	O
somatic	B
cell	I
hybrids	I
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
two	O
nuclear	O
proteins	O
NF	O
-	O
kappa	O
B	O
(	O
consisting	O
of	O
subunits	O
p50	O
an	O
dp65	O
)	O
and	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	O
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	B
T	I
-	I
cell	I
line	I
IARC	B
301.5	I
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	B
301.5	I
and	O
a	O
murine	B
myeloma	I
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	O
and	O
NF	O
-	O
kappa	O
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	O
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	B
expressing	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	O
by	O
itself	O
is	O
not	O
sufficient	O
.	O

We	O
propose	O
that	O
KBF1	O
is	O
a	O
competitive	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	O
and	O
IL-2	O
alpha	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Binding	O
of	O
erythroid	O
and	O
non	O
-	O
erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin	O
-	O
encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-392	O
to	O
-177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
86	O
(	O
1989	O
)	O
5306	O
-	O
5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	B
cells	I
,	O
as	O
compared	O
to	O
K562	B
human	I
erythroleukemia	I
cells	I
.	O

Using	O
deletion	O
mutants	O
and	O
cis	O
-	O
cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	O
to	O
-251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	O
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	B
and	O
K562	B
cells	I
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	B
cells	I
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon	O
-	O
globin	O
-	O
encoding	O
gene	O
in	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
are	O
discussed	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
in	O
man	O
:	O
relationship	O
to	O
glucocorticoid	O
receptors	O
.	O

Interrelations	O
between	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
(	O
HPA	O
)	O
and	O
the	O
immune	O
system	O
represent	O
a	O
well	O
-	O
documented	O
biological	O
phenomenon	O
.	O

While	O
in	O
vitro	O
administration	O
of	O
glucocorticoids	O
may	O
inhibit	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
-	O
and	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
T	O
-	O
cell	O
proliferation	O
,	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
-driven	O
B	O
-	O
cell	O
mitogenesis	O
is	O
relatively	O
resistant	O
to	O
glucocorticoids	O
.	O

To	O
further	O
explore	O
the	O
link	O
between	O
the	O
HPA	O
and	O
the	O
immune	O
system	O
in	O
relation	O
to	O
glucocorticoid	O
receptor	O
function	O
,	O
dose	O
-	O
response	O
curves	O
were	O
obtained	O
for	O
Con	O
A	O
-and	O
PHA	O
-induced	O
T	O
-	O
cell	O
mitogenesis	O
,	O
PWM	O
-generated	O
B	O
-	O
cell	O
mitogenesis	O
and	O
spontaneous	O
lymphocyte	O
proliferation	O
in	O
13	O
healthy	O
controls	O
.	O

Glucocorticoid	O
effects	O
were	O
assessed	O
in	O
vivo	O
by	O
depletion	O
of	O
endogenous	O
glucocorticoids	O
after	O
oral	O
administration	O
of	O
1.5	O
g	O
metyrapone	O
(	O
MET	O
)	O
and	O
subsequent	O
glucocorticoid	O
replacement	O
,	O
and	O
in	O
vitro	O
by	O
incubation	O
of	O
the	O
cells	O
with	O
different	O
doses	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
PWM	O
-induced	O
B	O
-	O
cell	O
mitogenesis	O
and	O
a	O
more	O
pronounced	O
effect	O
of	O
DEX	O
administered	O
in	O
vitro	O
on	O
spontaneous	O
lymphocyte	O
proliferation	O
after	O
MET	O
treatment	O
when	O
compared	O
with	O
the	O
DEX	O
plus	O
MET	O
pretreated	O
condition	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
spontaneous	O
lymphocyte	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
is	O
related	O
to	O
glucocorticoid	O
receptor	O
function	O
.	O

The	O
decrease	O
in	O
PWM	O
-generated	O
B	O
-	O
cell	O
proliferation	O
following	O
cortisol	O
depletion	O
by	O
MET	O
may	O
be	O
seen	O
in	O
connection	O
with	O
impaired	O
glucocorticoid	O
-	O
mediated	O
induction	O
of	O
interleukin-1	O
receptor	O
synthesis	O
.	O

Leukotriene	O
B4	O
stimulates	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
transcription	O
and	O
AP-1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	O
of	O
the	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP-1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
gene	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
c	O
-	O
jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral	O
-	O
blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c	O
-	O
fos	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c	O
-	O
fos	O
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c	O
-	O
jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
was	O
not	O
affected	O
by	O
LTB4	O
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
7-fold	O
and	O
the	O
c	O
-	O
jun	O
gene	O
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP-1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1	O
-binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	O
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	O
factors	O
such	O
as	O
AP-1	O
-binding	O
proto	O
-	O
oncogene	O
products	O
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	O
D	O
receptor	O
in	O
human	B
HL60	I
leukemia	I
cells	I
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA	O
-	O
relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	O
affinity	O
receptors	O
(	O
VDR	O
)	O
for	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	B
cells	I
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	B
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	O
/	O
VDR	O
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(	O
-9	O
)	O
M	O
/	O
l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol	O
/	O
VDR	O
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites	O
/	O
nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	B
cells	I
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites	O
/	O
nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	B
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	O
serum	O
and	O
calcitriol	O
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	O
radiolabeled	O
VDR	O
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	O
by	O
24	O
h	O
.	O

Radiolabeled	O
VDR	O
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse	O
/	O
chase	O
-	O
experiments	O
)	O
.	O

No	O
difference	O
of	O
VDR	O
retention	O
in	O
pulse	O
and	O
pulse	O
/	O
chase	O
-	O
experiments	O
was	O
seen	O
in	O
PBL	O
,	O
where	O
VDR	O
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	O
specific	O
translocation	O
into	O
the	O
nuclear	O
compartment	O
was	O
seen	O
when	O
isolated	O
nuclei	O
were	O
incubated	O
in	O
[	O
3H	O
]	O
calcitriol	O
.	O

Radiolabeled	O
hormone	O
/	O
receptor	O
complexes	O
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	O
disappear	O
from	O
the	O
nuclear	O
compartment	O
upon	O
incubation	O
of	O
nuclei	O
with	O
identical	O
concentrations	O
of	O
the	O
unlabeled	O
compound	O
.	O

The	O
activity	O
of	O
DNA	O
relaxing	O
enzymes	O
(	O
e.g	O
.	O
topoisomerases	O
I	O
and	O
II	O
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation	O
-	O
assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v	O
/	O
v	O
)	O
in	O
HL60	B
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	B
.	O

No	O
effect	O
was	O
seen	O
in	O
ethanol	B
treated	I
controls	I
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	O
proteins	O
after	O
hormone	O
binding	O
.	O

Translocated	O
hormone	O
/	O
receptor	O
complexes	O
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	O
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	O
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA	O
-	O
unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

Specific	O
NF	O
-	O
kappa	O
B	O
subunits	O
act	O
in	O
concert	O
with	O
Tat	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
protein	O
complex	O
which	O
functions	O
in	O
concert	O
with	O
the	O
tat	O
-	O
I	O
gene	O
product	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF	O
-	O
kappa	O
B	O
subunits	O
to	O
act	O
with	O
Tat	O
-	O
I	O
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	O
(	O
100	O
)	O
DNA	O
binding	O
subunit	O
,	O
together	O
with	O
p65	O
,	O
can	O
act	O
in	O
concert	O
with	O
Tat	O
-	O
I	O
to	O
stimulate	O
the	O
expression	O
of	O
HIV	O
-	O
CAT	O
plasmid	O
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	O
forms	O
of	O
p105	O
NF	O
-	O
kappa	O
B	O
or	O
rel	O
,	O
in	O
combination	O
with	O
p65	O
or	O
full	O
-	O
length	O
c	O
-	O
rel	O
,	O
which	O
do	O
not	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
these	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	O
(	O
100	O
)	O
and	O
p65	O
NF	O
-	O
kappa	O
B	O
can	O
act	O
in	O
concert	O
with	O
the	O
tat	O
-	O
I	O
gene	O
product	O
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type	O
-	O
specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	B
cells	I
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer	O
/	O
promoter	O
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	O
kappa	O
enhancer	O
(	O
or	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	O
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer	O
/	O
promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility	O
/	O
cell	O
type	O
specificity	O
.	O

Oct2	O
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B	O
-	O
cell	O
-	O
restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte	O
-	O
specific	O
transcription	O
factor	O
Oct2	O
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	O
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	O
octamer	O
enhancer	O
element	O
in	O
HeLa	B
cells	I
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	O
isoforms	O
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B	B
-	I
cell	I
line	I
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	O
isoforms	O
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B	O
-	O
cell	O
-	O
specific	O
cofactor	O
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	O
or	O
the	O
Oct2	O
protein	O
in	O
Oct2	O
-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy	O
-	O
terminal	O
domain	O
of	O
Oct2	O
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	O
protein	O
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine	O
-	O
rich	O
activation	O
domain	O
present	O
in	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Oct2	O
and	O
the	O
POU	O
domain	O
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

TAR	O
-independent	O
transactivation	O
by	O
Tat	O
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	O
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	O
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS	B
-	I
derived	I
cells	I
Tat	O
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR	O
-independent	O
pathway	O
.	O

A	O
Tat	O
-	O
responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial	B
-	I
derived	I
cell	I
lines	I
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat	O
-	O
responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV-1	O
enhancer	O
,	O
or	O
NF	O
-	O
kappa	O
B	O
domain	O
.	O

DNA	O
band	O
-	O
shift	O
analysis	O
reveals	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR	O
-	O
deleted	O
mutants	O
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	O
p24	O
antigen	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Natural	O
variants	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG	O
-	O
motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	O
positive	O
effect	O
of	O
the	O
duplicated	O
CTG	O
-	O
motif	O
could	O
be	O
detected	O
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild	O
-	O
type	O
plasmid	O
were	O
cotransfected	O
into	O
T	O
-	O
cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG	O
-	O
monomer	O
virus	O
outcompeted	O
the	O
CTG	O
-	O
dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5	O
-	O
10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation	O
-	O
induced	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein	O
-	O
tyrosine	O
kinase	O
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B	O
-	O
lymphocyte	O
precursors	O
,	O
irradiation	O
with	O
gamma	O
-	O
rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine	O
-	O
specific	O
protein	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

All	O
of	O
the	O
radiation	O
-	O
induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein	O
-	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
cascade	O
in	O
human	O
B	O
-	O
lymphocyte	O
precursors	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation	O
-	O
induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
Egr-1	O
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	B
leukemia	I
HL-60	I
cells	I
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

The	O
Egr-1	O
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	B
cells	I
,	O
but	O
active	O
in	O
U-937	B
and	O
M1	B
cells	I
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	O
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	B
leukemia	I
cell	I
lines	I
and	O
normal	O
myeloblasts	O
.	O

HL-60	B
cells	I
constitutively	O
expressing	O
an	O
Egr-1	O
transgene	O
(	O
HL-60Egr-1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	O
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	O
to	O
-130	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	O
and	O
-130	O
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	O
transcriptional	O
activity	O
in	O
a	O
T	B
-	I
cell	I
line	I
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65	O
:	O
2436	O
-	O
2444	O
,	O
1991	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	O
to	O
-	O
184	O
,	O
-183	O
to	O
-166	O
,	O
-165	O
to	O
-148	O
,	O
and	O
-148	O
to	O
-130	O
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	B
RD	I
cells	I
with	O
CEMx174	B
cells	I
.	O

In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	O
and	O
-76	O
and	O
between	O
-75	O
and	O
-58	O
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
-	O
and	O
Sp1-binding	O
sites	O
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Three	O
mutants	O
(	O
-201	O
/	O
-184	O
NXS	O
,	O
-165	O
/	O
-148	O
NXS	O
,	O
and	O
-147	O
/	O
-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	O
effects	O
of	O
two	O
LS	O
mutations	O
(	O
-201	O
/	O
-184	O
NXS	O
and	O
-183	O
/	O
-166	O
NXS	O
)	O
were	O
not	O
predicted	O
by	O
their	O
effects	O
in	O
transfection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type	O
-	O
specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF	O
-	O
kappa	O
B	O
and	O
SP1-binding	O
sites	O
but	O
also	O
for	O
several	O
regions	O
between	O
-201	O
and	O
-130	O
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Human	O
CD4	O
lymphocytes	O
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	O
protein	O
pml	O
/	O
RAR	O
alpha	O
present	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	O
cells	O
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	O
point	O
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1	O
/	O
25	O
)	O
encompassing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	O
molecule	O
pml	O
/	O
RAR	O
alpha	O
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
recognized	O
by	O
human	O
T	O
lymphocytes	O
in	O
vitro	O
.	O

CD4	O
+	O
lymphocytes	O
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1	O
/	O
25	O
in	O
an	O
HLA	O
-	O
DR	O
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
or	O
by	O
APC	O
expressing	O
the	O
HLA	O
-	O
DR11	O
restricting	O
molecule	O
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	O
and	O
RAR	O
alpha	O
proteins	O
were	O
not	O
recognized	O
.	O

One	O
clone	O
(	O
DEG5	B
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B
cells	I
pulsed	O
with	O
BCR1	O
/	O
25	O
.	O

The	O
autologous	B
DE	I
LCL	I
containing	O
a	O
transduced	O
pml	O
/	O
RAR	O
alpha	O
fusion	O
gene	O
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml	O
/	O
RAR	O
alpha	O
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	B
anti	I
-	I
BCR1	I
/	I
25	I
T	I
cell	I
clones	I
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	O
type	O
-	O
pml	O
/	O
RAR	O
alpha	O
fusion	O
protein	O
of	O
APL	B
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	B
CD4	I
+	I
lymphocytes	I
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid	O
-	O
specific	O
promoter	O
.	O

Mammal	O
pyruvate	O
kinases	O
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	O
the	O
erythroid	O
(	O
R	O
-	O
PK	O
)	O
or	O
the	O
hepatic	O
(	O
L	O
-	O
PK	O
)	O
isozymes	O
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	O
and	O
trans	O
-	O
acting	O
elements	O
involved	O
in	O
the	O
tissue	O
-	O
specific	O
activity	O
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R	O
-	O
PK	O
DNA	O
fragment	O
extending	O
from	O
-870	O
to	O
+	O
54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-62	O
to	O
+	O
54	O
)	O
that	O
displays	O
erythroid	O
-	O
specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC	O
/	O
Sp1	O
family	O
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	O
factor	O
GATA-1	O
.	O

Although	O
the	O
-20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	O
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC	O
/	O
Sp1	O
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
this	O
R	O
-	O
PK	O
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co	O
-	O
transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R	O
-	O
PK	O
promoter	O
in	O
HeLa	B
cells	I
.	O

Cell	O
type-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
the	O
CD20	O
/	O
B1	O
antigen	O
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	O
(	O
B1	O
)	O
gene	O
encodes	O
a	O
B	O
cell	O
-	O
specific	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	O
promoter	O
-	O
CAT	O
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	O
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	O
in	O
pre	O
-	O
B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter	O
-	O
CAT	O
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA	O
-	O
rich	O
sequence	O
present	O
in	O
the	O
CD21	O
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	O
proteins	O
suggesting	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct-1	O
and	O
Oct-2	O
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
confirmed	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct-1	O
and	O
Oct-2	O
.	O

The	O
affinity	O
of	O
the	O
BAT	O
box	O
binding	O
proteins	O
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	O
box	O
binding	O
proteins	O
dissociated	O
from	O
the	O
BAT	O
box	O
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	O
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	B
cells	I
.	O

The	O
BAT	O
box	O
and	O
Oct-2	O
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	O
in	O
the	O
pre	B
-	I
B	I
cell	I
line	I
,	O
PB-697	B
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	O
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	O
mRNA	O
and	O
a	O
BAT	O
box	O
-	O
deleted	O
CD20-CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	O
and	O
perhaps	O
CD21	O
.	O

NF	O
-	O
kappa	O
B	O
controls	O
expression	O
of	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
.	O

Phorbol	O
ester	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
induction	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	O
kappa	O
B	O
alpha	O
and	O
the	O
activation	O
of	O
I	O
kappa	O
B	O
alpha	O
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65-kilodalton	O
transactivating	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
with	O
p65	O
restores	O
intracellular	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF	O
-	O
kappa	O
B	O
controls	O
the	O
expression	O
of	O
I	O
kappa	O
B	O
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	B
B	I
-	I
cells	I
.	O

Lytic	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

Two	O
stable	O
B	B
cell	I
lines	I
were	O
established	O
:	O
R59Z	B
activator	I
cells	I
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	O
1	O
trans	O
-	O
activator	O
(	O
Zta	O
)	O
.	O

R7	B
-	I
57	I
reporter	I
cells	I
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	O
origin	O
of	O
EBV	O
replication	O
(	O
ori	O
Lyt	O
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans	O
-	O
activation	O
converted	O
the	O
recombinant	O
ori	O
Lyt	O
element	O
in	O
R7	B
-	I
57	I
reporter	I
cells	I
.	O

BZLF	O
1	O
,	O
transiently	O
expressed	O
in	O
R7	B
-	I
57	I
reporter	I
cells	I
,	O
was	O
the	O
only	O
EBV	O
trans	O
-	O
activator	O
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans	O
-	O
cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	O
1-expressing	O
R59Z	O
activator	O
cells	O
with	O
the	O
R7	B
-	I
57	I
reporter	I
line	I
.	O

No	O
lytic	O
effect	O
on	O
the	O
reporter	O
cells	O
could	O
be	O
measured	O
,	O
neither	O
by	O
cocultivation	O
of	O
activator	B
cells	I
nor	O
by	O
coincubation	O
of	O
BZLF	O
1	O
-containing	O
cell	O
lysates	O
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	B
to	O
reporter	B
cells	I
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	O
gene	O
BZLF	O
1	O

Immobilization	O
and	O
recovery	O
of	O
fusion	O
proteins	O
and	O
B	O
-	O
lymphocyte	O
cells	O
using	O
magnetic	O
separation	O
.	O

A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	O
proteins	O
and	O
selected	O
human	O
B	O
lymphocytes	O
has	O
been	O
developed	O
.	O

Using	O
magnetic	O
beads	O
with	O
attached	O
DNA	O
containing	O
the	O
Escherichia	O
coli	O
lac	O
operator	O
,	O
fusion	O
proteins	O
comprising	O
the	O
DNA	O
-	O
binding	O
lac	O
repressor	O
could	O
be	O
affinity	O
-	O
purified	O
and	O
recovered	O
by	O
gentle	O
elution	O
conditions	O
,	O
such	O
as	O
with	O
a	O
lactose	O
analogue	O
or	O
by	O
enzymatic	O
means	O
using	O
either	O
deoxyribonuclease	O
(	O
DNase	O
)	O
or	O
restriction	O
endonucleases	O
.	O

The	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
DNA	O
-	O
binding	O
protein	O
can	O
be	O
used	O
for	O
affinity	O
purification	O
of	O
fusion	O
proteins	O
as	O
exemplified	O
by	O
the	O
specific	O
and	O
gentle	O
recovery	O
of	O
beta	O
-	O
galactosidase	O
and	O
alkaline	O
phosphatase	O
from	O
bacterial	O
lysates	O
using	O
immunomagnetic	O
separation	O
.	O

The	O
approach	O
was	O
further	O
extended	O
to	O
cell	O
separation	O
by	O
the	O
efficient	O
recovery	O
and	O
elution	O
of	O
human	B
CD37	I
B	I
lymphocytes	I
from	O
peripheral	O
blood	O
.	O

[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	O
]	O

Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	O
biology	O
since	O
genes	O
association	O
with	O
eosinophils	O
such	O
as	O
interleukin-5	O
or	O
eosinophil	O
granule	O
proteins	O
(	O
EPO	O
,	O
ECP	O
,	O
EDN	O
,	O
MBP	O
,	O
and	O
CLC	O
)	O
,	O
were	O
isolated	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
commitment	O
of	O
progenitors	O
to	O
the	O
eosinophil	O
lineage	O
has	O
not	O
been	O
determined	O
.	O

The	O
mechanism	O
by	O
which	O
eosinophil	O
-	O
specific	O
genes	O
encoding	O
primary	O
and	O
secondary	O
granule	O
proteins	O
(	O
e.g	O
.	O
ECP	O
,	O
EDN	O
,	O
EPO	O
,	O
MBP	O
,	O
and	O
CLC	O
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
I	O
described	O
the	O
characterization	O
of	O
genes	O
encoding	O
eosinophil	O
granule	O
proteins	O
and	O
the	O
mRNA	O
expression	O
of	O
GATA-1	O
binding	O
transcription	O
factor	O
during	O
eosinophil	O
differentiation	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	O
and	O
activation	O
of	O
c	O
-	O
Rel	O
and	O
related	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
human	B
monocytic	I
THP-1	I
cells	I
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA	O
-	O
binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
transcription	O
factor	O
family	O
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS	O
-	O
generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c	O
-	O
Rel	O
/	O
p50	O
heterodimers	O
as	O
well	O
as	O
p50	O
/	O
p65	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
kappa	O
B	O
DNA	O
-	O
binding	O
complexes	O
in	O
human	B
monocytic	I
THP-1	I
cells	I
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	O
ester	O
-	O
sensitive	O
protein	O
kinase	O
C	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c	O
-	O
Rel	O
,	O
p105	O
,	O
and	O
p50	O
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP-1	B
cells	I
.	O

LPS	O
activation	O
of	O
THP-1	B
cells	I
resulted	O
in	O
phosphorylation	O
of	O
MAD3	O
(	O
an	O
I	O
kappa	O
B	O
-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	O
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	O
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c	O
-	O
Rel	O
/	O
p50	O
and	O
p50	O
/	O
p65	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	O
.	O

Regulation	O
of	O
lymphoid	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
enhancer	O
by	O
ETS	O
-	O
domain	O
proteins	O
.	O

The	O
enhancer	O
for	O
the	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
(	O
IgH	O
)	O
activates	O
a	O
heterologous	O
gene	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
of	O
B	O
lymphocyte	O
differentiation	O
.	O

A	O
lymphoid	O
-	O
specific	O
element	O
,	O
microB	O
,	O
is	O
necessary	O
for	O
enhancer	O
function	O
in	O
pre	O
-	O
B	O
cells	O
.	O

A	O
microB	O
binding	O
protein	O
is	O
encoded	O
by	O
the	O
PU.1	O
/	O
Spi-1	O
proto	O
-	O
oncogene	O
.	O

Another	O
sequence	O
element	O
,	O
microA	O
,	O
was	O
identified	O
in	O
the	O
mu	O
enhancer	O
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	O
proto	O
-	O
oncogene	O
.	O

The	O
microA	O
motif	O
was	O
required	O
for	O
microB	O
-	O
dependent	O
enhancer	O
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	O
B	O
cell	O
-	O
specific	O
enhancer	O
is	O
composed	O
of	O
both	O
the	O
PU.1	O
and	O
Ets-1	O
binding	O
sites	O
.	O

Co	O
-	O
expression	O
of	O
both	O
PU.1	O
and	O
Ets-1	O
in	O
nonlymphoid	O
cells	O
trans	O
-	O
activated	O
reporter	O
plasmids	O
that	O
contained	O
the	O
minimal	O
mu	O
enhancer	O
.	O

These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	O
family	O
in	O
the	O
activation	O
of	O
IgH	O
gene	O
expression	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
-	O
transduction	O
pathway	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
receptor	O
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second	O
-	O
messenger	O
Ca2	O
+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL-2	O
,	O
among	O
which	O
are	O
calmodulin	O
,	O
calcineurin	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
.	O

Hence	O
,	O
Ca2	O
+	O
binds	O
to	O
calmodulin	O
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	O
to	O
calcineurin	O
;	O
the	O
activated	O
calcineurin	O
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	O
subunit	O
of	O
NF	O
-	O
AT	O
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	O
transcriptional	O
activator	O
.	O

As	O
described	O
by	O
Jun	O
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	O
directly	O
intercept	O
intracellular	O
signalling	O
molecules	O
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	O
receptors	O
called	O
immunophilins	O
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin	O
-	O
drug	O
complexes	O
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
.	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	O
factors	O
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	O
factors	O
(	O
MyoD	O
,	O
myogenin	O
,	O
myf5	O
,	O
and	O
myf6	O
)	O
that	O
are	O
`	O
`	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
''	O
proteins	O
that	O
bind	O
to	O
the	O
promoters	O
of	O
muscle	O
-	O
specific	O
genes	O
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	O
binding	O
basic	O
domain	O
of	O
MyoD	O
confers	O
c	O
-	O
myc	O
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	O
domains	O
of	O
all	O
the	O
myogenic	O
factors	O
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	O
transcription	O
factors	O
.	O

The	O
SCL	O
protein	O
displays	O
cell	O
-	O
specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	O
protein	O
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	B
cell	I
lines	I
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	O
protein	O
was	O
detected	O
in	O
erythroid	B
,	I
megakaryocyte	I
,	I
mast	I
and	I
early	I
myeloid	I
cell	I
lines	I
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	B
leukemia	I
cell	I
lines	I
which	O
are	O
known	O
to	O
harbor	O
SCL	O
gene	O
rearrangements	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	O
weight	O
species	O
of	O
24	O
and	O
22	O
kDa	O
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell	O
-	O
specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	O
gene	O
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	B
lines	I
(	O
GP+E-86	B
,	O
AT2.5	B
,	O
M1	B
)	O
but	O
only	O
the	O
22	O
kDa	O
form	O
in	O
the	O
myeloid	B
cell	I
line	I
,	O
WEHI-3B	B
/	I
D+	I
.	O

Overexpression	O
of	O
full	O
-	O
length	O
SCL	O
protein	O
in	O
the	O
lymphoid	B
cell	I
lines	I
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	O
transcription	O
.	O

The	O
restricted	O
pattern	O
of	O
SCL	O
protein	O
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	O
mRNA	O
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	O
protein	O
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O

Activation	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoter	O
in	O
T	O
cells	O
requires	O
cooperative	O
binding	O
of	O
Elf-1	O
and	O
AP-1	O
transcription	O
factors	O
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T	O
-	O
lymphocyte	O
activation	O
.	O

The	O
GM	O
-	O
CSF	O
gene	O
is	O
not	O
expressed	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	O
surface	O
T	O
-	O
cell	O
receptor	O
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
TATA	O
box	O
(	O
bp	O
-34	O
to	O
-52	O
)	O
,	O
herein	O
called	O
purine	O
box	O
1	O
(	O
PB1	O
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T	O
-	O
cell	O
nuclear	O
protein	O
complex	O
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
following	O
T	O
-	O
cell	O
activation	O
.	O

The	O
PB1	O
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	O
and	O
murine	O
GM	O
-	O
CSF	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	O
element	O
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B
Jurkat	I
T	I
cells	I
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	O
nuclear	O
protein	O
-	O
binding	O
complex	O
that	O
is	O
not	O
present	O
in	O
resting	O
peripheral	O
blood	O
T	O
cells	O
but	O
is	O
rapidly	O
induced	O
following	O
T	O
-	O
cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	O
is	O
composed	O
of	O
adjacent	O
binding	O
sites	O
for	O
Ets	O
and	O
AP-1	O
transcription	O
factors	O
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	O
and	O
AP-1	O
sites	O
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	O
nuclear	O
protein	O
complex	O
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
activated	O
T	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Stress	O
response	O
of	O
senescent	O
T	O
lymphocytes	O
:	O
reduced	O
hsp70	O
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	B
human	I
T	I
lymphocyte	I
cultures	I
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B
passage	I
cells	I
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

A	O
second	O
feature	O
of	O
senescent	B
T	I
cells	I
is	O
the	O
dramatic	O
reduction	O
in	O
hsp70	O
production	O
in	O
response	O
to	O
heat	O
shock	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	O
heat	O
shock	O
element	O
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	B
T	I
cells	I
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

This	O
suggests	O
that	O
for	O
senescent	O
T	O
cells	O
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	O
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

The	O
interleukin-8	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin-8	O
(	O
IL-8	O
)	O
in	O
a	O
human	B
T	I
cell	I
line	I
,	O
Jurkat	B
cells	I
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2	O
+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	O
promoters	O
,	O
the	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	O
or	O
kappa	O
B	O
-	O
like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2	O
+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	O
site	O
of	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti	O
-	O
JunD	O
or	O
c	O
-	O
Fos	O
antibody	O
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2	O
+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B	O
-	O
like	O
site	O
binding	O
complexes	O
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	O
against	O
the	O
human	O
Rel	O
family	O
proteins	O
(	O
c	O
-	O
Rel	O
,	O
p65	O
,	O
p50	O
,	O
and	O
p49	O
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA	O
/	O
ionomycin	O
-	O
induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF	O
-	O
kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	O
kappa	O
B	O
-	O
like	O
site	O
and	O
Ig	O
kappa	O
B	O
site	O
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	O
NF	O
-	O
AT	O
and	O
NFIL-2A	O
sites	O
and	O
Ig	O
kappa	O
B	O
site	O
,	O
but	O
also	O
the	O
IL-8	O
AP-1	O
and	O
kappa	O
B	O
-	O
like	O
sites	O
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2	O
+	O
mobilization	O
.	O

Activation	O
of	O
a	O
novel	O
serine	O
/	O
threonine	O
kinase	O
that	O
phosphorylates	O
c	O
-	O
Fos	O
upon	O
stimulation	O
of	O
T	O
and	O
B	O
lymphocytes	O
via	O
antigen	O
and	O
cytokine	O
receptors	O
.	O

Ligation	O
of	O
Ag	O
receptors	O
in	O
T	O
and	O
B	O
lymphocytes	O
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	O
tyrosine	O
and	O
serine	O
/	O
threonine	O
kinases	O
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine	O
/	O
threonine	O
kinase	O
that	O
phosphorylated	O
the	O
proto	O
-	O
oncogene	O
product	O
,	O
c	O
-	O
Fos	O
,	O
and	O
is	O
termed	O
Fos	O
kinase	O
.	O

Fos	O
kinase	O
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	O
and	O
CD2	O
receptors	O
in	O
Jurkat	B
and	O
normal	O
human	O
T	O
lymphocytes	O
and	O
in	O
response	O
to	O
IL-6	O
and	O
anti	O
-	O
IgM	O
in	O
the	O
human	B
B	I
cell	I
lines	I
AF10	B
and	O
Ramos	B
,	O
respectively	O
.	O

The	O
phorbol	O
ester	O
,	O
PMA	O
,	O
was	O
also	O
a	O
potent	O
inducer	O
of	O
Fos	O
kinase	O
activity	O
in	O
all	O
of	O
the	O
above	O
populations	O
,	O
suggesting	O
that	O
PKC	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
this	O
enzyme	O
.	O

Fos	O
kinase	O
phosphorylates	O
c	O
-	O
Fos	O
at	O
a	O
site	O
near	O
the	O
C	O
-	O
terminus	O
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	O
359	O
-	O
370	O
,	O
RKGSSSNEPSSD	O
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c	O
-	O
Fos	O
phosphorylation	O
.	O

Fos	O
kinase	O
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine	O
/	O
threonine	O
kinases	O
,	O
including	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
casein	O
kinase	O
II	O
,	O
MAP	O
kinases	O
,	O
p70S6	O
K	O
and	O
p90RSK	O
.	O

Fos	O
kinase	O
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M	O
(	O
r	O
)	O
=	O
65	O
,	O
000	O
and	O
isoelectric	O
point	O
=	O
6.1	O
.	O

Fos	O
kinase	O
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c	O
-	O
Fos	O
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	O
.	O

A	O
novel	O
heterodimerization	O
partner	O
for	O
thyroid	O
hormone	O
receptor	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
.	O

Retinoid	O
-	O
like	O
receptors	O
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	O
with	O
other	O
nuclear	O
hormone	O
receptors	O
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
as	O
a	O
new	O
thyroid	O
hormone	O
receptor	O
(	O
THR	O
)	O
auxiliary	O
nuclear	O
protein	O
,	O
heterodimerizing	O
with	O
THR	O
in	O
solution	O
.	O

Although	O
these	O
heterodimers	O
do	O
not	O
recognize	O
a	O
classical	O
thyroid	O
hormone	O
response	O
element	O
(	O
TRE	O
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	O
)	O
,	O
PPAR	O
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH	O
-	O
dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	O
beta	O
-	O
PPAR	O
but	O
not	O
the	O
THR	O
alpha	O
-	O
PPAR	O
heterodimer	O
with	O
a	O
novel	O
TRE	O
(	O
DR+2	O
)	O
.	O

The	O
critical	O
region	O
of	O
THR	O
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	O
box	O
of	O
the	O
DNA	O
binding	O
domain	O
.	O

Hence	O
,	O
PPAR	O
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	O
isotype	O
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	O
gene	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte	O
-	O
mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia	O
/	O
reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14	O
-	O
18	O
Torr	O
,	O
led	O
to	O
time	O
-	O
dependent	O
release	O
of	O
IL-8	O
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	O
.	O

Production	O
of	O
IL-8	O
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	O
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	O
transcription	O
,	O
based	O
on	O
nuclear	O
run	O
-	O
on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	O
for	O
macrophage	O
chemotactic	O
protein-1	O
,	O
another	O
member	O
of	O
the	O
chemokine	O
superfamily	O
of	O
proinflammatory	O
cytokines	O
.	O

IL-8	O
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF	O
-	O
kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	O
antigen	O
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30	O
-	O
40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	O
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	O
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	O
family	O
related	O
to	O
IL-8	O
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Patterns	O
of	O
Pan	O
expression	O
and	O
role	O
of	O
Pan	O
proteins	O
in	O
endocrine	O
cell	O
type	O
-	O
specific	O
complex	O
formation	O
.	O

The	O
Pan	O
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	O
and	O
Pan-2	O
(	O
also	O
known	O
as	O
E47	O
and	O
E12	O
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	O
proteins	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	B
lines	I
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	O
proteins	O
have	O
suggested	O
that	O
significant	O
E2A	O
protein	O
expression	O
is	O
restricted	O
to	O
B	O
-	O
lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	O
antibody	O
,	O
Yae	O
,	O
which	O
is	O
specific	O
for	O
Pan	O
/	O
E2A	O
proteins	O
,	O
and	O
have	O
used	O
the	O
Yae	O
antibody	O
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan	O
/	O
E2A	O
protein	O
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan	O
/	O
E2A	O
proteins	O
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	O
proteins	O
in	O
GH	B
/	I
PRL-	I
and	I
insulin	I
-	I
producing	I
,	I
B-	I
and	I
T	I
-	I
lymphocyte	I
cells	I
.	O

IEF-1	O
,	O
a	O
pancreatic	O
beta	O
-	O
cell	O
type	O
-	O
specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	O
molecules	O
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta	O
-	O
cells	O
share	O
identical	O
Pan	O
/	O
E2A	O
complexes	O
,	O
native	O
-	O
Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta	O
-	O
cells	O
detect	O
Pan	O
proteins	O
in	O
distinct	O
cell	O
type	O
-	O
specific	O
complexes	O
.	O

Novel	O
aldosterone	O
receptors	O
:	O
specificity	O
-	O
conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra	O
-	O
renal	O
,	O
nonepithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non	O
-	O
genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium	O
/	O
proton	O
-	O
exchanger	O
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate	O
/	O
calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
-	O
related	O
rapid	O
responses	O
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	O
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
of	O
the	O
receptor	O
protein	O
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two	O
-	O
step	O
model	O
for	O
non	O
-	O
genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity	O
-	O
conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

Multiple	O
prolactin	O
-	O
responsive	O
elements	O
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	O
regulatory	O
factor-1	O
gene	O
.	O

The	O
interferon	O
regulatory	O
factor-1	O
(	O
IRF-1	O
)	O
gene	O
is	O
both	O
an	O
immediate	O
-	O
early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	O
by	O
PRL	O
in	O
rat	B
Nb2	I
T	I
lymphocytes	I
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	O
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	O
,	O
we	O
cloned	O
the	O
rat	O
IRF-1	O
gene	O
and	O
functionally	O
characterized	O
the	O
IRF-1	O
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	B
T	I
cells	I
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	O
5'-flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	O
enzyme	O
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	O
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	O
,	O
0.6	O
,	O
and	O
0.2	O
kb	O
5'-flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	O
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	O
to	O
respond	O
to	O
PRL	O
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	O
PRL	O
response	O
elements	O
may	O
require	O
an	O
interaction	O
with	O
promoter	O
-	O
proximal	O
elements	O
.	O

By	O
assaying	O
CAT	O
enzyme	O
activity	O
across	O
a	O
24-h	O
PRL	O
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	O
responses	O
of	O
the	O
IRF-1	O
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF-1	O
5'-flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0.2-kb	O
IRF	O
-	O
CAT	O
construct	O
was	O
induced	O
by	O
PRL	O
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-	O
CAT	O
construct	O
was	O
inducible	O
by	O
PRL	O
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	O
-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	O
gene	O
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL	O
-	O
responsive	O
elements	O
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	O
promoter	O
region	O
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

HLA	O
-	O
DR-	O
,	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16-	O
myeloid	O
/	O
natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French	O
-	O
American	O
-	O
British	O
acute	O
myeloid	O
leukemia	O
-	O
M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	O
and	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+	O
/	O
-	O
,	O
HLA	O
-	O
DR	O
-	O
,	O
CD16	O
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	O
(	O
CD33	O
,	O
CD13	O
,	O
CD15	O
)	O
and	O
NK	O
cell	O
-	O
associated	O
(	O
CD56	O
)	O
antigens	O
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	O
(	O
neural	O
cell	O
adhesion	O
molecule	O
)	O
in	O
leukemic	O
blasts	O
.	O

Although	O
two	O
cases	O
expressed	O
CD4	O
,	O
no	O
case	O
expressed	O
CD2	O
,	O
CD3	O
,	O
or	O
CD8	O
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
beta	O
,	O
gamma	O
,	O
delta	O
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	O
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	O
variant	O
(	O
FAB	O
AML	O
-	O
M3v	O
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic	O
/	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
fusion	O
transcript	O
in	O
RT	O
-	O
PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	O
17q	O
:	O
1	O
with	O
del	O
(	O
17	O
)	O
(	O
q25	O
)	O
and	O
the	O
other	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q23	O
;	O
q21	O
)	O
and	O
the	O
promyelocytic	O
leukemia	O
zinc	O
finger	O
/	O
RAR	O
alpha	O
fusion	O
transcript	O
.	O

All	O
cases	O
tested	O
(	O
6	O
/	O
20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	O
(	O
11	O
;	O
17	O
)	O
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33	O
+	O
,	O
CD56	O
+	O
,	O
CD16	O
-acute	O
leukemias	O
and	O
normal	O
CD56	O
+	O
,	O
CD16-	O
NK	O
precursor	O
cells	O
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	O
CD56	O
+	O
,	O
CD33	O
+	O
,	O
CD16-	O
counterpart	O
cell	O
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	O
and	O
NK	O
cell	O
lineages	O
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid	O
/	O
NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA	O
-	O
nonresponsive	O
cases	O
from	O
ATRA	O
-	O
responsive	O
true	O
APL	O
.	O

Upregulation	O
of	O
bcl-2	O
by	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
:	O
a	O
B	O
-	O
cell	O
-	O
specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
to	O
induction	O
of	O
cell	O
surface	O
markers	O
.	O

An	O
ability	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	O
of	O
the	O
bcl-2	O
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1	B
+	I
clones	I
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107	O
-	O
1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	O
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	O
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2	B
+	I
cells	I
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	O
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	O
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
and	O
upregulation	O
of	O
the	O
cell	O
adhesion	O
molecule	O
ICAM-1	O
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	O
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B	B
-	I
cell	I
lines	I
carrying	O
an	O
LMP1	O
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	O
to	O
express	O
LMP1	O
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK	O
-	O
kappa	O
B	O
and	O
upregulation	O
of	O
ICAM-1	O
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	O
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	O
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B	B
-	I
cell	I
lines	I
tested	O
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
response	O
to	O
LMP1	O
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	O
and	O
Bcl-2	O
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-	O
B	B
-	I
cell	I
lines	I
showed	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ICAM-1	O
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl-2	O
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	O
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	O
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	O
signal	O
transduction	O
,	O
other	O
cell	O
-	O
specific	O
factors	O
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	O
protein	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
in	O
relation	O
to	O
CD4	O
cell	O
number	O
and	O
antibody	O
titres	O
to	O
EBV	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	O
cells	O
of	O
AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4	O
+	O
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti	O
-	O
Z	O
Epstein	O
-	O
Barr	O
replicative	O
activator	O
(	O
ZEBRA	O
)	O
,	O
anti	O
-	O
early	O
antigen	O
(	O
EA	O
)	O
,	O
anti	O
-	O
viral	O
capsid	O
antigen	O
(	O
VCA	O
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4	O
+	O
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	O
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

METHODS	O
:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein	O
-	O
Barr	O
early	O
region	O
(	O
EBER	O
)	O
RNA	O
-	O
positive	O
]	O
.	O

Immunohistochemistry	O
was	O
performed	O
with	O
anti	O
-	O
ZEBRA	O
,	O
anti	O
-	O
EA	O
-	O
restricted	O
,	O
anti	O
-	O
VCA	O
antibodies	O
and	O
in	O
situ	O
hybridization	O
with	O
BHLF1	O
/	O
NotI	O
oligoprobes	O
on	O
tumour	O
samples	O
.	O

Results	O
were	O
statistically	O
correlated	O
with	O
those	O
of	O
CD4	O
+	O
cell	O
counts	O
(	O
17	O
out	O
of	O
17	O
)	O
and	O
with	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
13	O
out	O
of	O
17	O
)	O
assessed	O
using	O
standard	O
immunofluorescence	O
method	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
procedure	O
using	O
recombinant	O
ZEBRA	O
protein	O
and	O
synthetic	O
peptides	O
as	O
antigens	O
.	O

RESULTS	O
:	O
BZLF1	O
(	O
ZEBRA	O
)	O
or	O
early	O
gene	O
products	O
(	O
EA	O
-	O
R	O
and	O
EA	O
-	O
D	O
/	O
BHLF1	O
/	O
NotI	O
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01	O
-	O
5	O
%	O
)	O
of	O
tumour	O
cells	O
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4	O
+	O
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti	O
-	O
EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Anti-	O
ZEBRA	O
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	O
cells	O
of	O
ARNHL	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	O
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Displacement	O
of	O
an	O
E	O
-	O
box	O
-	O
binding	O
repressor	O
by	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
:	O
implications	O
for	O
B	O
-	O
cell	O
specificity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
.	O

The	O
activity	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
is	O
restricted	O
to	O
B	O
cells	O
,	O
although	O
it	O
binds	O
both	O
B	O
-	O
cell	O
-	O
restricted	O
and	O
ubiquitous	O
transcription	O
factors	O
.	O

Activation	O
of	O
the	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
upon	O
overexpression	O
of	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
protein	O
E2A	O
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	O
to	O
its	O
cognate	O
E	O
box	O
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	O
from	O
that	O
same	O
site	O
.	O

We	O
have	O
identified	O
a	O
`	O
`	O
two	O
-	O
handed	O
''	O
zinc	O
finger	O
protein	O
,	O
denoted	O
ZEB	O
,	O
the	O
DNA	O
-	O
binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	O
repressor	O
.	O

By	O
employing	O
a	O
derivative	O
E	O
box	O
that	O
binds	O
ZEB	O
but	O
not	O
E2A	O
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	O
is	O
active	O
in	O
B	O
cells	O
and	O
the	O
IgH	O
enhancer	O
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	O
proteins	O
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	O
activity	O
is	O
the	O
B	O
-	O
cell	O
-	O
specific	O
displacement	O
of	O
a	O
ZEB	O
-	O
like	O
repressor	O
by	O
bHLH	O
proteins	O
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	O
and	O
interleukin	O
2	O
-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV	O
-	O
infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	O
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	O
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free	O
-	O
radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	B
cells	I
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	B
cells	I
.	O

Both	O
antioxidants	O
inhibited	O
TNF	O
-or	O
PMA	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
U1	B
cells	I
,	O
as	O
well	O
as	O
the	O
sustained	O
NF	O
-	O
kappa	O
B	O
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV	O
-	O
infected	O
U937	B
cells	I
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	O
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	B
cells	I
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	B
infected	I
U937	I
cells	I
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK	O
-	O
kappa	O
B	O
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	O
PBMC	O
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant	O
-	O
based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

A	O
low	O
NM23.H1	O
gene	O
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis	O
-	O
suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	O
was	O
identified	O
in	O
a	O
system	O
of	O
murine	B
melanoma	I
cell	I
lines	I
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	O
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	O
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	O
gene	O
in	O
cell	B
lines	I
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease	O
-	O
free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	B
lines	I
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	B
lines	I
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	B
lines	I
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24	O
-	O
58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	B
lines	I
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease	O
-	O
free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6	O
-	O
15	O
months	O
)	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	O
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid	O
-	O
induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat	O
-	O
activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1-infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	O
(	O
IFN	O
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV-1-infected	B
cells	I
,	O
HIV-1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
of	O
the	O
HIV-1	O
LTR	O
significantly	O
inhibited	O
Tat	O
-mediated	O
transactivation	O
in	O
T	B
-	I
cell	I
lines	I
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B
line	I
,	O
U937	B
.	O

Replacement	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
elements	O
in	O
the	O
HIV-1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5'-flanking	O
region	O
of	O
IFN	O
-	O
stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN	O
-	O
stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat	O
-mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	O
gene	O
directed	O
high	O
levels	O
of	O
IFN	O
synthesis	O
in	O
Tat	B
-	I
expressing	I
cells	I
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	O
necrosis	O
factor	O
alpha	O
-mediated	O
activation	O
.	O

ISG15-LTR	O
-	O
IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	B
and	O
U937	B
cells	I
.	O

Selected	O
transfected	B
clones	I
produced	O
low	O
levels	O
of	O
IFN	O
A	O
(	O
IFNA	O
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	O
and	O
interleukin-2	O
receptor	O
upon	O
stimulation	O
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	O
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA	B
-	I
producing	I
cells	I
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	B
cells	I
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	B
cells	I
transduced	O
with	O
the	O
IFNA	O
gene	O
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	O
synthesis	O
to	O
HIV-1-infected	B
cells	I
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	O
synthesis	O
results	O
in	O
a	O
long	O
-	O
lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	O
receptor	O
on	O
peripheral	O
blood	O
lymphocytes	O
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
expression	O
of	O
the	O
progesterone	O
receptor	O
in	O
human	O
peripheral	O
blood	O
lymphocytes	O
was	O
analysed	O
,	O
using	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
Abbott	O
PgR	O
-	O
EIA	O
monoclonal	O
)	O
,	O
in	O
order	O
to	O
evaluate	O
its	O
prognostic	O
character	O
in	O
the	O
context	O
of	O
spontaneous	O
abortion	O
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non	O
-	O
pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

In	O
addition	O
,	O
a	O
human	B
breast	I
carcinoma	I
cell	I
line	I
(	O
ZR-75	B
-	I
1	I
)	O
,	O
which	O
expresses	O
the	O
progesterone	O
receptor	O
,	O
was	O
analysed	O
throughout	O
.	O

The	O
ZR-75	B
-	I
1	I
cell	I
line	I
showed	O
an	O
expression	O
of	O
642	O
fmol	O
/	O
mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol	O
/	O
mg	O
.	O

Lymphocytes	O
of	O
non	O
-	O
pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre	O
-	O
term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+	O
/-	O
1	O
,	O
3	O
+	O
/-	O
2	O
and	O
5	O
+	O
/-	O
4	O
fmol	O
/	O
mg	O
respectively	O
.	O

These	O
results	O
show	O
that	O
there	O
is	O
no	O
evidence	O
of	O
specific	O
expression	O
of	O
the	O
progesterone	O
receptor	O
in	O
pregnancy	O
and	O
exclude	O
any	O
prognostic	O
character	O
in	O
spontaneous	O
abortion	O
.	O

A	O
role	O
for	O
the	O
progesterone	O
receptor	O
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	O
blood	O
lymphocytes	O
is	O
also	O
excluded	O
.	O

Characterization	O
of	O
the	O
CD48	O
gene	O
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
and	O
contains	O
an	O
essential	O
NF	O
-	O
kappa	O
B	O
site	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	O
B	O
cells	O
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	O
,	O
characteristically	O
expressed	O
on	O
normal	O
activated	O
B	O
cells	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	O
element	O
in	O
the	O
CD48	O
gene	O
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV	B
-	I
positive	I
B	I
-	I
lymphoblastoid	I
cell	I
lines	I
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV	B
-	I
negative	I
B	I
-	I
cell	I
lines	I
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	O
phenotype	O
.	O

An	O
NF	O
-	O
kappa	O
B	O
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	O
protein	O
complex	O
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF	O
-	O
kappa	O
B1	O
(	O
p50	O
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV	O
-	O
encoded	O
latent	O
membrane	O
protein	O
1	O
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
not	O
the	O
intact	O
element	O
,	O
suggesting	O
that	O
the	O
latent	O
membrane	O
protein	O
1	O
-driven	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	O
B	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O

Activation	O
of	O
human	O
thymocytes	O
after	O
infection	O
by	O
EBV	O
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	O
receptor	O
,	O
CR2	O
/	O
CD21	O
,	O
on	O
a	O
population	O
of	O
immature	O
thymocytes	O
,	O
T	B
lymphoblastoid	I
cell	I
lines	I
,	O
and	O
childhood	O
acute	O
T	O
lymphoblastic	O
leukemia	O
cells	O
suggested	O
that	O
EBV	O
-	O
receptor	O
interactions	O
on	O
T	O
cells	O
may	O
be	O
of	O
importance	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	O
,	O
immature	O
cells	O
expresses	O
CD21	O
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	O
thymocytes	O
in	O
vitro	O
.	O

Triggering	O
through	O
CD2	O
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	O
cells	O
.	O

However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	O
caused	O
thymocytes	O
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	O
cytokines	O
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	O
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	O
mAb	O
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95	O
-	O
8	O
.	O

Immature	O
thymocytes	O
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	O
genome	O
and	O
its	O
transcriptional	O
activity	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95	O
-	O
8	O
,	O
EBNA-2	O
transcripts	O
were	O
identified	O
within	O
infected	B
thymocyte	I
populations	I
.	O

In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	O
.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	O
,	O
an	O
early	O
gene	O
that	O
characterizes	O
EBV	O
-	O
infected	O
B	O
cells	O
after	O
disruption	O
of	O
latency	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	O
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
consequences	O
of	O
EBV	O
infection	O
of	O
T	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
may	O
lead	O
to	O
failure	O
of	O
normal	O
T	O
cell	O
repertoire	O
development	O
,	O
autoimmunity	O
,	O
or	O
malignancy	O
.	O

Protein	O
kinase	O
C	O
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	O
in	O
activated	O
T	O
cells	O
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
downstream	O
of	O
p21ras	O
,	O
in	O
activating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	O
is	O
an	O
effector	O
of	O
p21ras	O
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	O
inhibitor	O
Ro	O
31	O
-	O
8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	O
is	O
not	O
downstream	O
of	O
p21ras	O
in	O
the	O
induction	O
of	O
NF	O
-	O
AT	O
and	O
AP-1	O
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL-2	O
in	O
human	B
Jurkat	I
T	I
cells	I
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	O
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	O
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	O
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	O
during	O
T	O
cell	O
activation	O
.	O

Detection	O
of	O
the	O
chromosome	O
16	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcript	O
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	O
beta	O
and	O
MYH11	O
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	O
transcripts	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
by	O
RT	O
-	O
PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty	O
-	O
three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	O
abnormal	O
eosinophils	O
(	O
AML	O
M4	O
`	O
`	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT	O
-	O
PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	O
eosinophils	O
were	O
CBF	O
beta	O
-MYH11	O
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	O
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT	O
-	O
PCR	O
positive	O
.	O

Follow	O
-	O
up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	O
beta	O
-	O
MYH11	O
fusion	O
transcripts	O
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	O
16	O
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	O
beta	O
-	O
MYH11	O
transcripts	O
in	O
the	O
absence	O
of	O
apparent	O
chromosome	O
16	O
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT	O
-	O
PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	O
transcript	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM	O
-	O
CSF	O
,	O
IL-3	O
,	O
M	O
-	O
CSF	O
receptor	O
(	O
C	O
-	O
FMS	O
)	O
,	O
early	O
growth	O
response	O
gene-1	O
(	O
EGR-1	O
)	O
and	O
M	O
-	O
CSF	O
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	O
,	O
GM	O
-	O
CSF	O
,	O
FMS	O
and	O
EGR-1	O
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	B
clones	I
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M	O
-	O
CSF	O
gene	O
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	O
and	O
the	O
EGR-1	O
genes	O
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M	O
-	O
CSF	O
and	O
FMS	O
genes	O
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	O
growth	O
factors	O
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

A	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
in	O
the	O
progesterone	O
receptor	O
gene	O
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	O
receptor	O
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	O
leucocyte	O
genomic	O
DNAs	O
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	O
progesterone	O
receptor	O
(	O
hPR	O
)	O
cDNA	O
probe	O
identified	O
a	O
germline	O
TaqI	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	O
,	O
represented	O
by	O
a	O
2.7	O
kb	O
fragment	O
;	O
and	O
T2	O
,	O
represented	O
by	O
a	O
1.9	O
kb	O
fragment	O
and	O
characterised	O
by	O
an	O
additional	O
TaqI	O
restriction	O
site	O
with	O
respect	O
to	O
T1	O
.	O

An	O
over	O
-	O
representation	O
of	O
T2	O
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish	O
/	O
German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	O
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy	O
-	O
Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	O
cDNA	O
region	O
-	O
specific	O
probes	O
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	O
G	O
of	O
the	O
hPR	O
gene	O
.	O

IL-1	O
receptor	O
and	O
TCR	O
signals	O
synergize	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	O
receptor	O
(	O
IL-1R	O
)	O
-	O
and	O
TCR	O
-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	O
I	O
IL-1R	O
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
synergistic	O
antigen	O
receptor	O
initiated	O
signals	O
are	O
mediated	O
through	O
protein	O
kinase	O
C	O
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	O
rather	O
than	O
by	O
antigen	O
receptor	O
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
functional	O
activity	O
is	O
independent	O
of	O
I	O
kappa	O
B	O
alpha	O
(	O
MAD3	O
)	O
-	O
NF	O
-	O
kappa	O
B	O
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	O
kappa	O
B	O
nuclear	O
translocation	O
.	O

The	O
IL-1	O
-induced	O
NF	O
-	O
kappa	O
B	O
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor	O
-	O
initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	O
induces	O
both	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF	O
-	O
kappa	O
B	O
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF	O
-	O
kappa	O
B	O
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	O
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	O
-induced	O
NF	O
-	O
kappa	O
B	O
-dependent	O
gene	O
transcription	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
-	O
alpha	O
,	O
-epsilon	O
,	O
and	O
-zeta	O
in	O
T	O
cell	O
activation	O
.	O

T	O
cells	O
express	O
multiple	O
isotypes	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	O
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	O
isotypes	O
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC	O
-	O
alpha	O
,	O
-epsilon	O
,	O
or	O
-zeta	O
have	O
been	O
transfected	O
into	O
T	O
cells	O
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	O
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	O
active	O
PKCs	O
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	O
.	O

The	O
data	O
indicate	O
that	O
PKC	O
-	O
epsilon	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC	O
-	O
alpha	O
but	O
not	O
-zeta	O
,	O
can	O
regulate	O
the	O
transcription	O
factors	O
AP-1	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT-1	O
)	O
.	O

The	O
ability	O
of	O
PKC	O
-	O
epsilon	O
to	O
induce	O
transactivation	O
of	O
NF	O
-	O
AT-1	O
and	O
AP-1	O
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	O
activated	O
p21ras	O
.	O

PKC	O
-	O
epsilon	O
,	O
but	O
not	O
PKC	O
-	O
alpha	O
nor	O
activated	O
p21ras	O
,	O
was	O
able	O
to	O
induce	O
NF	O
-	O
KB	O
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	O
whereas	O
none	O
of	O
the	O
activated	O
PKC	O
isotypes	O
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	O
and	O
p21ras	O
were	O
able	O
to	O
induce	O
CD69	O
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	O
isotypes	O
in	O
T	O
cells	O
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	O
Ras	O
and	O
PKC	O
mutants	O
suggest	O
that	O
PKC	O
-	O
alpha	O
,	O
p21ras	O
,	O
and	O
PKC	O
-	O
epsilon	O
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Identification	O
of	O
two	O
novel	O
regulatory	O
elements	O
within	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
A	O
gamma	O
-	O
globin	O
gene	O
.	O

Interaction	O
between	O
the	O
stage	O
selector	O
element	O
(	O
SSE	O
)	O
in	O
the	O
proximal	O
gamma	O
-	O
globin	O
promoter	O
and	O
hypersensitivity	O
site	O
2	O
in	O
the	O
locus	O
control	O
region	O
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE	O
-	O
like	O
element	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
gamma	O
-	O
gene	O
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta	O
-	O
gene	O
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	B
erythroid	I
cell	I
line	I
,	O
K562	B
,	O
we	O
have	O
shown	O
that	O
the	O
core	O
enhancer	O
of	O
hypersensitivity	O
site	O
2	O
can	O
preferentially	O
interact	O
with	O
the	O
proximal	O
gamma	O
-	O
promoter	O
in	O
the	O
absence	O
of	O
the	O
SSE	O
,	O
completely	O
silencing	O
a	O
linked	O
beta	O
-	O
promoter	O
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma	O
-	O
gene	O
5'-untranslated	O
region	O
(	O
UTR	O
)	O
led	O
to	O
derepression	O
of	O
beta	O
-	O
promoter	O
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma	O
-	O
promoter	O
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	O
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	O
+	O
13	O
to	O
+	O
15	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	O
and	O
erythroid	O
-	O
specific	O
protein	O
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	O
was	O
localized	O
to	O
tandem	O
GATA	O
-	O
like	O
sites	O
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	O
transcription	O
factor	O
GATA-1	O
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	O
of	O
the	O
gamma	O
-	O
gene	O
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP-1	O
alpha	O
gene	O
.	O

Murine	O
macrophage	O
inflammatory	O
protein	O
1	O
alpha	O
(	O
MIP-1	O
alpha	O
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	O
,	O
LD78	O
,	O
or	O
AT464	O
)	O
are	O
members	O
of	O
the	O
-C	O
-	O
C	O
family	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
chemokines	O
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow	O
-	O
derived	O
MIP-1	O
alpha	O
/	O
GOS19	O
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	O
alpha	O
/GOS19	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B
T	I
cells	I
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK-1	O
family	O
)	O
affect	O
the	O
GOS19	O
promoter	O
.	O

One	O
member	O
,	O
ICK-1A	O
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B
cell	I
line	I
U937	B
is	O
different	O
from	O
that	O
in	O
Jurkat	B
cells	I
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	O
binding	O
site	O
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	B
cells	I
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP-1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK-1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	B
cell	I
lines	I
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast	O
-	O
migrating	O
protein	O
-	O
DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	O
promoter	O
in	O
U937	B
cells	I
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B
cells	I
.	O

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

The	O
transcription	O
factor	O
,	O
Nm23H2	O
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	O
site	O
on	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	O
site	O
on	O
the	O
silent	O
normal	O
c	O
-	O
myc	O
allele	O
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
SDS	O
-	O
gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	O
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c	O
-	O
myc	O
PuF	O
site	O
.	O

Transfection	O
experiments	O
with	O
c	O
-	O
myc	O
promoter	O
constructs	O
in	O
both	O
DHL-9	B
and	O
Raji	B
cells	I
revealed	O
that	O
the	O
PuF	O
site	O
functioned	O
as	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
cells	O
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	O
silent	O
c	O
-	O
myc	O
allele	O
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	O
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c	O
-	O
myc	O
allele	O
in	O
Burkitt	B
's	I
lymphoma	I
cells	I
.	O

Modulation	O
of	O
transcription	O
factor	O
NF	O
kappa	O
B	O
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV	O
-	O
infected	O
individuals	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	B
T	I
cell	I
line	I
(	O
Molt-4	B
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA	O
-	O
binding	O
and	O
transactivating	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

Because	O
inhibition	O
of	O
DNA	O
-	O
binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	O
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
directly	O
in	O
cell	O
-	O
free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	O
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	O
cells	O
also	O
.	O

NF	O
kappa	O
B	O
controls	O
many	O
immunologically	O
important	O
genes	O
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Thapsigargin	O
induces	O
IL-2	O
receptor	O
alpha	O
-	O
chain	O
in	O
human	O
peripheral	O
and	O
Jurkat	B
T	I
cells	I
via	O
a	O
protein	O
kinase	O
C	O
-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-ATPase	O
,	O
depletes	O
intracellular	O
Ca2	O
+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2	O
+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	O
in	O
Jurkat	B
T	I
cells	I
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	O
alpha	O
protein	O
as	O
well	O
as	O
IL-2R	O
alpha	O
mRNA	O
in	O
Jurkat	B
T	I
cells	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	O
alpha	O
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	O
kappa	O
B	O
in	O
Jurkat	B
T	I
cells	I
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	O
alpha	O
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	O
alpha	O
through	O
distinct	O
pathways	O
.	O

PMA	O
-but	O
not	O
TG	O
-	O
induced	O
IL-2R	O
alpha	O
is	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
H7	O
,	O
whereas	O
TG	O
-but	O
not	O
PMA	O
-	O
induced	O
IL-2R	O
alpha	O
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	O
alpha	O
in	O
human	O
T	O
cells	O
through	O
a	O
PKC	O
-independent	O
pathway	O
.	O

Interleukin	O
4	O
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
which	O
interacts	O
with	O
an	O
interferon	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	B
B	I
cell	I
line	I
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	O
kinase	O
3	O
and	O
interleukin-4	O
Stat	O
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL-4	O
in	O
the	O
human	B
B	I
cell	I
line	I
,	O
BL-2	B
.	O

Utilizing	O
a	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	O
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	B
cells	I
.	O

This	O
factor	O
was	O
designated	O
IL-4	O
NAF	O
(	O
IL-4-induced	O
nuclear	O
-	O
activating	O
factors	O
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	O
phosphoprotein	O
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	O
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
,	O
we	O
determined	O
whether	O
antibodies	O
to	O
Stat	O
proteins	O
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	O
to	O
IL-4	O
Stat	O
,	O
also	O
known	O
as	O
Stat6	O
,	O
but	O
not	O
antibodies	O
to	O
other	O
Stat	O
proteins	O
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	O
NAF	O
complex	O
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	O
protein	O
,	O
IL-4	O
induced	O
robust	O
Janus	O
kinase	O
3	O
(	O
JAK3	O
)	O
activity	O
in	O
BL-2	B
cells	I
.	O

Cotransfection	O
of	O
JAK3	O
with	O
IL-4	O
Stat	O
into	O
COS-7	B
cells	I
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN	O
-	O
gamma	O
activation	O
site	O
-	O
like	O
sequence	O
and	O
comigrated	O
with	O
IL-4	O
NAF	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	O
NAF	O
is	O
IL-4	O
Stat	O
,	O
which	O
is	O
activated	O
by	O
JAK3	O
in	O
response	O
to	O
IL-4	O
receptor	O
engagement	O
.	O

Interleukin	O
12	O
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	O
in	O
human	O
lymphocytes	O
.	O

Interleukin	O
12	O
(	O
IL-12	O
)	O
is	O
an	O
important	O
immunoregulatory	O
cytokine	O
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	O
receptor	O
superfamily	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	O
T	O
and	O
natural	O
killer	O
cells	O
with	O
IL-12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	O
family	O
tyrosine	O
kinase	O
JAK2	O
and	O
Tyk2	O
,	O
implicating	O
these	O
kinases	O
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	O
.	O

Recently	O
,	O
transcription	O
factors	O
known	O
as	O
STATs	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	O
that	O
bind	O
hematopoietin	O
receptors	O
and	O
activate	O
JAK	O
kinases	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	O
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	O
family	O
member	O
,	O
STAT4	O
,	O
and	O
show	O
that	O
STAT4	O
expression	O
is	O
regulated	O
by	O
T	O
-	O
cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	O
stimulates	O
formation	O
of	O
a	O
DNA	O
-	O
binding	O
complex	O
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	O
proteins	O
and	O
that	O
this	O
complex	O
contains	O
STAT4	O
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	O
phosphorylation	O
by	O
IL-12	O
,	O
identify	O
a	O
rapid	O
signal	O
-	O
transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	O
-induced	O
gene	O
expression	O
.	O

Overexpression	O
of	O
DR	O
-	O
nm23	O
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	O
gene	O
family	O
,	O
inhibits	O
granulocyte	O
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	B
myeloid	I
cells	I
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	O
clone	O
,	O
DR	O
-	O
nm23	O
,	O
differentially	O
expressed	O
in	O
a	O
blast	O
-	O
crisis	O
cDNA	O
library	O
,	O
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	O
metastatic	O
suppressor	O
genes	O
,	O
nm23-H1	O
and	O
nm23-H2	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	O
zipper	O
-	O
like	O
and	O
the	O
RGD	O
domain	O
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	O
and	O
in	O
the	O
COOH	O
-	O
terminal	O
portion	O
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	O
function	O
.	O

DR	O
-	O
nm23	O
mRNA	O
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B
purified	I
CD34	I
+	I
cells	I
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	B
precursor	I
32Dc13	I
cell	I
line	I
,	O
which	O
is	O
growth	O
-	O
factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR	O
-	O
nm23	O
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

Transcription	O
factors	O
as	O
targets	O
for	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

We	O
previously	O
have	O
demonstrated	O
a	O
requirement	O
for	O
oxidative	O
events	O
during	O
cell	O
cycle	O
entry	O
in	O
T	O
lymphocytes	O
and	O
have	O
hypothesised	O
that	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
intracellular	O
signalling	O
agents	O
during	O
lymphocyte	O
activation	O
.	O

In	O
the	O
current	O
study	O
,	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
antioxidant	O
activity	O
,	O
has	O
been	O
used	O
to	O
further	O
investigate	O
the	O
role	O
of	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O

Treatment	O
of	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
cysteamine	O
in	O
vitro	O
was	O
found	O
to	O
inhibit	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
essentially	O
complete	O
inhibition	O
occurring	O
at	O
a	O
dose	O
of	O
400	O
microM	O
.	O

This	O
inhibitory	O
effect	O
was	O
limited	O
to	O
the	O
first	O
2	O
h	O
after	O
mitogenic	O
activation	O
,	O
localizing	O
the	O
time	O
-	O
frame	O
of	O
action	O
of	O
cysteamine	O
to	O
within	O
the	O
commitment	O
period	O
.	O

It	O
therefore	O
was	O
of	O
interest	O
to	O
establish	O
which	O
,	O
if	O
any	O
,	O
commitment	O
events	O
were	O
affected	O
by	O
oxidative	O
signalling	O
during	O
cell	O
cycle	O
entry	O
.	O

Taking	O
the	O
IL-2	O
gene	O
as	O
a	O
candidate	O
,	O
we	O
examined	O
the	O
effect	O
of	O
cysteamine	O
treatment	O
on	O
early	O
gene	O
expression	O
during	O
lymphocyte	O
activation	O
,	O
and	O
on	O
the	O
activity	O
of	O
transcription	O
factors	O
AP-1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
and	O
Oct1	O
,	O
whose	O
functions	O
are	O
required	O
for	O
expression	O
of	O
the	O
IL-2	O
mRNA	O
.	O

Cysteamine	O
treatment	O
inhibited	O
both	O
expression	O
of	O
the	O
IL-2	O
mRNA	O
and	O
secretion	O
of	O
IL-2	O
into	O
the	O
culture	O
medium	O
.	O

The	O
inhibitory	O
effect	O
of	O
cysteamine	O
may	O
be	O
mediated	O
at	O
least	O
in	O
part	O
by	O
an	O
effect	O
on	O
transcription	O
factor	O
function	O
,	O
as	O
the	O
DNA	O
binding	O
activities	O
of	O
AP-1	O
and	O
NF	O
-	O
kappa	O
B	O
extracted	O
from	O
mitogen	O
-	O
stimulated	O
cells	O
were	O
significantly	O
inhibited	O
by	O
cysteamine	O
treatment	O
.	O

Interestingly	O
,	O
Oct1	O
and	O
NF	O
-	O
AT	O
DNA	O
binding	O
activity	O
were	O
not	O
affected	O
by	O
cysteamine	O
treatment	O
,	O
suggesting	O
that	O
oxidative	O
signalling	O
processes	O
operate	O
in	O
a	O
selective	O
manner	O
.	O

The	O
identification	O
of	O
regulatory	O
proteins	O
,	O
such	O
as	O
transcription	O
factors	O
,	O
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
provides	O
further	O
evidence	O
to	O
implicate	O
oxidative	O
signalling	O
as	O
being	O
intimately	O
involved	O
in	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
in	O
T	O
lymphocytes	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN	O
-	O
gamma	O
production	O
induced	O
by	O
IL-2	O
and	O
IL-12	O
in	O
a	O
human	B
NK	I
cell	I
line	I
.	O

Interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
is	O
an	O
important	O
immunoregulatory	O
protein	O
produced	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
(	O
LGL	O
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	O
(	O
ILs	O
)	O
,	O
IL-2	O
and	O
IL-12	O
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN	O
-	O
gamma	O
gene	O
expression	O
in	O
both	O
T	O
cells	O
and	O
LGL	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B
cell	I
lines	I
that	O
produce	O
IFN	O
-	O
gamma	O
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B
killer	I
(	I
NK	I
)	I
cell	I
line	I
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B
line	I
NK3.3	I
derived	O
from	O
human	O
NK	O
cells	O
,	O
responds	O
to	O
both	O
IL-2	O
and	O
IL-12	O
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN	O
-	O
gamma	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	O
and	O
IL-12	O
synergized	O
in	O
the	O
induction	O
of	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
mRNAs	O
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	O
and	O
IL-12	O
on	O
NK3.3	B
cells	I
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	O
induction	O
of	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
cytoplasmic	O
mRNA	O
.	O

In	O
contrast	O
,	O
IL-12	O
induction	O
of	O
IFN	O
-	O
gamma	O
cytoplasmic	O
mRNA	O
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Furthermore	O
,	O
both	O
transforming	O
growth	O
factor	O
-	O
beta	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	O
and	O
IL-12	O
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	O
gene	O
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	O
but	O
not	O
IL-12	O
induced	O
nuclear	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP1	O
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	O
binding	O
protein	O
complexes	O
is	O
correlated	O
with	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	O
and	O
IL-12	O
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN	O
-	O
gamma	O
and	O
GM	O
-	O
CSF	O
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B
cell	I
line	I
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

Restoration	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
ZEBRA	O
protein	O
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	O
activation	O
regions	O
.	O

The	O
ZEBRA	O
protein	O
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	O
proteins	O
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	O
is	O
a	O
bZIP	O
transcriptional	O
activator	O
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	O
response	O
elements	O
within	O
EBV	O
promoters	O
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	O
lytic	O
origin	O
.	O

We	O
have	O
employed	O
the	O
ZEBRA	O
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	O
activation	O
domain	O
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	O
domain	O
)	O
.	O

The	O
ZEBRA	O
activation	O
region	O
was	O
replaced	O
with	O
the	O
potent	O
acid	O
activation	O
region	O
from	O
the	O
herpes	O
simplex	O
virus	O
VP16	O
protein	O
or	O
with	O
the	O
activation	O
region	O
of	O
the	O
EBV	O
R	O
protein	O
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	O
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell	O
-	O
type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	O
's	O
ability	O
to	O
induce	O
early	O
antigen	O
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	O
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	O
domain	O
present	O
within	O
ZEBRA	O
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	O
factors	O
of	O
activated	O
T	O
cells	O
,	O
NFATp	O
and	O
NFATc	O
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	O
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	O
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFATp	O
)	O
,	O
a	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
-sensitive	O
factor	O
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	O
,	O
mediates	O
CD16	O
-induced	O
activation	O
of	O
cytokine	O
genes	O
in	O
human	O
NK	O
cells	O
.	O

CD16	O
(	O
Fc	O
gamma	O
RIIIA	O
)	O
-induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	O
ligands	O
induces	O
NFAT	O
-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA	O
-	O
sensitive	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	O
require	O
de	O
novo	O
protein	O
synthesis	O
.	O

NK	O
cell	O
NFAT	O
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	O
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	O
and	O
NFATc	O
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	O
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	O
and	O
NFATc-	O
specific	O
antibodies	O
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	O
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	O
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	O
express	O
NFATc	O
constitutively	O
,	O
but	O
NFATc	O
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	O
recognizing	O
the	O
T	O
cell	O
NFATc	O
revealed	O
no	O
detectable	O
NFATc	O
protein	O
in	O
nuclear	O
and	O
cytoplasmic	O
extracts	O
from	O
CD16-	O
or	O
phorbol	B
ester	I
-	I
stimulated	I
cells	I
at	O
any	O
time	O
tested	O
,	O
up	O
to	O
4	O
h	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA	O
-	O
sensitive	O
transcription	O
factors	O
,	O
NFATp	O
and	O
NFATc	O
,	O
are	O
expressed	O
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	O
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	O
mRNA	O
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	O
receptor	O
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	O
cells	O
(	O
U937	B
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	O
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein	O
-	O
labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double	O
-	O
labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	O
receptor	O
expression	O
in	O
U937	B
cells	I
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up	O
-	O
regulation	O
of	O
GR	O
mRNA	O
while	O
no	O
enhanced	O
GR	O
expression	O
was	O
perceived	O
with	O
RA	O
/	O
VD	O
treatment	O
.	O

Up	O
-	O
regulation	O
of	O
high	O
-	O
affinity	O
dehydroepiandrosterone	O
binding	O
activity	O
by	O
dehydroepiandrosterone	O
in	O
activated	O
human	O
T	O
lymphocytes	O
.	O

Although	O
evidence	O
indicates	O
that	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
exerts	O
direct	O
physiological	O
effects	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
unknown	O
.	O

DHEA	O
binding	O
sites	O
were	O
examined	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
in	O
a	O
human	B
T	I
lymphoid	I
cell	I
line	I
,	O
PEER	B
,	O
revealing	O
that	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
binding	O
sites	O
for	O
DHEA	O
(	O
dissociation	O
constant	O
=	O
7.4	O
+	O
/-	O
0.53	O
nmol	O
/	O
L	O
,	O
mean	O
+	O
/-	O
SE	O
,	O
n	O
=	O
4	O
)	O
was	O
greatly	O
increased	O
when	O
treated	O
with	O
DHEA	O
,	O
phorbol-12-myristate-13-acetate	O
,	O
and	O
the	O
Ca2	O
+	O
ionophore	O
A23187	O
.	O

Bound	O
[	O
3H	O
]	O
DHEA	O
was	O
displaced	O
sensitively	O
by	O
DHEA	O
and	O
secondarily	O
by	O
dihydrotestosterone	O
,	O
but	O
not	O
effectively	O
by	O
other	O
steroids	O
,	O
including	O
DHEA	O
sulfate	O
.	O

These	O
results	O
not	O
only	O
indicate	O
the	O
existence	O
of	O
a	O
DHEA	O
receptor	O
,	O
but	O
also	O
suggest	O
that	O
T	O
cells	O
become	O
susceptible	O
to	O
regulation	O
by	O
DHEA	O
during	O
the	O
process	O
of	O
signal	O
-	O
induced	O
activation	O
.	O

Attenuation	O
of	O
gamma	O
interferon	O
-induced	O
tyrosine	O
phosphorylation	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
:	O
selective	O
inhibition	O
of	O
signaling	O
through	O
Janus	O
kinases	O
and	O
Stat1	O
.	O

The	O
induction	O
of	O
gene	O
transcription	O
in	O
response	O
to	O
gamma	O
interferon	O
is	O
impaired	O
in	O
mononuclear	O
phagocytes	O
infected	O
with	O
Leishmania	O
donovani	O
,	O
and	O
the	O
mechanisms	O
involved	O
are	O
not	O
fully	O
understood	O
.	O

The	O
changes	O
in	O
gene	O
expression	O
brought	O
about	O
by	O
gamma	O
interferon	O
are	O
thought	O
to	O
involve	O
transient	O
increases	O
in	O
the	O
activities	O
of	O
cellular	O
protein	O
tyrosine	O
kinases	O
,	O
including	O
the	O
Janus	O
kinases	O
Jak1	O
and	O
Jak2	O
,	O
leading	O
to	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
Stat1	O
.	O

To	O
investigate	O
the	O
mechanisms	O
accounting	O
for	O
the	O
impaired	O
responses	O
to	O
gamma	O
interferon	O
,	O
a	O
model	O
system	O
for	O
examining	O
overall	O
changes	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
activation	O
of	O
Jak1	O
and	O
Jak2	O
and	O
phosphorylation	O
of	O
Stat1	O
was	O
developed	O
in	O
phorbol	B
12-myristate	I
13-acetate	I
-	I
differentiated	I
U-937	I
cells	I
.	O

Analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
by	O
antiphosphotyrosine	O
immunoblotting	O
showed	O
that	O
incubation	O
with	O
gamma	O
interferon	O
brought	O
about	O
specific	O
increases	O
in	O
phosphotyrosine	O
labeling	O
of	O
several	O
proteins	O
.	O

Increased	O
labeling	O
of	O
these	O
proteins	O
occurred	O
to	O
similar	O
extents	O
in	O
control	O
cells	O
and	O
in	O
cells	O
that	O
had	O
been	O
infected	O
with	O
L.	O
donovani	O
for	O
16	O
h	O
.	O

Jak1	O
,	O
Jak2	O
,	O
and	O
Stat1	O
were	O
immunoprecipitated	O
from	O
control	O
and	O
interferon	B
-	I
treated	I
cells	I
,	O
and	O
tyrosine	O
phosphorylation	O
of	O
these	O
proteins	O
,	O
detected	O
by	O
antiphosphotyrosine	O
immunoblotting	O
was	O
used	O
to	O
measured	O
their	O
activation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak1	O
,	O
Jak2	O
,	O
and	O
Stat1	O
increased	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
U-937	B
cells	I
incubated	O
with	O
gamma	O
interferon	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
infected	O
with	O
L.	O
donovani	O
,	O
tyrosine	O
phosphorylation	O
of	O
Jak1	O
,	O
Jak2	O
,	O
and	O
Stat1	O
was	O
markedly	O
impaired	O
.	O

This	O
effect	O
was	O
dependent	O
upon	O
the	O
duration	O
of	O
exposure	O
to	O
L.	O
donovani	O
and	O
was	O
maximal	O
and	O
complete	O
at	O
16	O
h	O
.	O

Results	O
similar	O
to	O
those	O
observed	O
with	O
U-937	B
cells	I
were	O
also	O
obtained	O
with	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

These	O
findings	O
indicate	O
that	O
infection	O
of	O
human	O
mononuclear	O
phagocytes	O
with	O
L.	O
donovani	O
leads	O
to	O
impaired	O
gamma	O
interferon	O
-mediated	O
tyrosine	O
phosphorylation	O
and	O
selective	O
effects	O
on	O
the	O
Jak-	O
Stat1	O
pathway	O
.	O

Unresponsiveness	O
to	O
gamma	O
interferon	O
for	O
activation	O
of	O
this	O
pathway	O
may	O
explain	O
impaired	O
transcriptional	O
responses	O
in	O
leishmania	O
-	O
infected	O
cells	O
.	O

Regulation	O
of	O
IkB	O
alpha	O
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
phosphatase	O
calcineurin	O
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC	O
-induced	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
in	O
T	B
cell	I
lines	I
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	B
cell	I
line	I
U937	I
calcineurin	O
is	O
also	O
sufficient	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
PKC	O
-	O
dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	O
alpha	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	O
alpha	O
phosphorylation	O
.	O

While	O
PKC	O
-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	O
alpha	O
in	O
T	B
cell	I
lines	I
,	O
co	O
-	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	O
alpha	O
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	O
result	O
in	O
the	O
phosphorylation	O
and/or	O
degradation	O
of	O
IkB	O
alpha	O
in	O
Jurkat	B
T	I
or	O
in	O
U937	B
cells	I
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	O
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA	O
-	O
induced	O
IkB	O
alpha	O
phosphorylation	O
/	O
degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkB	O
alpha	O
induced	O
by	O
TNF	O
-	O
alpha	O
,	O
a	O
PKC	O
-independent	O
stimulus	O
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF	O
-	O
alpha	O
not	O
at	O
the	O
level	O
of	O
IkB	O
alpha	O
phosphorylation	O
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	O
calcineurin	O
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC	O
-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	O
alpha	O
phosphorylation	O
and	O
degradation	O
.	O

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal	O
-	O
induced	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	O
protein	O
I	O
kappa	O
B	O
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
to	O
release	O
NF	O
kappa	O
B	O
.	O

Cu2	O
+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF	O
-	O
alpha	O
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF	O
-	O
alpha	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	O
kappa	O
B	O
alpha	O
,	O
indicating	O
that	O
Cu2	O
+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B	O
-	O
I	O
kappa	O
B	O
complex	O
.	O

Neither	O
phosphorylation	O
nor	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
was	O
observed	O
upon	O
TNF	O
-	O
alpha	O
stimulation	O
in	O
the	O
presence	O
of	O
Cu2	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Cu2	O
+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

ETS1	O
transactivates	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	B
T	I
cells	I
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP-1	O
and	O
ETS	O
-	O
like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	O
and	O
ELF1	O
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-47	O
to	O
-40	O
upstream	O
of	O
the	O
GM	O
-	O
CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	O
,	O
but	O
not	O
ELF1	O
,	O
can	O
transactivate	O
GM	O
-	O
CSF	O
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA	O
/	O
ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS	O
-	O
like	O
factors	O
present	O
in	O
Jurkat	B
cells	I
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-GGAA-	O
to	O
-GGAT-	O
prevents	O
the	O
binding	O
of	O
ETS	O
-	O
like	O
factors	O
with	O
the	O
exception	O
of	O
ETS1	O
.	O

The	O
GM	O
-	O
CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	O
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA	O
/	O
ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	O
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	O
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM	O
-	O
CSF	O
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Regulation	O
of	O
the	O
balance	O
of	O
cytokine	O
production	O
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factor	O
activity	O
by	O
cytokines	O
and	O
inflammatory	O
synovial	O
fluids	O
.	O

The	O
balance	O
between	O
type	O
1	O
and	O
2	O
T	O
helper	O
cell	O
cytokine	O
production	O
plays	O
an	O
important	O
role	O
in	O
several	O
animal	O
models	O
of	O
autoimmunity	O
,	O
and	O
skewed	O
patterns	O
of	O
cytokine	O
expression	O
have	O
been	O
described	O
in	O
human	O
inflammatory	O
diseases	O
.	O

Many	O
cytokines	O
activate	O
signal	O
transducer	O
and	O
activation	O
of	O
transcription	O
(	O
STAT	O
)	O
transcription	O
factors	O
,	O
which	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
inflammatory	O
effector	O
genes	O
.	O

We	O
used	O
mononuclear	B
cell	I
priming	I
cultures	I
and	O
inflammatory	O
synovial	O
fluids	O
(	O
SFs	O
)	O
derived	O
from	O
arthritis	O
patients	O
to	O
examine	O
the	O
regulation	O
of	O
cytokine	O
production	O
and	O
STAT	O
activity	O
by	O
an	O
inflammatory	O
synovial	O
microenvironment	O
.	O

Exposure	O
to	O
SFs	O
during	O
priming	O
resulted	O
in	O
an	O
81	O
%	O
inhibition	O
of	O
interferon	O
(	O
IFN	O
)	O
-gamma	O
,	O
but	O
not	O
interleukin	O
(	O
IL	O
)	O
4	O
,	O
production	O
by	O
effector	O
cells	O
generated	O
in	O
priming	O
cultures	O
.	O

SF	O
suppression	O
was	O
mediated	O
by	O
IL-4	O
and	O
IL-10	O
and	O
inhibition	O
of	O
IL-12	O
expression	O
,	O
and	O
it	O
was	O
reversed	O
in	O
a	O
dominant	O
fashion	O
by	O
exogenous	O
IL-12	O
.	O

SFs	O
blocked	O
the	O
sustained	O
activity	O
of	O
transcription	O
factor	O
Stat1	O
,	O
but	O
not	O
Stat3	O
,	O
during	O
the	O
priming	O
period	O
,	O
and	O
Stat1	O
activity	O
was	O
differentially	O
regulated	O
by	O
cytokines	O
in	O
parallel	O
with	O
their	O
positive	O
or	O
negative	O
regulation	O
of	O
IFN	O
-	O
gamma	O
production	O
.	O

Active	O
Stat3	O
,	O
but	O
not	O
Stat1	O
,	O
was	O
detected	O
in	O
cells	O
from	O
inflamed	O
joints	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
altered	O
balance	O
of	O
Stat1	O
and	O
Stat3	O
transcriptional	O
activity	O
in	O
the	O
regulation	O
of	O
T	O
cell	O
differentiation	O
and	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
synovitis	O
.	O

MEK1	O
and	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL-2	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

TCR	O
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
Raf-1	O
.	O

Active	O
Raf-1	O
phosphorylates	O
and	O
activates	O
the	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
/	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
kinase	O
1	O
(	O
MEK1	O
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	O
kinases	O
/	O
extracellular	O
signal	O
regulated	O
kinases	O
,	O
ERK1	O
and	O
ERK2	O
.	O

Raf-1	O
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	O
and	O
ERK	O
activities	O
also	O
stimulate	O
IL-2	O
gene	O
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf-1	O
or	O
MEK1	O
in	O
Jurkat	B
T	I
cells	I
enhanced	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF	O
-	O
AT	O
activity	O
.	O

Expression	O
of	O
MEK1-interfering	O
mutants	O
inhibited	O
the	O
stimulation	O
of	O
IL-2	O
promoter	O
-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	O
and	O
Raf-1	O
to	O
costimulate	O
NF	O
-	O
AT	O
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	O
kinase	O
-	O
specific	O
phosphatase	O
,	O
MKP-1	O
,	O
which	O
blocks	O
ERK	O
activation	O
,	O
inhibited	O
IL-2	O
promoter	O
and	O
NF	O
-	O
AT	O
-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	O
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	O
kinase	O
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	O
,	O
MEK1	O
,	O
and	O
ERK1	O
and	O
ERK2	O
functions	O
in	O
the	O
stimulation	O
IL-2	O
gene	O
transcription	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
NF	O
-	O
AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
calcineurin	O
.	O

An	O
inhibitory	O
,	O
`	O
`	O
dominant	O
-	O
negative	O
,	O
''	O
form	O
of	O
the	O
calcineurin	O
catalytic	O
(	O
A	O
)	O
subunit	O
was	O
prepared	O
,	O
which	O
lacks	O
the	O
calmodulin	O
-	O
binding	O
domain	O
,	O
autoinhibitory	O
domain	O
and	O
most	O
of	O
its	O
catalytic	O
core	O
but	O
possesses	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin	O
-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
`	O
`	O
B	O
-	O
subunit	O
knock	O
-	O
out	O
''	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF	O
-	O
AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope	O
-	O
labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	O
B	O
subunit	O
in	O
Jurkat	B
cells	I
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	O
subunit	O
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF	O
-	O
AT	O
activity	O
produced	O
by	O
co	O
-	O
transfecting	O
BKO	O
could	O
be	O
`	O
`	O
rescued	O
''	O
by	O
overexpression	O
of	O
transfected	O
B	O
subunit	O
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin	O
-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	O
A	O
and	O
B	O
subunits	O
.	O

Inhibition	O
of	O
vitamin	O
D	O
receptor	O
-	O
retinoid	O
X	O
receptor	O
-	O
vitamin	O
D	O
response	O
element	O
complex	O
formation	O
by	O
nuclear	O
extracts	O
of	O
vitamin	O
D	O
-	O
resistant	O
New	O
World	O
primate	O
cells	O
.	O

Most	O
New	O
World	O
primate	O
(	O
NWP	O
)	O
genera	O
evolved	O
to	O
require	O
high	O
circulating	O
levels	O
of	O
steroid	O
hormones	O
and	O
vitamin	O
D	O
.	O

We	O
hypothesized	O
that	O
an	O
intracellular	O
vitamin	O
D	O
binding	O
protein	O
(	O
IDBP	O
)	O
,	O
present	O
in	O
both	O
nuclear	O
and	O
cytoplasmic	O
fractions	O
of	O
NWP	B
cells	I
,	O
or	O
another	O
protein	O
(	O
s	O
)	O
may	O
cause	O
or	O
contribute	O
to	O
the	O
steroid	O
hormone	O
-	O
resistant	O
state	O
in	O
NWP	B
by	O
disruption	O
of	O
the	O
receptor	O
dimerization	O
process	O
and/or	O
by	O
interference	O
of	O
receptor	O
complex	O
binding	O
to	O
the	O
consensus	O
response	O
elements	O
present	O
in	O
the	O
enhancer	O
regions	O
of	O
steroid	O
-	O
responsive	O
genes	O
.	O

We	O
employed	O
electromobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
to	O
screen	O
for	O
the	O
presence	O
of	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
vitamin	O
D	O
response	O
element	O
(	O
VDRE	O
)	O
.	O

Nuclear	O
and	O
post	O
-	O
nuclear	O
extracts	O
were	O
prepared	O
from	O
two	O
B	B
-	I
lymphoblastoid	I
cell	I
lines	I
known	O
to	O
be	O
representative	O
of	O
the	O
vitamin	B
D	I
-	I
resistant	I
and	O
wild	B
type	I
phenotypes	I
,	O
respectively	O
.	O

The	O
extracts	O
were	O
compared	O
for	O
their	O
ability	O
to	O
retard	O
the	O
migration	O
of	O
radiolabeled	O
double	O
stranded	O
oligomers	O
representative	O
of	O
the	O
VDREs	O
of	O
the	O
human	O
osteocalcin	O
and	O
the	O
mouse	O
osteopontin	O
gene	O
promoters	O
.	O

A	O
specific	O
,	O
retarded	O
band	O
containing	O
VDR	O
-	O
RXR	O
was	O
identified	O
when	O
wild	O
type	O
cell	O
but	O
not	O
when	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
was	O
used	O
in	O
the	O
binding	O
reaction	O
with	O
either	O
probe	O
.	O

In	O
addition	O
,	O
vitamin	O
D	O
-	O
resistant	O
cell	O
nuclear	O
extract	O
contained	O
a	O
protein	O
(	O
s	O
)	O
which	O
was	O
bound	O
specifically	O
to	O
the	O
VDRE	O
and	O
was	O
capable	O
of	O
completely	O
inhibiting	O
VDR	O
-	O
RXR	O
-	O
VDRE	O
complex	O
formation	O
;	O
these	O
effects	O
were	O
not	O
demonstrated	O
with	O
nuclear	O
extract	O
from	O
the	O
wild	B
type	I
cell	I
line	I
or	O
with	O
the	O
post	O
-	O
nuclear	O
extract	O
of	O
the	O
vitamin	B
D	I
-	I
resistant	I
cell	I
line	I
.	O

We	O
conclude	O
that	O
a	O
VDRE	O
-	O
binding	O
protein	O
(	O
s	O
)	O
,	O
distinct	O
from	O
IDBP	O
and	O
present	O
in	O
nuclear	O
extract	O
of	O
cells	O
from	O
a	O
prototypical	B
vitamin	I
D	I
-	I
resistant	I
NWP	I
,	O
is	O
capable	O
of	O
inhibiting	O
normal	O
VDR	O
-	O
RXR	O
heterodimer	O
binding	O
to	O
the	O
VDRE	O
.	O

Glucocorticoids	O
induced	O
down	O
-	O
regulation	O
of	O
glucocorticoid	O
receptor	O
mRNA	O
expression	O
in	O
asthma	O
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	O
receptor	O
and	O
the	O
AP-1	O
complex	O
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes	O
,	O
including	O
glucocorticoid	O
receptor	O
itself	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
expression	O
of	O
mRNA	O
for	O
glucocorticoid	O
receptor	O
in	O
human	O
blood	O
monocytes	O
obtained	O
from	O
seven	O
unstable	O
untreated	O
asthmatic	O
patients	O
who	O
were	O
subsequently	O
treated	O
with	O
high	O
doses	O
of	O
parenteral	O
corticosteroid	O
(	O
methyl	O
prednisolone	O
120	O
mg	O
/	O
day	O
)	O
for	O
10	O
days	O
.	O

mRNA	O
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	O
transcriptase	O
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+	O
/-	O
4.93	O
versus	O
95.57	O
+	O
/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	O
receptor	O
mRNA	O
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down	O
-	O
regulation	O
for	O
the	O
glucocorticoid	O
receptor	O
mRNA	O
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

Differential	O
regulation	O
of	O
IL-6	O
gene	O
transcription	O
and	O
expression	O
by	O
IL-4	O
and	O
IL-10	O
in	O
human	B
monocytic	I
cell	I
lines	I
.	O

IL-4	O
and	O
IL-10	O
inhibit	O
the	O
cytokine	O
production	O
and	O
mRNA	O
expression	O
by	O
monocytes	O
/	O
macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post	O
-	O
transcriptional	O
regulation	O
of	O
IL-6	O
gene	O
expression	O
by	O
IL-4	O
and	O
IL-10	O
,	O
we	O
studied	O
IL-6	O
production	O
,	O
expression	O
level	O
of	O
IL-6	O
mRNA	O
,	O
IL-6	O
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
IL-6	O
,	O
and	O
IL-6	O
mRNA	O
stability	O
in	O
human	B
monocytic	I
cell	I
lines	I
,	O
THP-1	B
and	O
U937	B
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	O
or	O
IL-10	O
.	O

Both	O
IL-4	O
and	O
IL-10	O
were	O
seen	O
to	O
inhibit	O
IL-6	O
production	O
and	O
the	O
expression	O
of	O
IL-6	O
mRNA	O
in	O
both	O
monocytic	B
cell	I
lines	I
studied	O
.	O

In	O
chloramphenicol	O
acetyltransferase	O
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
plasmid	O
containing	O
the	O
IL-6	O
gene	O
promoter	O
,	O
IL-4	O
,	O
but	O
not	O
IL-10	O
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	O
,	O
but	O
not	O
IL-10	O
,	O
inhibited	O
nuclear	O
NF	O
-	O
kappaB	O
activity	O
,	O
and	O
that	O
IL-4	O
and	O
IL-10	O
did	O
not	O
affect	O
NF-	O
IL-6	O
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	O
enhanced	O
the	O
degradation	O
of	O
IL-6	O
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	O
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL-6	O
gene	O
by	O
affecting	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
while	O
IL-10	O
may	O
inhibit	O
the	O
IL-6	O
mRNA	O
levels	O
post	O
-	O
transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	O
and	O
IL-10	O
inhibit	O
IL-6	O
production	O
by	O
different	O
mechanisms	O
in	O
human	B
monocytic	I
cell	I
lines	I
.	O

Cyclic	O
AMP	O
-responsive	O
element	O
-dependent	O
activation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
zebra	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
.	O

We	O
have	O
recently	O
shown	O
that	O
infection	O
of	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
genome	I
-	I
positive	I
B	I
cells	I
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
results	O
in	O
the	O
expression	O
of	O
the	O
immediate	O
-	O
early	O
EBV	O
Zebra	O
gene	O
,	O
followed	O
by	O
virus	O
replication	O
(	O
L.Flamand	O
,	O
I.Stefanescu	O
,	O
D.V.Ablashi	O
,	O
and	O
J.Menezes	O
,	O
J.Virol.67	O
:	O
6768	O
-	O
6777	O
,	O
1993	O
)	O
.	O

Here	O
we	O
show	O
that	O
HHV-6	O
upregulates	O
Zebra	O
gene	O
transcription	O
through	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
located	O
within	O
the	O
Zebra	O
promoter	O
(	O
Zp	O
)	O
.	O

Using	O
human	B
B-	I
or	I
T	I
-	I
cell	I
lines	I
transfected	O
with	O
ZpCat	O
reporter	O
gene	O
constructs	O
,	O
we	O
demonstrate	O
that	O
a	O
region	O
designated	O
the	O
ZII	O
domain	O
of	O
Zp	O
is	O
the	O
target	O
of	O
HHV-6	O
transactivation	O
.	O

Mutation	O
of	O
the	O
consensus	O
AP-1	O
/	O
CRE	O
site	O
within	O
ZII	O
abolished	O
the	O
inducibility	O
of	O
Zp	O
by	O
HHV-6	O
,	O
whereas	O
positioning	O
of	O
the	O
ZII	O
domain	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
minimal	O
promoter	O
conferred	O
responsiveness	O
following	O
HHV-6	O
infection	O
.	O

Binding	O
of	O
these	O
factors	O
to	O
ZII	O
was	O
prevented	O
by	O
oligonucleotides	O
containing	O
CRE	O
but	O
not	O
by	O
AP-1	O
consensus	O
sequences	O
.	O

Antibodies	O
against	O
CRE	O
-	O
binding	O
(	O
CREB	O
)	O
protein	O
but	O
not	O
against	O
c	O
-	O
Fos	O
or	O
c	O
-	O
Jun	O
were	O
able	O
to	O
supershift	O
the	O
DNA	O
-	O
protein	O
complex	O
,	O
identifying	O
the	O
nature	O
of	O
the	O
transcription	O
factor	O
which	O
binds	O
to	O
ZII	O
as	O
a	O
member	O
of	O
the	O
CREB	O
family	O
of	O
proteins	O
.	O

Finally	O
,	O
transfection	O
of	O
CREB	O
protein	O
and	O
protein	O
kinase	O
A	O
expression	O
vectors	O
were	O
found	O
to	O
activate	O
Zp	O
in	O
Jurkat	O
cells	O
,	O
suggesting	O
that	O
phosphorylated	O
form	O
of	O
CREB	O
protein	O
can	O
play	O
a	O
determining	O
role	O
in	O
the	O
EBV	O
reactivation	O
process	O
.	O

Expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
proteins	O
and	O
AP-1	O
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	B
cells	I
and	O
phytohemagglutinin	B
-	I
stimulated	I
lymphocytes	I
.	O

The	O
protein	O
products	O
of	O
the	O
c	O
-	O
fos	O
(	O
p62c	O
-	O
fos	O
)	O
and	O
c	O
-	O
jun	O
(	O
p39c	O
-	O
jun	O
)	O
genes	O
are	O
members	O
of	O
the	O
AP-1	O
transcription	O
factor	O
family	O
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	O
give	O
direct	O
information	O
about	O
the	O
presence	O
of	O
the	O
proteins	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	B
systems	I
:	O
a	O
continuously	B
growing	I
myeloid	I
leukemic	I
cell	I
line	I
,	O
HL60	B
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto-	B
hemagglutinin	I
(	I
PHA	I
)	I
-stimulated	I
normal	I
human	I
peripheral	I
blood	I
lymphocytes	I
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP-1	O
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	O
and	O
Jun	O
family	O
proteins	O
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c	O
-	O
fos	O
,	O
p39c	O
-	O
jun	O
,	O
and	O
AP-1	O
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	B
cells	I
and	O
in	O
PHA	B
-	I
stimulated	I
PBL	I
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	O
transiently	O
in	O
the	O
G0	O
to	O
G1	O
transition	O
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	O
binding	O
activity	O
from	O
p62c	O
-	O
fos	O
,	O
and	O
p39c	O
-	O
jun	O
AP-1	O
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2	O
/	O
M	O
-	O
phase	O
enriched	O
samples	O
than	O
in	O
the	O
S	O
-	O
phase	O
enriched	O
samples	O
of	O
HL60	B
cells	I
,	O
while	O
levels	O
of	O
nuclear	O
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
,	O
but	O
AP-1	O
was	O
not	O
detected	O
in	O
the	O
majority	O
of	O
samples	O
.	O

Following	O
PHA	O
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP-1	O
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c	O
-	O
jun	O
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	O
p62c	O
-	O
fos	O
and	O
p39c	O
-	O
jun	O
were	O
present	O
in	O
HL60	B
cells	I
and	O
PHA	B
-	I
stimulated	I
PBL	I
.	O

However	O
,	O
no	O
cytoplasmic	O
p62c	O
-	O
fos	O
was	O
detected	O
in	O
unstimulated	O
PBL	O
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	O
p39c	O
-	O
jun	O
was	O
detected	O
,	O
suggesting	O
that	O
subcellular	O
compartmentalization	O
of	O
these	O
proteins	O
may	O
occur	O
under	O
certain	O
circumstances	O
.	O

Soluble	O
tumor	O
necrosis	O
factor	O
receptors	O
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine	O
-	O
induced	O
HIV-1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
binding	O
protein-1	O
(	O
r	O
-	O
h	O
TBP-1	O
)	O
and	O
recombinant	O
human	O
soluble	O
dimeric	O
TNF	O
receptor	O
(	O
rhu	O
TNFR	O
:	O
Fc	O
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine	O
-	O
induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1-infected	O
promonocytic	O
U1	O
cells	O
with	O
r	O
-	O
h	O
-	O
TBP-1	O
or	O
rhu	O
TNFR	O
:	O
Fc	O
reduced	O
PMA	O
-	O
induced	O
HIV-1	O
p24	O
antigen	O
production	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	O
antigen	O
production	O
in	O
T	B
-	I
lymphocytic	I
ACH-2	I
cells	I
was	O
47	O
%	O
with	O
r	O
-	O
hTBP-1	O
and	O
42	O
%	O
with	O
rhu	O
TNFR	O
:	O
Fc	O
.	O

r	O
-	O
hTBP-1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
also	O
decreased	O
p24	O
antigen	O
synthesized	O
by	O
U1	B
cells	I
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
supernatant	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
interleukin-6	O
,	O
and	O
TNF	O
.	O

Addition	O
of	O
r	O
-	O
hTBP-1	O
to	O
U1	B
cells	I
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	O
antigen	O
production	O
by	O
15	O
%	O
.	O

U1	B
cells	I
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng	O
/	O
ml	O
endogenous	O
TBP-1	O
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r	O
-	O
hTBP-1	O
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r	O
-	O
hTBP-1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
blocked	O
PMA	O
induction	O
of	O
nuclear	O
factor	O
(	O
NK	O
)	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
U1	B
cells	I
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli	O
-	O
induced	O
HIV-1	O
expression	O
and	O
NK-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

Reversible	O
differentiation	O
of	O
human	B
monoblastic	I
leukemia	I
U937	I
cells	I
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
.	O

Human	B
monoblastic	I
leukemia	I
U937	I
cells	I
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H	O
-	O
hexahydro-1	O
,	O
4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
,	O
induces	O
differentiation	O
of	O
monocytoid	B
leukemia	I
cell	I
lines	I
U937	B
and	O
THP-1	B
but	O
not	O
of	O
myeloblastic	B
leukemic	I
ML-1	I
cell	I
or	O
erythroleukemia	B
K562	I
cells	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	B
cell	I
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML-9	O
also	O
induced	O
alpha	O
-	O
naphthyl	O
acetate	O
esterase	O
(	O
ANAE	O
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML-9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML-9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML-9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation	O
-	O
associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	B
cells	I
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	B
monoblastic	I
cells	I
,	O
THP-1	B
.	O

ML-9	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
morphology	O
of	O
U937	B
cells	I
but	O
increased	O
the	O
expression	O
of	O
monocyte	O
-	O
macrophage	O
lineage	O
-	O
associated	O
surface	O
antigen	O
,	O
CD14	O
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
myc	O
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
,	O
but	O
ML-9	O
did	O
not	O
affect	O
the	O
expression	O
of	O
these	O
oncogenes	O
appreciably	O
.	O

ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti	O
-	O
cancer	O
drug	O
such	O
as	O
1-beta	O
-	O
D	O
-	O
arabino	O
-	O
furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
1	O
(	O
TGF	O
-	O
beta	O
1	O
)	O
,	O
which	O
did	O
not	O
induce	O
differentiation	O
of	O
U937	B
cells	I
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML-9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

The	O
myeloid	O
-	O
cell	O
-	O
specific	O
c	O
-	O
fes	O
promoter	O
is	O
regulated	O
by	O
Sp1	O
,	O
PU.1	O
,	O
and	O
a	O
novel	O
transcription	O
factor	O
.	O

The	O
protein	O
product	O
of	O
the	O
c	O
-	O
fps	O
/	O
fes	O
(	O
c	O
-	O
fes	O
)	O
proto	O
-	O
oncogene	O
has	O
been	O
implicated	O
in	O
the	O
normal	O
development	O
of	O
myeloid	O
cells	O
(	O
macrophages	O
and	O
neutrophils	O
)	O
.	O

mRNA	O
for	O
c	O
-	O
fes	O
has	O
been	O
detected	O
exclusively	O
in	O
myeloid	O
cells	O
and	O
vascular	O
endothelial	O
cells	O
in	O
adult	O
mammals	O
.	O

Although	O
a	O
13-kilobase	O
-	O
pair	O
(	O
kb	O
)	O
human	O
c	O
-	O
fes	O
transgene	O
exhibits	O
high	O
levels	O
of	O
expression	O
in	O
mice	O
,	O
the	O
sequences	O
that	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
human	O
c	O
-	O
fes	O
gene	O
have	O
not	O
been	O
defined	O
.	O

Transient	O
-	O
transfection	O
experiments	O
demonstrated	O
that	O
plasmids	O
containing	O
446	O
bp	O
of	O
c	O
-	O
fes	O
5'-flanking	O
sequences	O
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
active	O
exclusively	O
in	O
myeloid	O
cells	O
.	O

No	O
other	O
DNA	O
element	O
within	O
the	O
13-kb	O
human	O
c	O
-	O
fes	O
locus	O
contained	O
positive	O
cis	O
-	O
acting	O
elements	O
,	O
with	O
the	O
exception	O
of	O
a	O
weakly	O
active	O
region	O
within	O
the	O
3'-flanking	O
sequences	O
.	O

DNase	O
I	O
footprinting	O
assays	O
revealed	O
four	O
distinct	O
sites	O
that	O
bind	O
myeloid	O
nuclear	O
proteins	O
(	O
-408	O
to	O
-386	O
,	O
-293	O
to	O
-254	O
,	O
-76	O
to	O
-65	O
,	O
and	O
-34	O
to	O
+	O
3	O
)	O
.	O

However	O
,	O
the	O
first	O
two	O
footprints	O
resided	O
in	O
sequences	O
that	O
were	O
largely	O
dispensable	O
for	O
transient	O
activity	O
.	O

Plasmids	O
containing	O
151	O
bp	O
of	O
5'-flanking	O
sequences	O
confer	O
myeloid	O
-	O
cell	O
-	O
specific	O
gene	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analyses	O
demonstrated	O
that	O
the	O
151-bp	O
region	O
contains	O
nuclear	O
protein	O
binding	O
sites	O
for	O
Sp1	O
,	O
PU.1	O
,	O
and/or	O
Elf-1	O
,	O
and	O
a	O
novel	O
factor	O
.	O

This	O
unidentified	O
factor	O
binds	O
immediately	O
3	O
'	O
of	O
the	O
PU.1	O
/	O
Elf-1	O
sites	O
and	O
appears	O
to	O
be	O
myeloid	O
cell	O
specific	O
.	O

Mutation	O
of	O
the	O
PU.1	O
/Elf-1	O
site	O
or	O
the	O
3	O
'	O
site	O
(	O
FP4	O
-	O
3	O
'	O
)	O
within	O
the	O
context	O
of	O
the	O
c	O
-	O
fes	O
promoter	O
resulted	O
in	O
substantially	O
reduced	O
activity	O
in	O
transient	O
transfections	O
.	O

Furthermore	O
,	O
transient	O
-	O
cotransfection	O
assay	O
demonstrated	O
that	O
PU.1	O
(	O
and	O
not	O
Elf-1	O
)	O
can	O
transactivate	O
the	O
c	O
-	O
fes	O
promoter	O
in	O
nonmyeloid	B
cell	I
lines	I
.	O

We	O
conclude	O
that	O
the	O
human	O
c	O
-	O
fes	O
gene	O
contains	O
a	O
strong	O
myeloid	O
-	O
cell	O
-	O
specific	O
promoter	O
that	O
is	O
regulated	O
by	O
Sp1	O
,	O
PU.1	O
,	O
and	O
a	O
novel	O
transcription	O
factor	O
.	O

Transcriptional	O
activation	O
of	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
genes	O
by	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
tax	O
protein	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
-	O
encoded	O
tax	O
protein	O
is	O
a	O
potent	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
genes	O
transcribed	O
by	O
RNA	O
polymerase	O
II	O
.	O

We	O
find	O
that	O
both	O
chromatin	O
and	O
cell	O
extracts	O
derived	O
from	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1-infected	I
human	I
T	I
lymphocytes	I
support	O
higher	O
levels	O
of	O
5S	O
rRNA	O
and	O
tRNA	O
gene	O
transcription	O
than	O
chromatin	O
or	O
extracts	O
from	O
uninfected	O
T	O
lymphocytes	O
.	O

The	O
viral	O
protein	O
Tax	O
was	O
likely	O
responsible	O
for	O
this	O
higher	O
level	O
of	O
class	O
II	O
gene	O
transcription	O
,	O
as	O
purified	O
Tax	O
was	O
found	O
to	O
stimulate	O
both	O
genes	O
when	O
added	O
to	O
the	O
uninfected	O
cell	O
extract	O
or	O
in	O
reconstituted	O
systems	O
.	O

Both	O
limiting	O
-	O
component	O
transcription	O
assays	O
and	O
DNA	O
binding	O
assays	O
identified	O
the	O
class	O
III	O
gene	O
transcription	O
factor	O
TFIIIB	O
as	O
the	O
principle	O
target	O
of	O
Tax	O
activity	O
.	O

Surprisingly	O
,	O
we	O
find	O
that	O
Tax	O
increases	O
the	O
effective	O
concentration	O
of	O
active	O
TFIIIB	O
molecules	O
.	O

These	O
data	O
suggest	O
that	O
Tax	O
stimulates	O
RNA	O
polymerase	O
III	O
-	O
dependent	O
gene	O
expression	O
by	O
accelerating	O
the	O
rate	O
and/or	O
extent	O
of	O
transcription	O
initiation	O
complex	O
assembly	O
.	O

Induction	O
of	O
CIITA	O
and	O
modification	O
of	O
in	O
vivo	O
HLA	O
-	O
DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN	O
-	O
gamma	O
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA	O
-	O
DR	O
-	O
constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN	O
-	O
gamma	O
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	B
epithelial	I
cells	I
(	O
TEC	B
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	O
class	O
II	O
induction	O
is	O
studied	O
in	O
a	O
`	O
`	O
physiologic	O
''	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	O
trans	O
-	O
activator	O
,	O
a	O
crucial	O
MHC	O
class	O
II	O
gene	O
regulatory	O
factor	O
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	O
factors	O
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	O
I	O
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN	O
-	O
gamma	O
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	O
factors	O
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II	O
-	O
constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	B
lymphoma	I
line	I
Raji	I
and	O
normal	O
tonsil-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	B
,	O
either	O
IFN	O
-	O
gamma	O
-induced	O
or	O
not	O
,	O
and	O
the	O
constitutive	O
B	B
cells	I
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	O
trans	O
-	O
activator	O
,	O
and	O
distinct	O
tissue	O
-	O
specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN	O
-	O
gamma	O
-induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c	O
-	O
jun	O
and	O
suppress	O
IL-2	O
promoter	O
activation	O
in	O
Jurkat	B
T	I
cells	I
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c	O
-	O
Fos	O
/	O
c	O
-	O
Jun	O
AP-1	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
.	O

The	O
present	O
results	O
show	O
that	O
Jurkat	B
T	I
cells	I
acutely	O
exposed	O
to	O
micromolar	O
concentrations	O
of	O
H2O2	O
exhibit	O
substantial	O
increases	O
in	O
AP-1	O
binding	O
activity	O
and	O
the	O
expression	O
of	O
c	O
-	O
jun	O
but	O
not	O
c	O
-	O
fos	O
mRNA	O
.	O

The	O
preferential	O
induction	O
of	O
c	O
-	O
jun	O
by	O
H2O2	O
did	O
not	O
represent	O
redox	O
stabilization	O
of	O
mRNA	O
transcripts	O
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA	O
/	O
PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c	O
-	O
jun	O
promoter	O
via	O
the	O
proximal	O
jun1	O
tumor	O
promoter	O
-	O
responsive	O
element	O
(	O
TRE	O
)	O
-like	O
promoter	O
element	O
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	O
AP-1	O
TRE	O
and	O
jun	O
TRE	O
-	O
like	O
motifs	O
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA	O
/	O
PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c	O
-	O
Fos	O
,	O
c	O
-	O
Jun	O
,	O
and	O
JunD	O
.	O

However	O
,	O
PHA	O
/	O
PMA	O
but	O
not	O
oxidative	O
signals	O
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	O
constructs	O
containing	O
the	O
AP-1-TRE	O
,	O
NF	O
-	O
AT	O
,	O
and	O
IL-2	O
promoter	O
regions	O
along	O
with	O
IL-2	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF	O
-	O
AT	O
and	O
IL-2	O
reporters	O
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	O
mRNA	O
in	O
cells	O
stimulated	O
with	O
PHA	O
/	O
PMA	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF	O
-	O
AT	O
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	O
complexes	O
rather	O
than	O
the	O
binding	O
of	O
preformed	O
NF	O
-	O
AT	O
complexes	O
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	O
cell	O
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP-1	O
regulation	O
of	O
c	O
-	O
jun	O
from	O
transcriptional	O
up	O
-	O
regulation	O
of	O
IL-2	O
via	O
NF	O
-	O
AT	O
.	O

HIV-1	O
tat	O
induces	O
the	O
expression	O
of	O
a	O
new	O
hematopoietic	O
cell	O
-	O
specific	O
transcription	O
factor	O
and	O
downregulates	O
MIP-1	O
alpha	O
gene	O
expression	O
in	O
activated	O
T	O
-	O
cells	O
.	O

MIP-1	O
alpha	O
is	O
a	O
secreted	O
chemokine	O
which	O
can	O
inhibit	O
hematopoietic	O
stem	O
cells	O
and	O
modulate	O
inflammatory	O
responses	O
.	O

It	O
is	O
also	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
CD8	O
+	O
T	O
-	O
cells	O
.	O

The	O
expression	O
of	O
MIP-1	O
alpha	O
is	O
induced	O
during	O
cellular	O
activation	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
and	O
monocytes	O
.	O

It	O
is	O
also	O
expressed	O
in	O
transformed	B
B	I
-	I
cells	I
.	O

We	O
have	O
previously	O
identified	O
a	O
new	O
transcription	O
factor	O
family	O
(	O
the	O
MNP	O
family	O
)	O
whose	O
expression	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
MIP-1	O
alpha	O
transcription	O
during	O
cellular	O
activation	O
and	O
in	O
transformed	B
B	I
cells	I
.	O

Monocytes	O
and	O
transformed	B
B	I
-	I
cells	I
normally	O
express	O
MNP-1	O
strongly	O
and	O
MNP-2	O
weakly	O
,	O
while	O
T	O
-	O
cells	O
strongly	O
express	O
only	O
MNP-2	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
HIV-1	O
tat	O
downregulates	O
MIP-1	O
alpha	O
expression	O
in	O
Jurkat	B
T	I
-	I
cells	I
.	O

In	O
this	O
report	O
we	O
show	O
induction	O
of	O
MNP-1	O
in	O
Jurkat	B
T	I
-	I
cells	I
expressing	O
HIV-1	O
tat	O
.	O

Expression	O
of	O
neither	O
HTLV-1	O
tax	O
in	O
Jurkat	B
T	I
-	I
cells	I
nor	O
EBV	O
in	O
B	O
-	O
cells	O
had	O
any	O
effect	O
on	O
MNP-1	O
or	O
MNP-2	O
expression	O
,	O
showing	O
that	O
the	O
effect	O
is	O
specific	O
for	O
HIV-1	O
tat	O
.	O

We	O
propose	O
that	O
HIV-1	O
tat	O
may	O
inhibit	O
MIP-1	O
alpha	O
expression	O
by	O
inducing	O
MNP-1	O
expression	O
in	O
T	O
-	O
cells	O
,	O
probably	O
by	O
either	O
competing	O
with	O
MNP-2	O
for	O
binding	O
to	O
the	O
MIP-1	O
alpha	O
promoter	O
or	O
by	O
sequestering	O
it	O
into	O
inactive	O
forms	O
.	O

Cooperation	O
between	O
core	O
binding	O
factor	O
and	O
adjacent	O
promoter	O
elements	O
contributes	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	O
.	O

Tissue	O
-	O
specific	O
expression	O
of	O
interleukin-3	O
(	O
IL-3	O
)	O
is	O
mediated	O
via	O
cis	O
-	O
acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	O
and	O
Elf-1	O
sites	O
in	O
the	O
IL-3	O
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell	O
-	O
specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL-3	O
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act-1	O
.	O

Together	O
the	O
Act-1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	O
in	O
fibroblasts	O
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL-3	O
promoter	O
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL-3	O
is	O
not	O
specified	O
by	O
the	O
activity	O
of	O
a	O
single	O
tissue	O
-	O
specific	O
element	O
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G	O
-	O
protein	O
-	O
coupled	O
chemoattractant	O
receptors	O
.	O

Receptors	O
for	O
leukocyte	O
chemoattractants	O
,	O
including	O
chemokines	O
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G	O
-	O
protein	O
-	O
coupled	O
serpentine	O
receptors	O
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
NF	O
kappa	O
B	O
and	O
AP-1	O
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G	O
-	O
protein	O
coupling	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF	O
-	O
alpha	O
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate	O
-	O
early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	O
and	O
chemokine	O
gene	O
expression	O
.	O

Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T	O
-	O
cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL	O
-	O
mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	O
adenovirus	O
type	O
5	O
E1A	O
-	O
region	O
(	O
Ad5E1A234	O
-	O
243	O
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor	O
-	O
eradicating	O
CTL	O
,	O
enhances	O
rather	O
than	O
inhibits	O
the	O
growth	O
of	O
Ad5E1A	O
-	O
expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T	O
-	O
cell	O
-	O
mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A	O
-specific	O
CTL	O
activity	O
could	O
no	O
longer	O
be	O
isolated	O
from	O
mice	O
after	O
injection	O
of	O
Ad5E1A	O
-	O
peptide	O
,	O
indicating	O
that	O
tolerization	O
of	O
Ad5E1A	O
-specific	O
CTL	O
activity	O
causes	O
the	O
enhanced	O
tumor	O
outgrowth	O
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	O
,	O
induced	O
Ad5E1A	O
-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A	O
-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti	O
-	O
tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide	O
-	O
based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T	O
-	O
cell	O
-	O
mediated	O
autoimmune	O
diseases	O
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	O
gene	O
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c	O
-	O
Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
in	O
anergic	B
T	I
helper	I
1	I
cells	I
.	O

Anergic	B
CD4	I
+	I
Th	I
cells	I
do	O
not	O
produce	O
IL-2	O
when	O
challenged	O
with	O
Ag	B
-	I
pulsed	I
accessory	I
cells	I
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	B
T	I
cells	I
are	O
defective	O
in	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	O
DNA	O
enhancer	O
elements	O
:	O
NF	O
-	O
AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	O
NFATp	O
,	O
Fos	O
,	O
and	O
Jun	O
protein	O
complex	O
)	O
and	O
Activator	O
Protein-1	O
(	O
AP-1	O
)	O
(	O
that	O
binds	O
Fos	O
and	O
Jun	O
heterodimers	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA	O
-	O
protein	O
interactions	O
in	O
anergic	B
T	I
cells	I
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	O
family	O
members	O
c	O
-	O
Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	O
the	O
result	O
of	O
a	O
global	O
TCR	O
/	O
CD3	O
-signaling	O
defect	O
because	O
CD3	O
cross	O
-	O
linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular	O
-	O
free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	O
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	O
and	O
anergic	B
T	I
cells	I
.	O

Thus	O
,	O
defective	O
IL-2	O
gene	O
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	O
Fos	O
and	O
Jun	O
family	O
members	O
in	O
anergic	B
T	I
cells	I
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
gene	O
family	O
member	O
NFATc	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:	O
33705	O
]	O

The	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
/FK506-sensitive	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	O
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non	O
-	O
T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	O
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	O
proteins	O
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	B
B	I
cell	I
line	I
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	O
,	O
of	O
the	O
NFAT	O
gene	O
family	O
member	O
NFATc	O
(	O
designated	O
here	O
NFATc.alpha	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
NFATc.beta	O
differs	O
from	O
that	O
of	O
NFATc	O
.	O

alpha	O
in	O
the	O
first	O
NH2-terminal	O
29	O
residues	O
and	O
contains	O
an	O
additional	O
region	O
of	O
142	O
residues	O
at	O
the	O
COOH	O
terminus	O
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2.7	O
and	O
4.5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc.beta	O
-	O
specific	O
probe	O
detected	O
only	O
the	O
4.5-kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	O
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	O
NFAT	O
-	O
driven	O
reporter	O
gene	O
in	O
stimulated	B
Jurkat	I
cells	I
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	O
neither	O
bound	O
to	O
the	O
kappa3	O
element	O
(	O
an	O
NFAT	O
-	O
binding	O
site	O
)	O
in	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
nor	O
activated	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
cotransfection	O
assays	O
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

JNK	O
(	O
c	O
-	O
Jun	O
NH2-terminal	O
kinase	O
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	O
lymphocytes	O
.	O

AP-1	O
has	O
been	O
shown	O
to	O
behave	O
as	O
a	O
redox	O
-	O
sensitive	O
transcription	O
factor	O
that	O
can	O
be	O
activated	O
by	O
both	O
oxidant	O
and	O
antioxidant	O
stimuli	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	O
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	O
(	O
c	O
-	O
Jun	O
NH2-terminal	O
kinase	O
)	O
in	O
Jurkat	B
T	I
cells	I
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	O
against	O
the	O
T	O
cell	O
receptor	O
-	O
CD3	O
complex	O
and	O
to	O
CD28	O
.	O

The	O
activation	O
of	O
JNK	O
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	O
N	O
-	O
acetylcysteine	O
)	O
was	O
sustained	O
.	O

The	O
kinetics	O
of	O
JNK	O
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c	O
-	O
jun	O
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c	O
-	O
fos	O
.	O

In	O
addition	O
,	O
JNK	O
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2	O
+	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	O
to	O
inhibit	O
the	O
activation	O
mediated	O
by	O
PDTC	O
.	O

Transfection	O
of	O
trans	O
-	O
dominant	O
negative	O
expression	O
vectors	O
of	O
ras	O
and	O
raf	O
,	O
together	O
with	O
AP-1-dependent	O
reporter	O
constructs	O
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti	O
-	O
ERK	O
(	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
)	O
antibodies	O
,	O
indicated	O
that	O
the	O
Ras	O
/	O
Raf	O
/	O
ERK	O
pathway	O
did	O
not	O
appear	O
to	O
mediate	O
the	O
effect	O
of	O
the	O
antioxidant	O
.	O

However	O
,	O
the	O
combined	O
treatment	O
with	O
PDTC	O
and	O
PMA	O
,	O
two	O
agents	O
that	O
synergize	O
on	O
AP-1	O
activation	O
,	O
resulted	O
in	O
the	O
persistent	O
phosphorylation	O
of	O
ERK-2	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	O
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
murine	O
B	O
-	O
cell	O
specific	O
transcriptional	O
coactivator	O
Bob1	O
.	O

From	O
a	O
murine	O
B	O
-	O
cell	O
cDNA	O
-	O
library	O
we	O
have	O
cloned	O
a	O
cDNA	O
encoding	O
the	O
murine	O
B	O
-	O
cell	O
specific	O
coactivator	O
mBob1	O
.	O

The	O
protein	O
is	O
the	O
murine	O
homologue	O
to	O
the	O
recently	O
described	O
human	O
coactivator	O
Bob1	O
(	O
hBob1	O
)	O
,	O
also	O
referred	O
to	O
as	O
OBF-1	O
or	O
OCA	O
-	O
B	O
.	O

We	O
have	O
also	O
characterized	O
the	O
genomic	O
mBob1	O
clone	O
.	O

Analysis	O
of	O
its	O
intron	O
-	O
exon	O
structure	O
has	O
allowed	O
identification	O
of	O
a	O
C	O
-	O
terminal	O
splice	O
variant	O
.	O

mBob1	O
is	O
B	O
-	O
cell	O
restricted	O
,	O
and	O
is	O
found	O
in	O
all	O
B	B
-	I
cell	I
lines	I
representing	O
different	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

mBob1	O
interacts	O
with	O
the	O
octamer	O
transcription	O
factors	O
Oct-1	O
and	O
Oct-2	O
and	O
stimulates	O
transcription	O
mediated	O
by	O
these	O
factors	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic	O
/	O
fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	O
growth	O
factor	O
(	O
HGF	O
)	O
requirement	O
of	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
purified	O
from	O
embryonic	O
-	O
fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	O
(	O
Epo	O
)	O
for	O
colony	O
formation	O
by	O
early	O
erythroid	O
progenitors	O
(	O
burst	O
-	O
forming	O
units	O
-	O
erythroid	O
[	O
BFU	O
-	O
E	O
]	O
)	O
has	O
been	O
confirmed	O
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	O
,	O
FL	O
monocytic	O
progenitors	O
(	O
colony	O
-	O
forming	O
unit	O
monocyte	O
[	O
CFU	O
-	O
M	O
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes	O
-	O
macrophages	O
;	O
these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

On	O
this	O
basis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

Both	O
compounds	O
modulate	O
the	O
growth	O
of	O
purified	B
FL	I
HPCs	I
,	O
which	O
show	O
a	O
dose	O
-	O
dependent	O
shift	O
from	O
mixed	O
/	O
erythroid	O
/	O
monocytic	O
to	O
granulocytic	O
colony	O
formation	O
.	O

Studies	O
on	O
unicellular	B
and	I
paired	I
daughter	I
cell	I
culture	I
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA	O
-	O
induced	O
down	O
-	O
modulation	O
of	O
multipotent	O
/erythroid	O
/	O
monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	O
HPCs	O
)	O
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	O
HPCs	O
(	O
high	B
-	I
proliferative	I
potential	I
colony	I
-	I
forming	I
cells	I
[	O
HPP	B
-	I
CFCs	I
]	O
)	O
and	O
putative	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
;	O
assayed	O
in	O
Dexter	O
-	O
type	O
long	O
-	O
term	O
culture	O
)	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP	B
-	I
CFC	I
colonies	I
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	O
proliferation	O
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	O
transduced	O
with	O
dominant	O
negative	O
ATRA	O
receptor	O
(	O
RAR	O
)	O
gene	O
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA	O
/	O
9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR	O
/	O
RXR	O
heterodimer	O
,	O
ie	O
,	O
inhibition	O
of	O
HSC	B
/	I
primitive	I
HPC	I
proliferation	O
and	O
induction	O
of	O
CFU	O
-	O
GEMM	O
/	O
BFU	O
-	O
E	O
/	O
CFU	O
-	O
M	O
shift	O
from	O
the	O
multipotent	O
/	O
erythroid	O
/	O
monocytic	O
to	O
the	O
granulocytic	O
-	O
neutrophilic	O
differentiation	O
program	O
.	O

The	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
,	O
but	O
not	O
its	O
regulatory	O
domain	O
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	O
production	O
.	O

The	O
lymphoid	O
src	O
kinase	O
pp56	O
(	O
lck	O
)	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	O
lymphocyte	O
responses	O
,	O
including	O
CD4	O
-mediated	O
enhancement	O
of	O
Ag	O
-	O
induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	O
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	O
(	O
lck	O
)	O
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	O
regulatory	O
domain	O
is	O
sufficient	O
to	O
mediate	O
CD4	O
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	O
and	O
catalytic	O
domains	O
of	O
pp56	O
(	O
lck	O
)	O
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	O
:	O
TCR	O
-	O
induced	O
IL-2	O
production	O
.	O

Two	O
pp56	O
(	O
lck	O
)	O
mutants	O
lacking	O
either	O
the	O
entire	O
catalytic	O
domain	O
or	O
the	O
entire	O
NH2	O
regulatory	O
domain	O
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR	O
-	O
regulated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
region	O
of	O
the	O
IL-2	O
promoter	O
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	O
regulatory	O
,	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
was	O
able	O
to	O
induce	O
NF	O
-	O
AT	O
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
was	O
able	O
to	O
induce	O
IL-2	O
cytokine	O
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
pp56	O
(	O
lck	O
)	O
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	O
(	O
lck	O
)	O
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	O
regulatory	O
domain	O
is	O
sufficient	O
to	O
mediate	O
CD4	O
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	O
production	O
,	O
mimicking	O
TCR	O
ligation	O
.	O

Lack	O
of	O
IL-12	O
signaling	O
in	O
human	B
allergen	I
-	I
specific	I
Th2	I
cells	I
.	O

IL-12	O
is	O
a	O
powerful	O
skewer	O
of	O
CD4	O
+	O
T	O
cell	O
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN	O
-	O
gamma	O
production	O
in	O
naive	B
Th	I
cells	I
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	O
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1	O
/	O
Th0	O
responses	O
by	O
inducing	O
IFN	O
-	O
gamma	O
production	O
in	O
memory	B
Th2	I
cells	I
.	O

To	O
this	O
aim	O
,	O
allergen	B
-	I
specific	I
CD4	I
+	I
T	I
cell	I
clones	I
(	O
TCC	B
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	O
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	B
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	O
profile	O
,	O
and	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	O
.	O

Only	O
those	O
TCC	B
with	O
low	O
IFN	O
-	O
gamma	O
levels	O
in	O
the	O
absence	O
of	O
IL-12	O
responded	O
to	O
IL-12	O
by	O
additional	O
enhancement	O
of	O
IFN	O
-	O
gamma	O
production	O
.	O

The	O
IL-12	O
nonresponsiveness	O
of	O
the	O
Th2	B
clones	I
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	O
-induced	O
phosphorylation	O
of	O
STAT4	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-4	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
is	O
typically	O
involved	O
in	O
IL-12	O
signaling	O
.	O

Consequently	O
,	O
IL-12	O
also	O
failed	O
to	O
induce	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
STAT4-containing	O
complexes	O
in	O
the	O
nuclei	O
of	O
these	O
Th2	B
clones	I
.	O

All	O
TCC	B
expressed	O
equal	O
levels	O
of	O
the	O
low	O
-	O
affinity	O
IL-12R	O
beta1	O
subunit	O
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen	O
-	O
specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	O
profiles	O
do	O
not	O
respond	O
to	O
IL-12	O
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN	O
-	O
gamma	O
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	B
Th	I
cells	I
within	O
the	O
allergen	O
-	O
specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	O
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	B
cells	I
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
via	O
T	O
cell	O
receptor	O
requires	O
a	O
Raf	O
kinase	O
and	O
Ca2	O
+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	O
and	O
calcineurin	O
.	O

Signals	O
transduced	O
via	O
the	O
TCR	O
activate	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	O
kinase	O
C	O
activator	O
PMA	O
in	O
combination	O
with	O
Ca2	O
+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	O
stimulation	O
,	O
bypassing	O
the	O
TCR	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF	O
-	O
kappaB	O
following	O
TCR	O
stimulation	O
.	O

TCR	O
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	B
T	I
cells	I
with	O
PHA	O
or	O
anti	O
-	O
CD3	O
Abs	O
,	O
and	O
NF	O
-	O
kappaB	O
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	O
-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	O
kinase	O
C	O
is	O
involved	O
in	O
TCR	O
-mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
PHA	O
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	O
-induced	O
kappaB	O
-	O
dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	O
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	O
kinase	O
.	O

The	O
TCR	O
-mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
was	O
also	O
dependent	O
on	O
a	O
Ca2	O
+	O
influx	O
,	O
because	O
the	O
Ca2	O
+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2	O
+	O
influx	O
,	O
inhibited	O
NF	O
-	O
kappaB	O
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
largely	O
substituted	O
for	O
the	O
Ca2	O
+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	O
and	O
calcineurin	O
synergistically	O
induced	O
kappaB	O
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	O
and	O
the	O
phosphatase	O
.	O

Differentiation	O
-	O
dependent	O
expression	O
of	O
a	O
human	O
carboxylesterase	O
in	O
monocytic	O
cells	O
and	O
transcription	O
factor	O
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	O
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte	O
/	O
macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	B
cell	I
line	I
THP-1	I
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	O
carboxylesterase	O
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA	B
-	I
treated	I
THP-1	I
cells	I
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	B
cells	I
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-1	O
to	O
-275	O
,	O
which	O
contains	O
several	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
,	O
is	O
bound	O
by	O
nuclear	O
factors	O
Sp1	O
and	O
IRBP	O
but	O
not	O
by	O
C	O
/	O
EBPs	O
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	B
cells	I
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	O
and	O
IRBP	O
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation	O
-	O
dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Identification	O
of	O
Bcd	O
,	O
a	O
novel	O
proto	O
-	O
oncogene	O
expressed	O
in	O
B	O
-	O
cells	O
.	O

A	O
novel	O
B	O
-	O
cell	O
derived	O
(	O
Bcd	O
)	O
oncogene	O
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

The	O
Bcd	O
proto	O
-	O
oncogene	O
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	O
'	O
UTR	O
.	O

It	O
predicts	O
for	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

ORF1	O
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	O
ORF2	O
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

Predicted	O
peptide	O
sequence	O
of	O
ORF2	O
contained	O
a	O
zinc	O
finger	O
domain	O
which	O
showed	O
significant	O
homology	O
to	O
GC	O
box	O
binding	O
proteins	O
BTEB2	O
and	O
SP1	O
.	O

Transfection	O
of	O
an	O
expression	O
vector	O
containing	O
ORF2	O
but	O
not	O
full	O
length	O
cDNA	O
was	O
able	O
to	O
transform	O
NIH3T3	B
cells	I
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Bcd	O
mRNA	O
transcripts	O
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	B
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

Within	O
the	O
PBL	O
,	O
Bcd	O
gene	O
expression	O
was	O
restricted	O
to	O
CD19	O
+	O
B	O
-	O
cells	O
and	O
absent	O
from	O
CD14	O
+	O
monocytes	O
and	O
T	O
-	O
cells	O
.	O

Bcd	O
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	O
samples	O
tested	O
but	O
not	O
in	O
several	O
malignant	B
human	I
B	I
-	I
cell	I
lines	I
and	O
not	O
in	O
50	O
%	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O

However	O
,	O
stimulation	O
of	O
B	O
-	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	O
cells	O
was	O
associated	O
with	O
induction	O
of	O
Bcd	O
gene	O
expression	O
.	O

The	O
Bcd	O
gene	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B	O
-	O
cell	O
growth	O
and	O
development	O
.	O

Shared	O
gamma	O
(	O
c	O
)	O
subunit	O
within	O
the	O
human	O
interleukin-7	O
receptor	O
complex	O
.	O

A	O
molecular	O
basis	O
for	O
the	O
pathogenesis	O
of	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Genetic	O
evidence	O
suggests	O
that	O
mutations	O
in	O
the	O
gamma	O
(	O
c	O
)	O
receptor	O
subunit	O
cause	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
.	O

The	O
gamma	O
(	O
c	O
)	O
subunit	O
can	O
be	O
employed	O
in	O
receptor	O
complexes	O
for	O
IL-2	O
,	O
-4	O
,	O
-7	O
,	O
-9	O
,	O
and	O
-15	O
,	O
and	O
the	O
multiple	O
signaling	O
defects	O
that	O
would	O
result	O
from	O
a	O
defective	O
gamma	O
(	O
c	O
)	O
chain	O
in	O
these	O
receptors	O
are	O
proposed	O
to	O
cause	O
the	O
severe	O
phenotype	O
of	O
X	O
-	O
SCID	O
patients	O
.	O

Interestingly	O
,	O
gene	O
disruption	O
of	O
either	O
IL-7	O
or	O
the	O
IL-7	O
receptor	O
(	O
IL-7R	O
)	O
alpha	O
subunit	O
in	O
mice	O
leads	O
to	O
immunological	O
defects	O
that	O
are	O
similar	O
to	O
human	O
X	O
-	O
SCID	O
.	O

These	O
observations	O
suggest	O
the	O
functional	O
importance	O
of	O
gamma	O
(	O
c	O
)	O
in	O
the	O
IL-7R	O
complex	O
.	O

In	O
the	O
present	O
study	O
,	O
structure	O
/	O
function	O
analyses	O
of	O
the	O
IL-7R	O
complex	O
using	O
a	O
chimeric	O
receptor	O
system	O
demonstrated	O
that	O
gamma	O
(	O
c	O
)	O
is	O
indeed	O
critical	O
for	O
IL-7R	O
function	O
.	O

Nonetheless	O
,	O
only	O
a	O
limited	O
portion	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
gamma	O
(	O
c	O
)	O
is	O
necessary	O
for	O
IL-7R	O
signal	O
transduction	O
.	O

Furthermore	O
,	O
replacement	O
of	O
the	O
gamma	O
(	O
c	O
)	O
cytoplasmic	O
domain	O
by	O
a	O
severely	O
truncated	O
erythropoeitin	O
receptor	O
does	O
not	O
affect	O
measured	O
IL-7R	O
signaling	O
events	O
.	O

These	O
findings	O
support	O
a	O
model	O
in	O
which	O
gamma	O
(	O
c	O
)	O
serves	O
primarily	O
to	O
activate	O
signal	O
transduction	O
by	O
the	O
IL-7R	O
complex	O
,	O
while	O
IL-7R	O
alpha	O
determines	O
specific	O
signaling	O
events	O
through	O
its	O
association	O
with	O
cytoplasmic	O
signaling	O
molecules	O
.	O

Finally	O
,	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
molecular	O
pathogenesis	O
of	O
X	O
-	O
SCID	O
is	O
due	O
primarily	O
to	O
gamma	O
(	O
c	O
)	O
-mediated	O
defects	O
in	O
the	O
IL-7	O
/IL-7R	O
system	O

Generation	O
of	O
cytotoxic	O
T	O
lymphocytes	O
against	O
immunorecessive	O
epitopes	O
after	O
multiple	O
immunizations	O
with	O
adenovirus	O
vectors	O
is	O
dependent	O
on	O
haplotype	O
.	O

Currently	O
,	O
adenovirus	O
(	O
Ad	O
)	O
is	O
being	O
considered	O
as	O
a	O
vector	O
for	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
as	O
well	O
as	O
other	O
diseases	O
.	O

However	O
,	O
the	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
Ad	O
could	O
limit	O
the	O
effectiveness	O
of	O
such	O
approaches	O
.	O

Since	O
the	O
CTL	O
response	O
to	O
virus	O
infection	O
is	O
often	O
focused	O
on	O
one	O
or	O
a	O
few	O
immunodominant	O
epitopes	O
,	O
one	O
approach	O
to	O
circumvent	O
this	O
response	O
is	O
to	O
create	O
vectors	O
that	O
lack	O
these	O
immunodominant	O
epitopes	O
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
was	O
tested	O
by	O
immunizing	O
mice	O
with	O
human	O
group	O
C	O
adenoviruses	O
.	O

Three	O
mouse	O
strains	O
(	O
C57BL	O
/	O
10SnJ	O
[	O
H-2b	O
]	O
,	O
C3HeB	O
/	O
FeJ	O
[	O
H-2k	O
]	O
,	O
and	O
BALB	O
/	O
cByJ	O
[	O
H-2d	O
]	O
)	O
were	O
immunized	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
Ad	O
vectors	O
lacking	O
the	O
immunodominant	O
antigen	O
(	O
s	O
)	O
,	O
and	O
the	O
CTL	O
responses	O
were	O
measured	O
.	O

In	O
C57BL	O
/	O
10	O
(	O
B10	O
)	O
mice	O
,	O
a	O
single	O
inoculation	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
led	O
to	O
the	O
recognition	O
of	O
an	O
immunodominant	O
antigen	O
in	O
E1A	O
.	O

When	O
B10	O
mice	O
were	O
inoculated	O
multiple	O
times	O
either	O
i.p	O
.	O

or	O
intranasally	O
with	O
wild	O
-	O
type	O
Ad	O
or	O
an	O
Ad	O
vector	O
lacking	O
most	O
of	O
the	O
E1	O
region	O
,	O
subdominant	O
epitopes	O
outside	O
this	O
region	O
were	O
recognized	O
.	O

In	O
contrast	O
,	O
C3H	O
mice	O
inoculated	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
an	O
epitope	O
mapping	O
within	O
E1B	O
.	O
When	O
inoculated	O
twice	O
with	O
Ad	O
vectors	O
lacking	O
both	O
E1A	O
and	O
E1B	O
,	O
no	O
immunorecessive	O
epitopes	O
were	O
recognized	O
.	O

The	O
immune	O
response	O
to	O
Ad	O
in	O
BALB	O
/	O
c	O
mice	O
was	O
more	O
complex	O
.	O

CTLs	O
from	O
BALB	O
/	O
c	O
mice	O
inoculated	O
i.p	O
.	O
with	O
wild	O
-	O
type	O
Ad	O
recognized	O
E1B	O
in	O
the	O
context	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
Dd	O
allele	O
and	O
a	O
region	O
outside	O
E1	O
associated	O
with	O
the	O
Kd	O
allele	O
.	O

When	O
BALB	O
/	O
c	O
mice	O
were	O
inoculated	O
with	O
E1	O
-deleted	O
Ad	O
vectors	O
,	O
only	O
the	O
immunodominant	O
Kd	O
-	O
restricted	O
epitope	O
was	O
recognized	O
,	O
and	O
Dd	O
-	O
restricted	O
CTLs	O
did	O
not	O
develop	O
.	O

This	O
report	O
indicates	O
that	O
the	O
emergence	O
of	O
CTLs	O
against	O
immunorecessive	O
epitopes	O
following	O
multiple	O
administrations	O
of	O
Ad	O
vectors	O
lacking	O
immunodominant	O
antigens	O
is	O
dependent	O
on	O
haplotype	O
and	O
could	O
present	O
an	O
obstacle	O
to	O
gene	O
therapy	O
in	O
an	O
MHC	O
-diverse	O
human	O
population	O
.	O

Involvement	O
of	O
Egr-1	O
/RelA	O
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
-induced	O
NF	O
-	O
kappa	O
B1	O
transcription	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
an	O
important	O
transcription	O
factor	O
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF	O
-	O
kappa	O
B1	O
gene	O
encodes	O
a	O
105-kD	O
protein	O
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	O
component	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
regulates	O
the	O
NF	O
-	O
kappa	O
B1	O
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	B
cell	I
lines	I
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	O
(	O
PHA	O
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF	O
-	O
kappa	O
B1	O
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF	O
-	O
kappa	O
B	O
.	O

Characterization	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
promoter	O
identified	O
an	O
Egr-1	O
site	O
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA	O
/	O
PHA	O
-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Egr-1	O
.	O

Furthermore	O
,	O
Egr-1	O
induction	O
was	O
required	O
for	O
endogenous	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
,	O
since	O
PMA	O
/	O
PHA	B
-	I
stimulated	I
T	I
cell	I
lines	I
expressing	O
antisense	O
Egr-1	O
RNA	O
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF	O
-	O
kappa	O
B1	O
transcription	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	O
and	O
NF	O
-	O
kappa	O
B	O
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF	O
-	O
kappa	O
B1	O
gene	O
expression	O
.	O

Jak1	O
expression	O
is	O
required	O
for	O
mediating	O
interleukin-4-induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
and	O
Stat6	O
signaling	O
molecules	O
.	O

The	O
Jak1	O
,	O
Jak2	O
,	O
Jak3	O
,	O
and	O
Fes	O
tyrosine	O
kinases	O
have	O
been	O
demonstrated	O
to	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
response	O
to	O
interleukin	O
(	O
IL	O
)	O
-4	O
stimulation	O
in	O
different	O
cell	O
systems	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
which	O
,	O
if	O
any	O
,	O
of	O
these	O
kinases	O
are	O
responsible	O
for	O
initiating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
of	O
intracellular	O
substrates	O
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
utilized	O
a	O
mutant	B
Jak1-deficient	I
HeLa	I
cell	I
line	I
,	O
E1C3	B
,	O
and	O
its	O
parental	B
Jak1-expressing	I
counterpart	I
,	O
1D4	B
,	O
to	O
analyze	O
the	O
role	O
of	O
Jak1	O
in	O
mediating	O
IL-4-induced	O
tyrosine	O
phosphorylation	O
events	O
.	O

IL-4	O
treatment	O
rapidly	O
induced	O
tyrosine	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate	O
(	O
IRS	O
)	O
-1	O
and	O
IRS-2	O
in	O
1D4	B
but	O
not	O
in	O
E1C3	B
cells	I
.	O

IL-4	O
-mediated	O
tyrosine	O
phosphorylation	O
of	O
Stat6	O
was	O
pronounced	O
in	O
1D4	B
cells	I
,	O
while	O
no	O
IL-4	O
-induced	O
Stat6	O
phosphorylation	O
was	O
detected	O
in	O
E1C3	B
cells	I
.	O

IL-4	O
also	O
induced	O
Stat6	O
DNA	O
binding	O
activity	O
from	O
lysates	O
of	O
1D4	B
but	O
not	O
E1C3	B
cells	I
utilizing	O
a	O
radiolabeled	O
immunoglobulin	O
heavy	O
chain	O
germline	O
epsilon	O
promotor	O
sequence	O
(	O
Iepsilon	O
)	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Reconstitution	O
of	O
Jak1	O
expression	O
in	O
E1C3	B
cells	I
restored	O
the	O
ability	O
of	O
IL-4	O
to	O
induce	O
IRS	O
and	O
Stat6	O
tyrosine	O
phosphorylation	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
Jak1	O
expression	O
is	O
required	O
for	O
mediating	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
crucial	O
molecules	O
involved	O
in	O
IL-4	O
signal	O
transduction	O
.	O

Interleukin-4	O
signaling	O
in	O
B	O
lymphocytes	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
.	O

Interleukin-4	O
(	O
IL-4	O
)	O
is	O
an	O
important	O
cytokine	O
for	O
B	O
and	O
T	O
lymphocyte	O
function	O
and	O
mediates	O
its	O
effects	O
via	O
a	O
receptor	O
that	O
contains	O
gammac	O
.	O

B	O
cells	O
derived	O
from	O
patients	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
X	O
-	O
SCID	O
)	O
are	O
deficient	O
in	O
gammac	O
and	O
provide	O
a	O
useful	O
model	O
in	O
which	O
to	O
dissect	O
the	O
role	O
of	O
this	O
subunit	O
in	O
IL-4	O
-mediated	O
signaling	O
.	O

We	O
found	O
that	O
although	O
IL-4	O
stimulation	O
of	O
X	O
-	O
SCID	O
B	O
cells	O
did	O
not	O
result	O
in	O
Janus	O
tyrosine	O
kinase-3	O
(	O
JAK3	O
)	O
phosphorylation	O
,	O
other	O
IL-4	O
substrates	O
including	O
JAK1	O
and	O
IRS-1	O
were	O
phosphorylated	O
.	O

Additionally	O
,	O
we	O
detected	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
6	O
(	O
STAT6	O
)	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
in	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
a	O
wide	O
range	O
of	O
gammac	O
mutations	O
.	O

However	O
,	O
reconstitution	O
of	O
these	O
X	O
-	O
SCID	O
B	O
cells	O
with	O
gammac	O
enhanced	O
IL-4	O
-mediated	O
responses	O
including	O
STAT6	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
and	O
resulted	O
in	O
increased	O
CD23	O
expression	O
.	O

Thus	O
,	O
gammac	O
is	O
not	O
necessary	O
to	O
trigger	O
IL-4	O
-mediated	O
responses	O
in	O
B	O
cells	O
,	O
but	O
its	O
presence	O
is	O
important	O
for	O
optimal	O
IL-4	O
-signaling	O
.	O

These	O
results	O
suggest	O
that	O
two	O
distinct	O
IL-4	O
signaling	O
pathways	O
exist	O
.	O

Nuclear	O
Rel	O
-	O
A	O
and	O
c	O
-	O
Rel	O
protein	O
complexes	O
are	O
differentially	O
distributed	O
within	O
human	O
thymocytes	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/Rel	O
proteins	O
are	O
inducible	O
transcriptional	O
regulators	O
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	O
of	O
in	O
vitro	O
treatment	O
of	O
these	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF	O
-	O
kappa	O
B	O
proteins	O
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50	O
/	O
p65	O
and	O
p50	O
/	O
c	O
-	O
Rel	O
complexes	O
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	O
Abs	O
allowed	O
visualization	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50	O
/	O
c	O
-	O
Rel	O
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50	O
/	O
p65	O
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	O
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c	O
-	O
Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	O
and	O
CD8-positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	O
and	O
c	O
-	O
Rel	O
complexes	O
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF	O
-	O
kappa	O
B	O
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Common	O
and	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
human	O
neutrophils	O
utilized	O
by	O
platelet	O
activating	O
factor	O
and	O
FMLP	O
.	O

Stimulation	O
of	O
human	O
neutrophils	O
with	O
chemoattractants	O
FMLP	O
or	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
results	O
in	O
different	O
but	O
overlapping	O
functional	O
responses	O
.	O

We	O
questioned	O
whether	O
these	O
differences	O
might	O
reflect	O
patterns	O
of	O
intracellular	O
signal	O
transduction	O
.	O

Stimulation	O
with	O
either	O
PAF	O
or	O
FMLP	O
resulted	O
in	O
equivalent	O
phosphorylation	O
and	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPk	O
)	O
homologue	O
38-kD	O
murine	O
MAP	O
kinase	O
homologous	O
to	O
HOG-1	O
(	O
p38	O
)	O
MAPk	O
.	O

Neither	O
FMLP	O
nor	O
PAF	O
activated	O
c	O
-	O
jun	O
NH2-terminal	O
MAPk	O
(	O
JNKs	O
)	O
.	O

Under	O
identical	O
conditions	O
,	O
FMLP	O
but	O
not	O
PAF	O
,	O
resulted	O
in	O
significant	O
p42	O
/	O
44	O
(	O
ERK	O
)	O
MAPk	O
activation	O
.	O

Both	O
FMLP	O
and	O
PAF	O
activated	O
MAP	O
kinase	O
kinase-3	O
(	O
MKK3	O
)	O
,	O
a	O
known	O
activator	O
of	O
p38	O
MAPk	O
.	O

Both	O
MAP	O
ERK	O
kinase	O
kinase-1	O
(	O
MEKK1	O
)	O
and	O
Raf	O
are	O
activated	O
strongly	O
by	O
FMLP	O
,	O
but	O
minimally	O
by	O
PAF	O
.	O

Pertussis	O
toxin	O
blocked	O
FMLP	O
-induced	O
activation	O
of	O
the	O
p42	O
/	O
44	O
(	O
ERK	O
)	O
MAPk	O
cascade	O
,	O
but	O
not	O
that	O
of	O
p38	O
MAPk	O
.	O

A	O
specific	O
p38	O
MAPk	O
inhibitor	O
(	O
SK	O
&	O
F	O
86002	O
)	O
blocked	O
superoxide	O
anion	O
production	O
in	O
response	O
to	O
FMLP	O
and	O
reduced	O
adhesion	O
and	O
chemotaxis	O
in	O
response	O
to	O
PAF	O
or	O
FMLP	O
.	O

These	O
results	O
demonstrate	O
distinct	O
patterns	O
of	O
intracellular	O
signaling	O
for	O
two	O
chemoattractants	O
and	O
suggest	O
that	O
selective	O
activation	O
of	O
intracellular	O
signaling	O
cascades	O
may	O
underlie	O
different	O
patterns	O
of	O
functional	O
responses	O
.	O

Pivotal	O
role	O
for	O
the	O
NFIL3	O
/	O
E4BP4	O
transcription	O
factor	O
in	O
interleukin	O
3	O
-mediated	O
survival	O
of	O
pro	O
-	O
B	O
lymphocytes	O
.	O

The	O
E2A	O
-	O
HLF	O
(	O
hepatic	O
leukemia	O
factor	O
)	O
oncoprotein	O
,	O
generated	O
in	O
pro	O
-	O
B	O
lymphocytes	O
by	O
fusion	O
of	O
the	O
trans	O
-	O
activation	O
domain	O
of	O
E2A	O
to	O
the	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
domain	O
of	O
HLF	O
,	O
functions	O
as	O
an	O
anti	O
-	O
apoptotic	O
transcription	O
factor	O
in	O
leukemic	O
cell	O
transformation	O
.	O

When	O
introduced	O
into	O
interleukin	O
3	O
(	O
IL-3	O
)	O
-dependent	O
mouse	O
pro	O
-	O
B	O
lymphocytes	O
,	O
E2A	O
-	O
HLF	O
prevents	O
apoptosis	O
induced	O
by	O
growth	O
factor	O
deprivation	O
,	O
suggesting	O
that	O
IL-3	O
mediates	O
cell	O
survival	O
through	O
activation	O
of	O
a	O
transcription	O
factor	O
whose	O
activity	O
can	O
be	O
constitutively	O
replaced	O
by	O
the	O
chimeric	O
oncoprotein	O
.	O

We	O
considered	O
four	O
bZIP	O
transcription	O
factors	O
as	O
candidates	O
for	O
this	O
putative	O
IL-3-regulated	O
factor	O
,	O
each	O
of	O
which	O
binds	O
avidly	O
to	O
the	O
DNA	O
consensus	O
sequence	O
recognized	O
by	O
E2A	O
-	O
HLF	O
and	O
is	O
related	O
to	O
the	O
Caenorhabditis	O
elegans	O
CES-2	O
(	O
cell	O
death	O
specification	O
protein	O
)	O
neuron	O
-	O
specific	O
mediator	O
of	O
cell	O
death	O
.	O

The	O
expression	O
and	O
binding	O
activity	O
of	O
the	O
Nfil3	O
protein	O
(	O
also	O
called	O
E4bp4	O
)	O
,	O
but	O
not	O
of	O
Hlf	O
,	O
Dbp	O
,	O
or	O
Tef	O
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL-3	O
in	O
mouse	B
pro	I
-	I
B	I
cell	I
lines	I
(	O
Baf-3	B
and	O
FL5.12	B
)	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
Nfil3	O
/	O
E4bp4	O
is	O
regulated	O
as	O
a	O
`	O
`	O
delayed	O
-	O
early	O
''	O
IL-3-responsive	O
gene	O
,	O
requiring	O
de	O
novo	O
protein	O
synthesis	O
.	O

In	O
the	O
absence	O
of	O
IL-3	O
,	O
enforced	O
expression	O
of	O
the	O
human	O
NFIL3	O
/	O
E4BP4	O
cDNA	O
promoted	O
the	O
survival	O
but	O
not	O
the	O
growth	O
of	O
IL-3-dependent	O
pro	O
-	O
B	O
cells	O
.	O

Our	O
results	O
implicate	O
NFIL3	O
/	O
E4BP4	O
(	O
nuclear	O
factor	O
regulated	O
by	O
IL-3	O
/	O
adenovirus	O
E4	O
promoter	O
binding	O
protein	O
)	O
in	O
a	O
distinct	O
growth	O
factor	O
-	O
regulated	O
signaling	O
pathway	O
that	O
is	O
responsible	O
for	O
the	O
survival	O
of	O
early	O
B	O
-	O
cell	O
progenitors	O
,	O
and	O
whose	O
alteration	O
by	O
E2A	O
-	O
HLF	O
leads	O
to	O
childhood	O
B	O
lineage	O
leukemia	O
.	O

ALY	O
,	O
a	O
context	O
-	O
dependent	O
coactivator	O
of	O
LEF-1	O
and	O
AML-1	O
,	O
is	O
required	O
for	O
TCRalpha	O
enhancer	O
function	O
.	O

LEF-1	O
is	O
a	O
transcription	O
factor	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
alpha	O
)	O
enhancer	O
by	O
facilitating	O
the	O
assembly	O
of	O
multiple	O
proteins	O
into	O
a	O
higher	O
order	O
nucleoprotein	O
complex	O
.	O

The	O
function	O
of	O
LEF-1	O
is	O
dependent	O
,	O
in	O
part	O
,	O
on	O
the	O
HMG	O
domain	O
that	O
induces	O
a	O
sharp	O
bend	O
in	O
the	O
DNA	O
helix	O
,	O
and	O
on	O
an	O
activation	O
domain	O
that	O
stimulates	O
transcription	O
only	O
in	O
a	O
specific	O
context	O
of	O
other	O
enhancer	O
-	O
binding	O
proteins	O
.	O

With	O
the	O
aim	O
of	O
gaining	O
insight	O
into	O
the	O
function	O
of	O
context	O
-	O
dependent	O
activation	O
domains	O
,	O
we	O
cloned	O
ALY	O
,	O
a	O
novel	O
LEF-1-interacting	O
protein	O
.	O

ALY	O
is	O
a	O
ubiquitously	O
expressed	O
,	O
nuclear	O
protein	O
that	O
specifically	O
associates	O
with	O
the	O
activation	O
domains	O
of	O
LEF-1	O
and	O
AML-1	O
(	O
CBF	O
alpha2	O
,	O
PEBP2	O
alpha	O
(	O
B	O
)	O
,	O
which	O
is	O
another	O
protein	O
component	O
of	O
the	O
TCR	O
alpha	O
enhancer	O
complex	O
.	O

In	O
addition	O
,	O
ALY	O
can	O
increase	O
DNA	O
binding	O
by	O
both	O
LEF-1	O
and	O
AML	O
proteins	O
.	O

Overexpression	O
of	O
ALY	O
stimulates	O
the	O
activity	O
of	O
the	O
TCR	O
alpha	O
enhancer	O
complex	O
reconstituted	O
in	O
transfected	B
nonlymphoid	I
HeLa	I
cells	I
,	O
whereas	O
down	O
-	O
regulation	O
of	O
ALY	O
by	O
anti	O
-	O
sense	O
oligonucleotides	O
virtually	O
eliminates	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
T	O
cells	O
.	O

Similar	O
to	O
LEF-1	O
,	O
ALY	O
can	O
stimulate	O
transcription	O
in	O
the	O
context	O
of	O
the	O
TCR	O
alpha	O
enhancer	O
but	O
apparently	O
not	O
when	O
tethered	O
to	O
DNA	O
through	O
an	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
.	O

We	O
propose	O
that	O
ALY	O
mediates	O
context	O
-	O
dependent	O
transcriptional	O
activation	O
by	O
facilitating	O
the	O
functional	O
collaboration	O
of	O
multiple	O
proteins	O
in	O
the	O
TCR	O
alpha	O
enhancer	O
complex	O
.	O

Estrogen	O
and	O
progesterone	O
receptors	O
in	O
vernal	O
keratoconjunctivitis	O
.	O

PURPOSE	O
:	O
Sex	O
-	O
related	O
influences	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
vernal	O
keratoconjunctivitis	O
(	O
VKC	O
)	O
,	O
an	O
allergic	O
eosinophilic	O
disease	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
tarsal	O
and	O
bulbar	O
conjunctival	O
biopsies	O
from	O
seven	O
patients	O
with	O
severe	O
and	O
symptomatic	O
VKC	O
for	O
the	O
presence	O
of	O
estrogen	O
and	O
progesterone	O
receptors	O
by	O
using	O
monoclonal	O
antibodies	O
with	O
a	O
peroxidase	O
-	O
antiperoxidase	O
technique	O
.	O

RESULTS	O
:	O
Both	O
the	O
epithelium	O
and	O
subepithelium	O
of	O
the	O
tarsal	O
and	O
bulbar	O
conjunctiva	O
of	O
patients	O
with	O
VKC	O
,	O
but	O
not	O
those	O
of	O
four	O
nonatopic	O
control	O
subjects	O
,	O
showed	O
intense	O
positive	O
staining	O
for	O
estrogen	O
and	O
progesterone	O
receptors	O
.	O

Immunofluorescence	O
colocalization	O
of	O
both	O
estrogen	O
and	O
progesterone	O
receptors	O
with	O
eosinophil	O
cationic	O
protein	O
showed	O
that	O
approximately	O
70	O
%	O
of	O
positive	O
cells	O
were	O
eosinophils	O
.	O

CONCLUSIONS	O
:	O
Sexual	O
hormones	O
,	O
through	O
their	O
receptors	O
,	O
may	O
influence	O
the	O
activity	O
of	O
eosinophils	O
in	O
patients	O
with	O
VKC	O
.	O

Induction	O
of	O
relA	O
(	O
p65	O
)	O
and	O
I	O
kappa	O
B	O
alpha	O
subunit	O
expression	O
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
subunits	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	O
homodimers	O
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50	O
/	O
RelA	O
(	O
p65	O
)	O
heterodimers	O
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
was	O
significantly	O
higher	O
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40	O
,	O
000	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50	O
/	O
RelA	O
(	O
p65	O
)	O
heterodimers	O
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50	O
/	O
RelA	O
(	O
p65	O
)	O
complexes	O
that	O
are	O
readily	O
available	O
for	O
inducer	O
-	O
mediated	O
stimulation	O
.	O

Requirement	O
of	O
prestimulated	B
THP-1	I
monocytic	I
cells	I
for	O
endothelial	O
cell	O
activation	O
.	O

Involvement	O
of	O
TNF	O
alpha	O
.	O

Blood	O
monocytes	O
spontaneously	O
activate	O
endothelial	O
cells	O
in	O
culture	O
,	O
leading	O
to	O
adhesion	O
of	O
monocytic	O
cells	O
onto	O
the	O
endothelial	O
surface	O
and	O
overproduction	O
of	O
endothelial	O
proteins	O
such	O
as	O
von	O
Willebrand	O
factor	O
(	O
vWf	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
type	O
1	O
(	O
PAI-1	O
)	O
.	O

To	O
overcome	O
the	O
difficulty	O
in	O
obtaining	O
quiescent	O
monocytes	O
,	O
we	O
studied	O
the	O
ability	O
of	O
promonocytic	B
THP-1	I
cells	I
to	O
activate	O
endothelial	O
cells	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
-prestimulated	O
and	O
untreated	O
THP-1	B
cells	I
were	O
cocultured	O
with	O
resting	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
for	O
3	O
and	O
24	O
h	O
in	O
the	O
presence	O
of	O
colimycin	O
to	O
neutralize	O
LPS	O
traces	O
.	O

Addition	O
of	O
untreated	O
THP-1	B
cells	I
had	O
little	O
effect	O
on	O
HUVEC	O
adhesiveness	O
.	O

Addition	O
of	O
prestimulated	O
THP-1	B
cells	I
was	O
followed	O
by	O
a	O
noticeable	O
adhesion	O
after	O
3	O
h	O
which	O
reversed	O
to	O
basal	O
values	O
within	O
24	O
h	O
.	O

Under	O
these	O
conditions	O
HUVEC	O
adhesion	O
molecules	O
,	O
E	O
-	O
selectin	O
,	O
VCAM-1	O
and	O
ICAM-1	O
,	O
were	O
increased	O
at	O
3	O
h	O
with	O
only	O
ICAM-1	O
remaining	O
overexpressed	O
at	O
24	O
h	O
.	O

Diffusible	O
endothelial	O
proteins	O
such	O
as	O
soluble	O
E	O
-	O
selectin	O
,	O
PAI-1	O
and	O
vWf	O
to	O
a	O
minimal	O
extent	O
,	O
increased	O
in	O
supernatants	O
from	O
HUVEC	O
cocultured	O
for	O
24	O
h	O
with	O
prestimulated	O
THP-1	B
cells	I
.	O

In	O
those	O
cocultures	O
,	O
TNF	O
alpha	O
concentrations	O
peaked	O
at	O
3	O
h	O
whereas	O
IL-1	O
beta	O
levels	O
progressively	O
rose	O
until	O
24	O
h	O
.	O

Addition	O
of	O
an	O
anti	O
-	O
TNF	O
alpha	O
antibody	O
decreased	O
by	O
40	O
%	O
E	O
-	O
selectin	O
and	O
ICAM-1	O
induction	O
and	O
suppressed	O
PAI-1	O
overproduction	O
with	O
a	O
weak	O
effect	O
on	O
vWf	O
.	O

An	O
anti	O
-	O
IL-1	O
beta	O
antibody	O
had	O
negligible	O
effects	O
on	O
HUVEC	O
adhesion	O
molecules	O
,	O
PAI-1	O
or	O
vWf	O
production	O
.	O

These	O
results	O
provide	O
evidence	O
that	O
promonocytic	B
THP-1	I
cells	I
require	O
prestimulation	O
in	O
order	O
to	O
activate	O
HUVEC	O
and	O
that	O
TNF	O
alpha	O
contributes	O
to	O
this	O
phenomenon	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	O
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	O
-	O
Jkappa	O
or	O
nuclear	O
localization	O
sequences	O
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP	O
-	O
Jkappa	O
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	O
transmembrane	O
receptor	O
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	O
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	O
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	O
domain	O
(	O
DeltaE	O
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	O
domain	O
(	O
ICN	O
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	O
-	O
Jkappa	O
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	O
factor	O
RBP	O
-	O
Jkappa	O
in	O
extracts	O
prepared	O
from	O
human	B
and	I
murine	I
T	I
-	I
ALL	I
cell	I
lines	I
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP	O
-	O
Jkappa	O
-	O
binding	O
site	O
within	O
the	O
NOTCH1	O
ankyrin	O
repeat	O
region	O
of	O
the	O
intracellular	O
domain	O
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	O
-	O
Jkappa	O
-	O
binding	O
site	O
,	O
which	O
lies	O
within	O
the	O
intracellular	O
domain	O
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	O
-	O
Jkappa	O
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	O
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	O
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	O
localization	O
sequences	O
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	O
-	O
bound	O
DeltaE	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	O
-	O
bound	O
DeltaE	O
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	O
ICN	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	O
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP	O
-	O
Jkappa	O
at	O
promoter	O
sites	O
.	O

Glucocorticoid	O
-	O
resistance	O
in	O
peripheral	O
-	O
blood	O
lymphocytes	O
does	O
not	O
correlate	O
with	O
number	O
of	O
affinity	O
of	O
glucocorticoid	O
-	O
receptors	O
in	O
chronic	O
renal	O
failure	O
patients	O
.	O

Glucocorticoid	O
(	O
GC	O
)	O
resistance	O
in	O
patients	O
with	O
chronic	O
renal	O
failure	O
(	O
CRF	O
)	O
seriously	O
impairs	O
successive	O
GC	O
therapy	O
after	O
renal	O
transplantation	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
GC	O
-	O
receptor	O
(	O
GC	O
-	O
R	O
)	O
parameters	O
in	O
peripheral	O
-	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
PBMC	O
resistance	O
to	O
GC	O
in	O
21	O
CRF	O
patients	O
and	O
18	O
healthy	O
subjects	O
.	O

Each	O
subject	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
PBMC	O
sensitivity	O
to	O
prednisolone	O
in	O
a	O
mitogen	O
assay	O
procedure	O
;	O
i.e.	O
,	O
sensitive	O
(	O
IC50	O
<	O
381	O
ng	O
/	O
mL	O
)	O
and	O
resistant	O
(	O
IC50	O
>	O
381	O
ng	O
/	O
mL	O
)	O
groups	O
.	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
GC	O
-	O
R	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
2.89	O
+	O
/-	O
1.23	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.00	O
+	O
/-	O
2.24	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
in	O
these	O
subjects	O
significantly	O
increased	O
to	O
6.61	O
+	O
/-	O
2.02	O
(	O
257.7	O
+	O
/-	O
107.8	O
%	O
)	O
after	O
24	O
h	O
stimulation	O
with	O
concanavalin	O
A	O
(	O
p	O
<	O
0.01	O
)	O
,	O
while	O
the	O
Kd	O
change	O
was	O
not	O
significant	O
.	O

The	O
GC	O
-	O
R	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.33	O
+	O
/-	O
1.37	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.20	O
+	O
/-	O
1.39	O
nM	O
,	O
respectively	O
.	O

Both	O
of	O
these	O
parameters	O
,	O
however	O
,	O
did	O
not	O
change	O
significantly	O
after	O
mitogen	O
stimulation	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
IC50S	O
of	O
prednisolone	O
and	O
increase	O
-	O
ratios	O
(	O
post	O
/	O
pre	O
ratio	O
)	O
of	O
Bmax	O
after	O
mitogen	O
stimulation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
CRF	O
patients	O
,	O
Bmax	O
and	O
Kd	O
in	O
quiescent	O
PBMC	O
of	O
the	O
GC	O
-	O
sensitive	O
group	O
were	O
6.04	O
+	O
/-	O
2.35	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
3.49	O
+	O
/-	O
1.72	O
nM	O
,	O
respectively	O
,	O
while	O
those	O
in	O
PBMC	O
of	O
the	O
GC	O
-	O
resistant	O
group	O
were	O
5.13	O
+	O
/-	O
2.31	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
and	O
4.04	O
+	O
/-	O
1.62	O
nM	O
,	O
respectively	O
.	O

The	O
Bmax	O
and	O
Kd	O
were	O
not	O
significantly	O
changed	O
after	O
mitogen	O
stimulation	O
in	O
both	O
subgroups	O
of	O
CRF	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
healthy	O
subjects	O
,	O
there	O
was	O
no	O
correlation	O
between	O
IC50	O
and	O
GC	O
-	O
R	O
parameters	O
in	O
CRF	O
.	O

We	O
concluded	O
that	O
,	O
in	O
healthy	O
subjects	O
,	O
decreased	O
PBMC	O
capacity	O
to	O
amplify	O
GC	O
-	O
R	O
numbers	O
in	O
response	O
to	O
mitogen	O
is	O
correlated	O
with	O
GC	O
resistance	O
,	O
whereas	O
in	O
CRF	O
patients	O
the	O
resistant	O
mechanism	O
is	O
not	O
correlated	O
with	O
GC	O
-	O
R	O
parameters	O
.	O

An	O
unknown	O
event	O
might	O
be	O
involved	O
in	O
GC	O
-	O
resistance	O
of	O
CRF	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
.	O

Germline	O
transcripts	O
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	O
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
(	O
BSAP	O
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	O
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	O
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	O
plays	O
a	O
role	O
in	O
both	O
IL-4	O
-dependent	O
induction	O
and	O
CD40	O
-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	O
is	O
unique	O
among	O
the	O
transcription	O
factors	O
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	O
switching	O
.	O

Molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

The	O
immunoregulatory	O
properties	O
of	O
prolactin	O
,	O
a	O
pituitary	O
peptide	O
hormone	O
,	O
have	O
received	O
renewed	O
attention	O
.	O

The	O
prolactin	O
receptor	O
,	O
a	O
member	O
of	O
the	O
hematopoietin	O
/	O
cytokine	O
receptor	O
superfamily	O
,	O
is	O
ubiquitously	O
expressed	O
by	O
cells	O
in	O
the	O
immune	O
system	O
.	O

Certain	O
subpopulations	O
of	O
lymphocytes	O
synthesize	O
and	O
secrete	O
biologically	O
active	O
prolactin	O
,	O
which	O
suggests	O
that	O
prolactin	O
can	O
act	O
as	O
an	O
autocrine	O
and/or	O
paracrine	O
factor	O
to	O
modulate	O
the	O
activities	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

This	O
review	O
focuses	O
on	O
the	O
molecular	O
actions	O
of	O
prolactin	O
in	O
the	O
immune	O
system	O
.	O

Emphasis	O
is	O
given	O
to	O
recent	O
information	O
about	O
the	O
molecular	O
mechanisms	O
of	O
prolactin	O
receptor	O
signal	O
transduction	O
,	O
and	O
the	O
signaling	O
molecules	O
and	O
prolactin	O
-	O
inducible	O
target	O
genes	O
that	O
participate	O
in	O
these	O
responses	O
.	O

In	O
particular	O
,	O
the	O
prolactin	O
-	O
inducible	O
interferon	O
regulatory	O
factor-1	O
gene	O
and	O
its	O
roles	O
in	O
mediating	O
diverse	O
immune	O
responses	O
.	O

A	O
new	O
mouse	O
gene	O
,	O
SRG3	O
,	O
related	O
to	O
the	O
SWI3	O
of	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
required	O
for	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
in	O
a	O
thymoma	B
cell	I
line	I
.	O

We	O
isolated	O
a	O
new	O
mouse	O
gene	O
that	O
is	O
highly	O
expressed	O
in	O
thymocytes	O
,	O
testis	O
,	O
and	O
brain	O
.	O

This	O
gene	O
,	O
SRG3	O
,	O
showed	O
a	O
significant	O
sequence	O
homology	O
to	O
SWI3	O
,	O
a	O
yeast	O
transcriptional	O
activator	O
,	O
and	O
its	O
human	O
homolog	O
BAF155	O
.	O

SRG3	O
encodes	O
1	O
,	O
100	O
amino	O
acids	O
and	O
has	O
33	O
-	O
47	O
%	O
identity	O
with	O
SWI3	O
protein	O
over	O
three	O
regions	O
.	O

The	O
SRG3	O
protein	O
contains	O
an	O
acidic	O
NH2	O
terminus	O
,	O
a	O
myb	O
-	O
like	O
DNA	O
binding	O
domain	O
,	O
a	O
leucine	O
-	O
zipper	O
motif	O
,	O
and	O
a	O
proline-	O
and	O
glutamine	O
-	O
rich	O
region	O
at	O
its	O
COOH	O
terminus	O
.	O

Rabbit	O
antiserum	O
raised	O
against	O
a	O
COOH	O
-	O
terminal	O
polypeptide	O
of	O
the	O
SRG3	O
recognized	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
155	O
kD	O
.	O

The	O
serum	O
also	O
detected	O
a	O
170-kD	O
protein	O
that	O
seems	O
to	O
be	O
a	O
mouse	O
homologue	O
of	O
human	O
BAF170	O
.	O

Immunoprecipitation	O
of	O
cell	O
extract	O
with	O
the	O
antiserum	O
against	O
the	O
mouse	O
SRG3	O
also	O
brought	O
down	O
a	O
195-kD	O
protein	O
that	O
could	O
be	O
recognized	O
by	O
an	O
antiserum	O
raised	O
against	O
human	O
SWI2	O
protein	O
.	O

The	O
results	O
suggest	O
that	O
the	O
SRG3	O
protein	O
associates	O
with	O
a	O
mouse	O
SWI2	O
.	O

The	O
SRG3	O
protein	O
is	O
expressed	O
about	O
three	O
times	O
higher	O
in	O
thymocytes	O
than	O
in	O
peripheral	O
lymphocytes	O
.	O

The	O
expression	O
of	O
anti	O
-	O
sense	O
RNA	O
to	O
SRG3	O
mRNA	O
in	O
a	O
thymoma	B
cell	I
line	I
,	O
S49.1	B
,	O
reduced	O
the	O
expression	O
level	O
of	O
the	O
SRG3	O
protein	O
,	O
and	O
decreased	O
the	O
apoptotic	O
cell	O
death	O
induced	O
by	O
glucocorticoids	O
.	O

These	O
results	O
suggest	O
that	O
the	O
SRG3	O
protein	O
is	O
involved	O
in	O
the	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
the	O
thymoma	B
cell	I
line	I
.	O

This	O
implicates	O
that	O
the	O
SRG3	O
may	O
play	O
an	O
important	O
regulatory	O
role	O
during	O
T	O
cell	O
development	O
in	O
thymus	O
.	O

The	O
IL-4	O
receptor	O
alpha	O
-	O
chain	O
cytoplasmic	O
domain	O
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	O
and	O
STAT6	O
and	O
the	O
induction	O
of	O
IL-4	O
-specific	O
gene	O
expression	O
.	O

The	O
common	O
gamma	O
-	O
chain	O
(	O
gamma	O
(	O
c	O
)	O
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	O
,	O
yet	O
cells	O
lacking	O
gamma	O
(	O
c	O
)	O
are	O
able	O
to	O
respond	O
to	O
IL-4	O
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	O
gamma'-chain	O
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	O
alpha	O
chain	O
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	O
(	O
c	O
)	O
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	O
(	O
c	O
)	O
,	O
the	O
IL-4R	O
alpha	O
chain	O
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	O
receptor	O
containing	O
the	O
extracellular	O
domain	O
of	O
c	O
-	O
kit	O
(	O
the	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
receptor	O
)	O
and	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
the	O
IL-4R	O
alpha	O
chain	O
was	O
generated	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	O
receptor	O
kit	O
/	O
IL-4R	O
alpha	O
with	O
SCF	O
induces	O
activation	O
of	O
the	O
IL-4R	O
alpha	O
-	O
associated	O
kinase	O
JAK-1	O
and	O
the	O
transcription	O
factor	O
STAT6	O
.	O

However	O
,	O
tyrosine	O
phosphorylation	O
of	O
JAK-3	O
,	O
which	O
associates	O
with	O
gamma	O
(	O
c	O
)	O
,	O
is	O
not	O
induced	O
by	O
SCF	O
in	O
these	O
cells	O
.	O

SCF	O
-mediated	O
ligation	O
of	O
kit	O
/	O
IL-4R	O
alpha	O
is	O
sufficient	O
to	O
elicit	O
IL-4	O
-specific	O
gene	O
expression	O
,	O
including	O
up	O
-	O
regulation	O
of	O
CD23	O
and	O
synthesis	O
of	O
germ	O
-	O
line	O
epsilon	O
transcripts	O
.	O

In	O
the	O
T	B
cell	I
line	I
CTLL2	I
,	O
ligation	O
of	O
kit	O
/	O
IL-4R	O
alpha	O
induces	O
cellular	O
proliferation	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	B
HeLa	I
cells	I
,	O
STAT6	O
activation	O
by	O
IL-4	O
is	O
completely	O
abolished	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	O
alpha	O
cytoplasmic	O
domain	O
is	O
sufficient	O
to	O
activate	O
JAK-1	O
and	O
STAT6	O
and	O
to	O
induce	O
expression	O
of	O
IL-4	O
target	O
genes	O
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	O
signaling	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
JAK-3	O
and	O
gamma	O
(	O
c	O
)	O
.	O

AP-1	O
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV	O
-	O
I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	O
factors	O
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV	O
-	O
I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	B
lines	I
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	O
factors	O
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1	O
-	O
4	O
)	O
.	O

ATF	O
/	O
CREB	O
and	O
Sp	O
family	O
members	O
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA	O
-	O
protein	O
complexes	O
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA	O
-	O
protein	O
complex	O
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	B
MG	I
glioblastoma	I
cell	I
line	I
or	O
the	O
THP-1	B
mature	I
monocytic	I
cell	I
line	I
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA	O
-	O
protein	O
complex	O
is	O
comprised	O
of	O
the	O
AP-1	O
components	O
,	O
Fos	O
and	O
Jun	O
.	O

Expression	O
of	O
transcription	O
factors	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
in	O
K562	B
cells	I
.	O

During	O
15	O
days	O
of	O
treatment	O
of	O
K562	B
cells	I
with	O
sodium	O
phenylacetate	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cellular	O
hemoglobin	O
concentration	O
with	O
a	O
similar	O
increase	O
in	O
the	O
expression	O
of	O
gamma	O
-	O
globin	O
mRNA	O
.	O

Morphological	O
studies	O
demonstrated	O
characteristic	O
features	O
of	O
erythroid	O
differentiation	O
and	O
maturation	O
.	O

At	O
the	O
same	O
time	O
there	O
was	O
no	O
change	O
in	O
the	O
level	O
of	O
expression	O
of	O
the	O
cell	O
surface	O
antigenes	O
CD33	O
,	O
CD34	O
,	O
CD45	O
,	O
CD71	O
and	O
glycophorin	O
A	O
.	O

Likewise	O
,	O
the	O
level	O
of	O
expression	O
of	O
the	O
erythroid	O
transcription	O
factors	O
GATA-1	O
,	O
GATA-2	O
,	O
NF	O
-	O
E2	O
,	O
SCL	O
and	O
RBTN2	O
,	O
all	O
expressed	O
in	O
untreated	O
K562	B
cells	I
,	O
did	O
not	O
increase	O
during	O
sodium	O
phenylacetate	O
induced	O
erythroid	O
differentiation	O
.	O

The	O
expression	O
of	O
the	O
nuclear	O
factors	O
Evi-1	O
and	O
c	O
-	O
myb	O
,	O
known	O
to	O
inhibit	O
erythroid	O
differentiation	O
,	O
did	O
not	O
decrease	O
.	O

We	O
conclude	O
that	O
sodium	O
phenylacetate	O
treatment	O
of	O
K562	B
cells	I
increases	O
gamma	O
-	O
globin	O
mRNA	O
and	O
induces	O
cell	O
maturation	O
as	O
judged	O
by	O
morphology	O
without	O
affecting	O
the	O
expression	O
of	O
the	O
erythroid	O
transcription	O
factors	O
,	O
some	O
of	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

c	O
-	O
Myb	O
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	O
.	O

The	O
Zfh	O
family	O
of	O
zinc	O
finger	O
/	O
homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	O
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	O
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	O
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c	O
-	O
Myb	O
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	O
blocks	O
the	O
activity	O
of	O
c	O
-	O
Myb	O
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c	O
-	O
Myb	O
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	O
and	O
transcriptional	O
activation	O
by	O
c	O
-	O
Myb	O
/Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive	O
/	O
negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	O
integrin	O
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

Opposite	O
effects	O
of	O
the	O
acute	O
promyelocytic	O
leukemia	O
PML	O
-	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
and	O
PLZF	O
-	O
RAR	O
alpha	O
fusion	O
proteins	O
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
and	O
the	O
PML	O
or	O
PLZF	O
nuclear	O
protein	O
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML	O
-	O
RAR	O
alpha	O
or	O
the	O
PLZF	O
-	O
RAR	O
alpha	O
fusion	O
protein	O
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML	O
-	O
RAR	O
alpha	O
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF	O
-	O
RAR	O
alpha	O
do	O
not	O
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML	O
-	O
RAR	O
alpha	O
expression	O
,	O
PLZF	O
-	O
RAR	O
alpha	O
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	B
and	O
HL-60	B
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML	O
-	O
RAR	O
alpha	O
,	O
but	O
not	O
PLZF	O
-	O
RAR	O
alpha	O
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	O
precursor	O
cells	O
and	O
restores	O
RA	O
sensitivity	O
of	O
RA	O
-	O
resistant	O
hematopoietic	O
cells	O
;	O
(	O
iii	O
)	O
PML	O
-	O
RAR	O
alpha	O
and	O
PLZF	O
-	O
RAR	O
alpha	O
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML	O
-	O
RAR	O
alpha	O
enhances	O
the	O
RA	O
response	O
of	O
RA	O
target	O
genes	O
(	O
those	O
for	O
RAR	O
beta	O
,	O
RAR	O
gamma	O
,	O
and	O
transglutaminase	O
type	O
II	O
[	O
TGase	O
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF	O
-	O
RAR	O
alpha	O
expression	O
has	O
either	O
no	O
effect	O
(	O
RAR	O
beta	O
)	O
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	O
gamma	O
and	O
type	O
II	O
TGase	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML	O
-	O
RAR	O
alpha	O
and	O
PLZF	O
-	O
RAR	O
alpha	O
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA	O
-	O
dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA	O
-	O
dependent	O
enhancers	O
or	O
inhibitors	O
of	O
RA	O
-	O
responsive	O
genes	O
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML	O
-	O
RAR	O
alpha	O
and	O
PLZF	O
-	O
RAR	O
alpha	O
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF	O
-	O
RAR	O
alpha	O
fusion	O
protein	O
contains	O
an	O
approximately	O
120-amino	O
-	O
acid	O
N	O
-	O
terminal	O
motif	O
(	O
called	O
the	O
POZ	O
domain	O
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	O
proteins	O
and	O
which	O
mediates	O
protein	O
-	O
protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	O
POZ	O
domain	O
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF	O
-	O
RAR	O
alpha	O
on	O
RA	O
-	O
induced	O
differentiation	O
and	O
on	O
RA	O
-	O
mediated	O
type	O
II	O
TGase	O
up	O
-	O
regulation	O
,	O
suggesting	O
that	O
POZ	O
-	O
mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF	O
-	O
RAR	O
alpha	O
.	O

Regulation	O
of	O
B	O
-	O
cell	O
commitment	O
to	O
plasma	O
cells	O
or	O
to	O
memory	O
B	O
cells	O
.	O

During	O
humoral	O
immune	O
responses	O
,	O
B	O
-	O
lymphocyte	O
activation	O
is	O
followed	O
by	O
differentiation	O
along	O
either	O
the	O
plasma	O
cell	O
pathway	O
or	O
the	O
memory	O
B	O
-	O
cell	O
pathway	O
.	O

Recent	O
studies	O
suggest	O
that	O
CD40-CD40	O
ligand	O
,	O
OX	O
-	O
OX40	O
ligand	O
,	O
a	O
group	O
of	O
cytokines	O
and	O
intracellular	O
transcriptional	O
factors	O
may	O
all	O
contribute	O
to	O
B	O
-	O
lymphocyte	O
differentiation	O
control	O
.	O

Transcription	O
factor	O
GATA-3	O
is	O
differentially	O
expressed	O
in	O
murine	B
Th1	I
and	I
Th2	I
cells	I
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	O
gene	O
.	O

Interleukin-5	O
(	O
IL-5	O
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	O
by	O
Th1	O
cells	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1-	O
and	O
Th2-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
GATA-3	O
in	O
IL-5	O
promoter	O
activation	O
in	O
EL-4	B
cells	I
,	O
which	O
express	O
both	O
Th1-	O
and	O
Th2-type	O
cytokines	O
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA-3	O
is	O
critical	O
for	O
expression	O
of	O
the	O
IL-5	O
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	O
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	O
in	O
Th1	O
cells	O
or	O
in	O
a	O
non	B
-	I
lymphoid	I
,	I
non	I
-	I
IL-5-producing	I
cell	I
line	I
activated	O
the	O
IL-5	O
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	O
gene	O
expression	O
was	O
up	O
-	O
regulated	O
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
Th1	O
cells	O
,	O
and	O
antigen-	O
or	O
cAMP	O
-	O
activated	O
Th2	O
cells	O
(	O
but	O
not	O
Th1	O
cells	O
)	O
expressed	O
the	O
GATA-3	O
protein	O
.	O

Thus	O
,	O
GATA-3	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA-3	O
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas	O
-	O
mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus	O
-	O
infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	O
,	O
an	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
early	O
-	O
lytic	O
-	O
cycle	O
protein	O
with	O
distant	O
homology	O
to	O
Bcl-2	O
,	O
as	O
an	O
anti	O
-	O
apoptosis	O
protein	O
.	O

Expression	O
of	O
BHRF1	O
in	O
MCF	B
-	I
Fas	I
cells	I
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti	O
-	O
Fas	O
antibody	O
and	O
TNF	O
-	O
mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	O
protected	O
these	O
cells	O
from	O
monocyte	O
-	O
mediated	O
killing	O
but	O
failed	O
to	O
protect	O
them	O
from	O
killing	O
mediated	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
protect	O
MCF	B
-	I
Fas	I
cells	I
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	O
and	O
Bcl	O
-	O
xL	O
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	O
resembled	O
that	O
of	O
Bcl-2	O
and	O
Bcl	O
-	O
xL	O
as	O
it	O
inhibited	O
TNF-	O
and	O
anti	O
-	O
Fas	O
-	O
induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	O
phospholipase	O
A2	O
and	O
caspase-3	O
/	O
CPP32	O
,	O
but	O
did	O
not	O
interfere	O
with	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
like	O
transcription	O
factors	O
.	O

A	O
putative	O
function	O
of	O
BHRF1	O
in	O
EBV	O
-	O
infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus	O
-	O
infected	O
cells	O
from	O
TNF-	O
and/or	O
anti	O
-	O
Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	O
BHRF1	O
nor	O
Bcl-2	O
in	O
a	O
B	B
-	I
cell	I
line	I
,	O
BJAB	B
,	O
protected	O
the	O
cells	O
from	O
anti	O
-	O
Fas	O
-	O
mediated	O
apoptosis	O
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum	O
-	O
starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	O
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	O
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

Expression	O
of	O
bcl-6	O
protein	O
in	O
normal	O
skin	O
and	O
epidermal	O
neoplasms	O
.	O

Bcl-6	O
protein	O
is	O
a	O
recently	O
identified	O
novel	O
transcription	O
factor	O
whose	O
deregulated	O
expression	O
is	O
associated	O
with	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
.	O

It	O
was	O
recently	O
shown	O
by	O
us	O
that	O
the	O
protein	O
is	O
located	O
in	O
germinal	O
center	O
B	O
cells	O
and	O
their	O
neoplastic	O
counterparts	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
expression	O
of	O
bcl-6	O
protein	O
on	O
normal	O
epidermis	O
,	O
benign	O
,	O
and	O
malignant	O
tumors	O
originating	O
from	O
epidermal	O
cells	O
,	O
and	O
squamous	B
cell	I
carcinoma	I
(	I
SCC	I
)	I
cell	I
lines	I
are	O
investigated	O
.	O

With	O
the	O
use	O
of	O
immunohistochemistry	O
,	O
bcl-6	O
protein	O
was	O
shown	O
to	O
stain	O
intensely	O
on	O
normal	B
prickle	I
cells	I
,	O
but	O
none	O
to	O
only	O
slightly	O
on	O
epidermal	O
basal	O
cells	O
.	O

Papillomas	O
and	O
keratoacanthomas	O
copied	O
their	O
normal	O
counterparts	O
in	O
the	O
mode	O
of	O
expression	O
.	O

Various	O
levels	O
of	O
expression	O
were	O
found	O
on	O
seborrheic	O
keratoses	O
,	O
while	O
the	O
expression	O
level	O
on	O
basal	O
cell	O
epitheliomas	O
was	O
low	O
.	O

Peculiarly	O
,	O
eccrine	O
poromas	O
and	O
undifferentiated	O
spindle	O
-	O
shaped	O
basal	O
cell	O
epitheliomas	O
were	O
totally	O
unstained	O
.	O

Squamous	O
cell	O
carcinomas	O
showed	O
a	O
variety	O
of	O
expression	O
levels	O
,	O
while	O
two	O
undifferentiated	O
spindle	O
-	O
shaped	O
carcinomas	O
and	O
one	O
undifferentiated	O
SCC	B
cell	I
line	I
remained	O
unstained	O
.	O

These	O
results	O
suggest	O
that	O
the	O
expression	O
of	O
bcl-6	O
protein	O
may	O
be	O
associated	O
with	O
morphological	O
differentiation	O
in	O
normal	O
and	O
neoplastic	O
epidermal	O
cells	O
.	O

HIV-1	O
Vpr	O
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
[	O
see	O
comments	O
]	O

The	O
HIV-1	O
accessory	O
gene	O
product	O
Vpr	O
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	O
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	O
modulates	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	O
of	O
TCR	O
-mediated	O
activation	O
,	O
Vpr	O
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	O
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
via	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
,	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Further	O
,	O
Vpr	O
suppresses	O
expression	O
of	O
IL-2	O
,	O
IL-10	O
,	O
IL-12	O
,	O
TNF	O
alpha	O
and	O
IL-4	O
,	O
all	O
of	O
which	O
are	O
NF	O
-	O
kappa	O
B	O
-dependent	O
.	O

The	O
effects	O
of	O
Vpr	O
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	O
can	O
regulate	O
NF	O
-	O
kappa	O
B	O
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	O
.	O

Nuclear	O
localization	O
of	O
RelB	O
is	O
associated	O
with	O
effective	O
antigen	O
-	O
presenting	O
cell	O
function	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APCs	O
that	O
enter	O
resting	O
tissues	O
as	O
precursors	O
and	O
,	O
after	O
Ag	O
exposure	O
,	O
differentiate	O
and	O
migrate	O
to	O
draining	O
lymph	O
nodes	O
.	O

The	O
phenotype	O
of	O
RelB	O
knockout	O
mice	O
implicates	O
this	O
member	O
of	O
the	O
NF	O
kappa	O
B	O
/	O
Rel	O
family	O
in	O
DC	O
differentiation	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
RelB	O
in	O
DC	O
differentiation	O
,	O
mRNA	O
,	O
intracellular	O
protein	O
expression	O
,	O
and	O
DNA	O
binding	O
activity	O
of	O
RelB	O
were	O
examined	O
in	O
immature	O
and	O
differentiated	O
human	O
DC	O
,	O
as	O
well	O
as	O
other	O
PB	O
mononuclear	O
cell	O
populations	O
.	O

RelB	O
protein	O
and	O
mRNA	O
were	O
detected	O
constitutively	O
in	O
lymphocytes	O
and	O
in	O
activated	O
monocytes	O
,	O
differentiated	O
DC	O
,	O
and	O
monocyte	B
-	I
derived	I
DC	I
.	O

Immunohistochemical	O
staining	O
demonstrated	O
RelB	O
within	O
the	O
differentiated	O
lymph	O
node	O
interdigitating	O
DC	O
and	O
follicular	O
DC	O
,	O
but	O
not	O
undifferentiated	O
DC	O
in	O
normal	O
skin	O
.	O

Active	O
nuclear	O
RelB	O
was	O
detected	O
by	O
supershift	O
assay	O
only	O
in	O
differentiated	O
DC	O
derived	O
from	O
either	O
PB	O
precursors	O
or	O
monocytes	O
and	O
in	O
activated	O
B	O
cells	O
.	O

These	O
RelB+	O
APC	O
were	O
potent	O
stimulators	O
of	O
the	O
MLR	O
.	O

The	O
data	O
indicate	O
that	O
RelB	O
expression	O
is	O
regulated	O
both	O
transcriptionally	O
and	O
post	O
-	O
translationally	O
in	O
myeloid	O
cells	O
.	O

Within	O
the	O
nucleus	O
,	O
RelB	O
may	O
specifically	O
transactivate	O
genes	O
that	O
are	O
critical	O
for	O
APC	O
function	O
.	O

Expression	O
of	O
c	O
-	O
fos	O
correlates	O
with	O
IFN	O
-	O
alpha	O
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	O
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN	O
-	O
alpha	O
2c	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c	O
-	O
fos	O
,	O
c	O
-	O
myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr	O
/	O
abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c	O
-	O
fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN	O
-	O
alpha	O
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr	O
/	O
abl	O
,	O
c	O
-	O
myc	O
and	O
p53	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN	O
-	O
alpha	O
is	O
accompanied	O
by	O
upregulation	O
of	O
c	O
-	O
fos	O
and	O
downregulation	O
of	O
c	O
-	O
myc	O
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Aberrant	O
splicing	O
of	O
the	O
TSG101	O
and	O
FHIT	O
genes	O
occurs	O
frequently	O
in	O
multiple	O
malignancies	O
and	O
in	O
normal	O
tissues	O
and	O
mimics	O
alterations	O
previously	O
described	O
in	O
tumours	O
.	O

Intragenic	O
deletions	O
of	O
TSG101	O
,	O
the	O
human	O
homolog	O
of	O
a	O
mouse	O
gene	O
(	O
tsg101	O
)	O
that	O
acts	O
to	O
suppress	O
malignant	O
cell	O
growth	O
,	O
were	O
reported	O
in	O
human	O
breast	O
tumours	O
.	O

We	O
screened	O
TSG101	O
for	O
somatic	O
mutations	O
in	O
DNA	O
and	O
RNA	O
samples	O
isolated	O
from	O
a	O
variety	O
of	O
common	O
human	O
malignancies	O
,	O
EBV	O
-	O
immortalised	O
B	O
-	O
cells	O
,	O
and	O
normal	O
lung	O
parenchyma	O
.	O

Intragenic	O
TSG101	O
deletions	O
in	O
RNA	O
transcripts	O
were	O
frequently	O
found	O
in	O
all	O
types	O
of	O
samples	O
.	O

Analysis	O
of	O
DNA	O
failed	O
to	O
show	O
genomic	O
rearrangements	O
corresponding	O
to	O
transcripts	O
containing	O
deletions	O
in	O
the	O
same	O
samples	O
.	O

The	O
breakpoints	O
of	O
most	O
transcript	O
deletions	O
coincide	O
with	O
genuine	O
or	O
cryptic	O
splice	O
site	O
sequences	O
,	O
suggesting	O
that	O
they	O
result	O
from	O
alternative	O
or	O
aberrant	O
splicing	O
.	O

A	O
similar	O
spectrum	O
of	O
transcript	O
deletions	O
has	O
previously	O
been	O
described	O
in	O
the	O
putative	O
tumour	O
suppressor	O
gene	O
FHIT	O
.	O

We	O
analysed	O
FHIT	O
in	O
the	O
same	O
series	O
of	O
RNA	O
samples	O
and	O
detected	O
truncated	O
FHIT	O
transcripts	O
frequently	O
in	O
both	O
tumour	O
and	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
transcripts	O
from	O
TSG101	O
,	O
FHIT	O
and	O
seven	O
other	O
genes	O
were	O
analysed	O
in	O
RNA	O
isolated	O
from	O
normal	O
peripheral	O
blood	O
lymphocytes	O
.	O

Large	O
TSG101	O
and	O
FHIT	O
intragenic	O
transcript	O
deletions	O
were	O
detected	O
and	O
these	O
appeared	O
to	O
be	O
the	O
predominant	O
transcript	O
in	O
'	O
aged	O
'	O
lymphocytes	O
.	O

Similar	O
alterations	O
were	O
not	O
detected	O
in	O
transcripts	O
of	O
the	O
other	O
genes	O
which	O
were	O
analysed	O
.	O

Our	O
findings	O
demonstrate	O
that	O
truncated	O
TSG101	O
and	O
FHIT	O
transcripts	O
are	O
commonly	O
detected	O
in	O
both	O
normal	O
and	O
malignant	O
tissues	O
and	O
that	O
a	O
significant	O
fraction	O
of	O
these	O
are	O
likely	O
to	O
be	O
the	O
result	O
of	O
aberrant	O
splicing	O
.	O

While	O
we	O
can	O
not	O
exclude	O
that	O
alterations	O
in	O
TSG101	O
and	O
FHIT	O
occur	O
during	O
cancer	O
development	O
,	O
our	O
data	O
indicate	O
that	O
in	O
this	O
context	O
the	O
commonly	O
observed	O
transcript	O
abnormalities	O
are	O
misleading	O
.	O

OCA	O
-	O
B	O
is	O
a	O
functional	O
analog	O
of	O
VP16	O
but	O
targets	O
a	O
separate	O
surface	O
of	O
the	O
Oct-1	O
POU	O
domain	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1998	O
Apr	O
;	O
18	O
(	O
4	O
)	O
:	O
2430	O
]	O

OCA	O
-	O
B	O
is	O
a	O
B	O
-	O
cell	O
-	O
specific	O
coregulator	O
of	O
the	O
broadly	O
expressed	O
POU	O
domain	O
transcription	O
factor	O
Oct-1	O
.	O

OCA	O
-	O
B	O
associates	O
with	O
the	O
Oct-1	O
POU	O
domain	O
,	O
a	O
bipartite	O
DNA	O
-	O
binding	O
structure	O
containing	O
a	O
POU	O
-	O
specific	O
(	O
POU	O
[	O
S	O
]	O
)	O
domain	O
joined	O
by	O
a	O
flexible	O
linker	O
to	O
a	O
POU	O
homeodomain	O
(	O
POU	O
[	O
H	O
]	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
OCA	O
-	O
B	O
alters	O
the	O
activity	O
of	O
Oct-1	O
in	O
two	O
ways	O
.	O

It	O
provides	O
a	O
transcriptional	O
activation	O
domain	O
which	O
,	O
unlike	O
Oct-1	O
,	O
activates	O
an	O
mRNA	O
-	O
type	O
promoter	O
effectively	O
,	O
and	O
it	O
stabilizes	O
Oct-1	O
on	O
the	O
Oct-1-responsive	O
octamer	O
sequence	O
ATGCAAAT	O
.	O

These	O
properties	O
of	O
OCA	O
-	O
B	O
parallel	O
those	O
displayed	O
by	O
the	O
herpes	O
simplex	O
virus	O
Oct-1	O
coregulator	O
VP16	O
.	O

OCA	O
-	O
B	O
,	O
however	O
,	O
interacts	O
with	O
a	O
different	O
surface	O
of	O
the	O
DNA	O
-	O
bound	O
Oct-1	O
POU	O
domain	O
,	O
interacting	O
with	O
both	O
the	O
POU	O
(	O
S	O
)	O
and	O
POU	O
(	O
H	O
)	O
domains	O
and	O
the	O
center	O
of	O
the	O
ATGCAAAT	O
octamer	O
sequence	O
.	O

The	O
OCA	O
-	O
B	O
and	O
VP16	O
interactions	O
with	O
the	O
Oct-1	O
POU	O
domain	O
are	O
sufficiently	O
different	O
to	O
permit	O
OCA	O
-	O
B	O
and	O
VP16	O
to	O
bind	O
the	O
Oct-1	O
POU	O
domain	O
simultaneously	O
.	O

These	O
results	O
emphasize	O
the	O
structural	O
versatility	O
of	O
the	O
Oct-1	O
POU	O
domain	O
in	O
its	O
interaction	O
with	O
coregulators	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	O
factor	O
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	O
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	O
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	O
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes	O
/	O
macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	O
activity	O
generated	O
by	O
both	O
unstimulated	B
and	O
endotoxin	B
-	I
stimulated	I
cells	I
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	O
monocyte	O
TF	O
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	O
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	O
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon	O
-	O
gamma	O
or	O
interleukin-1beta	O
.	O

As	O
shown	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	O
mRNA	O
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	O
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	O
activation	O
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	O
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	O
expression	O
and	O
NF	O
-	O
kappaB	O
activation	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	O
polymerase	O
II	O
in	O
cell	O
-	O
free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	O
through	O
XPG	O
.	O

Of	O
these	O
,	O
the	O
XPB	O
and	O
XPD	O
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	O
transcription	O
factor	O
,	O
TFIIH	O
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	O
or	O
XPD	O
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper	O
-	O
sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	O
transcription	O
deficiency	O
has	O
been	O
demonstrated	O
in	O
either	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell	O
-	O
free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP	O
-	O
B	O
and	O
XP	O
-	O
D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP	B
-	I
B	I
and	I
XP	I
-	I
D	I
cells	I
contained	O
reduced	O
amounts	O
of	O
TFIIH	O
.	O

Extracts	O
prepared	O
from	O
XP	B
-	I
B	I
and	I
XP	I
-	I
D	I
lymphoblastoid	I
cells	I
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP	B
-	I
B	I
and	I
XP	I
-	I
D	I
lymphoblastoid	I
cells	I
do	O
not	O
have	O
impaired	O
RNA	O
transcription	O
activity	O
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	O
for	O
the	O
clinical	O
symptoms	O
in	O
XP	O
-	O
B	O
or	O
XP	O
-	O
D	O
patients	O
,	O
and	O
discuss	O
a	O
'	O
conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Temporal	O
control	O
of	O
IgH	O
gene	O
expression	O
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	O
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	O
3'LCR	O
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	O
gene	O
expression	O
and	O
compare	O
it	O
with	O
the	O
5'LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	O
cytokines	O
and	O
mononuclear	O
cell	O
attracting	O
chemokines	O
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
many	O
proinflammatory	O
cytokine	O
genes	O
,	O
but	O
can	O
not	O
be	O
the	O
only	O
mechanism	O
,	O
since	O
several	O
cytokine	O
genes	O
lack	O
respective	O
binding	O
sites	O
in	O
their	O
promoter	O
regions	O
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	O
factors	O
of	O
possible	O
importance	O
such	O
as	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
and	O
OTF-2	O
.	O

To	O
explore	O
long	O
-	O
term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	O
factors	O
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	O
transcription	O
factor	O
proteins	O
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell	O
-	O
type	O
-	O
specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
OFT-2	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
genes	O
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	B
cell	I
line	I
Mono	B
Mac	I
6	I
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	O
significant	O
changes	O
were	O
detected	O
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	O
,	O
CTF	O
,	O
and	O
OTF-2	O
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long	O
-	O
term	O
regulation	O
of	O
transcription	O
factor	O
gene	O
expression	O
in	O
non	O
-	O
proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	O
factor	O
proteins	O
is	O
required	O
.	O

Genes	O
that	O
regulate	O
interleukin-4	O
expression	O
in	O
T	O
cells	O
.	O

Interleukin-4	O
is	O
an	O
immunomodulatory	O
cytokine	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
allergic	O
and	O
atopic	O
immune	O
responses	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
gaining	O
a	O
detailed	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
the	O
interleukin-4	O
gene	O
.	O

The	O
recent	O
identification	O
and	O
characterization	O
of	O
several	O
key	O
transcription	O
factors	O
has	O
helped	O
to	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
T	O
helper	O
cell	O
cytokine	O
gene	O
expression	O
.	O

Role	O
of	O
cyclic	O
AMP	O
response	O
element	O
-	O
binding	O
protein	O
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
-mediated	O
transcription	O
.	O

The	O
NF	O
-	O
kappaB	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
elevation	O
of	O
intracellular	O
cyclic	O
AMP	O
inhibits	O
NF	O
-	O
kappaB	O
-mediated	O
transcription	O
in	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
without	O
preventing	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	O
kinase	O
A	O
signaling	O
pathway	O
may	O
inhibit	O
NF	O
-	O
kappaB	O
-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
1	O
-	O
450	O
)	O
of	O
CBP	O
specifically	O
interacts	O
with	O
the	O
carboxyl	O
-	O
terminal	O
region	O
(	O
amino	O
acids	O
286	O
-	O
551	O
)	O
of	O
NF	O
-	O
kappaB	O
p65	O
(	O
RelA	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Functional	O
studies	O
using	O
human	O
endothelial	O
cells	O
demonstrated	O
that	O
overexpression	O
of	O
CBP	O
rescued	O
cAMP	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
-mediated	O
transcription	O
and	O
transcription	O
mediated	O
by	O
a	O
chimeric	O
protein	O
,	O
GAL4-p65	O
(	O
286	O
-	O
551	O
)	O
,	O
which	O
contained	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
fused	O
to	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
p65	O
(	O
amino	O
acids	O
286	O
-	O
551	O
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	O
inhibited	O
GAL4	O
-p65	O
(	O
286	O
-	O
551	O
)	O
-mediated	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	O
kinase	O
A	O
pathway	O
inhibits	O
NF	O
-	O
kappaB	O
transcription	O
by	O
phosphorylating	O
CREB	O
,	O
which	O
competes	O
with	O
p65	O
for	O
limiting	O
amounts	O
of	O
CBP	O
.	O

Mycobacterium	O
tuberculosis	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
can	O
induce	O
NF	O
-	O
kappaB	O
-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose	O
-	O
capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4	O
-expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	B
cell	I
line	I
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR	O
-	O
dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	O
tyrosine	O
kinase	O
(	O
s	O
)	O
,	O
protein	O
kinase	O
A	O
and/or	O
protein	O
kinase	O
C	O
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
-	O
driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild	O
-	O
type	O
,	O
but	O
not	O
the	O
kappaB	O
-	O
mutated	O
,	O
HIV-1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM	O
-	O
mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
TNF	O
-	O
alpha	O
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Coactivation	O
by	O
OCA	O
-	O
B	O
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	O
-	O
B	O
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	O
promoters	O
through	O
interaction	O
with	O
octamer	O
-	O
bound	O
Oct-1	O
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	O
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct-1	O
and	O
OCA	O
-	O
B	O
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	O
and	O
the	O
PC4	O
-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	O
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1	O
/OCA	O
-	O
B	O
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	O
-	O
derived	O
PC2	O
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	O
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	O
in	O
the	O
reconstituted	O
system	O
,	O
OCA	O
-	O
B	O
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	O
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	O
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA	O
-	O
B	O
/	O
Oct-1	O
-dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct-1	O
and	O
OCA	O
-	O
B	O
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	O
coactivators	O
.	O

Differential	O
regulation	O
of	O
the	O
Janus	O
kinase	O
-STAT	O
pathway	O
and	O
biologic	O
function	O
of	O
IL-13	O
in	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
:	O
a	O
comparative	O
study	O
with	O
IL-4	O
.	O

IL-13	O
,	O
a	O
cytokine	O
similar	O
to	O
IL-4	O
,	O
is	O
a	O
regulator	O
of	O
human	O
B	O
cell	O
and	O
monocyte	O
functions	O
.	O

Biologic	O
effects	O
of	O
IL-13	O
on	O
primary	O
human	O
NK	O
and	O
T	O
cells	O
have	O
not	O
been	O
well	O
defined	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
primary	O
NK	O
cells	O
,	O
IL-13	O
,	O
but	O
not	O
IL-4	O
,	O
may	O
induce	O
low	O
levels	O
of	O
IFN	O
-	O
gamma	O
secretion	O
.	O

When	O
NK	O
cells	O
were	O
costimulated	O
with	O
IL-13	O
and	O
IL-2	O
,	O
IL-13	O
generally	O
resulted	O
in	O
two	O
types	O
of	O
reactivity	O
:	O
IL-13	O
synergized	O
with	O
IL-2	O
to	O
stimulate	O
IFN	O
-	O
gamma	O
production	O
or	O
it	O
modestly	O
inhibited	O
IL-2	O
-mediated	O
IFN	O
-	O
gamma	O
production	O
.	O

In	O
both	O
types	O
of	O
donors	O
,	O
the	O
effect	O
of	O
IL-13	O
on	O
IL-2	O
-induced	O
IFN	O
-	O
gamma	O
production	O
was	O
in	O
marked	O
contrast	O
to	O
the	O
strong	O
inhibition	O
seen	O
with	O
IL-4	O
in	O
NK	O
cells	O
.	O

Additionally	O
,	O
IL-13	O
suppresses	O
IL-2-induced	O
NK	O
cytolytic	O
and	O
proliferative	O
activities	O
although	O
less	O
efficiently	O
than	O
IL-4	O
.	O

In	O
T	O
cells	O
,	O
IL-13	O
inhibits	O
anti	O
-	O
CD3	O
mAb	O
/	O
IL-2-	O
or	O
PHA	O
-	O
mediated	O
IFN	O
-	O
gamma	O
production	O
and	O
enhances	O
cytolytic	O
potential	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
IL-13	O
,	O
like	O
IL-4	O
,	O
induces	O
distinct	O
STAT6-DNA	O
binding	O
complexes	O
and	O
tyrosine	O
phosphorylation	O
of	O
STAT6	O
and	O
Janus	O
kinase	O
3	O
(	O
JAK3	O
)	O
in	O
NK	O
and	O
T	O
cells	O
.	O

We	O
observed	O
that	O
Abs	O
directed	O
against	O
unique	O
domains	O
of	O
STAT6	O
have	O
differential	O
effects	O
on	O
complexes	O
in	O
T	O
cells	O
but	O
not	O
in	O
NK	O
cells	O
,	O
suggesting	O
different	O
STAT6	O
isoforms	O
.	O

These	O
findings	O
show	O
that	O
IL-13	O
and	O
IL-4	O
have	O
the	O
ability	O
to	O
regulate	O
NK	O
and	O
T	O
cell	O
activation	O
and	O
that	O
IL-13	O
is	O
a	O
potent	O
regulator	O
of	O
STAT6	O
and	O
JAK3	O
in	O
these	O
cell	O
types	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	O
factor	O
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation	O
-	O
dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	O
expression	O
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA	O
-	O
binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	O
factors	O
:	O
NFkappaB	O
,	O
AP-1	O
and	O
NFAT	O
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	O
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	O
induce	O
catalase	O
activity	O
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	O
factor	O
functions	O
can	O
potentially	O
serve	O
as	O
a	O
marker	O
of	O
exposure	O
to	O
oxidative	O
stress	O
and	O
its	O
effects	O
on	O
human	O
lymphocytes	O
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	O
induce	O
catalase	O
activity	O
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	O
factor	O
DNA	O
-	O
binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

Macrophages	O
in	O
human	O
atheroma	O
contain	O
PPARgamma	O
:	O
differentiation	O
-	O
dependent	O
peroxisomal	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
expression	O
and	O
reduction	O
of	O
MMP-9	O
activity	O
through	O
PPARgamma	O
activation	O
in	O
mononuclear	O
phagocytes	O
in	O
vitro	O
.	O

Mononuclear	O
phagocytes	O
play	O
an	O
important	O
role	O
in	O
atherosclerosis	O
and	O
its	O
sequela	O
plaque	O
rupture	O
in	O
part	O
by	O
their	O
secretion	O
of	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
including	O
MMP-9	O
.	O

Peroxisomal	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
,	O
a	O
transcription	O
factor	O
in	O
the	O
nuclear	O
receptor	O
superfamily	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
various	O
activators	O
,	O
including	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
and	O
the	O
antidiabetic	O
agent	O
troglitazone	O
.	O

The	O
role	O
of	O
PPARgamma	O
in	O
human	O
atherosclerosis	O
is	O
unexplored	O
.	O

We	O
report	O
here	O
that	O
monocytes	O
/	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
(	O
n	O
=	O
12	O
)	O
express	O
immunostainable	O
PPARgamma	O
.	O

Normal	O
artery	O
specimens	O
(	O
n	O
=	O
6	O
)	O
reveal	O
minimal	O
immunoreactive	O
PPARgamma	O
.	O

Human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
cultured	O
for	O
6	O
days	O
in	O
5	O
%	O
human	O
serum	O
expressed	O
PPARgamma	O
mRNA	O
and	O
protein	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
PPARgamma	O
mRNA	O
expression	O
in	O
U937	B
cells	I
increased	O
during	O
phorbol	O
12-myristate	O
13	O
acetate	O
-	O
induced	O
differentiation	O
.	O

Stimulation	O
of	O
PPARgamma	O
with	O
troglitazone	O
or	O
15-deoxy	O
-	O
delta12	O
,	O
14-prostaglandin	O
J2	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
inhibited	O
MMP-9	O
gelatinolytic	O
activity	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
as	O
revealed	O
by	O
zymography	O
.	O

This	O
inhibition	O
correlates	O
with	O
decreased	O
MMP-9	O
secretion	O
as	O
determined	O
by	O
Western	O
blotting	O
.	O

Thus	O
,	O
PPARgamma	O
is	O
present	O
in	O
macrophages	O
in	O
human	O
atherosclerotic	O
lesions	O
and	O
may	O
regulate	O
expression	O
and	O
activity	O
of	O
MMP-9	O
,	O
an	O
enzyme	O
implicated	O
in	O
plaque	O
rupture	O
.	O

PPARgamma	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
monocyte	O
/	O
macrophage	O
function	O
with	O
relevance	O
for	O
human	O
atherosclerotic	O
disease	O
.	O

Suppression	O
of	O
human	O
anti	O
-	O
porcine	O
T	O
-	O
cell	O
immune	O
responses	O
by	O
major	O
histocompatibility	O
complex	O
class	O
II	O
transactivator	O
constructs	O
lacking	O
the	O
amino	O
terminal	O
domain	O
.	O

BACKGROUND	O
:	O
The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
is	O
a	O
bi-	O
or	O
multifunctional	O
domain	O
protein	O
that	O
acts	O
as	O
a	O
transcriptional	O
activator	O
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
a	O
mutated	O
form	O
of	O
the	O
human	O
CIITA	O
gene	O
,	O
coding	O
for	O
a	O
protein	O
lacking	O
the	O
amino	O
terminal	O
151	O
amino	O
acids	O
,	O
acts	O
as	O
a	O
potent	O
dominant	O
-	O
negative	O
suppressor	O
of	O
HLA	O
class	O
II	O
expression	O
.	O

Porcine	O
MHC	O
class	O
II	O
antigens	O
are	O
potent	O
stimulators	O
of	O
direct	O
T	O
-	O
cell	O
recognition	O
by	O
human	O
CD4	O
+	O
T	O
cells	O
and	O
are	O
,	O
therefore	O
,	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
rejection	O
responses	O
to	O
transgenic	O
pig	O
donors	O
in	O
clinical	O
xenotransplantation	O
.	O

We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
examining	O
mutated	O
CIITA	O
constructs	O
for	O
their	O
effect	O
on	O
porcine	O
MHC	O
class	O
II	O
expression	O
.	O

METHODS	O
:	O
Stable	O
transfectants	O
of	O
the	O
porcine	B
vascular	I
endothelial	I
cell	I
line	I
PIEC	B
with	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
induction	O
by	O
recombinant	O
porcine	O
interferon	O
-	O
gamma	O
.	O

Transient	O
transfectants	O
of	O
the	O
porcine	B
B	I
-	I
cell	I
line	I
L23	I
with	O
the	O
mutated	O
CIITA	O
constructs	O
were	O
tested	O
for	O
the	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
expression	O
.	O

T	O
-	O
cell	O
proliferation	O
studies	O
were	O
performed	O
using	O
highly	O
purified	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

RESULTS	O
:	O
In	O
preliminary	O
studies	O
,	O
we	O
demonstrated	O
that	O
transfection	O
of	O
the	O
PIEC	B
line	I
with	O
full	O
-	O
length	O
human	O
CIITA	O
constructs	O
resulted	O
in	O
strong	O
expression	O
of	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
antigens	O
,	O
thus	O
establishing	O
the	O
cross	O
-	O
species	O
effectiveness	O
of	O
human	O
CIITA	O
in	O
the	O
pig	O
.	O

The	O
mutated	O
human	O
CIITA	O
constructs	O
were	O
,	O
therefore	O
,	O
tested	O
in	O
the	O
pig	O
.	O

PIEC	B
clones	I
stably	O
transfected	O
with	O
one	O
of	O
these	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
antigen	O
induction	O
and	O
marked	O
suppression	O
of	O
SLA	O
-	O
DRA	O
mRNA	O
induction	O
.	O

Moreover	O
,	O
transient	O
transfection	O
of	O
the	O
porcine	B
B	I
-	I
cell	I
line	I
L23	I
showed	O
up	O
to	O
90	O
%	O
suppression	O
of	O
constitutive	O
SLA	O
-	O
DR	O
and	O
SLA	O
-	O
DQ	O
antigen	O
expression	O
in	O
5	O
-	O
8	O
days	O
.	O

In	O
functional	O
studies	O
,	O
interferon	B
-	I
gamma	I
-	I
stimulated	I
PIEC	I
clones	I
transfected	O
with	O
this	O
mutated	O
CIITA	O
construct	O
failed	O
to	O
stimulate	O
purified	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O

CONCLUSION	O
:	O
Mutated	O
human	O
CIITA	O
constructs	O
are	O
potent	O
suppressors	O
of	O
porcine	O
MHC	O
class	O
II	O
expression	O
.	O

Redox	O
signals	O
and	O
NF	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL-2	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
several	O
T	O
cell	O
surface	O
receptors	O
.	O

Diminished	O
NF	O
-	O
kappaB	O
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF	O
-	O
kappaB	O
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF	O
-	O
kappaB	O
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV-1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	B
cell	I
lines	I
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF	O
-	O
kappaB	O
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF	O
-	O
kappaB	O
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF	O
-	O
kappaB	O
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF	O
-	O
kappaB	O
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF	O
-	O
kappaB	O
activation	O
may	O
be	O
relevant	O
to	O
immune	O
-	O
related	O
diseases	O
and	O
to	O
aging	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	O
transduction	O
molecules	O
.	O

The	O
adoptive	O
transfer	O
of	O
tumor	O
-	O
draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti	O
-	O
CD3	O
and	O
interleukin	O
2	O
(	O
IL-2	O
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	B
modified	I
variant	I
(	O
designated	O
D5G6	B
)	O
that	O
secretes	O
granulocyte	O
/	O
macrophage	O
-	O
colony	O
-	O
stimulating	O
factor	O
.	O

In	O
contrast	O
to	O
anti	B
-	I
CD3	I
/	I
IL-2-activated	I
LN	I
cells	I
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
has	O
no	O
therapeutic	O
activity	O
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
proteins	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
were	O
analyzed	O
in	O
tumor	O
-	O
draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	O
of	O
p56lck	O
and	O
p59fyn	O
were	O
lower	O
in	O
tumor	O
-	O
draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine	O
-	O
phosphorylated	O
substrates	O
was	O
markedly	O
depressed	O
following	O
anti	O
-	O
CD3	O
stimulation	O
.	O

After	O
5-day	O
anti	O
-	O
CD3	O
/IL-2	O
activation	O
,	O
levels	O
of	O
p56lck	O
and	O
p59fyn	O
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	O
,	O
p59fyn	O
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c	O
-	O
Rel	O
and	O
Rel	O
A	O
were	O
normal	O
in	O
freshly	O
isolated	O
tumor	O
-	O
draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
induced	O
by	O
anti	O
-	O
CD3	O
mAb	O
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	O
cell	O
receptor	O
/	O
CD3	O
complex	O
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	O
gene	O
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

MyD88	O
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	O
(	O
IL-1	O
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	O
receptor	O
complex	O
and	O
IL-1	O
receptor	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	O
MyD88	O
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	O
in	O
response	O
to	O
IL-1	O
.	O

Increases	O
in	O
interferon	O
-	O
gamma	O
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	O
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL-18	O
-induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
blocked	O
in	O
MyD88-	B
/	I
-	I
Th1-developing	I
cells	I
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	O
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	O
receptor	O
as	O
well	O
as	O
IL-18	O
receptor	O
.	O

Characterization	O
of	O
cytokine	O
differential	O
induction	O
of	O
STAT	O
complexes	O
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
.	O

Cytokines	O
,	O
IL-2	O
,	O
IL-4	O
,	O
IL-6	O
,	O
IL-7	O
,	O
IL-12	O
,	O
and	O
IL-15	O
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O

Recent	O
studies	O
reveal	O
that	O
a	O
family	O
of	O
transcription	O
factors	O
,	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
directly	O
mediate	O
many	O
cytokine	O
signals	O
.	O

We	O
analyzed	O
the	O
activation	O
of	O
STATs	O
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
by	O
a	O
variety	O
of	O
specific	O
cytokines	O
.	O

We	O
demonstrate	O
that	O
IL-12	O
induces	O
STAT4	O
only	O
in	O
freshly	O
isolated	O
primary	O
NK	O
cells	O
,	O
but	O
not	O
in	O
primary	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
lack	O
of	O
the	O
IL-12	O
receptor	O
in	O
resting	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
IL-4	O
induces	O
different	O
C	O
epsilon	O
GAS	O
DNA	O
-	O
protein	O
binding	O
complexes	O
in	O
both	O
T	O
and	O
NK	O
cells	O
.	O

Moreover	O
,	O
IL-4	O
costimulation	O
with	O
IL-2	O
or	O
IL-12	O
does	O
not	O
alter	O
their	O
own	O
preferential	O
GAS	O
-like	O
DNA	O
binding	O
patterns	O
when	O
C	O
epsilon-	O
,	O
Fc	O
gamma	O
RI-	O
,	O
and	O
SIE	O
GAS	O
motif	O
containing	O
oligonucleotide	O
probes	O
are	O
compared	O
,	O
suggesting	O
that	O
induction	O
of	O
GAS	O
-	O
like	O
DNA	O
-	O
protein	O
binding	O
complexes	O
by	O
IL-2	O
,	O
IL-4	O
,	O
and	O
IL-12	O
is	O
highly	O
selective	O
and	O
represents	O
one	O
important	O
factor	O
in	O
determining	O
specific	O
gene	O
activation	O
.	O

In	O
addition	O
,	O
IL-6	O
and	O
IL-2	O
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	O
alpha	O
and	O
STAT3	O
in	O
both	O
NK	O
and	O
T	O
cells	O
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	O
gene	O
expression	O
.	O

We	O
further	O
demonstrated	O
that	O
IL-2	O
,	O
-7	O
,	O
and	O
-15	O
induce	O
multiple	O
STAT	O
proteins	O
,	O
including	O
STAT5a	O
,	O
STAT5b	O
,	O
STAT1	O
alpha	O
,	O
STAT3	O
,	O
and	O
another	O
unidentified	O
Fc	O
gamma	O
RI	O
GAS	O
DNA	O
-	O
binding	O
protein	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	O
and	O
STAT5b	O
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	O
and	O
NK	O
cells	O
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	O
and	O
T	O
cells	O
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	O
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	O
transcription	O
factors	O
.	O

Interleukin-6	O
production	O
in	O
hemorrhagic	O
shock	O
is	O
accompanied	O
by	O
neutrophil	O
recruitment	O
and	O
lung	O
injury	O
.	O

Hemorrhagic	O
shock	O
(	O
HS	O
)	O
initiates	O
an	O
inflammatory	O
cascade	O
that	O
includes	O
the	O
production	O
of	O
cytokines	O
and	O
recruitment	O
of	O
neutrophils	O
(	O
PMN	O
)	O
and	O
may	O
progress	O
to	O
organ	O
failure	O
,	O
inducing	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
.	O

To	O
examine	O
the	O
hypothesis	O
that	O
interleukin-6	O
(	O
IL-6	O
)	O
contributes	O
to	O
PMN	O
infiltration	O
and	O
lung	O
damage	O
in	O
HS	O
,	O
we	O
examined	O
the	O
lungs	O
of	O
rats	O
subjected	O
to	O
unresuscitated	O
and	O
resuscitated	O
HS	O
for	O
the	O
production	O
of	O
IL-6	O
and	O
activation	O
of	O
Stat3	O
.	O

Using	O
semiquantitative	O
RT	O
-	O
PCR	O
,	O
we	O
found	O
a	O
striking	O
increase	O
in	O
IL-6	O
mRNA	O
levels	O
only	O
in	O
resuscitated	O
HS	O
,	O
with	O
peak	O
levels	O
observed	O
1	O
h	O
after	O
initiation	O
of	O
resuscitation	O
.	O

Increased	O
IL-6	O
protein	O
expression	O
was	O
localized	O
to	O
bronchial	O
and	O
alveolar	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
protein	O
extracts	O
from	O
shock	O
lungs	O
exhibited	O
an	O
increase	O
in	O
Stat3	O
activation	O
with	O
kinetics	O
similar	O
to	O
IL-6	O
mRNA	O
.	O

In	O
situ	O
DNA	O
binding	O
assay	O
determined	O
Stat3	O
activation	O
predominantly	O
within	O
alveoli	O
.	O

Intratracheal	O
instillation	O
of	O
IL-6	O
alone	O
into	O
normal	O
rats	O
resulted	O
in	O
PMN	O
infiltration	O
into	O
lung	O
interstitium	O
and	O
alveoli	O
,	O
marked	O
elevation	O
of	O
bronchoalveolar	O
lavage	O
cellularity	O
,	O
and	O
increased	O
wet	O
-	O
to	O
-	O
dry	O
ratio	O
.	O

These	O
findings	O
indicate	O
that	O
IL-6	O
production	O
and	O
Stat3	O
activation	O
occur	O
early	O
in	O
HS	O
and	O
may	O
contribute	O
to	O
PMN	O
-	O
mediated	O
lung	O
injury	O
,	O
including	O
ARDS	O
after	O
HS	O
.	O

Activation	O
of	O
distinct	O
transcription	O
factors	O
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon	O
-	O
gamma	O
,	O
and	O
GM	O
-	O
CSF	O
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	O
proteases	O
.	O

Human	O
neutrophils	O
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early	O
-	O
response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	O
,	O
chemokines	O
,	O
and	O
the	O
high	O
-	O
affinity	O
surface	O
receptor	O
for	O
IgG	O
,	O
FcgammaRI	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	O
factors	O
,	O
such	O
as	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
STAT	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	O
factors	O
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF	O
-	O
kappaB	O
/	O
Rel	O
and	O
STAT	O
proteins	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	O
induce	O
a	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50	O
/	O
RelA	O
dimers	O
,	O
and	O
that	O
IFNgamma	O
promotes	O
the	O
binding	O
of	O
STAT1	O
homodimers	O
to	O
the	O
IFNgamma	O
response	O
region	O
of	O
the	O
FcgammaRI	O
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM	O
-	O
CSF	O
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5	O
-containing	O
DNA	O
-	O
binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	O
proteases	O
.	O

Prostaglandin	O
E2	O
Up	O
-	O
regulates	O
HIV-1	O
long	O
terminal	O
repeat	O
-driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	O
and	O
host	O
cellular	O
factors	O
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	O
immunomodulatory	O
molecule	O
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	B
,	O
a	O
Jurkat	B
-	I
derived	I
T	I
cell	I
line	I
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	O
LTR	O
-mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	O
messengers	O
involved	O
in	O
this	O
PGE2-dependent	O
up	O
-	O
regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
Ca2	O
+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	O
LTR	O
-	O
based	O
vectors	O
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB	O
-	O
regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	O
LTR	O
-driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	O
receptor	O
subtype	O
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV-1	O
.	O

Differential	O
regulation	O
of	O
coproporphyrinogen	O
oxidase	O
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Coproporphyrinogen	O
oxidase	O
(	O
CPO	O
)	O
catalyzes	O
the	O
sixth	O
step	O
of	O
the	O
heme	O
biosynthetic	O
pathway	O
.	O

To	O
assess	O
the	O
tissue	O
-	O
specific	O
regulation	O
of	O
the	O
CPO	O
gene	O
promoter	O
,	O
mouse	O
genomic	O
DNA	O
clones	O
for	O
CPO	O
were	O
isolated	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
mouse	O
CPO	O
gene	O
spans	O
approximately	O
11	O
kb	O
and	O
consists	O
of	O
seven	O
exons	O
,	O
just	O
like	O
its	O
human	O
counterpart	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
by	O
transient	O
transfection	O
assays	O
indicated	O
that	O
synergistic	O
action	O
between	O
an	O
SP-1-like	O
element	O
at	O
-21	O
/	O
-12	O
,	O
a	O
GATA	O
site	O
at	O
-59	O
/	O
-54	O
,	O
and	O
a	O
novel	O
regulatory	O
element	O
,	O
CPRE	O
(	O
-	O
GGACTACAG	O
-	O
)	O
at	O
-49	O
/	O
-41	O
,	O
is	O
essential	O
for	O
the	O
promoter	O
activity	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
.	O

In	O
nonerythroid	B
NIH3T3	I
cells	I
,	O
however	O
,	O
the	O
GATA	O
site	O
is	O
not	O
required	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
specific	O
DNA	O
-	O
protein	O
complexes	O
can	O
be	O
formed	O
with	O
each	O
element	O
,	O
and	O
that	O
there	O
are	O
cell	O
-	O
specific	O
differences	O
in	O
factors	O
,	O
which	O
bind	O
to	O
the	O
SP-1-like	O
element	O
between	O
MEL	B
and	I
NIH3T3	I
cells	I
.	O

These	O
results	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
promoter	O
function	O
of	O
CPO	O
gene	O
between	O
erythroid	O
and	O
nonerythroid	O
cells	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O

Interleukin	O
1beta	O
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	O
on	O
LNCaP	O
human	O
prostate	O
cancer	O
cells	O
.	O

Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen	O
-	O
sensitive	O
prostate	O
cancer	O
LNCaP	O
cells	O
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation	O
-	O
promoting	O
substances	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	O
blood	O
monocytes	O
that	O
exhibit	O
anti	O
-	O
tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	B
cell	I
line	I
.	O

For	O
this	O
purpose	O
,	O
LNCaP	B
cells	I
were	O
incubated	O
with	O
monocyte	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
secretion	O
of	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
were	O
assessed	O
.	O

Conditioned	O
medium	O
from	O
monocytes	O
reduced	O
proliferation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
40	O
%	O
MCM	O
caused	O
a	O
50	O
%	O
reduction	O
in	O
cell	O
proliferation	O
.	O

AR	O
protein	O
decreased	O
by	O
70	O
%	O
and	O
PSA	O
levels	O
in	O
supernatants	O
from	O
LNCaP	B
cells	I
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	O
,	O
prostaglandin	O
E2	O
and	O
interleukin	O
1beta	O
(	O
IL-1beta	O
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O

LNCaP	B
cells	I
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down	O
-	O
regulation	O
of	O
AR	O
and	O
PSA	O
levels	O
.	O

The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	O
protein	O
and	O
PSA	O
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti	O
-	O
IL-1beta	O
antibody	O
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	O
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down	O
-	O
regulation	O
of	O
AR	O
and	O
PSA	O
proteins	O
.	O

LNCaP	B
cells	I
were	O
shown	O
to	O
express	O
the	O
IL-1beta	O
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	O
signal	O
.	O

Our	O
findings	O
reveal	O
that	O
monocyte	O
-	O
derived	O
IL-1beta	O
inhibits	O
the	O
proliferation	O
of	O
androgen	O
-	O
responsive	O
prostate	O
tumour	O
cells	O
and	O
reduces	O
AR	O
and	O
PSA	O
levels	O
.	O

p21ras	O
initiates	O
Rac-1	O
but	O
not	O
phosphatidyl	O
inositol	O
3	O
kinase	O
/	O
PKB	O
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	O
is	O
activated	O
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co	O
-	O
ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine	O
/	O
threonine	O
kinase	O
Raf-1	O
and	O
the	O
Ras	O
-	O
related	O
GTPase	O
Rac-1	O
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3-kinase	O
(	O
PtdIns	O
3-kinase	O
)	O
.	O

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac-1	O
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	O
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine	O
/	O
threonine	O
kinase	O
Akt	O
/	O
PKB	O
.	O

The	O
role	O
of	O
PtdIns	O
3-kinase	O
in	O
Ras	O
signaling	O
in	O
T	O
cells	O
has	O
not	O
been	O
explored	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3-kinase	O
to	O
initiate	O
the	O
Rac-1	O
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt	O
/	O
PKB	O
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac-1	O
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	O
complexes	O
.	O

PtdIns	O
3-kinase	O
signals	O
can	O
not	O
mimic	O
p21ras	O
and	O
induce	O
the	O
Rac	O
mediated	O
responses	O
of	O
AP-1	O
transcriptional	O
activation	O
.	O

Moreover	O
,	O
neither	O
TCR	O
or	O
Ras	O
activation	O
of	O
AP-1	O
is	O
dependent	O
on	O
PtdIns	O
3-kinase	O
.	O

PKB	O
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3-kinase	O
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	O
signals	O
are	O
unable	O
to	O
induce	O
Akt	O
/	O
PKB	O
activity	O
in	O
T	O
cell	O
nor	O
is	O
Ras	O
function	O
required	O
for	O
Akt	O
/	O
PKB	O
activation	O
in	O
response	O
to	O
the	O
TCR	O
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3-kinase	O
and	O
Akt	O
/	O
PKB	O
are	O
not	O
universal	O
Ras	O
effector	O
molecules	O
.	O

Ras	O
can	O
initiate	O
Rac-1	O
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3-kinase	O
activity	O
.	O

Differential	O
effects	O
of	O
protein	O
kinase	O
C	O
inhibitors	O
on	O
fibronectin	O
-induced	O
interleukin	O
-	O
beta	O
gene	O
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
when	O
stimulated	O
with	O
the	O
extracellular	O
matrix	O
glycoprotein	O
,	O
fibronectin	O
(	O
FN	O
)	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	O
acts	O
upon	O
to	O
mediate	O
the	O
FN	O
-induced	O
IL-1beta	O
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	O
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN	O
-induced	O
IL-1beta	O
response	O
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	O
protein	O
into	O
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	O
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
unde3r	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	O
protein	O
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	B
U937	I
promonocytic	I
cells	I
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full	O
-	O
length	O
IL-1beta	O
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	O
induction	O
of	O
IL-1beta	O
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	O
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	O
,	O
we	O
conclude	O
that	O
PKC	O
is	O
necessary	O
for	O
FN	O
-induced	O
IL-1beta	O
protein	O
production	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL-1beta	O
by	O
unknown	O
mechanisms	O

In	O
situ	O
RT	O
-	O
PCR	O
detection	O
of	O
Epstein	O
-	O
Barr	O
virus	O
immediate	O
-	O
early	O
transcripts	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

AIDS	O
-	O
related	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
T	O
cell	O
lymphomas	O
are	O
emerging	O
as	O
a	O
new	O
,	O
distinct	O
histopathological	O
entity	O
.	O

The	O
pathway	O
whereby	O
EBV	O
infects	O
T	O
cells	O
as	O
well	O
as	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
T	O
cells	O
has	O
not	O
been	O
established	O
.	O

In	O
order	O
to	O
shed	O
light	O
on	O
the	O
early	O
events	O
of	O
the	O
EBV	O
infection	O
of	O
T	O
cells	O
,	O
we	O
have	O
used	O
in	O
situ	O
reverse	O
transcription	O
based	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
study	O
the	O
initial	O
EBV	O
transcriptional	O
program	O
in	O
homogeneous	O
CD4	O
+	O
and	O
CD8	O
+	O
lymphocytes	O
.	O

Following	O
EBV	O
infection	O
,	O
Epstein	O
-	O
Barr	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
expression	O
could	O
be	O
detected	O
in	O
T	O
rosetting	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
lymphocytes	O
.	O

Only	O
a	O
few	O
cells	O
showed	O
viral	O
capsid	O
antigen	O
(	O
VCA	O
)	O
.	O

EBV	O
immediate	O
-	O
early	O
gene	O
transcripts	O
(	O
BZLF1	O
,	O
BRLF1	O
,	O
and	O
BMLF1	O
)	O
encoded	O
in	O
the	O
BamHI	O
Z	O
,	O
R	O
,	O
and	O
M	O
fragments	O
could	O
be	O
detected	O
by	O
in	O
situ	O
RT	O
-	O
PCR	O
in	O
the	O
EBV	O
producer	O
cell	O
line	O
B95.8	O
.	O

Both	O
BZLF1	O
and	O
BRLF1	O
immediate	O
-	O
early	O
transcripts	O
,	O
but	O
not	O
BMLF1	O
transcript	O
,	O
could	O
be	O
detected	O
in	O
individual	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
infected	O
with	O
EBV	O
.	O

Demonstration	O
of	O
EBV	O
mRNA	O
transcripts	O
encoding	O
immediate	O
-	O
early	O
transcriptional	O
transactivators	O
in	O
EBV	O
-	O
infected	O
T	O
cells	O
provides	O
the	O
first	O
evidence	O
for	O
a	O
possible	O
mechanism	O
whereby	O
EBV	O
could	O
contribute	O
to	O
T	O
cell	O
proliferation	O
and	O
EBV	O
-	O
associated	O
T	O
cell	O
malignancies	O
.	O

Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	O
human	O
T	O
cells	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
by	O
dendritic	O
cells	O
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
are	O
potent	O
APC	O
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	O
DC	O
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	O
CD4	O
+	O
T	O
cells	O
to	O
epitopes	O
of	O
the	O
immediate	O
early	O
62	O
(	O
IE62	O
)	O
protein	O
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

The	O
induction	O
of	O
CD4	O
+	O
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	O
IE62	O
protein	O
was	O
assessed	O
using	O
T	O
cells	O
and	O
DC	O
from	O
VZV	O
-	O
susceptible	O
donors	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	O
T	O
cells	O
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

T	O
cell	O
proliferation	O
was	O
induced	O
by	O
three	O
peptides	O
,	O
P1	O
,	O
P4	O
,	O
and	O
P7	O
,	O
in	O
71	O
-	O
100	O
%	O
of	O
the	O
donors	O
tested	O
before	O
and	O
after	O
vaccination	O
using	O
DC	O
as	O
APC	O
.	O

Monocytes	O
were	O
effective	O
APC	O
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	O
cells	O
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	O
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	O
as	O
APC	O
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	O
as	O
APC	O
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

A	O
novel	O
growth	B
-	I
factor	I
-	I
dependent	I
myeloid	I
cell	I
line	I
derived	O
from	O
mouse	O
bone	O
marrow	O
cells	O
contains	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
.	O

Constitutive	O
expression	O
of	O
human	O
colony	O
-	O
stimulating	O
factor-1	O
receptor	O
(	O
CSF-1R	O
)	O
confers	O
long	O
-	O
lasting	O
CSF-1	O
-dependent	O
proliferation	O
to	O
mouse	B
myeloid	I
cell	I
lines	I
.	O

We	O
developed	O
mice	O
transgenic	O
for	O
human	O
CSF-1R	O
because	O
mouse	O
CSF-1	O
can	O
not	O
activate	O
human	O
CSF-1R	O
.	O

Then	O
bone	O
marrow	O
cells	O
from	O
transgenic	O
mice	O
were	O
plated	O
onto	O
MS-5	O
stromal	O
cells	O
expressing	O
the	O
membrane	O
form	O
of	O
human	O
CSF-1	O
(	O
2M-1	B
cells	I
)	O
in	O
order	O
to	O
combine	O
the	O
hematopoietic	O
supporting	O
properties	O
of	O
stromal	O
cells	O
and	O
the	O
proliferative	O
effects	O
of	O
CSF-1	O
.	O

Thus	O
,	O
we	O
were	O
able	O
to	O
derive	O
a	O
hematopoietic	B
cell	I
line	I
,	O
called	O
47.10	B
,	O
that	O
grew	O
indefinitely	O
under	O
these	O
conditions	O
,	O
whereas	O
no	O
cell	O
line	O
could	O
be	O
developed	O
from	O
nontransgenic	O
mice	O
.	O

Proliferation	O
of	O
47.10	B
cells	I
is	O
severely	O
affected	O
by	O
neutralizing	O
anti	O
-	O
CSF-1R	O
monoclonal	O
antibodies	O
.	O

Morphologic	O
and	O
cytofluorometry	O
analysis	O
established	O
that	O
most	O
47.10	B
cells	I
are	O
immature	O
myelomonocytic	O
cells	O
.	O

Consistent	O
with	O
this	O
phenotype	O
,	O
the	O
myeloid	O
transcription	O
factor	O
PU.1	O
,	O
but	O
not	O
the	O
erythroid	O
transcription	O
factor	O
GATA-1	O
,	O
is	O
expressed	O
in	O
47.10	B
cells	I
.	O

A	O
few	O
47.10	B
cells	I
(	O
3	O
-	O
5	O
%	O
)	O
do	O
not	O
express	O
lineage	O
specific	O
markers	O
;	O
they	O
differentiate	O
spontaneously	O
to	O
lineage	B
-	I
positive	I
cells	I
after	O
replating	O
on	O
2M-1	B
cells	I
.	O

In	O
agar	O
cultures	O
,	O
47.10	B
cells	I
form	O
7-	O
and	O
14-day	O
colonies	O
in	O
response	O
to	O
a	O
cocktail	O
of	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
2.5	O
ng	O
/	O
mL	O
)	O
,	O
interleukin-3	O
(	O
1	O
ng	O
/	O
mL	O
)	O
,	O
and	O
mouse	O
CSF-1	O
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
about	O
0.5	O
%	O
of	O
47.10	B
cells	I
formed	O
large	O
14-day	O
colonies	O
(	O
>	O
1	O
mm	O
)	O
composed	O
of	O
mature	O
monocytes	O
and	O
granulocytes	O
,	O
reflecting	O
the	O
presence	O
of	O
progenitors	O
endowed	O
with	O
high	O
proliferative	O
potential	O
(	O
HPP-47.10	B
cells	I
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
continuous	B
myeloid	I
cell	I
line	I
presenting	O
a	O
hierarchical	O
structure	O
similar	O
to	O
that	O
of	O
the	O
bone	B
marrow	I
progenitor	I
cell	I
compartment	I
.	O

Phenotypic	O
and	O
functional	O
studies	O
of	O
leukocytes	O
in	O
human	O
endometrium	O
and	O
endometriosis	O
.	O

The	O
aetiology	O
of	O
endometriosis	O
,	O
a	O
common	O
and	O
disabling	O
disorder	O
,	O
is	O
presently	O
unknown	O
,	O
although	O
immune	O
dysfunction	O
could	O
allow	O
ectopic	O
endometrial	O
fragments	O
to	O
survive	O
outside	O
the	O
uterine	O
cavity	O
.	O

These	O
studies	O
investigate	O
the	O
relationship	O
between	O
leukocyte	O
populations	O
,	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	O
expression	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
endometrium	O
from	O
women	O
with	O
endometriosis	O
or	O
adenomyosis	O
at	O
different	O
phases	O
of	O
the	O
menstrual	O
cycle	O
.	O

Significantly	O
increased	O
oestrogen	O
receptor	O
expression	O
,	O
bcl-2	O
expression	O
and	O
numbers	O
of	O
CD8	O
+	O
leukocytes	O
were	O
found	O
in	O
ectopic	O
compared	O
with	O
eutopic	O
endometrium	O
in	O
endometriosis	O
,	O
and	O
CD56	O
+	O
endometrial	O
granulated	O
lymphocytes	O
(	O
eGLs	O
)	O
were	O
significantly	O
reduced	O
in	O
ectopic	O
endometrium	O
.	O

Apoptotic	O
cells	O
were	O
rarely	O
found	O
in	O
control	O
and	O
subject	O
endometria	O
.	O

In	O
contrast	O
with	O
endometriosis	O
,	O
adenomyotic	O
lesions	O
showed	O
identical	O
steroid	O
hormone	O
receptor	O
expression	O
,	O
proliferative	O
activity	O
,	O
bcl-2	O
expression	O
and	O
leukocyte	O
subpopulations	O
to	O
eutopic	O
endometrium	O
,	O
indicating	O
different	O
aetiologies	O
for	O
these	O
disorders	O
.	O

The	O
unusual	O
CD56	O
+	O
CD16-	O
eGLs	O
present	O
in	O
large	O
numbers	O
in	O
late	O
secretory	O
phase	O
eutopic	O
endometrium	O
were	O
highly	O
purified	O
(	O
>	O
98	O
%	O
)	O
by	O
immunomagnetic	O
separation	O
.	O

Except	O
for	O
a	O
negligible	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
early	O
proliferative	O
samples	O
,	O
cytotoxic	O
activity	O
of	O
eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
during	O
the	O
menstrual	O
cycle	O
was	O
comparable	O
with	O
those	O
in	O
peripheral	O
blood	O
,	O
predominantly	O
CD56	O
+	O
CD16	O
+	O
natural	O
killer	O
cells	O
.	O

eGLs	O
from	O
non	O
-	O
pregnant	O
endometrium	O
and	O
early	O
pregnancy	O
showed	O
a	O
variable	O
proliferative	O
response	O
to	O
5	O
and	O
100	O
U	O
/	O
ml	O
interleukin-2	O
over	O
48-h	O
and	O
120-h	O
time	O
courses	O
.	O

eGLs	O
are	O
evidently	O
functionally	O
important	O
in	O
the	O
eutopic	O
endometrium	O
.	O

Their	O
absence	O
in	O
endometriotic	O
lesions	O
together	O
with	O
increased	O
CD+8	O
T	O
-	O
cell	O
numbers	O
and	O
increased	O
oestrogen	O
receptor	O
and	O
bcl-2	O
expression	O
may	O
have	O
significant	O
effects	O
on	O
the	O
development	O
and	O
progression	O
of	O
endometriosis	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	O
or	O
protease	O
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	B
cell	I
lines	I
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long	O
-	O
terminal	O
repeat	O
transcription	O
in	O
HIV	O
-	O
infected	O
cells	O
and	O
increased	O
NF	O
-	O
kappaB	O
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Alternative	O
polyadenylation	O
events	O
contribute	O
to	O
the	O
induction	O
of	O
NF	O
-	O
ATc	O
in	O
effector	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
ATc	O
is	O
synthesized	O
in	O
three	O
prominent	O
isoforms	O
.	O

These	O
differ	O
in	O
the	O
length	O
of	O
their	O
C	O
terminal	O
peptides	O
and	O
mode	O
of	O
synthesis	O
.	O

Due	O
to	O
a	O
switch	O
from	O
the	O
use	O
of	O
a	O
3	O
'	O
polyA	O
site	O
to	O
a	O
more	O
proximal	O
polyA	O
site	O
,	O
NF	O
-	O
ATc	O
expression	O
switches	O
from	O
the	O
synthesis	O
of	O
the	O
two	O
longer	O
isoforms	O
in	O
naive	O
T	O
cells	O
to	O
that	O
of	O
short	O
isoform	O
A	O
in	O
T	O
effector	O
cells	O
.	O

The	O
relative	O
low	O
binding	O
affinity	O
of	O
cleavage	O
stimulation	O
factor	O
CstF-64	O
to	O
the	O
proximal	O
polyA	O
site	O
seems	O
to	O
contribute	O
to	O
its	O
neglect	O
in	O
naive	O
T	O
cells	O
.	O

These	O
alternative	O
polyadenylation	O
events	O
ensure	O
the	O
rapid	O
accumulation	O
of	O
high	O
concentrations	O
of	O
NF	O
-	O
ATc	O
necessary	O
to	O
exceed	O
critical	O
threshold	O
levels	O
of	O
NF	O
-	O
ATc	O
for	O
gene	O
induction	O
in	O
effector	O
T	O
cells	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
induces	O
differentiation	O
of	O
a	O
retinoic	B
acid	I
-	I
resistant	I
acute	I
promyelocytic	I
leukemia	I
cell	I
line	I
(	O
UF-1	B
)	O
associated	O
with	O
expression	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
resistance	O
is	O
a	O
serious	O
problem	O
for	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
who	O
are	O
receiving	O
all	O
-	O
trans	O
RA	O
.	O

However	O
,	O
the	O
mechanisms	O
and	O
strategies	O
to	O
overcome	O
RA	O
resistance	O
by	O
APL	O
cells	O
are	O
still	O
unclear	O
.	O

The	O
biologic	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcriptional	O
factors	O
:	O
RA	O
receptors	O
(	O
RARs	O
)	O
and	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
.	O

RXRs	O
heterodimerize	O
with	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
receptor	O
(	O
VDR	O
)	O
,	O
enabling	O
their	O
efficient	O
transcriptional	O
activation	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
cdk	O
)	O
inhibitor	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
has	O
a	O
vitamin	O
D3-responsive	O
element	O
(	O
VDRE	O
)	O
in	O
its	O
promoter	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhances	O
the	O
expression	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
induces	O
differentiation	O
of	O
selected	O
myeloid	B
leukemic	I
cell	I
lines	I
.	O

We	O
have	O
recently	O
established	O
a	O
novel	O
APL	B
cell	I
line	I
(	O
UF-1	B
)	O
with	O
features	O
of	O
RA	O
resistance	O
.	O

1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
induce	O
growth	O
inhibition	O
and	O
G1	O
arrest	O
of	O
UF-1	B
cells	I
,	O
resulting	O
in	O
differentiation	O
of	O
these	O
cells	O
toward	O
granulocytes	O
.	O

This	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-induced	O
G1	O
arrest	O
is	O
enhanced	O
by	O
all	O
-	O
trans	O
RA	O
.	O

Also	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
(	O
-10	O
)	O
to	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
in	O
combination	O
with	O
RA	O
markedly	O
inhibits	O
cellular	O
proliferation	O
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Associated	O
with	O
these	O
findings	O
,	O
the	O
levels	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
mRNA	O
and	O
protein	O
increased	O
in	O
these	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
transcripts	O
were	O
induced	O
after	O
6	O
hours	O
'	O
exposure	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
then	O
decreased	O
to	O
basal	O
levels	O
over	O
48	O
hours	O
.	O

Western	O
blot	O
experiments	O
showed	O
that	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
protein	O
levels	O
increased	O
and	O
became	O
detectable	O
after	O
12	O
hours	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
treatment	O
and	O
induction	O
of	O
p27	O
(	O
KIP1	O
)	O
protein	O
was	O
much	O
more	O
gradual	O
and	O
sustained	O
in	O
UF-1	B
cells	I
.	O

Interestingly	O
,	O
the	O
combination	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
RA	O
markedly	O
enhanced	O
the	O
levels	O
of	O
p27	O
(	O
KIP1	O
)	O
transcript	O
and	O
protein	O
as	O
compared	O
with	O
levels	O
induced	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
alone	O
.	O

In	O
addition	O
,	O
exogenous	O
p27	O
(	O
KIP1	O
)	O
expression	O
can	O
enhance	O
the	O
level	O
of	O
CD11b	O
antigen	O
in	O
myeloid	O
leukemic	O
cells	O
.	O

In	O
contrast	O
,	O
RA	O
alone	O
can	O
induce	O
G1	O
arrest	O
of	O
UF-1	B
cells	I
;	O
however	O
,	O
it	O
did	O
not	O
result	O
in	O
an	O
increase	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
p27	O
(	O
KIP1	O
)	O
transcript	O
and	O
protein	O
expression	O
in	O
RA	O
-	O
resistant	O
cells	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
induces	O
increased	O
expression	O
of	O
cdk	O
inhibitors	O
,	O
which	O
mediates	O
a	O
G1	O
arrest	O
,	O
and	O
this	O
may	O
be	O
associated	O
with	O
differentiation	O
of	O
RA	O
-	O
resistant	O
UF-1	B
cells	I
toward	O
mature	O
granulocytes	O
.	O

IL-2	O
-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	O
require	O
NF	O
-	O
kappa	O
B	O
or	O
activating	O
protein-1	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
.	O

The	O
IL-2	O
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL-2	O
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag	O
-	O
activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and/or	O
activating	O
protein-1	O
(	O
AP-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	O
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	O
does	O
not	O
induce	O
I	O
kappa	O
B	O
alpha	O
degradation	O
or	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
primary	O
human	O
T	O
cells	O
that	O
respond	O
to	O
IL-2	O
by	O
entering	O
the	O
cell	O
cycle	O
and	O
avoiding	O
apoptosis	O
.	O

Similarly	O
,	O
IL-2	O
neither	O
activates	O
JNK	O
nor	O
increases	O
AP-1	O
binding	O
activity	O
to	O
a	O
consensus	O
o	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
response	O
element	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	O
the	O
activation	O
of	O
STAT3	O
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	O
NF	O
-	O
kappa	O
B	O
nor	O
AP-1	O
activation	O
is	O
required	O
for	O
IL-2	O
-mediated	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
activated	O
primary	O
human	O
T	O
cells	O
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus	O
-	O
mediated	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
(	O
mut	O
-	O
I	O
kappa	O
B	O
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF	O
-	O
kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44	O
-CD25	O
+	O
,	O
CD4	O
-	O
CD8	O
-	O
double	O
-	O
negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double	O
-	O
positive	O
and	O
single	O
-	O
positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	O
beta	O
-	O
chain	O
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut	O
-	O
I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Transient	O
pseudo	O
-	O
hypoaldosteronism	O
following	O
resection	O
of	O
the	O
ileum	O
:	O
normal	O
level	O
of	O
lymphocytic	O
aldosterone	O
receptors	O
outside	O
the	O
acute	O
phase	O
.	O

Pseudo	O
-	O
hypoaldosteronism	O
(	O
PHA	O
)	O
is	O
due	O
to	O
mineralocorticoid	O
resistance	O
and	O
manifests	O
as	O
hyponatremia	O
and	O
hyperkalemia	O
with	O
increased	O
plasma	O
aldosterone	O
levels	O
.	O

It	O
may	O
be	O
familial	O
or	O
secondary	O
to	O
abnormal	O
renal	O
sodium	O
handling	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
54-year	O
-	O
old	O
woman	O
with	O
multifocal	O
cancer	O
of	O
the	O
colon	O
,	O
who	O
developed	O
PHA	O
after	O
subtotal	O
colectomy	O
,	O
ileal	O
resection	O
and	O
jejunostomy	O
.	O

She	O
was	O
treated	O
with	O
6	O
g	O
of	O
salt	O
daily	O
to	O
prevent	O
dehydration	O
,	O
which	O
she	O
stopped	O
herself	O
because	O
of	O
reduced	O
fecal	O
losses	O
.	O

One	O
month	O
later	O
she	O
was	O
admitted	O
with	O
signs	O
of	O
acute	O
adrenal	O
failure	O
,	O
i.e.	O
fatigue	O
,	O
severe	O
nausea	O
,	O
blood	O
pressure	O
of	O
80	O
/	O
60	O
mmHg	O
,	O
extracellular	O
dehydration	O
,	O
hyponatremia	O
(	O
118	O
mmol	O
/	O
l	O
)	O
;	O
hyperkalemia	O
(	O
7.6	O
mmol	O
/	O
l	O
)	O
,	O
increased	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
(	O
200	O
mg	O
/	O
dl	O
)	O
and	O
creatininemia	O
(	O
2.5	O
mg	O
/	O
dl	O
)	O
,	O
and	O
decreased	O
plasma	O
bicarbonates	O
level	O
(	O
HCO3-	O
:	O
16	O
mmol	O
/	O
l	O
;	O
N	O
:	O
27	O
-	O
30	O
)	O
.	O

However	O
,	O
the	O
plasma	O
cortisol	O
was	O
high	O
(	O
66	O
microg	O
/	O
100	O
ml	O
at	O
10	O
:	O
00	O
h	O
;	O
N	O
:	O
8	O
-	O
15	O
)	O
and	O
the	O
ACTH	O
was	O
normal	O
(	O
13	O
pg	O
/	O
ml	O
,	O
N	O
:	O
10	O
-	O
60	O
)	O
;	O
there	O
was	O
a	O
marked	O
increase	O
in	O
plasma	O
renin	O
activity	O
(	O
>	O
37	O
ng	O
/	O
ml	O
/	O
h	O
;	O
N	O
supine	O
<	O
3	O
)	O
,	O
active	O
renin	O
(	O
869	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
:	O
1.120	O
)	O
,	O
aldosterone	O
(	O
>	O
2000	O
pg	O
/	O
ml	O
;	O
N	O
supine	O
<	O
150	O
)	O
and	O
plasma	O
AVP	O
(	O
20	O
pmol	O
/	O
l	O
;	O
N	O
:	O
0.5	O
-	O
2.5	O
)	O
.	O

The	O
plasma	O
ANH	O
level	O
was	O
38	O
pmol	O
/	O
l	O
(	O
N	O
supine	O
:	O
5	O
-	O
25	O
)	O
.	O

A	O
urinary	O
steroidogram	O
resulted	O
in	O
highly	O
elevated	O
tetrahydrocortisol	O
(	O
THF	O
:	O
13.3	O
mg	O
/	O
24h	O
;	O
N	O
:	O
1.4+	O
/	O
-0.8	O
)	O
with	O
no	O
increase	O
in	O
tetrahydrocortisone	O
(	O
THE	O
:	O
3.16	O
mg	O
/	O
24h	O
;	O
N	O
:	O
2.7+	O
/	O
-2.0	O
)	O
excretion	O
,	O
and	O
with	O
low	O
THE	O
/	O
THF	O
(	O
0.24	O
;	O
N	O
:	O
1.87+	O
/	O
-0.36	O
)	O
and	O
alpha	O
THF	O
/	O
THF	O
(	O
0.35	O
;	O
N	O
:	O
0.92+	O
/	O
-0.42	O
)	O
ratios	O
.	O

The	O
number	O
of	O
mineralocorticoid	O
receptors	O
in	O
mononuclear	O
leukocytes	O
was	O
in	O
the	O
lower	O
normal	O
range	O
for	O
age	O
,	O
while	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
was	O
reduced	O
.	O

Small	O
-	O
bowel	O
resection	O
in	O
ileostomized	O
patients	O
causes	O
excessive	O
fecal	O
sodium	O
losses	O
and	O
results	O
in	O
chronic	O
sodium	O
depletion	O
with	O
contraction	O
of	O
the	O
plasma	O
volume	O
and	O
severe	O
secondary	O
hyperaldosteronism	O
.	O

Nevertheless	O
,	O
this	O
hyperaldosteronism	O
may	O
be	O
associated	O
with	O
hyponatremia	O
and	O
hyperkalemia	O
suggesting	O
PHA	O
related	O
to	O
the	O
major	O
importance	O
of	O
the	O
colon	O
for	O
the	O
absorption	O
of	O
sodium	O
.	O

In	O
conclusion	O
,	O
this	O
case	O
report	O
emphasizes	O
1	O
)	O
the	O
possibility	O
of	O
a	O
syndrome	O
of	O
acquired	O
PHA	O
with	O
severe	O
hyperkalemia	O
after	O
resection	O
of	O
the	O
ileum	O
and	O
colon	O
responding	O
to	O
oral	O
salt	O
supplementation	O
;	O
2	O
)	O
the	O
major	O
increase	O
in	O
AVP	O
and	O
the	O
small	O
increase	O
in	O
ANH	O
;	O
3	O
)	O
the	O
strong	O
increase	O
in	O
urinary	O
THF	O
with	O
low	O
THE	O
/	O
THF	O
and	O
alpha	O
THF	O
/	O
THF	O
ratios	O
;	O
4	O
)	O
the	O
normal	O
number	O
of	O
lymphocytic	O
mineralocorticoid	O
receptors	O
outside	O
the	O
acute	O
episode	O
.	O

SHP2-interacting	O
transmembrane	O
adaptor	O
protein	O
(	O
SIT	O
)	O
,	O
a	O
novel	O
disulfide	O
-	O
linked	O
dimer	O
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	O
molecular	O
weight	O
transmembrane	O
adaptor	O
proteins	O
that	O
recruit	O
src	O
homology	O
(	O
SH	O
)	O
2	O
domain	O
-	O
containing	O
intracellular	O
molecules	O
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	O
(	O
SHP2	O
interacting	O
transmembrane	O
adaptor	O
protein	O
)	O
.	O

SIT	O
is	O
a	O
disulfide	O
-	O
linked	O
homodimeric	O
glycoprotein	O
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	O
and	O
possibly	O
syk	O
protein	O
tyrosine	O
kinases	O
SIT	O
recruits	O
the	O
SH2	O
domain	O
-	O
containing	O
tyrosine	O
phosphatase	O
SHP2	O
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	O
in	O
Jurkat	B
cells	I
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	O
C	O
.	O

However	O
,	O
binding	O
of	O
SHP2	O
to	O
SIT	O
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	O
-	O
AT	O
induction	O
,	O
suggesting	O
that	O
SIT	O
not	O
only	O
regulates	O
NF	O
-	O
AT	O
activity	O
but	O
also	O
controls	O
NF	O
-	O
AT	O
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	O
.	O

GrpL	O
,	O
a	O
Grb2	O
-related	O
adaptor	O
protein	O
,	O
interacts	O
with	O
SLP-76	O
to	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	O
domain	O
-	O
containing	O
protein	O
76	O
(	O
SLP-76	O
)	O
interacts	O
with	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
Vav	O
to	O
activate	O
the	O
nuclear	O
factor	O
of	O
activated	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	O
adaptor	O
molecule	O
designated	O
as	O
Grb2-related	O
protein	O
of	O
the	O
lymphoid	O
system	O
(	O
GrpL	O
)	O
.	O

Expression	O
of	O
GrpL	O
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	O
by	O
having	O
a	O
proline	O
-	O
rich	O
region	O
.	O

GrpL	O
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	O
but	O
not	O
with	O
Sos1	O
or	O
Sos2	O
from	O
Jurkat	B
cell	I
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	O
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	O
and	O
Sos2	O
but	O
not	O
with	O
SLP-76	O
.	O

Moreover	O
,	O
tyrosine	O
-	O
phosphorylated	O
LAT	O
/	O
pp36	O
/	O
38	O
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	O
but	O
not	O
GrpL	O
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	O
and	O
Grb2	O
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL	O
-	O
SLP-76	O
complex	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	O
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	O
to	O
augment	O
NF	O
-	O
AT	O
activation	O
in	O
Jurkat	B
T	O
cells	O
.	O

Transcription	O
factors	O
Sp1	O
and	O
AP-2	O
mediate	O
induction	O
of	O
acid	O
sphingomyelinase	O
during	O
monocytic	O
differentiation	O
.	O

Cells	O
from	O
the	O
human	B
monocytic	I
leukemia	I
cell	I
line	I
THP-1	B
differentiate	O
towards	O
a	O
macrophage	O
-	O
like	O
phenotype	O
when	O
stimulated	O
with	O
phorbol	O
12-myristate	O
-13-	O
acetate	O
(	O
PMA	O
)	O
,	O
1	O
,	O
25-dihydroxy	O
-	O
vitamin	O
D3	O
,	O
and	O
various	O
other	O
agents	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
expression	O
of	O
the	O
lysosomal	O
enzyme	O
acid	O
sphingomyelinase	O
(	O
ASM	O
;	O
E.C.3.1.4.12	O
)	O
is	O
induced	O
during	O
this	O
process	O
and	O
is	O
strongly	O
elevated	O
in	O
differentiated	O
THP-1	B
cells	I
,	O
as	O
well	O
as	O
in	O
differentiated	O
human	O
mononuclear	O
phagocytes	O
.	O

Using	O
Northern	O
blotting	O
,	O
RNase	O
protection	O
assay	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
show	O
that	O
the	O
up	O
-	O
regulation	O
of	O
ASM	O
expression	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
transcription	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
enhanced	O
ASM	O
activity	O
.	O

This	O
cell	O
-	O
type	O
specific	O
induction	O
by	O
PMA	O
treatment	O
was	O
further	O
investigated	O
with	O
respect	O
to	O
transcriptional	O
control	O
.	O

A	O
series	O
of	O
5	O
'	O
deletion	O
derivatives	O
of	O
the	O
upstream	O
regulatory	O
region	O
were	O
used	O
in	O
transient	O
transfection	O
assays	O
to	O
identify	O
promoter	O
elements	O
required	O
for	O
basal	O
and	O
inducible	O
gene	O
expression	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-319	O
and	O
-219	O
bp	O
upstream	O
of	O
the	O
initiation	O
codon	O
and	O
co	O
-	O
transfections	O
with	O
transcription	O
factor	O
expression	O
plasmids	O
for	O
AP-2	O
and	O
Sp1	O
resulted	O
in	O
augmented	O
ASM	O
promoter	O
activity	O
,	O
which	O
was	O
abolished	O
when	O
the	O
binding	O
sites	O
for	O
these	O
two	O
factors	O
were	O
deleted	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
supershift	O
assays	O
we	O
demonstrate	O
that	O
this	O
region	O
is	O
specifically	O
bound	O
by	O
Sp1	O
and	O
AP-2	O
.	O

These	O
factors	O
are	O
present	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
both	O
induced	O
and	O
uninduced	O
THP-1	B
cells	I
.	O

However	O
,	O
the	O
intensity	O
of	O
the	O
complex	O
formed	O
appeared	O
to	O
increase	O
when	O
nuclear	O
extracts	O
from	O
PMA	B
-	I
treated	I
cells	I
were	O
used	O
.	O

From	O
these	O
studies	O
,	O
we	O
conclude	O
that	O
a	O
concerted	O
action	O
of	O
the	O
transcription	O
factors	O
AP-2	O
and	O
Sp1	O
is	O
essential	O
for	O
the	O
up	O
-regulation	O
of	O
ASM	O
expression	O
during	O
the	O
process	O
of	O
macrophage	O
differentiation	O
.	O

Grf40	O
,	O
A	O
novel	O
Grb2	O
family	O
member	O
,	O
is	O
involved	O
in	O
T	O
cell	O
signaling	O
through	O
interaction	O
with	O
SLP-76	O
and	O
LAT	O
.	O

We	O
molecularly	O
cloned	O
a	O
new	O
Grb2	O
family	O
member	O
,	O
named	O
Grf40	O
,	O
containing	O
the	O
common	O
SH3-SH2-SH3	O
motif	O
.	O

Expression	O
of	O
Grf40	O
is	O
predominant	O
in	O
hematopoietic	O
cells	O
,	O
particularly	O
T	O
cells	O
.	O

Grf40	O
binds	O
to	O
the	O
SH2	O
domain	O
-	O
containing	O
leukocyte	O
protein	O
of	O
76	O
kD	O
(	O
SLP-76	O
)	O
via	O
its	O
SH3	O
domain	O
more	O
tightly	O
than	O
Grb2	O
.	O

Incidentally	O
,	O
Grf40	O
binds	O
to	O
linker	O
for	O
activation	O
of	O
T	O
cells	O
(	O
LAT	O
)	O
possibly	O
via	O
its	O
SH2	O
domain	O
.	O

Overexpression	O
of	O
wild	O
-	O
type	O
Grf40	O
in	O
Jurkat	B
cells	I
induced	O
a	O
significant	O
increase	O
of	O
SLP-76-dependent	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
activation	O
upon	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
stimulation	O
,	O
whereas	O
the	O
COOH	O
-	O
terminal	O
SH3-deleted	O
Grf40	O
mutant	O
lacked	O
any	O
recognizable	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
the	O
SH2-deleted	O
Grf40	O
mutant	O
led	O
to	O
a	O
marked	O
inhibition	O
of	O
these	O
regulatory	O
activities	O
,	O
the	O
effect	O
of	O
which	O
is	O
apparently	O
stronger	O
than	O
that	O
of	O
the	O
SH2-deleted	O
Grb2	O
mutant	O
.	O

Our	O
data	O
suggest	O
that	O
Grf40	O
is	O
an	O
adaptor	O
molecule	O
involved	O
in	O
TCR	O
-mediated	O
signaling	O
through	O
a	O
more	O
efficient	O
interaction	O
than	O
Grb2	O
with	O
SLP-76	O
and	O
LAT	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T	O
-	O
cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	O
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
activation	O
of	O
NF	O
-	O
kappaB	O
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	O
molecules	O
.	O

It	O
was	O
postulated	O
that	O
this	O
NF	O
-	O
kappaB	O
-	O
regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV-1	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
.	O

HLA	O
class	O
I	O
-mediated	O
induction	O
of	O
cell	O
proliferation	O
involves	O
cyclin	O
E	O
-mediated	O
inactivation	O
of	O
Rb	O
function	O
and	O
induction	O
of	O
E2F	O
activity	O
.	O

Chronic	O
rejection	O
of	O
transplanted	O
organs	O
is	O
manifested	O
as	O
atherosclerosis	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
allograft	O
.	O

HLA	O
class	O
I	O
Ags	O
have	O
been	O
implicated	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
,	O
since	O
signaling	O
via	O
HLA	O
class	O
I	O
molecules	O
can	O
induce	O
the	O
proliferation	O
of	O
aortic	O
endothelial	O
as	O
well	O
as	O
smooth	O
muscle	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HLA	O
class	O
I	O
-mediated	O
induction	O
of	O
cell	O
proliferation	O
correlates	O
with	O
inactivation	O
of	O
the	O
Rb	O
protein	O
in	O
the	O
T	B
cell	I
line	I
Jurkat	I
as	O
well	O
as	O
human	O
aortic	O
endothelial	O
cells	O
.	O

HLA	O
class	O
I	O
-mediated	O
inactivation	O
of	O
Rb	O
can	O
be	O
inhibited	O
specifically	O
by	O
neutralizing	O
Abs	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
FGF	O
receptors	O
in	O
the	O
signaling	O
process	O
.	O

Signaling	O
through	O
HLA	O
class	O
I	O
molecules	O
induced	O
cyclin	O
E	O
-associated	O
kinase	O
activity	O
within	O
4	O
h	O
in	O
quiescent	O
endothelial	O
cells	O
,	O
and	O
appeared	O
to	O
mediate	O
the	O
inactivation	O
of	O
Rb	O
.	O

A	O
cdk2	O
inhibitor	O
,	O
Olomoucine	O
,	O
as	O
well	O
as	O
a	O
dominant	O
-	O
negative	O
cdk2	O
construct	O
prevented	O
HLA	O
class	O
I	O
-mediated	O
inactivation	O
of	O
Rb	O
;	O
in	O
contrast	O
,	O
dominant	O
-	O
negative	O
cdk4	O
and	O
cdk6	O
constructs	O
had	O
no	O
effect	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increase	O
in	O
cyclin	O
D	O
-	O
associated	O
kinase	O
activity	O
upon	O
HLA	O
class	O
I	O
ligation	O
,	O
suggesting	O
that	O
cyclin	O
E	O
-	O
dependent	O
kinase	O
activity	O
mediates	O
Rb	O
inactivation	O
,	O
leading	O
to	O
E2F	O
activation	O
and	O
cell	O
proliferation	O
.	O

Protein	O
kinase	O
B	O
(	O
c	O
-	O
Akt	O
)	O
,	O
phosphatidylinositol	O
3-kinase	O
,	O
and	O
STAT5	O
are	O
activated	O
by	O
erythropoietin	O
(	O
EPO	O
)	O
in	O
HCD57	B
erythroid	I
cells	I
but	O
are	O
constitutively	O
active	O
in	O
an	O
EPO	B
-	I
independent	I
,	I
apoptosis	I
-	I
resistant	I
subclone	I
(	O
HCD57-SREI	B
cells	I
)	O
.	O

We	O
found	O
that	O
erythropoietin	O
(	O
EPO	O
)	O
and	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
activated	O
protein	O
kinase	O
B	O
(	O
PKB	O
/	O
Akt	O
)	O
in	O
EPO	B
-	I
dependent	I
HCD57	I
erythroid	I
cells	I
.	O

To	O
better	O
understand	O
signals	O
controlling	O
proliferation	O
and	O
viability	O
,	O
erythroid	O
cells	O
that	O
resist	O
apoptosis	O
in	O
the	O
absence	O
of	O
EPO	O
were	O
subcloned	O
and	O
characterized	O
(	O
HCD57-SREI	B
cells	I
)	O
.	O

Constitutive	O
activations	O
of	O
PKB	O
/	O
Akt	O
,	O
STAT5a	O
,	O
and	O
STAT5b	O
were	O
noted	O
in	O
these	O
EPO	B
-	I
independent	I
cells	I
.	O

PI3-kinase	O
activity	O
was	O
an	O
upstream	O
activator	O
of	O
PKB	O
/	O
Akt	O
because	O
the	O
PI3-kinase	O
inhibitor	O
LY294002	O
blocked	O
both	O
constitutive	O
PKB	O
/	O
Akt	O
and	O
factor	O
-	O
dependent	O
PKB	O
/	O
Akt	O
activity	O
.	O

The	O
LY294002	O
study	O
showed	O
that	O
proliferation	O
and	O
viability	O
of	O
both	O
HCD57-SREI	B
and	O
HCD57	B
cells	I
correlated	O
with	O
the	O
activity	O
of	O
PKB	O
/	O
Akt	O
;	O
however	O
,	O
PKB	O
/	O
Akt	O
activity	O
alone	O
did	O
not	O
protect	O
these	O
cells	O
from	O
apoptosis	O
.	O

Treatment	O
of	O
HCD57	B
cells	I
with	O
SCF	O
also	O
activated	O
PKB	O
/	O
Akt	O
,	O
but	O
did	O
not	O
protect	O
from	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
PKB	O
/	O
PI3-kinase	O
activity	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
promote	O
viability	O
and/or	O
proliferation	O
.	O

Constitutive	O
STAT5	O
activity	O
,	O
activated	O
through	O
an	O
unknown	O
pathway	O
not	O
including	O
JAK2	O
or	O
EPOR	O
,	O
may	O
act	O
in	O
concert	O
with	O
the	O
constitutive	O
PI3-kinase	O
/PKB	O
/	O
Akt	O
pathway	O
to	O
protect	O
the	O
EPO	B
-	I
independent	I
HCD57-SREI	I
cells	I
from	O
apoptosis	O
and	O
promote	O
limited	O
proliferation	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta	O
-	O
globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
assumes	O
a	O
transcriptionally	O
-	O
active	O
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta	O
-	O
like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta	O
-	O
globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid	O
-	O
specific	O
DNase	O
1	O
hypersensitive	O
site	O
-	O
forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF	O
-	O
E2	O
,	O
AP-1	O
,	O
GATA-1	O
and	O
Sp-1	O
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	O
1	O
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta	O
-	O
globin	O
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta	O
-	O
globin	O
gene	O
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long	O
-	O
term	O
beta	O
-	O
globin	O
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis	O
-	O
acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta	O
-	O
globin	O
gene	O
expression	O
.	O

Modulation	O
of	O
CD28	O
expression	O
:	O
distinct	O
regulatory	O
pathways	O
during	O
activation	O
and	O
replicative	O
senescence	O
.	O

The	O
costimulatory	O
molecule	O
CD28	O
has	O
a	O
restricted	O
tissue	O
distribution	O
and	O
is	O
expressed	O
on	O
T	O
cells	O
and	O
some	O
plasmacytoma	O
cells	O
.	O

Although	O
CD28	O
is	O
constitutively	O
expressed	O
,	O
its	O
expression	O
is	O
transiently	O
down	O
-	O
regulated	O
following	O
T	O
cell	O
activation	O
and	O
declines	O
progressively	O
with	O
in	O
vitro	O
senescence	O
.	O

In	O
vivo	O
,	O
CD8	O
+	O
T	O
cells	O
and	O
,	O
less	O
frequently	O
,	O
CD4	O
+	O
T	O
cells	O
may	O
completely	O
lose	O
CD28	O
surface	O
expression	O
during	O
chronic	O
infections	O
and	O
with	O
aging	O
.	O

This	O
correlates	O
with	O
changes	O
of	O
nuclear	O
protein	O
-	O
binding	O
activities	O
to	O
two	O
motifs	O
,	O
site	O
alpha	O
and	O
beta	O
,	O
within	O
the	O
CD28	O
minimal	O
promoter	O
.	O

Both	O
alpha-	O
and	O
beta	O
-	O
bound	O
complexes	O
are	O
found	O
only	O
in	O
lymphoid	O
tissues	O
,	O
in	O
CD28	O
+	O
T	O
cells	O
,	O
and	O
in	O
some	O
transformed	B
B	I
cells	I
.	O

These	O
complexes	O
are	O
coordinately	O
expressed	O
except	O
during	O
replicative	O
senescence	O
,	O
which	O
is	O
characterized	O
by	O
the	O
down	O
-	O
modulation	O
of	O
site	O
beta	O
-but	O
not	O
site	O
alpha	O
-binding	O
activities	O
.	O

In	O
contrast	O
,	O
T	O
cell	O
activation	O
induces	O
a	O
parallel	O
decline	O
in	O
both	O
site	O
alpha-	O
and	O
beta	O
-	O
binding	O
activities	O
.	O

CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
differ	O
in	O
their	O
beta	O
-	O
binding	O
profiles	O
,	O
which	O
may	O
explain	O
the	O
more	O
pronounced	O
down	O
-	O
regulation	O
of	O
CD28	O
in	O
senescent	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
vivo	O
expanded	O
CD4+CD28null	B
and	I
CD8+CD28null	I
T	I
cells	I
uniformly	O
lack	O
alpha-	O
and	O
beta-	O
bound	O
complexes	O
,	O
resembling	O
the	O
pattern	O
seen	O
in	O
chronically	O
activated	O
cells	O
and	O
not	O
of	O
senescent	O
cells	O
.	O

UV	O
-	O
induced	O
CYP1A1	O
gene	O
expression	O
in	O
human	O
cells	O
is	O
mediated	O
by	O
tryptophan	O
.	O

Induction	O
of	O
cytochrome	O
P-4501A1	O
(	O
CYP1A1	O
)	O
activity	O
by	O
UV	O
has	O
been	O
observed	O
earlier	O
in	O
animal	O
studies	O
via	O
a	O
mechanism	O
that	O
has	O
not	O
yet	O
been	O
resolved	O
.	O

Our	O
previous	O
data	O
have	O
indicated	O
that	O
formylated	O
indolocarbazoles	O
which	O
are	O
formed	O
by	O
UV	O
irradiation	O
of	O
tryptophan	O
solutions	O
are	O
very	O
potent	O
Ah	O
-	O
receptor	O
agonists	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
UV	O
light	O
on	O
cytochrome	O
P4501A1	O
gene	O
expression	O
,	O
we	O
studied	O
the	O
induction	O
of	O
CYP1A1	O
mRNA	O
by	O
UV	O
irradiation	O
of	O
cultured	B
human	I
keratinocytes	I
(	O
HaCaT	B
cell	I
line	I
)	O
,	O
primary	O
human	O
blood	O
lymphocytes	O
and	O
mouse	B
Hepa-1	I
cells	I
.	O

The	O
cells	O
were	O
exposed	O
to	O
UV	O
light	O
delivered	O
by	O
a	O
bank	O
of	O
6	O
Philips	O
TL20	O
/	O
12RS	O
sun	O
lamps	O
emitting	O
primarily	O
in	O
the	O
UVB	O
range	O
in	O
the	O
absence	O
and	O
presence	O
of	O
tryptophan	O
.	O

A	O
semiquantitative	O
reverse	O
transcriptase	O
-linked	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
was	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
in	O
the	O
treated	O
cells	O
.	O

The	O
results	O
show	O
that	O
the	O
CYP1A1	O
mRNA	O
level	O
induced	O
by	O
UV	O
in	O
the	O
presence	O
of	O
tryptophan	O
was	O
higher	O
than	O
that	O
induced	O
by	O
UV	O
alone	O
in	O
both	O
HaCaT	B
cells	I
and	O
lymphocytes	O
after	O
3	O
h	O
of	O
incubation	O
post	O
-	O
UV	O
irradiation	O
.	O

To	O
find	O
out	O
if	O
the	O
induction	O
by	O
UV	O
light	O
is	O
caused	O
by	O
the	O
formation	O
of	O
an	O
Ah	O
receptor	O
ligand	O
,	O
Hepa-1	B
wild	I
-	I
type	I
and	I
Ah	I
receptor	I
deficient	I
c12	I
cell	I
lines	I
were	O
applied	O
.	O

Wild	B
-	I
type	I
(	I
wt	I
)	I
cells	I
were	O
inducible	O
either	O
by	O
the	O
tryptophan	O
photoproduct	O
6-formylindolo	O
[	O
3	O
,	O
2-b	O
]	O
carbazole	O
(	O
FICZ	O
)	O
or	O
by	O
UV	O
-	O
irradiation	O
but	O
very	O
low	O
or	O
undetectable	O
levels	O
were	O
observed	O
in	O
the	O
c12	O
cells	O
.	O

This	O
shows	O
that	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
FICZ	O
and	O
UV	O
is	O
Ah	O
receptor	O
dependent	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
UV	O
-	O
induced	O
CYP1A1	O
gene	O
expression	O
in	O
mammalian	O
cells	O
is	O
mediated	O
by	O
an	O
Ah	O
receptor	O
ligand	O
formed	O
from	O
tryptophan	O
.	O

Thus	O
,	O
the	O
photoproducts	O
of	O
tryptophan	O
are	O
suggested	O
to	O
be	O
mediators	O
of	O
light	O
via	O
binding	O
to	O
the	O
Ah	O
receptor	O
and	O
as	O
such	O
also	O
could	O
have	O
a	O
role	O
in	O
light	O
-	O
regulated	O
biological	O
rhythms	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell	O
-	O
surface	O
receptors	O
,	O
intracellular	O
signaling	O
molecules	O
,	O
and	O
nuclear	O
transcription	O
factors	O
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	O
cell	O
transcription	O
factors	O
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	O
,	O
LKLF	O
,	O
and	O
GATA3	O
zinc	O
-	O
finger	O
proteins	O
;	O
the	O
Ets	O
,	O
CREB	O
/	O
ATF	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
/	O
NFAT	O
transcription	O
factors	O
;	O
the	O
Stat	O
proteins	O
;	O
and	O
HMG	O
box	O
transcription	O
factors	O
such	O
as	O
LEF1	O
,	O
TCF1	O
,	O
and	O
Sox4	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

20-Epi	O
analogues	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
are	O
highly	O
potent	O
inducers	O
of	O
DRIP	O
coactivator	O
complex	O
binding	O
to	O
the	O
vitamin	O
D3	O
receptor	O
.	O

1	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
plays	O
a	O
major	O
role	O
in	O
the	O
stimulation	O
of	O
bone	O
growth	O
,	O
mineralization	O
,	O
and	O
intestinal	O
calcium	O
and	O
phosphate	O
absorption	O
;	O
it	O
also	O
acts	O
as	O
a	O
general	O
inhibitor	O
of	O
cellular	O
proliferation	O
.	O

Several	O
new	O
,	O
clinically	O
relevant	O
compounds	O
dissociate	O
antiproliferative	O
and	O
calcemic	O
activities	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
this	O
has	O
not	O
been	O
clearly	O
elucidated	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
the	O
potency	O
of	O
one	O
class	O
of	O
compounds	O
,	O
20-epi	O
analogues	O
,	O
to	O
induce	O
myeloid	O
cell	O
differentiation	O
,	O
is	O
because	O
of	O
direct	O
molecular	O
effects	O
on	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
.	O

We	O
report	O
that	O
two	O
20-epi	O
analogues	O
,	O
MC1627	O
and	O
MC1288	O
,	O
induced	O
differentiation	O
and	O
transcription	O
of	O
p21	O
(	O
Waf1	O
,	O
Cip1	O
)	O
,	O
a	O
key	O
VDR	O
target	O
gene	O
involved	O
in	O
growth	O
inhibition	O
,	O
at	O
a	O
concentration	O
100-fold	O
lower	O
than	O
that	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
compared	O
this	O
sensitivity	O
to	O
analogue	O
effects	O
on	O
VDR	O
interacting	O
proteins	O
:	O
RXR	O
,	O
GRIP-1	O
,	O
and	O
DRIP205	O
,	O
a	O
subunit	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
.	O

Compared	O
with	O
the	O
interaction	O
of	O
VDR	O
with	O
RXR	O
or	O
GRIP-1	O
,	O
the	O
differentiation	O
dose	O
-	O
response	O
most	O
closely	O
correlated	O
to	O
the	O
ligand	O
-	O
dependent	O
recruitment	O
of	O
the	O
DRIP	O
coactivator	O
complex	O
to	O
VDR	O
and	O
to	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
activate	O
transcription	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

These	O
results	O
provide	O
compelling	O
links	O
between	O
the	O
efficiency	O
of	O
the	O
20-epi	O
analogue	O
in	O
inducing	O
VDR	O
/DRIP	O
interactions	O
,	O
transactivation	O
in	O
vitro	O
,	O
and	O
its	O
enhanced	O
ability	O
to	O
induce	O
cellular	O
differentiation	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	O
binding	O
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
transcription	O
factor	O
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
--	O
although	O
still	O
difficult	O
--	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O
Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti	O
-	O
TNF	O
antibody	O
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF	O
-	O
alpha	O
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O
The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	O
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	O
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	O
inhibitors	O
.	O

The	O
biological	O
significance	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
T.	O
parva	O
-	O
infected	O
cells	O
,	O
however	O
,	O
has	O
not	O
yet	O
been	O
defined	O
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite	O
-	O
mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	O
negative	O
mutant	O
forms	O
of	O
components	O
of	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	O
or	O
p65	O
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	O
parva	O
-	O
transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite	O
-	O
induced	O
constitutive	O
NF	O
-	O
kappaB	O
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide	O
-	O
activated	O
toll	O
-	O
like	O
receptor	O
2	O
.	O

Human	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF	O
-	O
kappaB	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	O
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	O
associates	O
with	O
the	O
high	O
-	O
affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	O
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R	O
-	O
associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	O
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	O
lacking	O
C	O
-	O
terminal	O
13	O
or	O
141	O
aa	O
fail	O
to	O
recruit	O
IRAK	O
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild	O
-	O
type	O
TLR2	O
and	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2	O
-mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
6	O
,	O
and	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
,	O
when	O
coexpressed	O
with	O
TLR2	O
,	O
abrogate	O
TLR2	O
-mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	O
and	O
IL-1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	O
by	O
DN	O
variants	O
.	O

Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA	O
-	O
DR	O
-restricted	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	O
interferon	O
-induced	O
class	O
II	O
transactivator	O
expression	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
-induced	O
HLA	O
-	O
DR	O
expression	O
in	O
U373	B
MG	I
astrocytoma	I
cells	I
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	O
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN	O
-	O
gamma	O
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
synthesis	O
.	O

This	O
defect	O
leads	O
to	O
the	O
absence	O
of	O
presentation	O
of	O
the	O
major	O
immediate	O
-	O
early	O
protein	O
IE1	O
to	O
specific	O
CD4	B
(	I
+	I
)	I
T	I
-	I
cell	I
clones	I
when	O
U373	B
MG	I
cells	I
,	O
used	O
as	O
antigen	O
-	O
presenting	O
cells	O
,	O
are	O
treated	O
with	O
IFN	O
-	O
gamma	O
plus	O
HCMV	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	O
can	O
be	O
restored	O
when	O
U373	B
MG	I
cells	I
are	O
transfected	O
with	O
CIITA	O
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN	O
-	O
gamma	O
-	O
responsive	O
promoter	O
of	O
CIITA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
viral	O
inhibition	O
of	O
CIITA	O
expression	O
.	O

Bcl-2	O
-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
(	O
NFAT	O
)	O
-induced	O
Fas	O
ligand	O
transcription	O
.	O

Bcl-2	O
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	O
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	O
family	O
such	O
as	O
Bax	O
and	O
Bad	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	O
/Fas	O
ligand	O
(	O
FasL	O
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	O
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	O
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	O
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	O
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
,	O
a	O
transcription	O
factor	O
activated	O
by	O
microtubule	O
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium	O
-	O
dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	O
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	O
nuclear	O
translocation	O
,	O
the	O
FasL	O
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	O
.	O

Furthermore	O
,	O
Bcl-2	O
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	O
activation	O
,	O
blocking	O
NFAT	O
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	O
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	O
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	O
.	O

Phosphorylated	O
Bcl-2	O
can	O
not	O
bind	O
calcineurin	O
,	O
and	O
NFAT	O
activation	O
,	O
FasL	O
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl-2	O
phosphorylation	O
.	O

TCL1	O
oncogene	O
expression	O
in	O
AIDS	O
-	O
related	O
lymphomas	O
and	O
lymphoid	O
tissues	O
.	O

AIDS	O
-	O
related	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
AIDS	O
NHL	O
)	O
comprises	O
a	O
diverse	O
and	O
heterogeneous	O
group	O
of	O
high	O
-	O
grade	O
B	O
cell	O
tumors	O
.	O

Certain	O
classes	O
of	O
AIDS	O
NHL	O
are	O
associated	O
with	O
alterations	O
in	O
oncogenes	O
or	O
tumor	O
-	O
suppressor	O
genes	O
or	O
infections	O
by	O
oncogenic	O
herpesviruses	O
.	O

However	O
,	O
the	O
clinically	O
significant	O
class	O
of	O
AIDS	O
NHL	O
designated	O
immunoblastic	O
lymphoma	O
plasmacytoid	O
(	O
AIDS	O
IBLP	O
)	O
lacks	O
any	O
consistent	O
genetic	O
alterations	O
.	O

We	O
identified	O
the	O
TCL1	O
oncogene	O
from	O
a	O
set	O
of	O
AIDS	O
IBLP	O
-	O
associated	O
cDNA	O
fragments	O
generated	O
by	O
subtractive	O
hybridization	O
with	O
non	O
-	O
AIDS	O
IBLP	O
.	O

Aberrant	O
TCL1	O
expression	O
has	O
been	O
implicated	O
in	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
development	O
,	O
and	O
its	O
expression	O
also	O
has	O
been	O
seen	O
in	O
many	O
established	O
B	B
cell	I
tumor	I
lines	I
.	O

However	O
,	O
TCL1	O
expression	O
has	O
not	O
been	O
reported	O
in	O
AIDS	O
NHL	O
.	O

We	O
find	O
that	O
TCL1	O
is	O
expressed	O
in	O
the	O
majority	O
of	O
AIDS	O
IBLP	O
tumors	O
examined	O
.	O

TCL1	O
protein	O
expression	O
is	O
restricted	O
to	O
tumor	O
cells	O
in	O
AIDS	O
IBLP	O
tissue	O
samples	O
analyzed	O
with	O
immunohistochemical	O
staining	O
.	O

Hyperplastic	O
lymph	O
node	O
and	O
tonsil	O
also	O
exhibit	O
strong	O
TCL1	O
protein	O
expression	O
in	O
mantle	O
zone	O
B	O
cells	O
and	O
in	O
rare	O
interfollicular	O
zone	O
cells	O
,	O
whereas	O
follicle	O
-	O
center	O
B	O
cells	O
(	O
centroblasts	O
and	O
centrocytes	O
)	O
show	O
weaker	O
expression	O
.	O

These	O
results	O
establish	O
TCL1	O
as	O
the	O
most	O
prevalent	O
of	O
all	O
of	O
the	O
surveyed	O
oncogenes	O
associated	O
with	O
AIDS	O
IBLP	O
.	O

They	O
also	O
indicate	O
that	O
abundant	O
TCL1	O
expression	O
in	O
quiescent	O
mantle	O
zone	O
B	O
cells	O
is	O
down	O
-	O
regulated	O
in	O
activated	O
germinal	O
center	O
follicular	O
B	O
cells	O
in	O
parallel	O
to	O
the	O
known	O
expression	O
pattern	O
of	O
BCL-2	O
.	O

High	O
-	O
level	O
expression	O
in	O
nonproliferating	O
B	O
cells	O
suggests	O
that	O
TCL1	O
may	O
function	O
in	O
protecting	O
naive	O
preactivated	O
B	O
cells	O
from	O
apoptosis	O
.	O

Induction	O
of	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
expression	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
through	O
NF	O
-	O
kappaB	O
in	O
apoptosis	B
-	I
resistant	I
T	I
-	I
cell	I
transfectants	I
with	O
Tax	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	O
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	O
protected	O
the	O
mouse	B
T	I
-	I
cell	I
line	I
CTLL-2	I
against	O
apoptosis	O
induced	O
by	O
interleukin-2	O
(	O
IL-2	O
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	O
dependent	O
to	O
being	O
IL-2	O
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl	O
-	O
xl	O
but	O
not	O
bcl-2	O
,	O
bcl	O
-	O
xs	O
,	O
bak	O
,	O
bad	O
,	O
or	O
bax	O
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	O
deprivation	O
in	O
CTLL-2	B
cells	I
that	O
expressed	O
Tax	O
.	O

Transient	O
-	O
transfection	O
assays	O
showed	O
that	O
bcl	O
-	O
x	O
promoter	O
was	O
transactivated	O
by	O
wild	O
-	O
type	O
Tax	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	O
retaining	O
transactivating	O
ability	O
through	O
NF	O
-	O
kappaB	O
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	O
NF	O
-	O
kappaB	O
binding	O
site	O
identified	O
in	O
the	O
bcl	O
-	O
x	O
promoter	O
significantly	O
decreased	O
Tax	O
-induced	O
transactivation	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF	O
-	O
kappaB	O
family	O
proteins	O
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax	O
-induced	O
transactivation	O
of	O
the	O
bcl	O
-	O
x	O
promoter	O
was	O
also	O
diminished	O
by	O
the	O
mutant	O
IkappaBalpha	O
,	O
which	O
specifically	O
inhibits	O
NF	O
-	O
kappaB	O
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
induced	O
by	O
Tax	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	B
cells	I
after	O
IL-2	O
deprivation	O
.	O

Renal	O
cell	O
carcinoma	O
-	O
derived	O
gangliosides	O
suppress	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NFkappaB	O
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	O
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus	O
-	O
induced	O
degradation	O
of	O
the	O
cytoplasmic	O
factor	O
IkappaBalpha	O
.	O

Tumor	O
-	O
derived	O
soluble	O
products	O
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	O
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus	O
-	O
induced	O
IkappaBalpha	O
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	O
but	O
not	O
protease	O
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	O
from	O
adjacent	O
normal	O
kidney	O
tissue	O
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	O
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	O
expression	O
of	O
the	O
cytokines	O
IL-2	O
and	O
IFN	O
-	O
gamma	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor	O
-	O
derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

